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Abstract   II 
II  Abstract 
This thesis examines the 1,2,4-oxadiazole heterocyclic unit as a participating structural feature of 
new ligand systems in supramolecular chemistry. These ligand systems were synthesised by reaction 
of phenyl, pyridyl or pyrimidyl amidoximes with corresponding acid chlorides to furnish novel, multi-
dentate ligand systems featuring at least one 1,2,4-oxadiazole unit. The ability of these heterocycles 
to form complexes with metal cations was investigated and several novel systems are reported. 
 
The synthesis and biological activity of a range of isothiazolo-isoxazoles was also studied. Such 
compounds were prepared through an eight-step synthesis, the critical reaction involving a 1,3-
dipolar cycloaddition of a nitrile oxide to an isothiazole-1,1-dioxide, which acted as an alkenic 1,3-
dipolarophile rather than as an iminic 1,3-dipolarophile.  
 
The synthesis of a range of catalytic, (S,S)-pseudoephedrine-containing hypervalent iodine systems is 
also described. The pre-catalytic iodine(I) systems were synthesised employing Schotten-Baumann 
conditions. The catalytic iodine(III) systems were achieved via in-situ mCPBA oxidation and the use of 
p-TsOH as a ligand-type additive. Attempts to produce 1,2,4-oxadiazole analogues of this system are 
also described in this thesis.  
X = N or CH 
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1  Introduction 
One of the key topics of this thesis is the 1,2,4-oxadiazole. The 1,2,4-oxadiazole is a versatile 
heterocycle and finds application across almost the entire spectrum of chemistry. This thesis 
explores these existing applications and attempts to build on them whilst investigating some new, 
very recent developments in the chemistry and application of the 1,2,4-oxadiazole. This project, like 
many, deviates from its path at several points with ventures through a broad range of organic 
chemistries, however the 1,2,4-oxadiazole always remains the heart of the matter and is the 
ultimate target of the all syntheses detailed.  
This introduction details the background chemistry and science which form the foundations for this 
research project. The chapter is categorised into four subchapters. The first provides a general 
overview of the 1,2,4-oxadiazole unit, its synthesis and reactivity. This forms a basis for the next 
three subchapters, each of which considers new investigations into an existing application of the 
1,2,4-oxadiazole.  
The second of these subchapters introduces the 1,2,4-oxadiazole in supramolecular chemistry- a 
relatively unexplored area for this heterocycle.  
The third subchapter focuses on introducing the 1,2,4-oxadiazoline as a key component in 
biologically active compounds popular amongst our research group. 
The fourth and final subchapter introduces the chemistry of the 1,2,4-oxadiazole with direction 
towards the development of novel asymmetric catalysts. 
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1.1  The Chemistry of the 1,2,4-Oxadiazole Heterocyclic Unit  
This sub-chapter of the introduction offers a general introduction to the chemistry of the 1,2,4-
oxadiazole. This area has been reviewed several times and so only a brief summary is provided here.  
Pƌioƌ to the late ϭϵϲϬ͛s, ϭ,Ϯ,ϰ-oxadiazole research was not popular, with only a handful of articles 
published. Since the 1962 discovery and 1967 publication of the Boulton-Katritzky rearrangement1,2,3 
(introduced more thoroughly later in this chapter), research interest in 1,2,4-oxadizoles has grown 
considerably.  
In recent decades, the 1,2,4-oxadiazole has found application across much of the chemical spectrum, 
from critical features of medicinal chemistry to new developments in materials and supramolecular 
chemistry, through to more peculiar uses such as the novel and insensitive high explosive shown 
below4. 
 
 
 
Figure 1.1 - High explosive 1,2,4-oxadiazole, synthesised by Chen and co-workers4. 
 
1.1.1  The Synthesis of 1,2,4-Oxadiazoles 
The 1,2,4-oxadiazole was first synthesised by the German chemist, Johann Karl Wilhelm Ferdinand 
Tiemann (1848-1899) in collaboration with a second chemist, Paul Kruger, some 125 years ago5. 
Since the original synthesis of the 1,2,4-oxadiazole, many alternative syntheses have arisen. This 
section of this sub-chapter focuses only on the most common of these syntheses. 
1.1.1.1  The Synthesis of 1,2,4-Oxadiazoles by Reaction of Amidoximes with  
  Reactive Carboxylic Species 
The most popular means of synthesising the 1,2,4-oxadiazole unit is through the reaction of an 
amidoxime with a reactive carboxylic unit6. Reaction commences with acylation of the amidoxime 
oxygen and subsequent loss of the carboxylic activating group or hydrogen halide, thus producing an 
intermediate O-acylamidoxime (1) (Scheme 1.1). This intermediate depending on substitution and 
stability can often be isolated if necessary, however one usually finds cyclodehydration to the 
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oxadiazole (2) a spontaneous process. If isolated, the intermediate can be cyclodehydrated under 
thermal conditions to the oxadiazole7.  
 
 
 
 
 
 
 
 
Scheme 1.1 
 
1.1.1.2  Sources of and Variations on the Amidoxime Component 
Some compounds with amidoxime functionality are available commercially; however a wide variety 
of alkyl and aryl amidoximes can easily and inexpensively be achieved from nitriles through reaction 
with hydroxylamine (Scheme 1.2). This step can be performed in a wide range of organic solvents 
but is also achievable under aqueous conditions6.  
 
 
 
 
Scheme 1.1 
 
 
(1) (2) 
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As an alternative, the prerequisite amidoxime can be obtained via reaction of imidoyl halides with 
ammonia (Scheme 1.3). The imidoyl halides are easily synthesised via chlorination of the 
corresponding oxime with chlorine gas or a source of cationic chlorine such as N-chlorosuccinimide8.  
 
Scheme 1.3 
 
1.1.1.3  Sources of and Variations on the Carboxylic Component 
Acid halides such as acid chlorides are popular and highly effective reagents in providing the 
necessary reactive carboxylic fragment for 1,2,4-oxadiazole formation6. Synthesis of 1,2,4-
oxadiazoles by this means remains popular since the reaction is tolerant of a wide range both alkyl 
and aryl amidoximes and acid chlorides. The mechanism for the reaction between acid halide and 
amidoxime is shown below in Scheme 1.4. 
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Scheme 1.4 
 
The reaction mechanism proceeds initially with the coupling of acid chloride to amidoxime and with 
loss of HX followed by cyclodehydration to the 1,2,4-oxadiazole. 
Usually, it is necessary to isolate the amidoxime prior to reaction with acid chloride in order to 
remove any aqueous impurities that would disrupt the coupling to the acid halide. However, the 
conversion of nitrile to amidoxime and then reaction with an acid chloride to 1,2,4-oxadiazole has 
been achieved as a one-pot synthesis with magnesia-supported sodium carbonate9. 
In cases where the acid chlorides are inconvenient or simply unavailable, several other alternatives 
are available- some long-known, some newly discovered. 
The carboxylic fragment can also be provided by a variety of carboxylic acids, through use of 
common coupling agents such as N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 1,1'-carbonyldiimidazole (CDI)10,11 (Scheme 1.5). This is 
a convenient synthesis since many of these reactions involve mild conditions and are tolerant of a 
wide range of substituted alkyl and aryl carboxylic acids. Once coupled, a switch to a high boiling 
solvent is often necessary to promote cyclodehydration of the O-acylated intermediate.  
.
.
.
. .
.
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Scheme 1.5 
 
Uronium salts such as (1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) 
in the presence of HOBt and DIPEA have also been shown to be strongly efficient coupling agents, 
particularly when faced with sterically challenging carboxylic acids12. They have also demonstrated 
rapid coupling kinetics and are soluble in polar organic solvents such as DMF12. Carboxylic acids have 
been shown to react with amidoximes under microwave conditions in DMF in the presence of HBTU 
(the hexafluorophosphate counterion derivative of TBTU) and DIPEA13.  
 
 
 
 
 
 
 
Figure 1.2 – Structure of TBTU. 
 
Esters have also found some appreciable application in providing the carboxylic fragment necessary 
to react with the amidoxime in 1,2,4-oxadiazole synthesis14,15. In the past, the synthesis of the 1,2,4-
oxadiazole unit via the ester functional group has suffered from low yields, the necessity for the 
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strong bases and harsh general conditions15. Recent research has shown that the ester can be a 
more practical and suitable source of the carboxylic fragment. Reactions involve moderate 
conditions, weak bases such as potassium carbonate and generally provide good yields (Scheme 1.6). 
However, this research used only relatively simple aryl esters and amidoximes15. 
 
Scheme 1.6 
 
Very recently, simple ethyl glycolates and ethyl lactates (3) have been demonstrated as effective 
substrates in the O-acylation of amidoximes, furnishing 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles in 
good yields (Scheme 1.7). This was achieved with potassium carbonate at reflux in a 9:1 
toluene:dimethylformamide solvent16. 
 
Scheme 1.7 
 
EǆteŶdiŶg fƌoŵ the ƌeaĐtiǀe poteŶtial of the esteƌ, it has ďeeŶ shoǁŶ that β-keto esters are highly 
satisfactory sources of the carboxylic fragment in the synthesis of 1,2,4-oxadiazoles from reaction 
with amidoximes, demonstrating simple achievement of 3-substituted-5-β-keto-1,2,4-oxadiazoles. 
Substitution at the 3-position is highly variable via this method with good yields observed through a 
wide range of aryl and alkyl amidoximes17. The most satisfactory results are obtained through use of 
tert-butyl-β-keto esters (4). The suďstituted β-keto ester, under thermal conditions, eliminates a 
molecule of alcohol- this elimination favouring the more hindered alcohols. This elimination yields 
an acyl ketene (5), a reactive intermediate which subsequently acylates the amidoxime oxygen with 
R = Me, H 
R1 = CH2Ph, 4-MePh, 4-MeOPh, 
t-Butylpropionate R2 = Me, 4-
MePh  
 
(3) 
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loss of a proton to promote conventional cyclodehydration and formation of the corresponding 
1,2,4-oxadiazole17 (Scheme 1.8). 
 
 
Scheme 1.8 
 
It has been demonstrated that O-acylation of the amidoxime can be achieved following a palladium 
catalysed coupling of the amidoxime with an aryl iodide in the presence of carbon monoxide. The 
reaction proceeds through an intermediate acyl-palladium complex which enables subsequent O-
acylation of the amidoxime (Scheme 1.9). At present the coupling reaction generally applies to 
methylamidoximes only18 giving 3-methyl-5-aryl-1,2,4-oxadiazoles (6).  
 
 
 
 
 
  
 
 
 
 
 
 
 
Scheme 1.9 
 
R = iPr, CO2Et, Ph, CH2OCH2Ph, 4-FPh, 
4-CO2Ph, 4-CF3, 3-pyridyl, 4-(CF3)-3-
pyridyl 
(4) 
(5) 
R = CO2Me, NO2, MeO, Br 
(6) 
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Recently, the cyclodehydration of O-acylated amidoximes has been improved with the catalytic use 
of TBAF19. Whilst in many cases cyclodehydration to the oxadiazole is spontaneous, this synthesis 
offers a mild alternative to the otherwise impractical high boiling solvent-switch and potentially time 
consuming reflux conditions. The catalytic role of fluoride is shown in Scheme 1.10 below19. This 
synthesis has been further developed to tolerate solvent free conditions20. 
 
 
 
Scheme 1.10 
 
 
1.1.2  The Synthesis of 1,2,4-Oxadiazoles Through the Cycloaddition of Nitrile  
  Oxides with Nitriles 
The 1,3-dipolar cycloaddition reaction between (the 1,3-dipolar) nitrile oxides and (the 
dipolarophilic) nitriles is a well-established route to 1,2,4-oxadiazoles (Scheme 1.11) and is second in 
popularity only to the cyclisation of O-acylamidoximes described earlier6,21,22. 
 
Scheme 1.11 
 
R1 = Ph, Me 
R2 = Ph, Me 
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Nitrile oxides are a class of chemical species with a zwitterionic, propargyl-type structure. This 
nature gives them both nucleophilic and electrophilic properties, the reactive effects of which are 
demonstrated in the reaction mechanism below (Scheme 1.12). 
 
Scheme 1.12 – Mechanism of the 1,3-dipolar cycloaddition reaction of nitrile oxides to nitriles. 
 
The synthesis of 1,2,4-oxadiazoles via this route is popular due to the mild conditions and the wide 
range of synthetic options available for acquiring the precursors to the nitrile oxides. 
In a recent piece of research, our group have demonstrated that the 1,3-dipolar cycloaddition of 
nitrile oxides with 4-aryl-1-azetines (7) generates oxadiazabicyclo[3.2.0]heptenes. These bicyclic 
compounds can then undergo a thermal [2+2] cycloreversion to yield 5-alkylthio-1,2,4-oxadiazoles23 
(Scheme 1.13), the 1-azetine therefore acting as a nitrile equivalent. 
 
Scheme 1.13 
 
 
 
 
(7) 
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1.1.2.1  Sources of the Nitrile Oxide Component 
Nitrile oxides readily dimerise (Scheme 1.14); a process which occurs should the nitrile oxide not 
hastily react by the desired means24. Some stabilised nitrile oxides have been synthesised and 
occasionally isolated, however, the vast majority are better handled as in-situ reactive 
intermediates. 
 
Scheme 1.14 
 
The most common means of accessing nitrile oxides is via the base mediated dehydrohalogenation 
of imidoyl halides6 (Schemes 1.15 and 1.16).  
 
 
 
 
Scheme 1.15 
 
 
Scheme 1.16 - Mechanism of the base mediated synthesis of nitrile oxides from imidoyl halides 
(chloroximes). 
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Sourcing the nitrile oxide from imidoyl halide species is not without issue. Since the imidoyl halide is 
synthesised through treatment of the precursor oxime with electrophilic halide, some multi-
functionalised substrates which may be sensitive to halogenation or oxidation may be produced, 
such as alkenes and the more electron rich arenes25. An alternative route to nitrile oxides is available 
through the Mukaiyama-Hoshino method (Scheme 1.17). This method involves reaction of a 
phenylisocyanate with a nitroalkane. The Mukaiyama-Hoshino method is widely used and tolerant of 
a wide range of conditions and reagents. The only limiting factor is the acquisition of potentially 
troublesome nitro precursors26.  
 
 
 
 
 
 
 
Scheme 1.17 – The Mukaiyama-Hoshino method. 
 
 
Scheme 1.18 – Suggested mechanism of the Mukaiyama-Hoshino method of nitrile oxide synthesis. 
 
CO2
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The generally accepted mechanism shown in Scheme 1.18 suggests initiation of the reaction with 
nucleophilic attack at the isocyanate from the nitroalkane. The resulting intermediate then 
undergoes intramolecular transfer of H2O, one atom at a time. The mechanism concludes with the 
expulsion of aniline and carbon dioxide and the synthesis of the desired nitrile oxide6,26. 
The nitrile oxide unit is also accessible via the dehydration of O-silylated hydroxamic acids. Prior to 
recent redevelopments, this route had previously been of poor comparative value, mainly due to the 
tendency for hydroxamic acids to suffer rearrangement to the isocyanate in conditions similar to 
those that promote dehydration. In a study by Carreira and co-workers, it has been demonstrated 
that O-silylated hydroxamic acids, following carbonyl activation by triflic anhydride and treatment 
with a deprotecting agent, can be converted to the corresponding nitrile oxide25 (Scheme 1.19). 
 
  
 
 
 
 
 
 
 
Scheme 1.19 
 
Further alternative routes to nitrile oxides are available. The conversion of a several halo- and 
methyl substituted aryl aldoximes to the corresponding nitrile oxide has been achieved27 without the 
necessity for base via the treatment of the aldoxime with 1-chlorobenzotriazole (NCBT) which 
affords the nitrile oxide product in near quantitative yield at room temperature in minutes (Scheme 
1.20). Whilst this reaction avoids the use of base, it was limited to a small range of aryl aldoximes 
only27. 
R = Ph, CH=CHPh, (CH2)2Ph 
-
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Scheme 1.20 
 
The hypervalent iodine(III) reagent iodobenzene dichloride has been reported as an effective 
reagent for the synthesis of nitrile oxides28 (Scheme 1.21). The treatment of a range of methoxy- and 
vinyloxy- aryl aldoximes with iodobenzene dichloride in the presence of triethylamine or pyridine in 
chloroform yields the corresponding nitrile oxide in strong yields28. 
 
 
 
Scheme 1.21 
 
 
 
 
 
 
R = 2,6-Cl2Ph, 2,4,6-Me3Ph 
Ar = Ph, 4-MeOPh, 3,4,5-(MeO)3Ph, 2-OCH2CH=CH 
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1.1.3  The Reactivity of 1,2,4-Oxadiazoles 
The 1,2,4-oxadiazole unit, relatively speaking, is highly stable and is thus a largely inert heterocycle. 
Whilst functional group manipulations of the oxadiazole unit are possible, these will not be 
considered in this thesis due to their standard nature. Instead this introduction will specifically focus 
on more interesting and unique reactions of the 1,2,4-oxadiazole unit.  
The 1,2,4-oxadiazole is almost completely inert towards attack from electrophiles. Nucleophilic 
displacement at the 3-position is also very uncommon. However, the nucleophilic displacement of 
suitable leaving groups at the 5-position is a commonly observed method of functionalisation in 
1,2,4-oxadiazoles. For example, it is well known that trichloromethyl groups can be displaced by 
oxygen and nitrogen nucleophiles at the 5-position29.  
Some 5-vinyl-1,2,4-oxadiazoles have been demonstrated to be very good Michael acceptors. 
Reaction of these derivatives with a good range of nucleophiles including primary and secondary 
amines, thiols and alcohols in the presence of a range of bases generates Michael addition products 
in strong yields30 (Scheme 1.22). 
 
Scheme 1.22 
 
One of the most well-known reactions of the 1,2,4-oxadiazole is the monocyclic rearrangement 
reaction of certain 5-membered heterocycles into other 5-membered heterocycles. This can occur 
via treatment with acid or base or under photoirradiative conditions1. This reaction is known 
commonly as the Boulton-Katritzky Rearrangement2. The reaction is observed with a wide range of 
5-membered heterocycles, however it is typically applied to isoxazoles and 1,2,4-oxadiazoles31. The 
mechanism for this popular reaction, applied to an example 1,2,4-oxadiazole is shown32. 
 
(21) 
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Scheme 1.23 – Example Boulton-Katritzky Rearrangement. 
 
Other rearrangement reactions of 1,2,4-oxadiazoles are possible under photoinduction. Vivona and 
co-workers have demonstrated the photo-rearrangement of certain 5-alkyl-3-amino-1,2,4-
oxadiazoles into the isomeric 1,3,4-oxadiazoles33 (Scheme 1.24). 
 
 
 
 
 
Scheme 1.24 
 
Further exploration of this work has seen the photo-rearrangement of 3-phenyl-1,2,4-oxadiazoles 
into 1,2,4-triazoles, indazoles and benzimidazoles through treatment with nitrogen nucleophiles34 
(Scheme 1.25).  
 
 
R = C6H17, C11H23 
.
-
.
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Scheme 1.25 
 
This research has subsequently led to the synthesis of 1,2,4-thiadiazoles when 3-phenyl-5-amino-
1,2,4-oxadiazoles were treated with various sulfur nucleophiles35. Extending this work further, 
Vivona has shown that a range of 5-aryl-1,2,4-oxadiazoles (22) can rearrange under similar 
conditions to form quinazolin-4-ones36 (23) (Scheme 1.26). 
 
Scheme 1.26 
 
During the synthesis of Conotoxin MVIIA, the venom from the cone shell, the hydrogenation of a 3-
aryl-5-methyl-1,2,4-oxadiazole over Raney Nickel catalyst in an ethanol/acetic acid/water solvent 
mix was shown to generate amidines in good yields (78%)37 (Scheme 1.27). 
 
 
 
 
 
Scheme 1.27 
R1 = NH2, NHMe, NMe2   
R2 = H, Me, Pr, Bu, NH2 
R1 = H, Me, CN, Cl 
R2 = MeO, Ph 
(22) (23) 
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Additionally, in a synthesis of some new antithrombotics, hydrogenation of 3-methyl-5-aryl-1,2,4-
oxadiazoles to the corresponding amidoxime has been shown to proceed effectively with catalytic 
palladium on carbon38. The ring-opening hydrogenation of such substituted 1,2,4-oxadiazoles is an 
interesting reaction and was observed experimentally during this project and is discussed further in 
section 3.3.2.2. It has also been observed that other standard reducing agents such as lithium 
aluminium hydride in THF can ring-open the heterocycle to the produce N-substituted amidoximes39.  
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1.2  The Supramolecular Chemistry of Ligand Systems Featuring the 
  1,2,4-Oxadiazole Unit 
This subchapter introduces the fundamentals that inspired an investigation into the 1,2,4-oxadiazole 
unit as a key feature of ligand systems and its subsequent significance in potential supramolecular 
structures that may form. A brief introduction to relevant research of supramolecular chemistry 
follows. 
1.2.1  Defining Supramolecular Chemistry 
Modern supramolecular chemistry, is truly a multidisciplinary field40,41. The versatility and growth of 
supramolecular chemistry was exemplified in 1987 with the award of the Nobel Prize for Chemistry 
to Cram, Lehn and Pederson for their early and pioneering work in this field42.  
A supermolecule can be defined as a multi-molecular chemical species in which the individual 
molecules are held together by non-covalent forces. These non-covalent bonding interactions, 
predictably, are significantly weaker than covalent bonds, can be of different types and often 
provide significant stability to the supramolecular structure. The major types of such bonding are 
discussed below.  
1.2.2.1  Hydrogen Bonding 
With an approximate strength of 4-30 KJmol-1, the hydrogen bond may be regarded amongst the 
stronger non-covalent interactions. Natural supramolecular systems commonly feature the 
hydrogen bond due to this strength along with the high levels of directionality the interaction offers. 
The hydrogen bond is often regarded as the most important non-covalent interaction of all57.  
 
 
 
 
Figure 1.3 – Popular illustration of Hydrogen Bonding. 
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1.2.2.2  Electrostatic Interactions 
Electrostatic interactions encompass interactions between two ions, or between two molecules with 
dipole moments, or, between an ion and a molecule with a dipole moment. An ion-ion interaction is 
the strongest electrostatic interaction, with an approximate strength between 200-300 KJmol-1,40. 
The interaction between two ions is non-directional. An example of this is the stabilising interaction 
between a halide anion and an ammonium cation. 
The interaction between an ion and a dipole on the other hand, does require some directionality and 
orientation. In order to sufficiently stabilise the complex, the interaction will only occur if both 
substrates are in the correct geometry. This is demonstrated in the example below (Figure 1.4), 
which shows a potassium ion interacting with the electronegative nitrogen and oxygen atoms of the 
polyetherial macrocycle in which it sits43,44.  
 
 
 
 
 
 
 
Figure 1.4 
 
1.2.2.3  π-Interactions 
IŶteƌaĐtioŶs iŶǀolǀiŶg π-bonding electrons are also commonly observed in supramolecular 
ĐheŵistƌǇ. Theƌe aƌe tǁo distiŶĐt, π-interactions observed in supramolecular chemistry that involve 
π-electron systems. These are cation-π iŶteƌaĐtioŶs aŶd π-π iŶteƌaĐtioŶs. IŶteƌaĐtioŶs ďetǁeeŶ 
ĐatioŶs aŶd π-electrons are often observed in organometallic chemistry, for example the interactions 
ďetǁeeŶ π-electrons of two cyclopentadiene rings and an iron centre as observed in ferrocene45 
(Figure 1.5). 
 
Cl- 
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Figure 1.5 
 
Non-ĐoǀaleŶt iŶteƌaĐtioŶs ďetǁeeŶ tǁo π-electron systems are encountered often throughout 
supramolecular chemistry largely due to the abundance of aromatic rings in many ligand systems. 
Tǁo tǇpes of π-π iŶteƌaĐtioŶ aƌe eŶĐouŶteƌed ;Figuƌe ϭ.ϲͿ. Face-to-face π-π iŶteƌaĐtioŶs aƌe those iŶ 
ǁhiĐh π-ring systems orientate in a parallel, offset fashion. These interactions are between the 
ĐoƌŶeƌ of oŶe π-ring system and the centre of the other. In addition to this orientation, there exists 
the edge-to-face setup, whereby one of the hydrogen atoms of one ring forms a perpendicular 
interaction with the second ring45.  
 
 
 
 
 
 
Figure 1.6 - Face to face (left) and edge to face (right) π-π iŶteƌaĐtioŶs. 
 
π-π IŶteƌaĐtioŶs ƌesult fƌoŵ the uŶiƋue, ĐoŶjugated attƌaĐtioŶ ďetǁeeŶ the π-electron cloud of one 
ƌiŶg sǇsteŵ aŶd the σ-framework of the second ring system, which are negatively charged and 
positively charged, respectively45-48.  
 
 
2+ 2Cl- 
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1.2.2.4  Van der Waals Interactions 
Van der Waals interactions are the weakest of all non-covalent interactions with approximate 
strength of less than 5 KJmol-1. Van der Waals interactions are attractive forces which occur between 
atoms which have experienced, at a given moment, a minute fluctuation in the transient location of 
their electron clouds. The instantaneous, uneven distribution of electrons about a nucleus creates a 
minor dipole which has the power to induce a momentary dipole on a neighbouring atom45. 
 
1.2.2.5  Hydrophobic Effects 
The hydrophobic effect describes the expulsion of hydrophobic molecules from aqueous solution. 
Polar molecules form an interaction more readily with other polar molecules than they do with non-
polar molecules. Likewise non-polar molecules interact more favourably with other non-polar 
molecules. This process is energetically favourable. The hydrophobic effect is observed commonly in 
supramolecular assemblies within living systems. 
 
1.2.3  The Common and Major Themes within Supramolecular Chemistry 
Supramolecular chemistry has become an all-encompassing field. However, one can attempt to 
categorise supramolecular chemistry and subsequent structures into two separate fields; host-guest 
chemistry and self-assembly. 
 
1.2.3.1  Host-Guest Chemistry 
Host-guest chemistry describes the formation of a supramolecular complex by the specific 
association of two molecules of suitable size and shape. The interaction is signified by one of the two 
molecules, usually the largest, acting as the host. This host molecule is able to encompass and 
effectively wrap around a second molecule of suitably smaller size and complementary shape. An 
excellent definition of the host and the guest was offered by Cram45: 
The host is defined as an organic molecule or ion whose binding sites converge in the complex...... 
The guest component is any molecule or ion whose binding sites diverge in the complex
45. 
 
Introduction   1 
23 
 
1.2.3.2  Self-Assembly 
Self-assembled systems can form by utilising any number of the non-covalent interactions described 
earlier. The supramolecular products of self-assembly are always the most thermodynamically stable 
products. In terms of enthalpy, the process is highly favourable, due to the high stability of the self-
assembled systems. However, the formation of self-assembled species does not proceed via an 
entropically favourable pathway due to the creation of an ordered, uniform system from disordered 
components. Self-assembly is therefore a seemingly reverse-entropy process. However, it is argued 
that the displacement of solvent molecules via hydrophobic interactions from the binding sites of 
dissembled ligand strands compensates for the entropic disfavourability of the assembly process45.   
 
1.2.3.3  Metallosupramolecular Chemistry 
The use of metal ions in devising potential self-assembling systems is a popular tactic in 
supramolecular chemistry. The term metallosupramolecular chemistry is now reserved for this 
study. The use of metal ions in supramolecular chemistry is popular since metal ions, particularly 
those of the d-block, have strict coordination parameters. This offers the opportunity to postulate 
some structures based on these strict coordinations.  
 
1.2.4  Common Structural Descriptions of Metallosupramolecular Systems 
Amongst the most popular metallosupramolecular themes are racks, ladders, grids and helicates. 
These are only considered themes, since many self-assembled systems adopt structures that feature 
some overlap between these structural descriptives. 
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1.2.4.1  Racks 
Racks consist of a single polytopic ligand strand, coordinated by metal ions at multiple ligand binding 
sites. The metal ions form the junction or joints of the rack. Further coordination of this metal ion to 
aŶotheƌ ligaŶd foƌŵs the ͚spoke͛ oƌ ͚shelf͛ of the rack62. An example of a rack-type 
metallosupramolecular system is shown below, which was synthesised by Lehn and co-workers in 
199548. This example has ruthenium(II) ions as the joints of the rack with the terpyridine units 
forming the spokes.  
 
 
 
 
 
 
 
 
 
 
Figure 1.7 – Simple Rack System. 
 
 
 
 
 
 
 
4(PF6)
- 
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1.2.4.2  Ladders 
Ladder-type supramolecular structures are closely related to racks; however, ladders incorporate a 
second polytopic ligand strand roughly parallel to the other. The polytopic ligands are linked by a 
further ligand which is bound to the parallel chains by metal ions. These central ligands and metal 
ions form the rungs of the ladder45. 
In the below 2-runged and 3-ƌuŶged sǇsteŵs, ƌepoƌted ďǇ LehŶ iŶ ϭϵϵϲ, the Ϯ,Ϯ͛-bipyrdine chains 
form the vertical supports for the ladder with the bipyrimidine units forming the rungs. These are 
held together by the 4-coordinate copper(I) ions which act as the joints49. 
 
 
 
 
 
Figure 1.8 – Two-runged (left) and three-runged (right) ladder systems. 
 
 
 
4(PF6)
- 
6(PF6)
- 
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1.2.4.3  Grids 
Grids are observed when polytopic ligand strands coordinate to metal ions in such a manner that 
orthogonal, linear assemblies are produced. For example, grids can exist as square grids, which are 
observed when 4-coordinate metal ion such as Cu2+ bind to certain polytopic ligands with linear 
binding sites. 
The polymeric square grid below (Figure 1.9), reported by Fujita and co-workers in 2004, comprises 
ϰ,ϰ͛-bipyridine units coordinated by Cd2+ ions in square planar geometry50.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 – Example grid system. 
 
 
n(NO3)
- 
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1.2.4.4  Helicates 
The helicates are a form of metallosupramolecular structure that have adopted helical character in 
their geometry. This helical nature is observed as multidentate ligand strands wrap around metal 
ions, forming an effect similar to that of a thread of a screw45. Classifying and defining helicates is 
challenging since helicating supramolecular structures are can be extremely varied in their nature. 
Current helicate nomenclature enables one to formulate only an approximate image of a 
supramolecular complex. The nuclearity of a helicate describes the number of metal ion centres 
within the structure. A mononuclear structure contains one metal centre, a dinuclear structure 
contains two, trinuclear structures contain three etc. Two ligand strands (or threads) are described 
as double helicates and three ligand strands as triple helicates etc. and those that form an eventual 
loop are described as cyclic or circular helicates45,51. Some helicate structures contain ligand strands 
of differing composition. Helicates containing consistent ligand strands are termed homostranded 
helicates whereas those containing more than one different ligand strand are termed 
heterostranded helicates51.  
 
Figure 1.10 – Example helicate structure, synthesised by Lehn52. 
3(BF4)
- 
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The example in Figure 1.10 first reported by Lehn in 1993, demonstrates the helicating effect of the 
ligand strands, spiralling down as they do in a screw-thread like manner52. In this example the 
copper(I) ions coordinate in a square planar geometry. The helicating effect is not observed around 
the metal ions due to this geometry; the effect is entirely observed in the ligands strands at non-
coordinating sites. 
 
1.2.5  Recent Advances in Supramolecular Chemistry Featuring the 1,2,4- 
  Oxadiazole Unit  
The 1,2,4-oxadiazole is virtually unknown in supramolecular chemistry. There have been a handful of 
articles reported that describe the 1,2,4-oxadiazole as a coordination unit with metal ions. This is 
highly surprising, since as a highly nitrogenous heterocyclic unit, the 1,2,4-oxadiazole at a glance 
offers great potential in metallosupramolecular chemistry.  
The 1,2,4-oxadiazole offers three potential binding sites. The research into metal ion coordination at 
these sites is described herein. 
 
1.2.5.1  Coordination via the Imine, N4 Atom 
This site is the strongest candidate for metal ion coordination. This is due to the marginal, but 
significantly higher basicity of this nitrogen atom over the oxime N2 nitrogen atom54. Very few 
examples of 1,2,4-oxadiazoles acting as coordinating units in ligands, exist in the literature. However, 
of the very few examples that do exist, the vast majority demonstrate coordination through this N4 
imine site.  
 
 
 
Figure 1.11 – 1,2,4-Oxadiazole coordination through N4. 
 
Reported in 2003 and 2005, Bokach and co-workers synthesised two mononuclear, 1,2,4-oxadiazole 
structures, one featuring a platinum(IV) and the other a platinum(II) centre55,56 (Scheme 1.28). These 
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complexes were not resultant from metallosupramolecular self-assembly however since both 
complexes were synthesised by 1,3-dipolar cycloaddition of a nitrile oxide with a pre-obtained 
platinum-nitrile complex.  
 
Scheme 1.28 
 
The first 1,2,4-oxadiazole complex was reported in 198557. Massacesi and co-workers synthesised a 
number of very simple 3-aryl-5-methyl-1,2,4-oxadiazoles and synthesised some simple complexes 
with metal ions57. Notably however, the group did not examine any 3-heteroaryl-1,2,4-oxadiazole 
systems, nor were any crystal structures of their materials published.  
 
 
 
 
 
Figure 1.12 – MasseĐesi͛s siŵple ϭϵϴϱ ϭ,Ϯ,ϰ-oxadiazole ligand. 
 
Massacesi and co-workers determined, largely through I.R spectroscopy, that ligand A formed simple 
mononuclear cis square planar complexes with a range of divalent metal ions, with coordination 
R1 = Me, Et, CH2Ph 
R2 = 2,4,6-Me3Ph, 2,4,6-(MeO)3Ph 
A: X = MeO, Y = H 
B: X = Me, Y = Cl   
C: X = Me, Y = H 
2Cl- 
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presumably through the methoxy oxygen57. Whilst ligands B and C also formed simple complexes, 
the lack of crystal data limits definitive information regarding specific coordination modes.  
In 1999, Goodwin and co-workers synthesised a tridentate 3-;Ϯ,Ϯ͛-biyridine)-5-methyl-1,2,4-
oxadiazole system and investigated its supramolecular potential. It was found that the ligand formed 
a simple, attractive and interesting mononuclear grid-type system with Fe2+ ions. Coordination about 
the 1,2,4-oxadiazole was observed solely through the N4 nitrogen atom58. To this day, it appears that 
this remains the only example of the 1,2,4-oxadiazole unit acting as part of a successful tridentate 
binding domain. 
 
 
 
 
 
 
 
Figure 1.13 – GoodǁiŶ͛s ϭϵϵϵ ϭ,Ϯ,ϰ-oxadiazole complex58. 
 
Brinn and co-workers were also amongst the first to demonstrate that the 1,2,4-oxadiazole unit is 
capable of acting as an effective binding site in more conventional ligand systems and showed that 
3-phenyl-5-(2-oxyphenyl)-1,2,4-oxadiazole was able to coordinate to Cu2+ ions to form a simple 
mononuclear complexes. The 1,2,4-oxadiazole coordinates to Cu2+ through only the imine N4 atom 
along with the phenolic oxygen atom which yielded two isomeric complexes59, an interesting result 
in its own right, since oxygen atoms acting as donor atoms in coordination chemistry is rarely seen 
with transition metals60. 
 
2(CF3SO3)
- 
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Figure 1.14 – BƌiŶŶ͛s isoŵeƌiĐ ϭ,Ϯ,ϰ-oxadiazole complexes59. 
 
In 2007, Steel and co-workers published the coordination chemistry and complexes of a simple bis-
oxadiazole ligand53. This work offered a greater insight into the coordination chemistry of the 1,2,4-
oǆadiazole uŶit. Steel͛s ƌeseaƌĐh gƌoup desĐƌďed theiƌ ligaŶd iŶ theiƌ ϮϬϬϳ puďliĐatioŶ as ‘a curiously 
ignored ligand
53
.  
 
 
 
Figure 1.15 – Steel͛s ϮϬϬϳ ďis-oxadiazole ligand. 
 
Due to ďoŶd ƌotatioŶ aďout the ϯ,ϯ͛-linking positions of the oxadiazole units, a total of five 
coordination modes were potentially offered by this simple ligand leading to three possible 
mononuclear species and two possible dinuclear species. Steel reported that reaction of the bis-
oxadiazole with Li2PdCl4 produced a simple mononuclear complex
 through only one specific binding 
mode, shown below in Figure 1.16.  
  
 
 
2(OAc)- 2(OAc)- 
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Figure 1.16 
 
Further exploration of this ligand with alternative metal ions was conducted and reaction with silver 
nitrate generated a highly interesting, one-dimensional coordination polymer. The Ag+ ions are 
three-coordinate, existing in a slightly distorted trigonal geometry, coordinating as they do through 
the imine N4 nitrogen atoms of two bis-oxadiazole ligands and a monodentate nitrate molecule53.  
 
Figure 1.17 – Steel͛s ϭD, ϭ,Ϯ,ϰ-oxadiazole coordination polymer. 
 
Once again, this metallosupramolecular structure demonstrates the seemingly highly preferential 
imine N4 coordination tendency. 
Though still simple, the most extensive 1,2,4-oxadiazole containing ligands have been synthesised by 
Pace and co-workers. Reported in 2011, Pace found that 3,5-bis-(2-pyridyl)-1,2,4-oxadiazole systems 
form simple mononuclear complexes with Cu2+, Ni2+ and Zn2+ ions61 (Figure 1.18). Coordination was 
again observed through the oxadiazole N4 atom and the 3-(2-pyridyl) nitrogen.   
 
2Cl- 
n(NO3)
-- 
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Figure 1.18 
 
1.2.5.2  Coordination via the Oxime, N2 Atom 
The second plausible means of coordination at the disposal of the 1,2,4-oxadiazole unit is via the 
oxime N2 atom.  
 
 
 
 
Figure 1.19 – The monodentate (left) and bidentate (right) potential 1,2,4-oxadiazole binding modes 
involving N2 coordination. 
 
As mentioned earlier, coordination via this atom is less promising than with N4, due to the electronic 
nature of the heterocycle. The lower basicity of this N2 nitrogen atom is caused by the electron 
withdrawing effect of the more electronegative, neighbouring oxygen atom. This shift in electron 
density towards the oxygen atom in the N-O bond reduces the nucleophilicity/basicity of the N2 
nitrogen atom. Thus the likelihood of preferential coordination over the imine N4 nitrogen is 
drastically reduced. To the best of our knowledge, coordination through the N2 has only ever been 
2(ClO4)
- 
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observed once. This was again by Pace and co-workers, who in 2011 reported a 3-(2-pyridyl)-5-
phenyl-1,2,4-oxadiazole system which coordinated to Cu2+, Ni2+ and Zn2+ ions via the oxadiazole N2 
atom and the 3-(2-pyridyl) nitrogen61 (Figure 1.20).  
 
 
 
 
 
 
 
 
 
Figure 1.20 
 
 
1.2.5.3  Coordination via the Oxygen Atom 
Coordination via the oxygen atom remains the least likely coordination prospect of the three 
heteroatoms comprising the 1,2,4-oxadiazole. Coordination of oxygen with alkali metals and alkali 
earth metals has been observed in oxygenated heterocycles on many occasions, particular since the 
discovery of crown ethers in 196760,62. Though coordination of O-sites to transition metals is 
possible63, is it rarely observed60. Early work in coordination chemistry predicted that oxygen 
coordination was just as likely as nitrogen coordination58,64. Since this is now widely accepted as a 
rarity, one should consider the 1,2,4-oxadiazole unit as primarily monodentate (through N4), with 
realistic bidentate potential (through N2), but with only theoretical tridentate potential (through O).  
 
 
 
2(ClO4)
- 
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1.2.6  Recent Advances in the Supramolecular Chemistry of the Thiazole 
The research conducted in this thesis on the use of 1,2,4-oxadiazoles as ligands in supramolecular 
chemistry was carried out in collaboration with Rice. Rice has had huge success with thiazoles and 
due to its ƌeleǀaŶĐe to this thesis, a ďƌief suƌǀeǇ of ‘iĐe͛s thiazoles follows. 
Rice and co-workers reported in 2000 a pyridine-thiazole-thiazole-pyridine ligand strand (24), which 
was shown to demonstrate great versatility with a variety of metal ions65. In reaction with first row 
divalent transition metal ions as such as Cu2+ ions this ligand self-assembles to form a dinuclear triple 
helicate65 (Figure 1.21). The helicating effect is mostly observed about the central thiazole-thiazole 
bond. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21 
(24) 
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Exploring the reactivity of this ligand further, this time towards second row transition metal ions, the 
formation of a dinuclear triple helicate complex with Cd2+ ions was observed66. However, one subtle 
difference in the assembled metallosupramolecular structure was noticed. The thiazole-pyridine 
partitioning was observed in accordance with the previous complex, but not in all three strands. This 
was observed in just two of the strands. The third ligand is partitioned into a bidentate thiazole-
pyridine unit on one side and a monodentate pyridyl domain on the other66. A water molecule 
completes the six-coordinate geometry of the lone pyridyl coordinated cadmium ion, resulting in a 
non-symmetric dinuclear triple helicate, shown in Figure 1.22.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22 
(1) 
(24) 
(24) 
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In 2001, Rice and co-workers synthesised a bipyridyl-centred ligand (26), flanked by thiazole-pyridine 
domains at both sides67. A dinuclear double helicate with Cu2+ and Zn2+ ions was observed, but the 
ligand did not partition into two tridentate domains, rather into two bidentate pyridine-thiazole 
domains, forming a complex with four-coordinate metal ions67 (Figure 1.23). The central bipyridine 
unit does not coordinate in these conditions67.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23 
 
(26) 
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Interestingly, this ligand formed a slightly different dinuclear double helicate in reaction with Ni2+ 
ions. The terminal pyridine-thiazole unit expands from a bidentate domain to a tridentate domain 
through additional coordination with one of the pyridine nitrogens of the inner bipyridine unit67 
(Figure 1.24). Each Ni2+ ion in this system is in six coordinate state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.24 
 
(26) 
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Other successful thiazole ligands synthesised by the Rice group include the pyridine-thiazole-
pyridine-thiazole-pyridine system (27), which was reported to behave as a full pentadentate ligand66. 
Reaction with Cd2+ ions led to the formation of mononuclear complex with a very slight helical twist, 
with coordination from all five ligand nitrogen atoms in a near planar fashion. Coordination from 
perchlorate anions both above and below the ligand in an axial fashion resulted in the Cd2+ ions 
adopting a seven-coordinate nature66 (Figure 1.25).    
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.25 
 
Following the success of several thiazole based ligands, in 2010 Rice and co-workers synthesised a 
seven-ringed, highly elaborate, bipyridine-thiazole-phenyl-thiazole-bipyridine system68 (28). This 
complex ligand, in reaction with Cd2+ ions, self-assembled into a dinuclear double helicate with the 
ligand partitioned by the phenylene spacer unit into two pyridine-pyridine-thiazole tridentate units 
with the Cd2+ ions residing in pseudo-octahedral geometries68 (Figure 1.26). 
 
 
 
 
(27) 
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Figure 1.26 
 
Additionally, this ligand produced one of the most significant metallosupramolecular systems 
developed by Rice. In 2010 it was reported that this seven-ringed ligand self-assembled in reaction 
with Zn2+ ions to form a pentanuclear, quintuple cyclic helicate68. The Zn2+ ions are six-coordinate 
and octahedral in geometry, coordinating to the pyridine-pyridine-thiazole tridentate domains of 
two ligand strands68 (Figure 1.27).  
(28) 
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Figure 1.27 
 
In 2010, Rice also reported the synthesis of another pentanuclear cyclic helicate, this time from the 
same ligand described above with one of the terminal pyridine units removed, rendering a 
potentially tridentate-bidentate partitioned system69 (29). This ligand self-assembled in reaction with 
Cu2+ ions into a pentanuclear cyclic helicate with the ligands adopting a head-to-tail arrangement 
(28) 
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about the five-coordinate Cu2+ ions (Figure 1.28). That is, each Cu2+ ion coordinates a bidentate 
domain from one ligand and a tridentate domain from another69.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.28 
 
 
(5) 
(29) 
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Extending this work by capitalising on the pentanuclear systems observed, Rice and co-workers 
synthesised a heteroleptic pentanuclear, cyclic helicate through deliberate selection of a pyridine-
thiazole-phenyl-thiazole-pyridine ligand (30) and the bipyridine-thiazole-phenyl-thiazole-bipyridine 
ligand (28) in reaction with Cu2+ ions69. This elaborate complex features three of the bipyridine-type 
ligands and two of pyridine-type ligands. Four of the copper(II) ions of this pentanuclear complex are 
in a five-coordinate state, binding to the tridentate pyridine-pyridine-thiazole domain of one ligand 
and the bidentate pyridine-thiazole domain of another (Figure 1.29). One of the five ions however, 
exists in a six coordinate state, bound to the tridentate pyridine-pyridine-thiazole domains of two 
bipyridine-thiazole-phenyl-thiazole-bipyridine ligand strands69.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.29 
(30) 
(28) 
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1.3  The 1,2,4-Oxadiazole Unit in Medicinal Chemistry 
 
The 1,2,4-oxadiazole unit is commonly observed throughout medicinal chemistry. It is also popular in 
agrochemistry, polymer science and also materials chemistry70. A 2012 study by AstraZeneca 
demonstrates the increasing extent to which the 1,2,4-oxadiazole unit has featured in patent 
applications in the last ten years- from approximately 180 applications in 2000 to 370 applications in 
2008. This illustrates an enormous increase in interest towards the 1,2,4-oxadiazole in medicinal 
chemistry alone70. 
The increased interest in the 1,2,4-oxadiazole unit has led to the heterocycle being exploited in a 
vast number of drug development programs. There are several reasons for this popularity. Often, 
the 1,2,4-oxadiazole unit forms a critical part of the pharmacophore of the molecule and as such is 
crucial in favourable ligand-receptor binding in some molecules70,71. In other situations, the 
regiochemistry of the 1,2,4-oxadiazole has been capitalised upon, since the unit has been utilised as 
an aromatic and planar linking scaffold, installed to ensure that certain substituents are present in 
the drug candidate in desired orientation72. The most frequently encountered reason why the 1,2,4-
oxadiazole unit has gained such popularity in recent years is the close structural and geometric 
relationship with esters and amides70. The 1,2,4-oxadiazole unit is thus deployed as a highly stable, 
hydrolysis resistant, bioisostere with such ester and amide functionalities.  
 
 
 
 
 
 
 
 
Figure 1.30 – The isosteric relationship between 1,2,4-oxadiazoles and esters/amides. 
 
 
The growing popularity of the 1,2,4-oxadiazole in industry has prompted an explosion of research, 
focussing on these unique medicinal properties. This topic has been extensively reviewed3,6,73,74,75, 
and will not be detailed further here. 
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1.3.1   The MediciŶal CheŵistrǇ of the β- aŶd γ-Sultams and Their Bicyclic  
  Derivatives 
Our group have previously synthesised a limited range of thiazete-1,1-dioxide derivatives and 
isothiazole-1,1-dioǆide deƌiǀatiǀes, also kŶoǁŶ as β-sultaŵs aŶd ɶ-sultams, respectively76. The major 
objective of this project was to extend this work by incorporating the 1,2,4-oxadiazole nucleus in a 
bid to boost activity.  
Various syntheses of sultams exist, however the synthesis that our group have particularly been 
interested in was pioneered by Clerici and co-workers77,78,79, as it offers several points at which the 
synthesis can be intercepted to install the 1,2,4-oxadiazole unit.  
The synthesis (Scheme 1.29) begins with a simple aldol reaction between an acetophenone 
deƌiǀatiǀe aŶd ďeŶzaldehǇde. The α,β-uŶsatuƌated ketoŶe is theŶ diďƌoŵiŶated aŶd the α,β-
dibrominated ketone is treated with a secondary amine to yield the corresponding enamine80,81. 
Following reaction with methanesulfonyl azide the enamine is converted to the amidine, which is 
then cyclised through treatment with base to yield the 4-hydroxyisothiazoline79. This heterocycle is 
then chlorinated using thionyl chloride and then subsequently dehydrochlorinated by treatment 
with sodium carbonate79. The ƌesultaŶt isothiazole is α-brominated, which enables the substitution 
of bromide by thiomethoxide to yield the methyl thioether. Oxidation with mCPBA yields the methyl 
sulfone which, following treatment with sodium azide undergoes a ring contraction to the thiazete-
1,1-dioxide. 
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Scheme 1.29 – Synthetic Route to β-sultams and ɶ-sultams. 
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1.3.2  The Thiazete and Thiazetidine-1,1-dioxides and Extensions with 1,2,4- 
  Oxadiazoles  
β-Sultams (32) are four-membered sulfonamide heterocycles82. They are analogous with the well-
kŶoǁŶ β-lactams (31) 76,82.  
 
 
 
 
Figure 1.31 - CoŵpaƌisoŶ of β-laĐtaŵ aŶd β-sultam heterocycles. 
 
The chemical and biological reactivity of the β-lactam has been very well explored throughout the 
last century. These heterocycles find broad use in several divisions of medicine, most prominently to 
combat bacterial infections83,84.  
The aŶalogous β-sultam was first synthesised in 196085. This heterocycle has been well explored and 
is a popular feature of much research at the University of Huddersfield84,86,87, most notably with 
interesting roles as inhibitors of serine proteases86.  
Theƌe aƌe a Ŷuŵďeƌ of sǇŶthetiĐ ƌoutes to the β-sultam heterocycle. These have been reviewed 
extensively76,82,88 and will not be discussed at length in this thesis. The synthesis outlined in Scheme 
1.29 is the major synthetic focus for this project, with several extensions planned. To the best of our 
knowledge, the only thiazete-1,1-dioxide that has seen its anticancer activity explored is that which 
was studied by our group previously76 (Figure 1.32). 
 
 
 
 
 
Figure 1.32 
(32) (31) 
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This β-sultam was yielded by the synthetic protocol in Scheme 1.29. This synthesis is versatile and 
enables several significant, yet simple changes to be made. The arene substituent can be varied in 
the initial aldol step. The amino functionality is also introduced early in the synthesis during the third 
step fƌoŵ ǁhiĐh the eŶaŵiŶe is geŶeƌated. The Ŷitƌile is a statiĐ featuƌe of the β-sultam and is 
resultant from the previous ring contraction reaction. Throughout this work our group hopes to vary 
these substituents and create an extensive library of such 3-amino-4-aryl-4-cyano-thiazete-1,1-
dioxides and explore their anticancer activity, in addition to incorporating the 1,2,4-oxadiazole unit. 
The most attractive means of expanding the molecule to include the 1,2,4-oxadiazole nucleus sits 
with the nitrile. Reaction with hydroxylamine should generate the corresponding amidoxime. 
Reaction of the amidoxime with an activated carboxylic unit completes the 1,2,4-oxadiazole 
introduction and adds a further variable (33) to the structure (Scheme 1.30).  
 
 
 
 
 
 
 
 
 
Scheme 1.30 
 
(33) 
(34) 
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We anticipated that the thiazete imine bond present in the starting material (see Figure 1.32) and 
products (33) and (34) may also offer potential roles as dipolarophiles, leading, as shown in Scheme 
ϭ.ϯϭ, to ďiĐǇĐliĐ β-sultams (35-37).   
 
 
Scheme 1.31 
 
With reference to Scheme 1.41, there is potential to incorporate the 1,2,4-oxadiazoline system at 
various points, with a 1,3-dipolar cycloaddition to the imine bond of the isothiazoles, which are 
candidate dipolarophiles. An example is shown in Scheme 1.32, giving the isothaizolo-1,2,4-
oxadiazoline (38). 
 
 
 
 
 
Scheme 1.32 
(38) 
(1,3-dipolar cycloaddition x2) 
(33) 
(35) 
(36) 
(37) 
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Our group have previously explored the possibility of synthesising a bicyclic isothiazolo-oxadiazole 
system via a 1,3-dipolar cycloaddition reaction at this imine bond. The substrate for this reaction was 
the 3-diethylamino-4-(4-methoxyphenyl)-isothiazole-1,1-dioxide that the pƌeǀiouslǇ desĐƌiďed β-
sultam (Figure 1.32) was synthesised from. The desired product was not achieved, as the competing 
alkene of the isothiazole acted as a stronger dipolarophile. Interestingly, cycloaddition did not occur 
at the imine at all, with the isothiazolo-isoxazole (39) the only product76 (Scheme 1.33). It was one of 
the aims of this thesis to explore this process further. 
 
 
 
 
 
Scheme 1.33 
 
This reaction was initially reported by Clerici in 2006, though with a narrow range of isothiazole 
substrates explored78. Thus it was felt that the chemistry in Scheme 1.29 offered a lot of scope with 
a ǁide ƌaŶge of isothiazoles aŶd β-sultams being available which could function as dipolarophiles. 
The biological activity of these systems could also be investigated. 
 
 
 
 
 
 
 
 
 
 
(39) 
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1.4 The Asymmetric Catalytic Potential of Chiral 1,2,4-Oxadiazole-
containing Systems 
 
Asymmetric synthesis is one of the most fundamental aspects of organic chemistry.   
One of the aims of this thesis is to explore novel, chiral, catalytic systems that contain the 1,2,4-
oxadiazole system. Despite the stability, isosteric and potential substituent geometry benefits of the 
system, the 1,2,4-oxadiazole unit has not been a popular structural feature in the field of asymmetric 
organocatalysis. In fact a thorough review of the literature does not reveal any reports of any 
organic catalytic systems featuring the 1,2,4-oxadiazole heterocycle. This bodes well for our research 
plans, the primary goal of which is to study existing organocatalysts which feature similar 
heterocyclic or ester or amide functionalities and exchange the ester/amide/heterocyclic 
functionality for the 1,2,4-oxadiazole heterocycle. The specific systems focussed upon in this 
preliminary study were L-proline based systems and chiral hypervalent iodine(III) systems. These are 
reviewed briefly below. 
 
1.4.1  L-Proline Mediated Asymmetric Synthesis 
L-Proline is a popular selection for enriching organic systems with chirality, not only due to its low 
cost and high commercial availability, but its chemistry also. L-Proline possesses secondary amine 
functionality and is the only common natural amino acid to do so. Relative to other amino acids, L-
proline is of stronger nucleophilicity and has a higher pKa89. This makes L-proline a useful tool in 
asymmetric chemistry since it is able to react with Michael acceptors or carbonyls to form enamines, 
imines or iminium ions89. In this thesis, the synthesis of an L-proline containing 1,2,4-oxadiazole will 
be described together with the attempted development of chiral hypervalent iodine (III) systems 
designed to eventually contain the L-proline-1,2,4-oxadiazole unit. 
1.4.2  Hypervalent Iodine Systems 
1.4.3  Significant Breakthroughs in Hypervalent Iodine   
The first hypervalent iodine compound was prepared in 1886 (iodobenzene dichloride by German 
chemist Conrad Willgerodt (1841 – 1930))90. Their first practical origin can be traced back to the 
early sixties and originated with iodobenzene diacetate or phenyliodine diacetate (PIDA), 
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synthesised originally by Alcock and Waddington91 ;Figuƌe ϭ.ϯϰͿ, iŶspiƌed ďǇ CoŶƌad Willgeƌodt͛s 
early work on iodobenzene dichlorides and diesters92.  
 
 
 
 
Figure 1.34 
 
One of the most useful hypervalent iodine(V) reagents utilised in recent times is 2-iodoxybenzoic 
acid (IBX) (Figure 1.35), a potent oxidising agent, particularly useful for converting primary and 
secondary alcohols to the corresponding carbonyls with little over-oxidation to the acid93,94.  
 
 
 
 
 
Figure 1.35 
 
One of the major drawbacks of IBX was its limited solubility in organic solvents94,95. Several 
successful, clean oxidations have been reported with DMSO as solvent96,97, however little else exists 
amongst the literature due to insolubility in the more practical organic solvents.  
Dess and Martin made what is probably the most significant discovery in the history of hypervalent 
iodine chemistry. Dess and Martin treated IBX (40) with acetic anhydride in acetic acid, which 
yielded the triacetate98 (Scheme 1.34). This compound proved to be much more soluble in organic 
solvents than the predecessor IBX and remained a highly significant oxidising agent, broadly tolerant 
of high functional group densities and capable of successfully reacting in the most tricky oxidation 
circumstances99. This reagent is known as the Dess-Martin Periodinane (41) (DMP). 
(41) 
(40) 
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Scheme 1.34 – The synthesis of DMP. 
 
1.4.4   Iodine(III) Reagents 
In 1977, Gerald F. Koser and co-workers attempted to synthesise the ditosylate from iodobenzene 
dichloride (Scheme 1.35)100. Instead of synthesising iodobenzene ditosylate, Koser synthesised the 
mono-tosylated, hydroxyl(tosyloxy)iodobenzene (HTIB) (42) ǁhiĐh lateƌ ďeĐaŵe kŶoǁŶ as Koseƌ͛s 
reagent100. 
 
 
 
 
 
 
Scheme 1.35 
 
 
 
(41) (40) 
(42) 
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In 1990, Moriarty and co-workers utilised HTIB in the lactonisation of 5-oxo-pentanoic acid 
derivatives101 (Scheme 1.36). This reaction will be revisited in detail later in this thesis.    
 
Scheme 1.36 
 
In addition to reporting the synthesis of PIDA, Alcock also reported the first synthesis of 
phenyliodosyl bis(trifluoroacetate) in 196391 (Figure 1.36), a reagent known as PIFA. 
 
 
 
 
 
 
Figure 1.36 
 
Tamura and co-workers reported the reactivity of PIFA towards 4-alkoxyphenols102. They found that 
the reaction of such substrates with PIFA and certain alcohols produced benzoquinone-4-
monoacetals102, shown in Scheme 1.37. 
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Scheme 1.37 
 
AlĐoĐk͛s PIDA aŶd PIFA aŶd Koseƌ͛s HTIB foƌŵ the ďasis of ŵodeƌŶ hǇpeƌǀaleŶt iodiŶe;IIIͿ ;HVIͿ 
research.  
During the mid 2000s, organoiodine research focussed on an alternative feature of the classic HTIB-
type iodine(III) structure. This focus was to vary the compounds, usually at the aryl unit, by enriching 
them with chirality in a bid to produce reagents capable of inducing asymmetry in synthesis.  
In 1986 Imamoto and co-workers reported the first synthesis of a chiral hypervalent iodine(III) 
reagent by reaction of iodosylbenzene with L-tartaric anhydride derivatives103 (Scheme 1.38). The 
catalyst was found to be effective in the asymmetric oxidation of sulfides to sulfoxides, delivering 
reasonable enantiomeric excesses of up to 53%103.   
 
 
Scheme 1.38 – Synthesis of early HVI asymmetric reagent. 
R1 = Me, Ph, tBu 
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In 2001, Wirth and co-workers synthesised a series of chiral hypervalent iodine(III) catalysts 
approximately based around the core structure of HTIB104,105,106 (Figure 1.37).  
 
 
 
 
 
 
Figure 1.37 
 
Wirth and co-ǁoƌkeƌs fouŶd this iodoŶiuŵ salt ĐatalǇst to suĐĐessfullǇ α-oxytosylate ketones104,106 
(Scheme 1.39) and ditosylate alkenes105,106 (Scheme 1.40) with some asymmetry, albeit minor. The 
ethǇl deƌiǀatiǀe gaǀe the ďest e.e͛s iŶ ďoth Đases ;ϰϬ-65%).  
 
 
 
 
Scheme 1.39 
 
 
 
 
 
Scheme 1.40 
 
Introduction   1 
57 
 
Until the mid-eaƌlǇ ϮϬϬϬ͛s, stoiĐhioŵetƌiĐ aŵouŶts ;at leastͿ of hǇpeƌǀaleŶt iodiŶe ǁeƌe ƌeƋuiƌed to 
in order to successfully synthesise the desired product. Soon after this time, it was discovered that 
only a catalytic amount of a monovalent iodine compound was required, providing there was a 
stoichiometric amount of oxidant present107. Previously, the iodine(III) species had been synthesised 
and then isolated before its use. The inclusion of a stoichiometric amount of oxidant along with the 
monovalent iodine compound to the reaction mixture enables the insitu generation of the reactive 
iodine(III) species107. The iodine(III) species then reacts accordingly with the substrate to synthesise 
the oxidised product, regenerating the reduced iodine(I) compound. This is then reoxidised by the 
stoichiometric oxidant, reproducing the reactive iodine(III) species.  
Since its use by Kita and co-workers108, mCPBA has been a popular co-oxidant for the in-situ 
generation of catalytic hypervalent iodine(III) species. mCPBA oxidises iodine(I) compounds to the 
hypervalent iodosylbenzene (Scheme 1.41). 
 
Scheme 1.41 - m-Chloroperoxybenzoic acid mediated in-situ generation of hypervalent iodine(III) species. 
 
In addition to the re-oxidation of iodine(I) back to the iodosylbenzene, it is necessary in many cases 
to conduct the reaction in the presence of an additive, usually an acid. For example the in-situ 
geŶeƌatioŶ of Koseƌ͛s ƌeageŶt ;HTIBͿ ǁould ƌeƋuiƌe the pƌeseŶĐe of p-toluenesulfonic acid in 
addition to an oxidant such as mCPBA (Scheme 1.42). In several reactions utilising HTIB the p-
toluenesulfonic acid is regenerated also151,109. 
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Scheme 1.42 
 
In 2005, Ochiai and co-workers ƌepoƌted the fiƌst ĐatalǇtiĐ α-acetoxylation of ketones110. This was 
achieved through a simple but highly effective return to PIDA as the hypervalent iodine(III) species 
The use of iodobenzene as precatalyst in the presence of acetic acid with mCPBA as oxidant enables 
the insitu generation of PIDA, which mediates the α-acetoxylation of ketones in good yields across a 
range of substrates110 (Scheme 1.43). Ochiai also reported that it was necessary for the reaction to 
be conducted in the presence of a Lewis acid such as BF3-Et2O, which induces enolisation and 
activates the ketone110. 
 
 
 
 
 
Scheme 1.43 
 
In addition to several other monoaryl iodine(III) species, Kita in 2005111 reported the use of catalytic 
PIFA, although with stoichiometric amounts of mCPBA and trifluoroacetic acid, in an adaptation of 
Taŵuƌa͛s102 1987 PIFA mediated spirocyclisation111 (Scheme 1.44).  
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Scheme 1.44 
 
TakiŶg MoƌiaƌtǇ͛s ϭϵϵϬ HTIB ŵediated laĐtoŶisatioŶ of ϱ-oxopentanoic acid derivatives, Ishihara and 
co-ǁoƌkeƌs utilised Kita͛s ĐatalǇtiĐ ƌeageŶts aŶd suĐĐessfullǇ ĐoŶǀeƌted the ƌeaĐtion to a fully 
catalytic process using 5mol% iodotoluene, 20mol% p-toluenesulfonic acid and 1 equivalent of 
mCPBA112 (Scheme 1.45). This latter reaction forms the basis of some of the work reported later in 
this thesis.    
 
Scheme 1.45 
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Wirth and co-workers in 2008 synthesised a range of chiral aryl iodides113 based around their earlier 
iodine(III) compounds106 aŶd iŶǀestigated theiƌ eŶaŶtioseleĐtiǀe ĐatalǇtiĐ pƌopeƌties iŶ the α-
oxytosylation of propiophenone113 (Scheme 1.46), the non-catalytic asymmetric induction of which106 
was described earlier (Scheme 1.39). 
 
 
 
 
 
Scheme 1.46 
 
Wirth synthesised a range of 11 chiral catalysts which featured ether functionality and a further 17 
which featured ester functionality. Wirth found that the highest enantiomeric excess was generally 
achieved with ester based catalysts113 such as that shown in Figure 1.38 below. 
 
   
 
 
 
 
 
 
Figure 1.38 
 
 
e.e - 39% (R), Yield - 42% 
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IŶ ϮϬϭϬ, Ishihaƌa ƌeǀisited Kita͛s oǆidatiǀe spiƌolaĐtoŶisatioŶ as the lead ƌeaĐtioŶ upoŶ ǁhiĐh to 
assess a new breed of chiral iodoarene, pre-hypervalent iodine(III) catalyst, with Ishihara utilising the 
same conditions as Kita114. These catalysts were symmetrical; the inactive iodine(I) and active 
iodine(III) derivatives are shown in Scheme 1.47 below. 
 
Scheme 1.47 
 
 
 
Ishihara and co-workers reported good to excellent e.e.s across the range of catalysts, with catalyst F 
delivering an e.e. of 84% and catalyst G an e.e. of 82%114. The latter catalyst was pursued further 
despite its marginally inferior e.e by virtue of the greatly superior yields it offered (64% vs 36%)114. 
Upon further investigation including solvent and temperature screening, it was determined that 
lower temperatures (-20 oC) provided better selectivities, with CHCl3 proving to be the best solvent. 
Enantioselectivities were boosted to a maximum of 92% under these conditions, a record high 
enantioselectivity by any hypervalent iodine(III) system114. 
Wirth and co-workers have investigated the asymmetric catalytic potential of hypervalent iodine(III) 
oŶ MoƌiaƌtǇ͛s ϭϵϵϬ laĐtoŶisatioŶ. Wiƌth has not reported any notable enantiomeric excesses for this 
reaction (Scheme 1.48). 
 
Scheme 1.48 
(A) – R = Me, X = OEt, (B) – R = Me, X = OH, (C) – R = Me, X = NH2, (D) – R = Me, X = NHPh, (E) – R = Me, 
X = NH[3,5-(CF3)2Ph], (F) – R = Me, X = NH[3,5-(tBu)2Ph], (G) – R = Me, X = NHMes, (H) – R = Me, X = N-
pyrr, (I) – R = Me, X = NPh2, (J) – R = iPr, X = NHMes 
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There are no reports of hypervalent iodine catalysts featuring 1,2,4-oxadiazoles. Several HVI 
catalysts have been synthesised which feature ester or amide functionality. Therefore our research 
group plan to capitalise on the isosteric nature of 1,2,4-oxadiazoles with such functional groups and 
synthesise the first chiral, 1,2,4-oxadiazole-containing, hypervalent iodine(III) catalyst. The above 
lactonisation reaction was chosen as an attractive reaction for screening. 
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2  Experimental 
All reactions monitored and analysed by TLC were done so using Macherey-Nagel 0.2 mm pre-
coated Alugram® N/UV254 silica gel or alumina gel plates. 
Column chromatography was conducted using 60 Å, 70-230 mesh, 63-200 μŵ siliĐa gel supplied ďǇ 
Sigma-Aldrich. Where necessary, 60 Å, 50-200 μŵ, ďasiĐ aluŵiŶa gel ǁas used aŶd ǁas supplied ďǇ 
Acros. 
Analysis by NMR spectroscopy was achieved using Bruker DPX, Bruker AVIII 400 MHz NMR and 
Bruker AV500 NMR spectrometers. 
Analysis by high resolution mass spectrometry was achieved using a Bruker Daltonics micrOTOF-Q 
Mass Spectrometer. 
Infra-red analysis was achieved using a Nicolet 380 FT-IR spectrometer. 
HPLC analysis was determined using a Hewlett-Packard Series 1050 chromatogram with a Chiralpak 
I-B column. 
Melting point determinations were made using a Stuart, SMP10 digital melting point apparatus. 
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2.1 Experimental Procedures for the Synthesis of Novel 1,2,4-
Oxadiazole Containing Ligand Systems 
2.1.1  Experimental Procedures for the Synthesis of Ligand Precursor Materials 
2.1.1.1  Synthesis of N'-hydroxypyridine-2-carboxamidine 
 
 
 
To hydroxylamine hydrochloride (735 mg, 10.57 mmol) in water (25 ml) sodium carbonate (1.12 g, 
10.57 mmol) was added in small portions. To this, 2-cyanopyridine (43) (1.00 g, 9.61 mmol) in 
ethanol (25 ml) was added and reaction mixture set to stir at reflux for 24 hours. After this time, the 
reaction mixture was extracted with dichloromethane (2 x 50 ml). The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated by rotary evaporation to yield the product 
as a white solid (1.01 g, 77%). 
 
1H NMR (400 MHz, CDCl3Ϳ: ɷϱ.ϲϳ ;ϮH, ďƌoad, NH2Ϳ; ɷϳ.Ϯϰ ;ϭH, ddd, J=ϲ.ϬHz, ϯ.ϵHz, Ϭ.ϵHz, AƌHͿ; ɷϳ.ϲϰ 
(1H, ddd, J=6.4Hz, 6.4Hz, 1.4Hz, ArHͿ; ɷϳ.ϴϰ-7.87 (1H, m, ArHͿ; ɷϴ.ϰϴ-8.51 (1H, m ArHͿ; ɷϴ.ϱϴ ;ϭH, 
broad OH). 
M.p.: 118-120 oC (Literature value 115-119 0C)92,167,168. 
 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
(43) 
(44) 
C6H7N3O 
MW = 137.14 g/mol 
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2.1.1.2  Synthesis of 1-oxido-2-(2-pyridyl)pyridin-1-ium 
 
 
 
 
 
 
To Ϯ,Ϯ͛-bipyridyl (45) (2.00 g, 12.80 mmol) in dichloromethane (30 ml) was added in small portions 
m-chloroperoxybenzoic acid (1.99 g, 11.52 mmol) over 8 hours. After this time the reaction mixture 
was concentrated by rotary evaporation. The crude product was purified by gravity column 
chromatography with a 100:1 dichloromethane:methanol solvent system to yield the pure product 
as a white solid (1.11 g, 50%). 
 
1H NMR (400 MHz, CDCl3Ϳ: ɷϳ.Ϭϱ ;ϭH, appt. td, J=6.8Hz, 2.2Hz, ArHͿ; ɷϳ.ϭϬ-7.16 (2H, m, ArHͿ; ɷϳ.ϲϬ 
(1H, appt. td, J=7.8Hz, 1.8Hz, ArHͿ; ɷϳ.ϵϱ ;ϭH, dd, J=ϴ.ϭHz, Ϯ.ϭHz, AƌHͿ; ɷϴ.ϭϭ ;ϭH, d, J=ϲ.ϰHz, AƌH); 
ɷϴ.ϰϵ-8.52 (1H, m, ArHͿ; ɷϴ.ϲϵ ;ϭH, d, J=ϴ.ϬHz, AƌH). 
13C NMR (100 MHz, CDCl3Ϳ: ɷϭϮϯ.ϰϱ ;AƌͿ, ϭϮϰ.ϱϱ ;AƌͿ, ϭϮϰ.ϱϵ ;AƌͿ, ϭϮϰ.ϵϮ ;AƌͿ, ϭϮϳ.ϬϮ ;AƌͿ, ϭϯϱ.ϯϴ 
(Ar), 139.77 (Ar), 146.35 (Ar), 148.55 (Ar), 148.78 (Ar). 
micrOTOF-Q MS m/z C10H8N2O+Na, calculated 195.0529, observed 195.0536. 
IR (cm-1): 760, 848, 1031, 1233, 1249, 1416, 1440, 1461, 1567, 1582, 1615, 3068. 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
 
 
(45) 
(46) 
C10H8N2O 
MW = 172.18 g/mol 
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2.1.1.3  Synthesis of 1-oxido-2-(1-oxidopyridin-1-ium-2-yl)pyridin-1-ium 
 
 
 
 
 
To Ϯ,Ϯ͛-bipyridyl (45) (2.00 g, 12.80 mmol) in glacial acetic acid (16 ml) was added 36% hydrogen 
peroxide (2 ml). The reaction mixture was stirred at 800C for 3 hours after which time a second 
amount of 36% hydrogen peroxide (5 ml) was added. The reaction mixture was heated for a further 
4 hours, cooled to room temperature, poured into acetone (150 ml) and stored at refrigerated 
temperature overnight. After this time, the precipitates were filtered, washed with acetone and 
dried under vacuum at RT with no further purification to yield the product as a white crystalline solid 
(2.25 g, 93%). 
 
1H NMR (400 MHz, CDCl3Ϳ: ɷϳ.ϮϮ-7.29 (4H, m, ArHͿ; ɷϳ.ϱϰ-7.59 (2H, m, ArHͿ; ɷϴ.ϮϮ-8.25 (2H, m, 
ArH). 
micrOTOF-Q MS m/z C10H8N2O2+Na, calculated 211.0478, observed 211.0482. 
IR (cm-1): 722, 763, 836, 958, 1020, 1145, 1251, 1425, 1495. 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
 
 
 
(45) 
(47) 
C10H8N2O2 
MW = 188.18 g/mol 
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2.1.1.4  Synthesis of 6-(2-pyridyl)pyridine-2-carbonitrile 
 
 
 
To 1-oxido-2-(2-pyridyl)pyridin-1-ium (46) (870 mg, 5.05 mmol) in dichloromethane (40 ml) was 
added benzoyl chloride (0.88 ml, 7.58 mmol) and trimethylsilyl cyanide (1.01 ml, 7.58 mmol) and the 
mixture set to stir at reflux for 24 hours. After this time, further additions of benzoyl chloride 
(0.29ml, 2.53 mmol) and trimethylsilyl cyanide (0.34 ml, 2.53 mmol) were made and the reaction 
mixture stirred at reflux for a further 4 hours. The reaction mixture was then concentrated by rotary 
evaporation. The crude product was purified by gravity column chromatography with a 100:1 
dichloromethane:methanol solvent system to yield the pure product as a white solid (505 mg, 55%). 
1H NMR (400 MHz, CDCl3Ϳ: ɷϳ.Ϯϵ ;ϭH, ddd, J=ϳ.ϲHz, ϰ.ϳHz, ϭ.ϭHz, AƌHͿ; ɷϳ.ϲϮ ;ϭH, dd, J=ϳ.ϳHz, ϭ.ϬHz, 
ArHͿ; ɷϳ.ϳϲ ;ϭH, appt. td, J=7.8Hz, 1.8Hz, ArHͿ; ɷϳ.ϴϲ ;ϭH, t, J=8.0Hz, ArHͿ; ɷϴ.ϯϴ-8.42 (1H, m, ArH); 
ɷϴ.ϱϳ-8.64 (2H, m, ArH). 
13C NMR (100 MHz, CDCl3Ϳ: ɷϭϮϬ.ϵϬ ;AƌCN), 123.55 (Ar), 124.13 (Ar), 127.48 (Ar), 127.69 (Ar), 128.89 
(Ar), 132.26 (Ar), 132.49 (Ar), 136.57 (Ar), 137.25 (Ar), 148.64 (Ar). 
micrOTOF-Q MS m/z C11H7N3+Na, calculated 204.0532, observed 204.0537. 
IR (cm-1): 738, 772, 987, 1277, 1424, 1451, 1555, 1582, 2250. 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
 
(46) (48) 
C11H7N3 
MW = 181.19 g/mol 
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2.1.1.5  Synthesis of 6-(6-cyano-2-pyridyl)pyridine-2-carbonitrile 
 
 
 
To 1-oxido-2-(1-oxidopyridin-1-ium-2-yl)pyridin-1-ium (47) (1.00 g, 5.31 mmol) in dichloromethane 
(40 ml) was added benzoyl chloride (1.54 ml, 13.28 mmol) and trimethylsilyl cyanide (1.77 ml, 13.28 
mmol) and the mixture set to stir at reflux for 24 hours. After this time, further additions of benzoyl 
chloride (0.31 ml, 2.67 mmol) and trimethylsilyl cyanide (0.36 ml, 2.67 mmol) were made and the 
reaction mixture stirred at reflux for a further 4 hours. The reaction mixture was then allowed to 
cool to room temperature, the precipitates filtered and washed with water and then with ethanol 
and dried under vacuum at RT with no further purification to yield the product as a white crystalline 
solid (820 mg, 74%). 
1H NMR (400 MHz, CDCl3Ϳ: ɷϳ.ϳϮ ;ϮH, dd, J=ϳ.ϴHz, Ϭ.ϵHz, AƌHͿ; ɷϴ.Ϭϯ ;ϮH, t, J=7.8Hz, ArHͿ; ɷϴ.ϳϯ ;ϮH, 
dd, J=8.2Hz, 0.9Hz, ArH). 
micrOTOF-Q MS m/z C12H6N4+Na, calculated 229.0485, observed 229.0488. 
IR (cm-1): 734, 800, 988, 1079, 1422, 1433, 1575, 2248. 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
 
 
 
(49) 
C12H6N4  
MW = 206.20g/mol 
(47) 
-
-
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2.1.1.6  Synthesis of N'-hydroxy-6-(2-pyridyl)pyridine-2-carboxamidine 
 
 
 
 
To hydroxylamine hydrochloride (117 mg, 1.69mmol) in water (10 ml) sodium carbonate (179 mg, 
1.69mmol) was added in small portions. To this, 6-(2-pyridyl)pyridine-2-carbonitrile (48) (280 mg, 
1.54 mmol) in ethanol (10 ml) was added and reaction mixture set to stir at reflux for 24 hours. After 
this time, the reaction mixture was extracted with dichloromethane. The organics were dried over 
anhydrous magnesium sulphate, filtered and concentrated by rotary evaporation to yield the 
product as a white solid (297 mg, 90%). 
 
1H NMR (400 MHz, CDCl3Ϳ: ɷϱ.ϲϵ ;ϮH, ďƌoad, NH2Ϳ; ɷϳ.ϭϵ ;ϭH, ďƌoad, OHͿ; ɷϳ.Ϯϴ ;ϭH, ddd, J=7.6Hz, 
4.8Hz, 1.2Hz, ArHͿ; ɷϳ.ϳϴ ;ϭH, appt. td, J=7.8Hz, 1.2Hz, ArHͿ; ɷϳ.ϳϵ ;ϭH, dd, J=7.8Hz, ArHͿ; ɷϳ.ϴϵ ;ϭH, 
dd, J=7.9Hz, 1.0Hz, ArHͿ; ɷϴ.ϯϱ-8.40 (2H, m, ArHͿ; ɷϴ.ϲϮ-8.65 (1H, m, ArH). 
13C NMR (100 MHz, CDCl3Ϳ: ɷϭϭϵ.ϯϱ ;NH2C=NOH), 120.34 (Ar), 121.12 (Ar), 123.31 (Ar), 136.27 (Ar), 
136.92 (Ar), 147.69 (Ar), 148.60 (Ar), 150.40 (Ar), 154.04 (Ar), 154.81 (Ar). 
IR (cm-1): 748, 778, 959, 1379, 1429, 1546, 1566, 1580, 1651, 2750-3100, 3400. 
 
 
 
 
 
 
 
 
 
 
(48) (50) 
C11H10N4O 
MW = 214.22g/mol 
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2.1.1.7  Synthesis of N'-hydroxypyrimidine-2-carboxamidine 
 
 
 
 
To hydroxylamine hydrochloride (727 mg, 10.46 mmol) in water (15 ml) sodium carbonate (1.11 g, 
10.46 mmol) was added in small portions. To this, 2-cyanopyrimidine (52) (1.00 g, 9.51 mmol) in 
ethanol (15 ml) was added and reaction mixture set to stir at reflux for 24 hours. After this time, the 
reaction mixture was cooled to 0 0C. The precipitates were filtered, washed with water and dried 
under vacuum at RT to yield the product as a yellow crystalline solid (897 mg, 68%).  
 
1H NMR (400 MHz, d-DMSOͿ: ɷϱ.ϴϱ ;ϮH, s, NH2Ϳ; ɷϳ.ϱϭ ;ϭH, t, J=ϭ.ϮHz, AƌHͿ; ɷϴ.ϴϰ ;ϮH, d, J=ϰ.ϴHz 
ArHͿ; ɷϭϬ.Ϯϭ ;ϭH, s, OH). 
13C NMR (100 MHz, d-DMSOͿ: ɷϭϮϭ.ϲϵ ;NH2C=NOH), 149.42 (Ar), 157.73 (Ar), 158.70 (Ar). 
IR (cm-1): 789, 808, 841, 939, 1375, 1471, 1563. 
micrOTOF-Q MS m/z C5H6N4O+Na, calculated 161.0434, observed 161.0438. 
M.p.: 258-260 oC. (Literature value 262 0C)130. 
 
 
 
 
 
 
 
 
 
(52) 
(53) 
C5H6N4O 
MW = 138.13g/mol 
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2.1.1.8  Synthesis of N'-hydroxy-4,6-dimethyl-pyrimidine-2-carboxamidine 
 
 
 
 
 
To hydroxylamine hydrochloride (574 mg, 8.26 mmol) in water (30 ml) sodium carbonate (875 mg, 
8.26 mmol) was added in small portions. To this, 4,6-dimethylpyrimidine-2-carbonitrile (54) (1.00 g, 
7.51 mmol) in ethanol (30 ml) was added and reaction mixture set to stir at reflux for 24 hours. After 
this time, the reaction mixture was extracted with dichloromethane. The organics were dried over 
anhydrous magnesium sulphate, filtered and concentrated by rotary evaporation to yield the 
product as a light yellow solid (872 mg, 70%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϱϱ ;ϲH, s, CH3Ϳ; ɷϱ.ϲϯ ;ϮH, s, NH2Ϳ; ɷϲ.ϴϳ ;ϭH, s, OHͿ; ɷϳ.Ϭϲ ;ϭH, s, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϰ.Ϭϰ ;CH3), 120.21 (NH2C=NOH), 149.96 (Ar), 157.13 (Ar), 167.03 (Ar). 
IR (cm-1): 910, 943, 1257, 1347, 1458, 1533, 1575, 1594, 1673, 3207. 
micrOTOF-Q MS m/z C7H10N4O+Na, calculated 189.0747, observed 189.0752. 
 
 
 
 
 
 
 
 
 
(880) 
(55) 
C7H10N4O  
MW = 166.18g/mol 
(54) 
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2.1.1.9  Synthesis 1,4-dibromobutane-2,3-dione 
 
 
 
 
 
 
 
 
 
 
2,3-Butanedione (56) (1.00ml, 11.39mmol) was set to stir at reflux under an atmosphere of nitrogen, 
in chloroform (10ml). Bromine (0.59ml, 22.79mmol) in chloroform (10ml) was added dropwise and 
the reaction mixture set to stir at reflux for 24 hours. The solvents were removed by rotary 
evaporation. 
The crude product was purified by recrystallisation from chloroform to yield the pure product as a 
yellow crystalline solid (2.52g, 91%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϰ.ϯϰ ;ϰH, s, CH2). 
13C NMR (100MHz, CDCl3Ϳ:ɷϮϴ.ϰϱ ;CH2); 187.98 (C=O). 
 
This data is consistent with that reported in the literature92,167,168. 
 
 
 
 
 
 
 
 
 
 
 
 
(57) 
C4H4Br2O2 
MW = 243.88g/mol 
(56) 
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2.1.2  Experimental Procedures for the Synthesis of 1,2,4-Oxadiazole Ligands 
2.1.2.1  Synthesis of 5-phenyl-3-(2-pyridyl)-1,2,4-oxadiazole 
 
 
 
 
To benzoyl chloride (0.47 ml, 4.07 mmol) in xylene (25 ml), N'-hydroxypyridine-2-carboxamidine (44) 
(507 mg, 3.70 mmol) and pyridine (0.33 ml, 4.07 mmol) were added. The reaction mixture was set to 
stir at reflux for 24 hours. After this time the precipitates were collected by vacuum filtration, 
washed with water and ethanol and dried yielding the product as a light brown solid (268 mg, 32%). 
1H NMR (400 MHz, CDCl3Ϳ: ɷϳ.ϰϵ ;ϭH, ddd, J=ϲ.ϭHz, ϰ.ϭHz, Ϭ.ϴHz, AƌHͿ; ɷϳ.ϱϵ ;ϮH, t, J=6.0Hz, ArH); 
ɷϳ.ϲϯ-7.68 (1H, m, ArHͿ; ɷϳ.ϵϭ ;ϭH, appt. td, J=6.2Hz, 1.4Hz, ArHͿ; ɷϴ.Ϯϰ-8.27 (1H, m, ArHͿ; ɷϴ.ϯϭ-
8.34 (2H, m, ArHͿ; ɷϴ.ϴϳ-8.89 (1H, m, ArH).  
13C NMR (100 MHz, CDCl3Ϳ: ɷϭϮϯ.Ϯϲ ;AƌͿ, ϭϮϰ.Ϭϰ ;AƌͿ, ϭϮϱ.ϱϭ ;AƌͿ, ϭϮϴ.ϯϳ ;AƌͿ, ϭϮϵ.ϭϬ ;AƌͿ, ϭϯϮ.ϵϱ 
(Ar), 137.04 (Ar), 146.51 (Ar), 150.47 (Ar), 168.81 (Ar), 176.51 (Ar). 
IR (cm-1): 724, 744, 900, 1361, 1448, 1559. 
M.p.: 133-135 oC (Literature value 128-130 0C)131. 
This data is consistent with that reported in the literature80,131. 
 
 
 
 
(58) 
C13H9N3O 
MW = 223.23g/mol 
(44) 
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2.1.2.2  Synthesis of 5-phenyl-3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-oxadiazole 
 
 
 
To benzoyl chloride (0.30 ml, 2.57 mmol) in xylene (25 ml), (N'-hydroxy-6-(2-pyridyl)-pyridine-2-
carboxamidine (50) (500 mg, 2.34 mmol) and pyridine (0.21 ml, 2.57 mmol) were added. The 
reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were collected 
by vacuum filtration, washed with water and ethanol and dried yielding the product as a white 
crystalline solid (650 mg, 98%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϯϮ-7.38 (1H, m, ArHͿ; ɷϳ.ϱϰ-7.64 (3H, m, ArHͿ; ɷϳ.ϴϯ-7.90 (1H, m, ArH); 
ɷϴ.Ϭϭ ;ϭH, appt. td, J=7.8Hz, 1.2Hz, ArHͿ; ɷϴ.Ϯϰ ;ϭH, dd, J=ϳ.ϲHz, ϭ.ϬHz, AƌHͿ; ɷϴ.Ϯϲ-8.31 (2H, m, 
ArHͿ; ɷϴ.ϲϬ ;ϭH, dd, J=ϴ.ϮHz, Ϭ.ϵHz, AƌHͿ; ɷϴ.ϲϳ (1H, t, J=8.2H, ArHͿ; ɷϴ.ϳϬ-8.73 (1H, m, ArH). 
13C NMR (100MHz, CDCl3): 121.95 (Ar), 122.94 (Ar), 123.44 (Ar), 124.10 (Ar), 124.25 (Ar), 128.34 (Ar), 
129.15 (Ar), 132.97 (Ar), 137.12 (Ar), 138.05 (Ar), 146.04 (Ar), 149.09 (Ar), 155.30 (Ar), 156.75 (Ar), 
168.87 (Ar), 176.38 (Ar). 
micrOTOF-Q MS m/z C18H12N4O+H calculated 301.1070, observed 301.1085. 
IR (cm-1): 677, 681, 731, 782, 793, 1017, 1261, 1344, 1426, 1562. 
M.p.: 142-145 oC. 
 
 
 
(50) (59) 
C18H12N4O 
MW = 300.31g/mol 
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2.1.2.3  Synthesis of 3-(2-pyridyl)-5-[3-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]phenyl]-
  1,2,4-oxadiazole 
 
 
 
To isophthaloyl chloride (372 mg, 1.83 mmol) in xylene (25 ml), N'-hydroxypyridine-2-carboxamidine 
(44) (500 mg, 3.65 mmol) and pyridine (0.65 ml, 8.03 mmol) were added. The reaction mixture was 
set to stir at reflux for 24 hours. After this time the precipitates were collected by vacuum filtration, 
washed with water and ethanol and dried yielding the product as a pale yellow crystalline solid (182 
mg, 27%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϱϬ ;ϮH, dd, J=ϳ.ϰHz, ϱ.ϰHz, AƌHͿ; ɷϳ.ϴϬ ;ϭH, t, J=ϳ.ϴHz, AƌHͿ; ɷϳ.ϵϯ ;ϮH, 
t, J=7.7Hz, ArHͿ; ɷϴ.Ϯϴ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϴ.ϱϱ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϴ.ϴϴ ;ϮH, d, J=ϰ.ϴHz, AƌH); 
ɷϵ.Ϯϯ ;ϭH, s, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϯ.ϰϮ (Ar), 125.25 (Ar), 125.76 (Ar), 128.10 (Ar), 130.19 (Ar), 132.28 
(Ar), 137.22 (Ar), 146.22 (Ar), 150.57 (Ar), 169.03 (Ar), 175.26 (Ar). 
micrOTOF-Q MS m/z C20H12N6O2+Na, calculated 391.0901, observed 391.0915. 
IR (cm-1): 676, 716, 734, 766, 995, 1286, 1353, 1552, 1610. 
M.p.: 226-229 oC. 
 
 
 
 
 
 
(60) 
C20H12N6O2 
MW = 368.35g/mol 
(44) 
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2.1.2.4  Synthesis of 3-(2-pyridyl)-5-[6-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]-2-pyridyl]-
  1,2,4-oxadiazole 
 
 
 
To 2,6-pyridine dicarbonyl chloride (373 mg, 1.83 mmol) in xylene (25 ml), N'-hydroxypyridine-2-
carboxamidine (44) (500 mg, 3.65 mmol) and pyridine (0.74 ml, 9.13 mmol) were added. The 
reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were collected 
by vacuum filtration, washed with water and ethanol dried yielding the product a brown crystalline 
solid (203 mg, 15%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϱϭ ;ϮH, dd, J=ϳ.ϴHz, ϰ.ϴHz, AƌHͿ; ɷϳ.ϵϰ ;ϮH, t, J=7.8Hz, ArHͿ; ɷϴ.Ϯϰ ;ϭH, 
t, J=7.8Hz, ArHͿ; ɷϴ.ϯϯ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϴ.ϲϴ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϴ.ϴϲ-8.90 (2H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϯ.ϲϬ ;AƌͿ, ϭϮϱ.ϴϵ ;AƌͿ, ϭϮϳ.Ϯϵ ;AƌͿ, ϭϯϳ.ϯϯ ;AƌͿ, ϭϯϵ.ϭϰ ;AƌͿ, ϭϰϰ.ϯϴ 
(Ar), 145.87 (Ar), 150.48 (Ar), 169.02 (Ar), 174.06 (Ar). 
micrOTOF-Q MS m/z C19H11N7O2+Na, calculated 392.0864, observed 392.0866. 
IR (cm-1): 619, 650, 684, 710, 728, 739, 992, 1149, 1360, 1551. 
M.p.: 241-243 oC. 
 
 
 
 
 
 
 
(61) 
C19H11N7O2 
MW = 369.34g/mol 
(44) 
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2.1.2.5  Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[3-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
  oxadiazol-5-yl]phenyl]-1,2,4-oxadiazole 
 
 
 
To isophthaloyl chloride (237 mg, 1.17 mmol) in xylene (25 ml), (N'-hydroxy-6-(2-pyridyl)-pyridine-2-
carboxamidine (50) (500 mg, 2.34 mmol) and pyridine (0.42 ml, 5.15 mmol) were added. The 
reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were collected 
by vacuum filtration, washed with water and ethanol and dried yielding the product as a pale yellow 
crystalline solid (213 mg, 35%). 
1H NMR (400MHz, pyridine-dͿ: ɷϳ.Ϯϳ ;ϮH, t, J=7.2Hz, ArHͿ; ɷϳ.ϳϯ ;ϯH, t, J=7.7Hz, ArHͿ; ɷϴ.Ϭϭ ;ϮH, dd, 
J=7.8Hz, ArHͿ; ɷϴ.ϯϭ ;ϮH, d, J=ϳ.ϲHz, AƌHͿ; ɷϴ.ϰϳ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϴ.ϳϰ-8.78 (2H, m, ArH); 
ɷϴ.ϴϰ ;ϰH, t, J=7.8Hz, ArHͿ; ɷϵ.ϭϳ ;ϭH, s, AƌH). 
13C NMR (100MHz, pyridine-dͿ: ɷϭϮϭ.ϱϳ ;AƌͿ, ϭϮϮ.ϳϰ ;AƌͿ, ϭϮϯ.ϳϵ ;AƌͿ, ϭϮϯ.ϵϱ ;AƌͿ, ϭϮϰ.ϰϵ ;AƌͿ, 
125.32 (Ar), 127.58 (Ar), 130.52 (Ar), 132.16 (Ar), 137.03 (Ar), 138.34 (Ar), 146.18 (Ar), 155.28 (Ar), 
159.87 (Ar), 169.33 (Ar), 175.11 (Ar). 
micrOTOF-Q MS m/z C30H18N8O2+H calculated 523.1626, observed 523.1648. 
IR (cm-1): 634, 679, 734, 751, 786, 817, 1343, 1411, 1424, 1550. 
M.p.: 255-260 oC. 
 
 
 
(62) 
C30H18N8O2 
MW = 522.52g/mol 
(50) 
Experimental   2 
78 
 
2.1.2.6  Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[6-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
  oxadiazol-5-yl]-2-pyridyl]-1,2,4-oxadiazole 
 
 
 
To 2,6-pyridine dicarbonyl chloride (339 mg, 1.17 mmol) in xylene (25 ml), (N'-hydroxy-6-(2-pyridyl)-
pyridine-2-carboxamidine (50) (500 mg, 2.34 mmol) and pyridine (0.47 ml, 5.85 mmol) were added. 
The reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were 
collected by vacuum filtration, washed with water and ethanol dried yielding the product as a fine 
tan powder (66 mg, 11%). 
1H NMR (400MHz, d-DMSOͿ: ɷϳ.ϱϲ ;ϮH, ddd, J=ϳ.ϱHz, ϰ.ϴHz, ϭ.ϭHz, AƌHͿ; ɷϴ.Ϭϳ ;ϮH, appt. td, 
J=7.6Hz, 1.7Hz, ArHͿ; ɷϴ.Ϯϳ ;ϮH, t, J=7.7Hz, ArHͿ; ɷϴ.ϯϯ ;ϮH, dd, J=ϳ.ϲHz, ϭ.ϭHz, AƌHͿ; ɷϴ.ϱϮ ;ϭH, t, 
J=7.7Hz, ArHͿ; ɷϴ.ϱϲ ;ϮH, t, J=7.9Hz, ArHͿ; ɷϴ.ϲϱ ;ϮH, dd, J=ϳ.ϵHz, ϭ.ϭHz, AƌHͿ; ɷϴ.ϳϮ ;ϮH, d, J=ϳ.ϴHz, 
ArHͿ; ɷϴ.ϳϲ-8.79 (2H, m, ArH). 
micrOTOF-Q MS m/z C29H17N9O2+Na, calculated 546.1397, observed 546.1396. 
IR (cm-1): 991, 1082, 1173, 1264, 1347, 1360, 1426, 1513, 1553, 1586. 
M.p.: 250-252 oC. 
 
 
 
 
 
 
(63) 
C29H17N9O2 
MW = 523.50g/mol 
(50) 
Experimental   2 
79 
 
2.1.2.7 Synthesis of 3-(2-pyridyl)-5-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]-1,2,4-
oxadiazole 
 
 
 
 
To oxalyl chloride (0.15 ml, 1.83 mmol) in xylene (25 ml), N'-hydroxypyridine-2-carboxamidine (44) 
(500 mg, 3.65 mmol) and pyridine (0.74 ml, 9.13 mmol) were added. The reaction mixture was set to 
stir at reflux for 24 hours. After this time the precipitates were collected by vacuum filtration, 
washed with water and ethanol and dried yielding the product as a yellow crystalline solid (102 mg, 
10%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϱϰ ;ϮH, ddd, J=ϳ.ϲHz, ϰ.ϳHz, Ϭ.ϵHz, AƌHͿ; ɷϳ.ϵϱ ;ϮH, appt. td, J=7.9Hz, 
1.6Hz, ArHͿ; ɷϴ.Ϯϵ ;ϮH, t, J=7.8Hz, ArHͿ; ɷϴ.ϴϳ-8.90 (2H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϯ.ϳϵ ;AƌͿ, 126.42 (Ar), 137.41 (Ar), 144.99 (Ar), 150.80 (Ar), 163.34 
(Ar), 169.56 (Ar). 
micrOTOF-Q MS m/z C14H8N6O2+Na, calculated 315.0612, observed 315.0601. 
IR (cm-1): 618, 714, 721, 742, 801, 1172, 1343, 1355, 1417, 1521. 
M.p.: 260-263 oC. 
 
 
 
 
 
 
(64) 
C14H8N6O2 
MW = 292.25g/mol 
(44) 
Experimental   2 
80 
 
2.1.2.8  Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
  oxadiazol-5-yl]-1,2,4-oxadiazole 
 
 
 
To oxalyl chloride (0.10 ml, 1.17 mmol) in xylene (25 ml), (N'-hydroxy-6-(2-pyridyl)-pyridine-2-
carboxamidine (50) (500 mg, 2.34 mmol) and pyridine (0.47 ml, 5.85 mmol) were added. The 
reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were collected 
by vacuum filtration, washed with water and ethanol and dried yielding the product as a fine tan 
powder (116 mg, 8%). 
1H NMR (400MHz, pyridine-dͿ: ɷϳ.Ϭϳ ;ϮH, dd, J=ϳ.ϲHz, ϱ.ϬHz, AƌHͿ; ɷϳ.ϱϱ ;ϮH, appt. td, J=7.8Hz, 
1.4Hz, ArHͿ; ɷϳ.ϳϳ ;ϮH, t, J=7.8Hz, ArHͿ; ɷϴ.ϭϬ ;ϮH, t, J=7.6Hz, ArHͿ; ɷϴ.ϱϯ-8.56 (2H, m, ArHͿ; ɷϴ.ϲϬ 
(4H, t, J=8.1Hz, ArH). 
13C NMR (100MHz, pyridine-dͿ: ɷϭϮϮ.ϲϵ ;AƌͿ, ϭϮϯ.ϴϳ ;AƌͿ, ϭϮϱ.ϭϲ ;AƌͿ, ϭϮϱ.ϳϰ ;AƌͿ, ϭϯϲ.ϵϮ ;AƌͿ, 
138.25 (Ar), 139.67 (Ar), 146.08 (Ar), 156.17 (Ar), 158.17 (Ar), 165.41 (Ar), 171.00 (Ar). 
micrOTOF-Q MS m/z C24H14N8O2+H calculated 447.1312, observed 447.1320. 
IR (cm-1): 633, 688, 730, 751, 789, 1173, 1263, 1424, 1523, 1581. 
M.p.: 281-283 oC. 
 
 
 
 
(50) (65) 
C24H14N8O2 
MW = 446.42g/mol 
Experimental   2 
81 
 
2.1.2.9  Synthesis of 5-(2-pyridyl)-3-[5-(2-pyridyl)-1,2,4-oxadiazol-3-yl]-1,2,4-
oxadiazole 
 
 
 
 
 
To pyridine-2-carbonyl chloride hydrochloride (66) (1.51 g, 8.47 mmol) in toluene (50 ml), pyridine 
(0.75 ml, 9.32 mmol) was added and the reaction mixture allowed to stir for 5 minutes. After this 
time, diaminoglyoxime (67) (1.00g mg, 8.47 mmol) and a second aliquot of pyridine (0.75 ml, 9.32 
mmol) were added and the reaction mixture was set to stir at reflux for 24 hours. After this time the 
precipitates were collected by vacuum filtration, washed with water, washed with ethanol and dried 
under vacuum yielding the product as a light yellow solid (189 mg, 8%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϲϮ ;ϮH, ddd, J=ϳ.ϲHz, ϰ.ϴHz, ϭ.ϮHz, AƌHͿ; ɷϴ.Ϭϭ ;ϮH, appt. td, J=7.8Hz, 
1.2Hz, ArHͿ; ɷϴ.ϰϴ ;ϮH, appt. dt, J=7.9Hz, 1.1Hz, ArHͿ; ɷϴ.ϵϬ-8.94 (2H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϰ.ϴϴ ;AƌͿ, ϭϮϱ.ϯϭ ;AƌͿ, ϭϮϳ.ϯϱ ;AƌͿ, 128.24 (Ar), 129.03 (Ar), 137.54 
(Ar), 150.82 (Ar). 
IR (cm-1): 723, 738, 799, 910, 1236, 1412, 1439, 1456, 1563, 1573. 
micrOTOF-Q MS m/z C14H8N6O2+Na, calculated 315.0601, observed 315.0605. 
M.p.: 282-284 oC. 
 
 
 
 
 
(68) 
C14H8N6O2 
MW = 292.25g/mol 
(66) (67) 
Experimental   2 
82 
 
2.1.2.10 Synthesis of 3,5-di(pyrimidin-2-yl)-1,2,4-oxadiazole 
 
 
 
 
 
To oxalyl chloride (0.20 ml, 2.33 mmol) in xylene (20 ml), N'-hydroxypyrimidine-2-carboxamidine 
(53) (643 mg, 4.66 mmol) and pyridine (0.90 ml, 11.64 mmol) were added. The reaction mixture was 
set to stir at reflux for 24 hours. After this time the precipitates were collected by vacuum filtration, 
washed with water and ethanol and dried yielding the product as a pale yellow solid (45 mg, 3%). 
1H NMR (400MHz, d-DMSOͿ: ɷϳ.ϳϴ ;ϭH, t, J=ϰ.ϵHz, AƌHͿ; ɷϳ.ϴϱ ;ϭH, t, J=ϰ.ϵHz, AƌHͿ; ɷϵ.ϭϬ ;ϮH, d, 
J=4.9Hz, ArHͿ; ɷϵ.ϭϲ ;ϮH, d, J=ϰ.ϵHz, AƌH). 
micrOTOF-Q MS m/z C10H6N6O+Na, calculated 249.0495, observed 249.0485. 
M.p.: 294-296 oC. 
  
 
 
 
 
 
 
 
 
 
 
 
(53) (70) 
C10H6N6O 
MW = 226.19g/mol 
Experimental   2 
83 
 
2.1.2.11 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[3-(4,6-dimethylpyrimidin-2-
yl)-1,2,4-oxadiazol-5-yl]-1,2,4-oxadiazole 
 
 
 
 
 
To oxalyl chloride (0.28 ml, 3.31 mmol) in xylene (50 ml), N'-hydroxy-4,6-dimethyl-pyrimidine-2-
carboxamidine (55) (1.10 g, 6.62 mmol) and pyridine (1.07 ml, 13.24 mmol) were added. The 
reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates were collected 
by vacuum filtration, washed with water and ethanol and dried yielding the product as a light yellow 
solid (80 mg, 3%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϭϮ.ϲϳ ;ϭϮH, s, CH3Ϳ; ɷϳ.Ϯϰ ;ϮH, s, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϰ.ϭϰ ;CH3), 122.02 (Ar), 154.42 (Ar), 163.67 (Ar), 168.42 (Ar), 169.25 
(Ar). 
IR (cm-1): 733, 850, 956, 994, 1152, 1239, 1344, 1433, 1523, 1594. 
micrOTOF-Q MS m/z C16H14N8O2+Na, calculated 373.1132, observed 373.1133. 
M.p.: >300 oC. 
 
 
 
 
 
 
 
 
(55) 
(71) 
C16H14N8O2 
MW = 350.33g/mol 
Experimental   2 
84 
 
2.1.2.12 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[3-[3-(4,6-dimethylpyrimidin-
  2-yl)-1,2,4-oxadiazol-5-yl]phenyl]-1,2,4-oxadiazole 
 
 
 
 
To isophthaloyl chloride (611 mg, 3.01 mmol) in toluene (50 ml), N'-hydroxy-4,6-dimethyl-
pyrimidine-2-carboxamidine (55) (1.00 g, 6.02 mmol) and pyridine (0.97 ml, 12.04 mmol) were 
added. The reaction mixture was set to stir at reflux for 24 hours. After this time the precipitates 
were collected by vacuum filtration, washed with water, washed with ethanol dried with no 
fupurification to yield the product a pale grey solid (183 mg, 7%). 
1H NMR (400MHz, CDCl3): ɷϮ.ϲϵ ;ϭϮH, s, CH3Ϳ; ɷϳ.Ϯϯ ;ϮH, s, AƌHͿ; ɷϳ.ϴϬ ;ϭH, t, J=ϳ.ϳHz, AƌHͿ; ɷϴ.ϲϬ 
(2H, dd, J=8.0Hz, 1.4Hz, ArHͿ; ɷϵ.Ϯϲ-9.28 (1H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϰ.Ϯϱ ;CH3), 121.55 (Ar), 124.98 (Ar), 128.36 (Ar), 130.04 (Ar), 132.64 
(Ar), 155.47 (Ar), 168.22 (Ar), 168.70 (Ar), 175.75 (Ar). 
IR (cm-1): 740, 858, 1241, 1259, 1342, 1368, 1387, 1428, 1559, 1590. 
micrOTOF-Q MS m/z C22H18N8O2+Na, calculated 449.1445, observed 449.1452. 
M.p.: 264-266 oC. 
 
 
 
 
 
 
 
(72) 
C22H18N8O2 
MW = 426.43g/mol 
(55) 
Experimental   2 
85 
 
2.1.2.13 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[6-[3-(4,6-dimethylpyrimidin-
  2-yl)-1,2,4-oxadiazol-5-yl]-2-pyridyl]-1,2,4-oxadiazole 
 
 
 
 
 
To pyridine-2-dicarbonyl dichloride (614 mg, 3.01 mmol) in toluene (50 ml), N'-hydroxy-4,6-
dimethyl-pyrimidine-2-carboxamidine (55) (1.00 g, 6.02 mmol) and pyridine (0.97 ml, 12.04 mmol) 
were added. The reaction mixture was set to stir at reflux for 24 hours. After this time the 
precipitates were collected by vacuum filtration, washed with water, washed with ethanol and dried 
yielding the product a pale orange crystalline solid (98 mg, 4%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϳϬ ;ϭϮH, s, CH3Ϳ; ɷϳ.Ϯϱ ;ϮH, s, AƌHͿ; ɷϴ.ϮϮ ;ϭH, t, J=ϳ.ϳHz, AƌHͿ; ɷϴ.ϳϮ 
(2H, d, J=7.8Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϰ.Ϯϱ ;CH3), 121.64 (Ar), 127.54 (Ar), 138.56 (Ar), 144.21 (Ar), 155.29 
(Ar), 168.32 (Ar), 168.78 (Ar), 174.60 (Ar). 
IR (cm-1): 742, 857, 992, 1079, 1124, 1240, 1345, 1386, 1417, 1589. 
micrOTOF-Q MS m/z C21H17N9O2+Na, calculated 450.1397, observed 450.1407. 
M.p.: 262-264 oC. 
 
 
 
 
 
 
 
(73) 
C21H17N9O2 
MW = 427.42g/mol 
(55) 
Experimental   2 
86 
 
2.1.2.14 Synthesis of 2-(2-pyridyl)-4-[2-(2-pyridyl)thiazol-4-yl]thiazole 
 
 
 
 
 
 
Pyridine-2-carbothioamide (74) and 1,4-dibromobutane-2,3-dione (57) were set to stir in methanol 
at reflux for 1 hour. The reaction mixture was filtered and the precipitates washed with water, 
ethanol and ether and air-dried for 1 hour, yielding the product as a pale tan solid (67 mg, 29%). 
 
1H NMR (400MHz, d-DMSOͿ: ɷϳ.ϱϲ (2H, ddd, J=7.4Hz, 4.8Hz, 1.1Hz, ArHͿ; ɷϴ.Ϭϱ ;ϮH, appt. td, 
J=8.2Hz, 1.8Hz, ArHͿ; ɷϴ.Ϯϱ ;ϮH, s, AƌHͿ; ɷϴ.Ϯϳ ;ϮH, appt. dt, J=7.9Hz, 1.0Hz, ArHͿ; ɷϴ.ϲϴ-8.71 (2H, m, 
ArH). 
This data is consistent with that reported in the literature94. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(75) 
C16H10N4S2 
MW = 322.41g/mol 
(57) (74) 
Experimental   2 
87 
 
2.1.2.15 Synthesis of 2-[6-(2-pyridyl)-2-pyridyl]-4-[2-[6-(2-pyridyl)-2-pyridyl]thiazol-
  4-yl]thiazole 
 
 
 
 
 
 
6-(2-Pyridyl)pyridine-2-carbothioamide (76) and 1,4-dibromobutane-2,3-dione (57) were set to stir 
in methanol at reflux for 1 hour. The reaction mixture was filtered and the precipitates washed with 
water, ethanol, and ether and air-dried for 1 hour, yielding the product as a pale tan solid (120 mg, 
19%). 
 
1H NMR (400MHz, d-DMSOͿ: ɷϳ.46-7.60 (2H, m, ArHͿ; ɷϳ.ϴϵ-8.90 (14H, m, ArH). 
This data is consistent with that reported in the literature94. 
 
 
 
 
 
 
 
 
 
 
(77) 
C26H16N6S2 
MW = 476.57g/mol 
(57) (76) 
Experimental   2 
88 
 
2.2  Experimental Procedures for the Synthesis of Extended  
  Isothiazole Dioxides 
2.2.1  Experimental Procedures for the Synthesis of 3-Phenyl-α,β-unsaturated  
  Arylketones 
2.2.1.1  Synthesis of 1,3-diphenylprop-2-en-1-one 
 
 
 
 
 
To benzaldehyde (79) (6.31 ml, 62.00 mmol) and acetophenone (78) (7.25 ml, 62.00 mmol) in 
ethanol (25 ml) was added sodium hydroxide (744 mg, 18.60 mmol) in water (2 ml). The reaction 
mixture was allowed to stir at room temperature for 30 minutes. After this time, the reaction 
mixture was cooled in an ice bath and precipitates collected by vacuum filtration. The crude product 
was purified by recrystallisation from ethanol to yield the pure product as a yellow crystalline solid 
(7.82 g, 61%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϯϵ-7.62 (3H, m, PhHͿ; ɷϳ.ϰϴ-7.62 (4H, m, PhH, PhHC); ɷϳ.ϲϯ-7.68 (2H, 
m, PhHͿ; ɷϳ.ϴϮ ;ϭH, d, J=ϭϱ.ϳHz, CHCOͿ; ɷϴ.Ϭϯ ;ϮH, d, J=ϳ.ϲHz, PhH).  
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϮ.Ϭϵ ;PhHC), 128.48 (PhC), 128.54 (PhC), 128.66 (PhC), 128.99 (PhC), 
130.59 (CHCO), 132.83 (PhC), 134.89 (PhC), 138.22 (PhC), 144.90 (PhC), 190.62 (C=O). 
micrOTOF-Q MS m/z C15H12O+Na, calculated 231.0780, observed 231.0789. 
IR (cm-1): 666, 686, 743, 976, 1014, 1215, 1337, 1573, 1602, 1660. 
M.p.: 57-59 oC. (Literature value 57 0C)132. 
This data is consistent with that reported in the literature132,169. 
(80) 
C15H12O 
MW = 208.25g/mol 
(79) (78) 
Experimental   2 
89 
 
2.2.1.2  Synthesis of 1-(4-nitrophenyl)-3-phenyl-prop-2-en-1-one 
 
 
 
 
 
To benzaldehyde (79) (15.43 ml, 151.38 mmol) and 4-nitroacetophenone (81) (25.00 g, 151.38 
mmol) in ethanol (75 ml) was added sodium hydroxide (1.82 g, 45.41 mmol) in water (10 ml). The 
reaction mixture was allowed to stir at room temperature for 30 minutes. After this time, the 
reaction mixture was cooled in an ice bath for 15 minutes and precipitates collected by vacuum 
filtration with no further purification required to yield the product as a yellow crystalline solid (6.04 
g, 16%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϰϰ-7.52 (4H, m, PhH, PhHCͿ; ɷϳ.ϲϰ-7.70 (2H, m, PhHͿ; ɷϳ.ϴϲ ;ϭH, d, 
J=15.7Hz, CHCOͿ; ɷϴ.ϭϱ ;ϮH, d, J=ϴ.ϲHz, AƌHͿ; ɷϴ.ϯϳ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
IR (cm-1): 843, 999, 1024, 1205, 1307, 1319, 1332, 1512, 1588. 
M.p.: 150-152 oC. (Literature value 146-147 0C)133. 
 
This data is consistent with that reported in the literature133,169. 
 
 
 
 
 
 
 
 
 
 
(82) 
C15H11NO2 
MW = 237.25g/mol 
(81) (79) 
Experimental   2 
90 
 
2.2.1.3  Synthesis of 1-(4-methoxyphenyl)-3-phenyl-prop-2-en-1-one 
 
 
 
 
 
To benzaldehyde (79) (16.95 ml, 166.47 mmol) and 4-methoxycetophenone (83) (25.00 g, 166.47 
mmol) in ethanol (75 ml) was added sodium hydroxide (2.00 g, 49.94 mmol) in water (10 ml). The 
reaction mixture was allowed to stir at room temperature for 30 minutes. After this time, the 
reaction mixture was cooled in an ice bath for 15 minutes and precipitates collected by vacuum 
filtration. The product was purified by recrystallisation from ethanol yielding a pale yellow crystalline 
solid (28.34g, 71%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϯ.ϵϬ ;ϯH, s, AƌOCH3Ϳ; ɷϲ.ϵϵ ;ϮH, d, J=ϴ.ϴHz, AƌH); ɷϳ.ϯϵ-7.45 (3H, m ArH); 
ɷϳ.ϱϱ ;ϭH, d, J=ϭϱ.ϲHz, PhHCͿ; ɷϳ.ϲϯ-7.68 (2H, m, ArHͿ; ɷϳ.ϴϭ ;ϭH, d, J=ϭϱ.ϲHz, CHCOͿ; ɷϴ.Ϭϱ ;ϮH, d, 
J=8.7Hz, ArH). 
This data is consistent with that reported in the literature169. 
 
 
 
 
 
 
 
 
 
 
 
 
(84) 
C16H14O2 
MW = 238.28g/mol (79) (83) 
Experimental   2 
91 
 
2.2.1.4  Synthesis of 1-(4-chlorophenyl)-3-phenyl-prop-2-en-1-one 
 
 
 
 
 
 
To benzaldehyde (79) (20.00 ml, 196.38 mmol) and 4-chloroacetophenone (85) (25.47 ml, 196.38 
mmol) in ethanol (200 ml) was added sodium hydroxide (2.36 g, 58.91 mmol) in water (10 ml). The 
reaction mixture was allowed to stir at room temperature for 30 minutes. After this time, the 
reaction mixture was cooled in an ice bath for 15 minutes and precipitates collected by vacuum 
filtration. The crude product was purified by recrystallisation from methylated spirits to yield the 
pure product as a yellow crystalline solid (42.89 g, 91%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϰϭ-7.46 (3H, m, PhHͿ; ɷϳ.ϰϳ-7.52 (3H, m, PhH, PhHCͿ; ɷϳ.ϲϮ-7.67 (2H, 
m, ArHͿ; ɷϳ.ϴϮ ;ϭH, d, J=ϭϱ.ϳHz, CHCOͿ; ɷϳ.ϵϳ ;ϮH, d, J=ϴ.ϰHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϮϭ.ϰϴ ;PhHC), 128.52 (Ar), 128.96 (Ar), 129.01 (Ar), 129.92 (Ar), 130.77 
(Ar), 134.68 (Ar), 136.48 (Ar), 139.23 (Ar), 145.39 (CHCO), 189.23 (C=O). 
micrOTOF-Q MS m/z C15H11ClO+Na, calculated 265.0390, observed 265.0394. 
IR (cm-1): 761, 826, 981, 1087, 1215, 1331, 1567, 1585, 1598, 1658. 
M.p.: 101-103 oC. (Literature value 101 0C)134. 
 
This data is consistent with that reported in the literature134,169. 
 
 
 
 
 
(86) 
C15H11ClO 
MW = 242.70g/mol 
(79) (85) 
Experimental   2 
92 
 
2.2.1.5  Synthesis of 3-phenyl-1-(p-tolyl)prop-2-en-1-one 
 
 
 
 
 
To benzaldehyde (79) (15.18 ml, 149.05 mmol) and 4-methylacetophenone (87) (20.00 ml, 149.05 
mmol) in ethanol (150 ml) was added sodium hydroxide (1.79 g, 44.72 mmol) in water (10 ml). The 
reaction mixture was allowed to stir at room temperature for 30 minutes. After this time, the 
reaction mixture was cooled in an ice bath for 15 minutes and precipitates collected by vacuum 
filtration with no further purification required to yield the product as an off-white solid (20.64 g, 
62%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϯϯ ;ϯH, s, AƌCH3Ϳ; ɷϳ.ϮϬ ;ϮH, d, J=ϴ.ϬHz, AƌHͿ; ɷϳ.Ϯϵ-7.34 (3H, m, ArH); 
ɷϳ.ϰϰ ;ϭH, d, J=ϭϱ.ϳHz, PhHCͿ; ɷϳ.ϱϮ-7.56 (2H, m, ArHͿ; ɷϳ.ϳϭ ;ϭH, d, J=ϭϱ.ϳHz, CHCOͿ; ɷϳ.ϴϱ ;ϮH, d, 
J=8.2Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.ϲϴ ;AƌCH3), 122.14 (PhHC), 128.42 (Ar), 128.68 (Ar), 128.95 (Ar), 
129.35 (Ar), 130.43 (Ar), 135.04 (Ar), 135.68 (Ar), 143.64 (Ar), 144.37 (CHCO), 189.98 (C=O). 
micrOTOF-Q MS m/z C16H14O+Na, calculated 245.0937, observed 245.0940. 
IR (cm-1): 977, 1180, 1206, 1220, 1286, 1305, 1333, 1567, 1592, 1652. 
This data is consistent with that reported in the literature169. 
 
 
 
 
 
 
(88) 
C16H14O 
MW = 222.28g/mol 
(79) (87) 
Experimental   2 
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2.2.2  Experimental Procedures for the Dibromination of 3-Phenyl-α,β-  
  dibrominated arylketones 
 
2.2.2.1  Synthesis of 2,3-dibromo-1,3-diphenyl-propan-1-one 
 
 
 
 
 
To 1,3-diphenylprop-2-en-1-one (80) (7.82 g, 37.55 mmol) in dry chloroform (25 ml) at room 
temperature under an atmosphere of nitrogen was added a 1M solution of bromine in chloroform 
(45.06 ml, 45.06 mmol) and the reaction mixture allowed to stir for one hour. After this time 
petroleum ether (60 ml) was added and the reaction mixture was allowed to stand for one hour at 
room temperature and for a further hour at 00C. The precipitates were collected by vacuum filtration 
yielding a pure white crystalline solid (4.71 g, 34%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϱ.ϲϱ ;ϭH, d, J=ϭϭ.ϱHz, PhHBƌCͿ; ɷϱ.ϴϰ ;ϭH, d, J=ϭϭ.ϯHz, CHBƌCOͿ; ɷϳ.ϯϲ-
7.47 (3H, m, PhHͿ; ɷϳ.ϱϭ-7.59 (4H, m, PhHͿ; ɷϳ.ϲϳ ;ϭH, ŵ, PhHͿ; ɷϴ.ϭϭ ;ϮH, d, J=ϳ.ϳHz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϰϲ.ϴϰ ;PhHBƌC), 49.78 (CHBrCO), 128.37 (PhC), 128.90 (PhC), 128.94 
(PhC), 129.04 (Ph), 129.34 (PhC), 134.23 (PhC), 134.42 (PhC), 138.25 (PhC), 191.21 (C=O). 
micrOTOF-Q MS m/z C15H12
79Br2O+Na, calculated 388.9147, observed 388.9148. 
IR (cm-1): 682, 696, 721, 981, 1148, 1227, 1272, 1448, 1596, 1678. 
M.p.: 160-162 oC. (Literature value 159-160 0C)135. 
 
This data is consistent with that reported in the literature135,170. 
 
 
(89) 
C15H12Br2O 
MW = 368.06g/mol 
(80) 
Experimental   2 
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2.2.2.2  Synthesis of 2,3-dibromo-1-(4-nitrophenyl)-3-phenyl-propan-1-one 
 
 
 
 
 
To 1-(4-nitrophenyl)-3-phenyl-prop-2-en-1-one (82) (6.04 g, 23.66 mmol) in dry chloroform (20 ml) 
at room temperature under an atmosphere of nitrogen was added a 1M solution of bromine in 
chloroform (28.39 ml, 28.39 mmol) and the reaction mixture allowed to stir for one hour. After this 
time petroleum ether (60 ml) was added and the reaction mixture was allowed to stand for one hour 
at room temperature and for a further hour at 00C. The precipitates were collected by vacuum 
filtration yielding the product as a yellow crystalline solid (6.08 g, 62%). 
 
1H NMR (400MHz, d-DMSOͿ: ɷϱ.ϴϮ ;ϭH, d, J=ϭϭ.ϮHz, PhHBƌCͿ; ɷϲ.ϴϰ ;ϭH, d, J=ϭϭ.ϮHz, CHBrCO); 
ɷϳ.ϯϲ-7.50 (3H, m, ArHͿ; ɷϳ.ϱϰ ;ϮH, d, ϳ.ϰHz, AƌHͿ; ɷϴ.ϰϱ ;ϮH, d, J=ϴ.ϲHz, AƌHͿ; ɷϴ.ϱϱ ;ϮH, d, J=ϴ.ϲHz, 
ArH). 
13C NMR (100MHz, d-DMSOͿ: ɷϰϲ.ϵϵ ;PhBƌC), 50.82 (CHBrCO), 124.71 (Ar), 129.11 (Ar), 129.31 (Ar), 
129.65 (Ar), 131.03 (Ar), 138.66 (Ar), 138.71 (Ar), 151.20 (Ar), 191.00 (C=O). 
IR (cm-1): 848, 863, 778, 979, 1026, 1216, 1317, 1352, 1517, 1693. 
M.p.: 201-203 oC. (Literature value 198 0C)136. 
This data is consistent with that reported in the literature136,170. 
 
 
 
 
 
 
(90) 
C15H11Br2NO2 
MW = 397.06g/mol 
(82) 
Experimental   2 
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2.2.2.3  Synthesis of 2,3-dibromo-1-(4-methoxyphenyl)-3-phenyl-propan-1-one 
   
 
 
 
 
 
To 1-(4-methoxyphenyl)-3-phenyl-prop-2-en-1-one (84) (28.34 g, 118.94 mmol) in dry chloroform 
(100 ml) at room temperature under an atmosphere of nitrogen was added a 1M solution of 
bromine in chloroform (118.94 ml, 118.94 mmol) and the reaction mixture allowed to stir for one 
hour. After this time petroleum ether (120 ml) was added and the reaction mixture was allowed to 
stand for one hour at room temperature and for a further hour at 00C. The precipitates were 
collected by vacuum filtration yielding the product as a pure white crystalline solid (36.08 g, 30%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϯ.ϵϮ ;ϯH, s, AƌOCH3Ϳ; ɷϱ.ϲϱ ;ϭH, d, J=ϭϭ.ϯHz, PhHBƌCͿ; ɷϱ.ϴϭ ;ϭH, d, 
J=11.3Hz, CHBƌCOͿ; ɷϳ.ϬϮ ;ϮH, d, J=ϴ.ϲHz, AƌHͿ; ɷϳ.ϯϱ-7.47 (3H, m, ArHͿ; ɷϳ.ϱϯ ;ϮH, d, J=ϳ.ϱHz, AƌH); 
ɷϴ.ϭϬ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
This data is consistent with that reported in the literature170. 
 
 
 
 
 
 
 
 
 
 
 
(91) 
C16H14Br2O2 
MW = 398.09g/mol 
(84) 
Experimental   2 
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2.2.2.4  Synthesis of 2,3-dibromo-1-(4-chlorophenyl)-3-phenyl-propan-1-one 
   
 
 
 
 
 
 
To 1-(4-chlorophenyl)-3-phenyl-prop-2-en-1-one (86) (42.50 g, 175.11 mmol) in dry chloroform (50 
ml) at room temperature under an atmosphere of nitrogen was added a 1M solution of bromine in 
chloroform (210.13 ml, 210.13 mmol) and the reaction mixture allowed to stir for one hour. After 
this time petroleum ether (100 ml) was added and the reaction mixture was allowed to stand for one 
hour at room temperature and for a further hour at 00C. The precipitates were collected by vacuum 
filtration yielding a yellow crystalline solid (14.53 g, 21%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϱ.ϲϯ ;ϭH, d, J=ϭϭ.ϯHz, PhHBƌCͿ; ɷϱ.ϳϳ ;ϭH, d, J=ϭϭ.ϯHz, ;CHBƌCOͿ; ɷϳ.ϯϲ-
7.47 (3H, m, ArHͿ; ɷϳ.ϱϬ-7.56 (4H, m, ArHͿ; ɷϴ.Ϭϱ ;ϮH, d, J=ϴ.ϭHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϰϲ.ϳϯ ;PhHBƌC), 49.63 (CHBrCO), 128.33 (Ar), 128.91 (Ar), 129.40 (Ar), 
130.30 (Ar), 132.68 (Ar), 138.02 (Ar), 140.84 (Ar), 190.05 (C=O). 
IR (cm-1): 755, 785, 824, 976, 1087, 1218, 1269, 1400, 1587, 1685. 
M.p.: 191-192 oC. (Literature value 193 0C)136. 
This data is consistent with that reported in the literature136,170. 
 
 
 
 
 
 
(92) 
C15H11Br2ClO 
MW = 402.51g/mol 
(86) 
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2.2.2.5  Synthesis of 2,3-dibromo-3-phenyl-1-(p-tolyl)propan-1-one 
 
 
 
 
To 3-phenyl-1-(p-tolyl)prop-2-en-1-one (88) (23.98 g, 107.88 mmol) in dry chloroform (100 ml) at 
room temperature under an atmosphere of nitrogen was added a 1M solution of bromine in 
chloroform (129.46 ml, 129.46 mmol) and the reaction mixture allowed to stir for one hour. After 
this time petroleum ether (150 ml) was added and the reaction mixture was allowed to stand for one 
hour at room temperature and for a further hour at 00C. The precipitates were collected by vacuum 
filtration yielding the product as a yellow crystalline solid (19.41 g, 47%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϰϲ ;ϯH, s, ArCH3); ɷϱ.ϲϱ ;ϭH, d, J=ϭϭ.ϯHz, PhHBrC); ɷϱ.ϴϮ ;ϭH, d, 
J=11.3Hz, CHBrCO); ɷϳ.ϯϯ-7.46 (5H, m, ArHͿ; ɷϳ.ϱϭ-7.55 (2H, m, ArHͿ; ɷϴ.Ϭϭ ;ϮH, d, J=ϴ.ϮHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.ϴϯ (ArCH3), 46.80 (PhHBrC), 49.85 (CHBrCO), 128.36 (Ar), 128.85 (Ar), 
129.06 (Ar), 129.27 (Ar), 129.73 (Ar), 131.84 (Ar), 138.34 (Ar), 145.40 (Ar), 190.76 (C=O). 
micrOTOF-Q MS m/z C16H14
79Br2O+Na, calculated 402.9304, observed 402.9304. 
IR (cm-1): 834, 967, 1142, 1208, 1225, 1272, 1324, 1372, 1606, 1683. 
M.p.: 180-182 oC.  
 
This data is consistent with that reported in the literature170. 
 
 
 
 
 
(93) 
C16H14Br2O 
MW = 382.09g/mol 
(88) 
Experimental   2 
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2.2.3  EǆperiŵeŶtal Procedures for the sǇŶthesis of α,β-unsaturated-3-phenyl-2-
  dialkylamino arylketones  
2.2.3.1  Synthesis of 2-(diethylamino)-1,3-diphenyl-prop-2-en-1-one 
 
 
 
 
 
To 2,3-dibromo-1,3-diphenyl-propan-1-one (89) (4.71 g, 12.80 mmol) stirring in ethanol (5 ml) at 
room temperature under an atmosphere of nitrogen was added diethylamine (2.65 ml, 25.60 mmol) 
and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (871 mg, 12.80 mmol) 
was added and the reaction mixture was stirred for a further 24 hours. Solvents were then removed 
under reduced pressure and the residues dissolved in dichloromethane (50 ml). The solution was 
then filtered to remove sodium bromide and the filtrate was concentrated under reduced pressure. 
The crude product was taken to the next stage without further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(89) 
(94) 
C19H21NO 
MW = 279.38g/mol 
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2.2.3.2  Synthesis of 2-(dipropylamino)-1,3-diphenyl-prop-2-en-1-one 
  
 
 
 
 
To 2,3-dibromo-1,3-diphenyl-propan-1-one (89) (5.90 g, 16.03 mmol) stirring in ethanol (6 ml) at 
room temperature under an atmosphere of nitrogen was added dipropylamine (4.40 ml, 32.06 
mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (369 mg, 16.03 
mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents were then 
removed under reduced pressure and the residues dissolved in dichloromethane. The solution was 
then filtered to remove sodium bromide and the filtrate was concentrated under reduced pressure. 
The crude product was taken to the next stage without further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(95) 
C21H25NO 
MW = 307.43g/mol 
(89) 
Experimental   2 
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2.2.3.3  Synthesis of 1,3-diphenyl-2-(1-piperidyl)prop-2-en-1-one  
 
 
 
To 2,3-dibromo-1,3-diphenyl-propan-1-one (89) (6.00 g, 16.30 mmol) stirring in ethanol (6 ml) at 
room temperature under an atmosphere of nitrogen was added piperidine (3.22 ml, 32.60 mmol) 
and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (375 mg, 16.30 mmol) 
was added and the reaction mixture was stirred for a further 24 hours. Solvents were then removed 
under reduced pressure and the residues dissolved in dichloromethane. The solution was then 
filtered to remove sodium bromide and the filtrate was concentrated under reduced pressure. The 
crude product was taken to the next stage without further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(96) 
C20H21NO  
MW = 291.39g/mol 
(89) 
Experimental   2 
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2.2.3.4  Synthesis of 2-(dipropylamino)-1-(4-methoxyphenyl)-3-phenyl-prop-2-en-1-
  one 
 
 
 
 
 
To 2,3-dibromo-1-(4-methoxyphenyl)-3-phenyl-propan-1-one (91) (5.00 g, 12.56 mmol) stirring in 
ethanol (6 ml) at room temperature under an atmosphere of nitrogen was added dipropylamine 
(3.40 ml, 25.12 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide 
(289 mg, 12.56 mmol) was added and the reaction mixture was stirred for a further 24 hours. 
Solvents were then removed under reduced pressure and the residues dissolved in 
dichloromethane. The solution was then filtered to remove sodium bromide and the filtrate was 
concentrated under reduced pressure. The crude product was taken to the next stage without 
further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(98) 
C22H27NO2 
MW = 337.45g/mol 
(91) 
Experimental   2 
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2.2.3.5  Synthesis of 1-(4-methoxyphenyl)-3-phenyl-2-(1-piperidyl)prop-2-en-1-one
   
 
 
 
 
To 2,3-dibromo-1-(4-methoxyphenyl)-3-phenyl-propan-1-one (91) (6.00 g, 15.07 mmol) stirring in 
ethanol (50 ml) at room temperature under an atmosphere of nitrogen was added piperidine (2.98 
ml, 30.14 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (347 
mg, 15.07 mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents 
were then removed under reduced pressure and the residues dissolved in dichloromethane. The 
solution was then filtered to remove sodium bromide and the filtrate was concentrated under 
reduced pressure. The crude product was taken to the next stage without further purification or 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(99) 
C21H23NO2 
MW = 321.41g/mol 
(91) 
Experimental   2 
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2.2.3.6  Synthesis of 1-(4-methoxyphenyl)-2-morpholino-3-phenyl-prop-2-en-1-one
   
 
 
 
 
To 2,3-dibromo-1-(4-methoxyphenyl)-3-phenyl-propan-1-one (91) (6.00 g, 15.07 mmol) stirring in 
ethanol (80 ml) at room temperature under an atmosphere of nitrogen was added morpholine (2.63 
ml, 30.14 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (347 
mg, 15.07 mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents 
were then removed under reduced pressure and the residues dissolved in dichloromethane. The 
solution was then filtered to remove sodium bromide and the filtrate was concentrated under 
reduced pressure. The crude product was taken to the next stage without further purification or 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(100) 
C20H21NO3 
MW = 323.38g/mol 
(91) 
Experimental   2 
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2.2.3.7  Synthesis of 1-(4-chlorophenyl)-2-(diethylamino)-3-phenyl-prop-2-en-1-one
   
 
 
 
 
 
To 2,3-dibromo-1-(4-chlorophenyl)-3-phenyl-propan-1-one (92) (4.60 g, 11.43 mmol) stirring in 
ethanol (10 ml) at room temperature under an atmosphere of nitrogen was added diethylamine 
(2.36 ml, 22.86 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide 
(263 mg, 11.43 mmol) was added and the reaction mixture was stirred for a further 24 hours. 
Solvents were then removed under reduced pressure and the residues dissolved in 
dichloromethane. The solution was then filtered to remove sodium bromide and the filtrate was 
concentrated under reduced pressure. The crude product was taken to the next stage without 
further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(101) 
C19H20ClNO 
MW = 313.82g/mol 
(92) 
Experimental   2 
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2.2.3.8  Synthesis of 1-(4-chlorophenyl)-2-(dipropylamino)-3-phenyl-prop-2-en-1-
  one 
 
 
 
 
 
To 2,3-dibromo-1-(4-chlorophenyl)-3-phenyl-propan-1-one (92) (5.00 g, 12.42 mmol) stirring in 
ethanol (10 ml) at room temperature under an atmosphere of nitrogen was added dipropylamine 
(3.40 ml, 24.84 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide 
(290 mg, 12.42 mmol) was added and the reaction mixture was stirred for a further 24 hours. 
Solvents were then removed under reduced pressure and the residues dissolved in 
dichloromethane. The solution was then filtered to remove sodium bromide and the filtrate was 
concentrated under reduced pressure. The crude product was taken to the next stage without 
further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(92) 
(102) 
C21H24ClNO 
MW = 341.87g/mol 
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2.2.3.9  Synthesis of 1-(4-chlorophenyl)-3-phenyl-2-(1-piperidyl)prop-2-en-1-one 
   
 
 
 
 
 
To 2,3-dibromo-1-(4-chlorophenyl)-3-phenyl-propan-1-one (92) (4.80 g, 11.93 mmol) stirring in 
ethanol (30 ml) at room temperature under an atmosphere of nitrogen was added piperidine (2.36 
ml, 23.86 mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (274 
mg, 11.93 mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents 
were then removed under reduced pressure and the residues dissolved in dichloromethane. The 
solution was then filtered to remove sodium bromide and the filtrate was concentrated under 
reduced pressure. The crude product was taken to the next stage without further purification or 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(103) 
C20H20ClNO 
MW = 325.83g/mol 
(92) 
Experimental   2 
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2.2.3.10 Synthesis of 2-(diethylamino)-3-phenyl-1-(p-tolyl)prop-2-en-1-one 
 
 
 
 
 
 
 
To 2,3-dibromo-3-phenyl-1-(p-tolyl)propan-1-one (93) (4.52 g, 11.83 mmol) stirring in ethanol (40 
ml) at room temperature under an atmosphere of nitrogen was added diethylamine (2.45 ml, 23.66 
mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (272 mg, 11.83 
mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents were then 
removed under reduced pressure and the residues dissolved in dichloromethane. The solution was 
then filtered to remove sodium bromide and the filtrate was concentrated under reduced pressure. 
The crude product was taken to the next stage without further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(93) 
(104) 
C20H23NO 
MW = 293.40g/mol 
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2.2.3.11 Synthesis of 3-phenyl-2-(1-piperidyl)-1-(p-tolyl)prop-2-en-1-one 
 
 
 
 
To 2,3-dibromo-3-phenyl-1-(p-tolyl)propan-1-one (93) (4.78 g, 12.51 mmol) stirring in ethanol (40 
ml) at room temperature under an atmosphere of nitrogen was added piperidine (2.50 ml, 25.02 
mmol) and the mixture allowed to stir for 24 hours. After this time sodium ethoxide (288 mg, 12.51 
mmol) was added and the reaction mixture was stirred for a further 24 hours. Solvents were then 
removed under reduced pressure and the residues dissolved in dichloromethane. The solution was 
then filtered to remove sodium bromide and the filtrate was concentrated under reduced pressure. 
The crude product was taken to the next stage without further purification or analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(105) 
C21H23NO 
MW = 305.41g/mol 
(93) 
Experimental   2 
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2.2.4  Experimental Procedures for the Synthesis of 2-Dialkylamino-N-  
  methanesulfonyl arylketoamidines 
2.2.4.1  Synthesis of N,N-diethyl-N'-methylsulfonyl-2-oxo-2-phenyl-acetamidine 
  
 
 
 
 
Under an atmosphere of nitrogen, a solution of 2-(diethylamino)-1,3-diphenyl-prop-2-en-1-one (94) 
(920 mg, 3.29 mmol) in ethanol (5 ml) was added to a solution of methanesulfonyl azide (398 mg, 
3.29 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 hours. After this 
time, solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a pink solid (533 mg, 57%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϵ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϭ.ϯϰ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϵϳ 
(3H, s, SO2CH3Ϳ; ɷϯ.ϭϱ ;ϮH, ŵ, NCH2CH3Ϳ; ɷϯ.ϰϲ-3.59 (1H, m, NCH2CH3Ϳ; ɷϯ.ϲϳ-3.83 (1H, m NCH2CH3); 
ɷϳ.ϱϯ ;ϮH, t, J=ϴ.ϬHz, PhHͿ; ɷϳ.ϲϱ ;ϭH, tt, J=ϳ.ϰHz, ϭ.ϮHz, PhHͿ; ɷϳ.ϵϬ ;ϮH, d, J=ϳ.ϯHz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϵϮ ;NCH2CH3), 13.69 (NCH2CH3), 42.58 (SO2CH3), 42.67 (NCH2CH3), 
44.24 (NCH2CH3), 128.84 (PhC), 129.23 (PhC), 134.38 (PhC), 134.83 (PhC), 161.94 (N=C-N), 192.57 
(C=O). 
micrOTOF-Q MS m/z C13H18N2O3S+Na, calculated 305.0928, observed 305.0930. 
IR (cm-1): 776, 843, 962, 1131, 1233, 1290, 1449, 1550, 1686. 
M.p.: 181-183 oC. 
 
(106) 
C13H18N2O3S 
MW = 282.36g/mol 
(94) 
Experimental   2 
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2.2.4.2  Synthesis of N'-methylsulfonyl-2-oxo-2-phenyl-N,N-dipropyl-acetamidine 
   
 
 
 
Under an atmosphere of nitrogen, a solution of 2-(dipropylamino)-1,3-diphenyl-prop-2-en-1-one 
(95) (4.69 g, 15.26 mmol) in ethanol (35 ml) was added to a solution of methanesulfonyl azide (1.85 
g, 15.26 mmol) in ethanol (20 ml). The reaction mixture was set to stir at reflux for 24 hours. After 
this time, solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as an orange solid (2.27 g, 48%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϳϮ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϭ.ϬϮ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϰϬ-1.65 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϮ-1.88 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϳ ;ϯH, s, SO2CH3Ϳ; ɷϯ.Ϭϭ ;ϮH, 
m, NCH2CH2CH3Ϳ; ɷϯ.ϯϯ-3.44 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϲϮ-3.76 (1H, m, NCH2CH2CH3Ϳ; ɷϳ.ϱϯ ;ϮH, t, 
J=7.8Hz, PhH); ɷϳ.ϳϱ ;ϭH, t, J=ϳ.ϰHz, PhHͿ; ɷϳ.ϵϬ ;ϮH, d, J=ϳ.ϱHz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϳ ;NCH2CH2CH3), 11.45 (NCH2CH2CH3), 19.87 (NCH2CH2CH3), 21.67 
(NCH2CH2CH3), 42.57 (SO2CH3), 49.64 (NCH2CH2CH3), 51.38 (NCH2CH2CH3), 128.83 (PhC), 129.20 
(PhC), 134.46 (PhC), 134.76 (PhC), 162.40 (N=C-N), 192.67 (C=O). 
micrOTOF-Q MS m/z C15H22N2O3S+Na calculated 333.1243, observed 333.1241. 
IR (cm-1): 695, 710, 797, 843, 900, 958, 1127, 1272, 1286, 1545. 
M.p.: 117-118 oC. 
 
 
(107) 
C15H22N2O3S 
MW = 310.41g/mol 
(95) 
Experimental   2 
111 
 
2.2.4.3  Synthesis of N-[2-oxo-2-phenyl-1-(1-piperidyl)ethylidene]   
  methanesulfonamide  
 
 
 
Under an atmosphere of nitrogen, a solution of 1,3-diphenyl-2-(1-piperidyl)prop-2-en-1-one (96) 
(5.17 g, 17.74 mmol) in ethanol (50 ml) was added to a solution of methanesulfonyl azide (2.15 g, 
17.74 mmol) in ethanol (20 ml). The reaction mixture was set to stir at reflux for 24 hours. After this 
time, solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as an off-white solid (896 mg, 17%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϱ-1.56 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϲϱ-1.80 (4H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϵϴ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϭϭ-3.29 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϴ-3.92 (2H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϳ.ϱϰ ;ϮH, t, J=ϳ.ϵHz, PhHͿ; ɷϳ.ϲϱ ;ϭH, tt, J=ϳ.ϰHz, ϭ.ϮHz, PhHͿ; ɷϳ.ϵϮ ;ϮH, d, 
J=7.3Hz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϴϳ ;N;CH2)2(CH2)2CH2), 25.27 (N(CH2)2(CH2)2CH2), 26.03 
(N(CH2)2(CH2)2CH2), 42.61 (SO2CH3), 45.90 (N(CH2)2(CH2)2CH2), 48.84 (N(CH2)2(CH2)2CH2), 128.85 (PhC), 
129.24 (PhC), 134.39 (PhC), 134.87 (PhC), 161.34 (N=C-N), 193.16 (C=O). 
micrOTOF-Q MS m/z C14H18N2O3S+Na calculated 317.0930, observed 317.0922. 
IR (cm-1): 758, 779, 821, 856, 963, 1130, 1226, 1295, 1444, 1549. 
M.p.: 164-166 oC. 
 
(96) (108) 
C14H18N2O3S 
MW = 294.37g/mol 
Experimental   2 
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2.2.4.4  Synthesis of 2-(4-methoxyphenyl)-N'-methylsulfonyl-2-oxo-N,N-dipropyl-
  acetamidine 
 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 2-(dipropylamino)-1-(4-methoxyphenyl)-3-phenyl-
prop-2-en-1-one (98) (4.58 g, 14.80 mmol) in ethanol (45 ml) was added to a solution of 
methanesulfonyl azide (1.79 g, 14.80 mmol) in ethanol (15 ml). The reaction mixture was set to stir 
at reflux for 24 hours. After this time, solvents were removed under reduced pressure. The crude 
product was purified by gravity column chromatography with a 1:1 petroleum ether:ethyl acetate 
solvent system to yield the pure product as an orange oil (3.40 g, 55%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϳϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϭ.Ϭϭ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϰϭ-1.69 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϮ-1.87 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϲ ;ϯH, s, SO2CH3Ϳ; ɷϮ.ϵϴ-3.10 
(2H, m, NCH2CH2CH3); ɷϯ.ϯϱ-3.44 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϲϭ-3.71 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϴϵ ;ϯH, 
s, ArOCH3Ϳ; ɷϳ.ϬϬ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϳ.ϴϲ ;ϮH, d, J=ϳ.ϴHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϵϰ ;NCH2CH2CH3), 11.47 (NCH2CH2CH3), 19.90 (NCH2CH2CH3), 21.72 
(NCH2CH2CH3), 42.60 (SO2CH3), 49.53 (NCH2CH2CH3), 51.36 (NCH2CH2CH3), 55.70 (ArOCH3), 114.57 
(Ar), 127.69 (Ar), 131.36 (Ar), 162.68 (Ar), 164.88 (N=C-N), 171.15 (C=O). 
micrOTOF-Q MS m/z C16H24N2O4S+Na, calculated 363.1349, observed 363.1348. 
IR (cm-1): 833, 959, 1015, 1128, 1168, 1234, 1258, 1291, 1541, 1596. 
 
 
(109) 
C16H24N2O4S 
MW = 340.44g/mol 
(98) 
Experimental   2 
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2.2.4.5  Synthesis of N-[2-(4-methoxyphenyl)-2-oxo-1-(1-piperidyl)ethylidene] 
methanesulfonamide 
 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 1-(4-methoxyphenyl)-3-phenyl-2-(1-piperidyl)prop-2-
en-1-one (99) (4.75 g, 14.78 mmol) in ethanol (40 ml) was added to a solution of methanesulfonyl 
azide (1.79 g, 14.78 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 
hours. After this time, solvents were removed under reduced pressure. The crude product was 
purified by gravity column chromatography with a 1:2 petroleum ether:ethyl acetate solvent system 
to yield the pure product as an orange solid (1.14 g, 24%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϲ-1.49 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϬ-1.61 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϲϰ-1.78 (4H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϵϴ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϭϯ-3.31 (2H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϮ-3.82 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϴϰ-3.91 (1H, m, N(CH2)2(CH2)2CH2); 
ɷϯ.ϴϵ ;ϯH, s, AƌOCH3Ϳ; ɷϳ.ϬϬ ;ϮH, d, J=ϴ.ϰHz, AƌHͿ; ɷϳ.ϴϵ (2H, d, J=8.4Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϴϵ ;N;CH2)2(CH2)2CH2), 25.29 (N(CH2)2(CH2)2CH2), 26.11 
(N(CH2)2(CH2)2CH2), 42.61 (SO2CH3), 43.37 (N(CH2)2(CH2)2CH2), 45.76 (N(CH2)2(CH2)2CH2), 55.69 
(ArOCH3), 114.60 (Ar), 127.63 (Ar), 131.40 (Ar), 161.56 (Ar), 164.95 (N=C-N), 191.14 (C=O). 
micrOTOF-Q MS m/z C15H20N2O4S+Na, calculated 347.1036, observed 347.1037. 
IR (cm-1): 809, 972, 1115, 1132, 1157, 1240, 1259, 1281, 1243, 1549. 
M.p.: 165-167 oC. 
 
 
(110) 
C15H20N2O4S 
MW = 324.39g/mol 
(99) 
Experimental   2 
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2.2.4.6  Synthesis of (NZ)-N-[2-(4-methoxyphenyl)-1-morpholino-2-oxo-ethylidene]
  methanesulfonamide  
 
 
 
 
Under an atmosphere of nitrogen, a solution of 1-(4-methoxyphenyl)-2-morpholino-3-phenyl-prop-
2-en-1-one (100) (5.82 g, 18.00 mmol) in ethanol (50 ml) was added to a solution of methanesulfonyl 
azide (2.18 g, 18.00 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 
hours. After this time, solvents were removed under reduced pressure. The crude product was 
purified by gravity column chromatography with a 1:2 petroleum ether:ethyl acetate solvent system 
to yield the pure product as a pale yellow solid (170 mg, 3%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϲϭ ;ϰH, t, J=ϰ.ϰHz, N;CH2)2(CH2)2OͿ; ɷϯ.ϳϳ (3H, s, SO2CH3Ϳ; ɷϯ.ϳϴ ;ϰH, t, 
J=4.6Hz, N(CH2)2(CH2)2OͿ; ɷϯ.ϴϴ ;ϯH, s, AƌOCH3Ϳ; ɷϲ.ϵϰ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϴ.ϬϬ ;ϮH, d, J=ϴ.ϵHz, 
ArH).  
13C NMR (100MHz, CDCl3Ϳ: ɷϱϯ.ϵϬ ;SO2CH3), 55.49 (N(CH2)2(CH2)2O), 64.55 (N(CH2)2(CH2)2O), 66.83 
(ArOCH3), 113.72 (Ar), 129.03 (Ar), 130.45 (Ar), 163.64 (N=C-N), 194.62 (C=O). 
IR (cm-1): 825, 973, 1022, 1112, 1161, 1226, 1255, 1510, 1597, 1672. 
 
 
 
 
 
 
 
(111) 
C14H18N2O5S 
MW = 326.37g/mol 
(100) 
Experimental   2 
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2.2.4.7  Synthesis of 2-(4-chlorophenyl)-N,N-diethyl-N'-methylsulfonyl-2-oxo- 
  acetamidine 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 1-(4-chlorophenyl)-2-(diethylamino)-3-phenyl-prop-
2-en-1-one (101) (4.50 g, 14.34 mmol) in ethanol (40 ml) was added to a solution of methanesulfonyl 
azide (1.74 g, 14.34 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 
hours. After this time, solvents were removed under reduced pressure. The crude product was 
purified by gravity column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system 
to yield the pure product as a red oil (1.92 g, 42%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϵ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϭ.ϯϯ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϵϳ 
(3H, s, SO2CH3Ϳ; ɷϯ.ϭϰ ;ϮH, Ƌ, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.ϰϲ-3.60 (1H, m, NCH2CH3Ϳ; ɷϯ.ϲϲ-3.81 (1H, m, 
NCH2CH3Ϳ; ɷϳ.ϱϭ ;ϮH, d, J=ϴ.ϴHz, AƌHͿ; ɷϳ.ϴϰ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϵϬ ;NCH2CH3), 13.73 (NCH2CH3), 42.59 (SO2CH3), 42.75 (NCH2CH3), 
44.26 (NCH2CH3), 124.65 (Ar), 130.11 (Ar), 132.78 (Ar), 141.36 (Ar), 161.32 (N=C-N), 191.35 (C=O). 
micrOTOF-Q MS m/z C13H17ClN2O3S+Na, calculated 339.0541, observed 339.0535. 
IR (cm-1): 781, 823, 950, 1132, 1239, 1291, 1439, 1558, 1681, 2980. 
M.p.: 177-179 oC. 
 
 
 
(112) 
C13H17ClN2O3S 
MW = 316.80g/mol 
(101) 
Experimental   2 
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2.2.4.8  Synthesis of 2-(4-chlorophenyl)-N'-methylsulfonyl-2-oxo-N,N-dipropyl- 
  acetamidine 
 
 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 1-(4-chlorophenyl)-2-(dipropylamino)-3-phenyl-
prop-2-en-1-one (102) (5.00 g, 14.63 mmol) in ethanol (40 ml) was added to a solution of 
methanesulfonyl azide (1.77 g, 14.63 mmol) in ethanol (10 ml). The reaction mixture was set to stir 
at reflux for 24 hours. After this time, solvents were removed under reduced pressure. The crude 
product was purified by gravity column chromatography with a 2:1 petroleum ether: ethyl acetate 
solvent system to yield the pure product as an orange oil (3.21 g, 64%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϳϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϭ.Ϭϭ ;ϯH, t, J=ϳ.4Hz, NCH2CH2CH3); 
ɷϭ.ϰϮ-1.66 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϬ-11.87 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϳ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϬϬ 
(2H, t, J=7.8Hz, NCH2CH2CH3Ϳ; ɷϯ.ϯϭ-3.46 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϲϬ-3.72 (1H, m, NCH2CH2CH3); 
ɷϳ.ϱϭ ;ϮH, d, J=ϴ.ϴHz, AƌHͿ; ɷϳ.ϴϰ ;ϮH, d, J=8.6Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϴ ;NCH2CH2CH3), 11.43 (NCH2CH2CH3), 19.87 (NCH2CH2CH3), 21.72 
(NCH2CH2CH3), 42.59 (SO2CH3), 49.71 (NCH2CH2CH3), 51.40 (NCH2CH2CH3), 129.66 (Ar), 130.10 (Ar), 
132.87 (Ar), 141.36 (Ar), 161.82 (N=C-N), 191.46 (C=O). 
micrOTOF-Q MS m/z C15H21ClN2O3S+Na, calculated 367.0854, observed 367.0849. 
IR (cm-1): 837, 956, 1008, 1083, 1110, 1126, 1222, 1285, 1551, 1684. 
M.p.: 174-176 oC. 
 
(113) 
C15H21ClN2O3S 
MW = 344.86g/mol 
(102) 
Experimental   2 
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2.2.4.9  Synthesis of N-[2-(4-chlorophenyl)-2-oxo-1-(1-piperidyl)ethylidene]  
  methanesulfonamide 
 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 1-(4-chlorophenyl)-3-phenyl-2-(1-piperidyl)prop-2-
en-1-one (103) (4.50 g, 13.81 mmol) in ethanol (40 ml) was added to a solution of methanesulfonyl 
azide (1.67 g, 13.81 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 
hours. After this time, solvents were removed under reduced pressure. The crude product was 
purified by gravity column chromatography using a 1:1 petroleum ether:ethyl acetate solvent system 
to yield the pure product as a dark red oil (2.01 g, 44%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϲ-1.61 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϲϱ-1.79 (4H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϵϴ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϭϮ-3.26 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϵ-3.88 (2H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϳ.ϱϮ ;ϮH, d, J=ϴ.ϳHz, AƌHͿ; ɷϳ.ϴϲ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϴϮ ;N;CH2)2(CH2)2CH2), 25.26 (N(CH2)2(CH2)2CH2), 26.10 
(N(CH2)2(CH2)2CH2), 42.62 (SO2CH3), 45.98 (N(CH2)2(CH2)2CH2), 48.85 (N(CH2)2(CH2)2CH2), 129.71 (Ar), 
130.11 (Ar), 132.78 (Ar), 141.54 (Ar), 160.78 (N=C-N), 191.98 (C=O). 
micrOTOF-Q MS m/z C14H17N2ClO3S+Na, calculated 351.0541, observed 351.0531. 
IR (cm-1): 762, 807, 966, 1089, 1131, 1221, 1282, 1293, 1549, 1682. 
M.p.: 163-165 oC. 
 
 
 
(114) 
C14H17ClN2O3S 
MW = 328.81g/mol 
(103) 
Experimental   2 
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2.2.4.10 Synthesis of N,N-diethyl-N'-methylsulfonyl-2-oxo-2-(p-tolyl)acetamidine 
   
 
 
 
 
Under an atmosphere of nitrogen, a solution of 2-(diethylamino)-3-phenyl-1-(p-tolyl)prop-2-en-1-
one (104) (5.00 g, 17.04 mmol) in ethanol (40 ml) was added to a solution of methanesulfonyl azide 
(2.06 g, 17.04 mmol) in ethanol (40 ml). The reaction mixture was set to stir at reflux for 24 hours. 
After this time, solvents were removed under reduced pressure. The crude product was purified by 
gravity column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system to yield the 
pure product as a dark yellow oil (1.01 g, 20%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϴ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.ϯϯ ;ϯH, t, J=ϳ.01Hz, NCH2CH3Ϳ; ɷϮ.ϰϯ 
(3H, s, ArCH3); ɷϮ.ϵϱ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϭϱ ;ϮH, sept, J=ϲ.ϳHz, NCH2CH3Ϳ; ɷϯ.ϰϱ-3.57 (1H, m, 
NCH2CH3Ϳ; ɷϯ.ϲϴ-3.79 (1H, m, NCH2CH3Ϳ; ɷϳ.ϯϯ ;ϮH, d, J=ϴ.ϭHz, AƌHͿ; ɷϳ.ϳϴ ;ϮH, d, J=ϴ.ϭHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϵϬ ;NCH2CH3), 13.69 (NCH2CH3), 21.92 (ArCH3), 42.58 (SO2CH3), 42.60 
(NCH2CH3), 44.23 (NCH2CH3), 128.94 (Ar), 129.96 (Ar), 131.99 (Ar), 146.17 (Ar), 162.03 (N=C-N), 
191.94 (C=O). 
micrOTOF-Q MS m/z C14H20N2O3S+Na, calculated 319.1087, observed 319.1077. 
IR (cm-1): 938, 950, 964, 1131, 1117, 1236, 1290, 1315, 1441, 1553. 
 
 
 
 
(104) (115) 
C14H20N2O3S 
MW = 296.38g/mol 
Experimental   2 
119 
 
2.2.4.11 Synthesis of N-[2-oxo-1-(1-piperidyl)-2-(p-tolyl)ethylidene]  
  methanesulfonamide 
 
 
 
 
 
 
Under an atmosphere of nitrogen, a solution of 3-phenyl-2-(1-piperidyl)-1-(p-tolyl)prop-2-en-1-one 
(105) (5.00 g, 16.37 mmol) in ethanol (40 ml) was added to a solution of methanesulfonyl azide (1.98 
g, 16.37 mmol) in ethanol (10 ml). The reaction mixture was set to stir at reflux for 24 hours. After 
this time, solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 1:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a dark red oil (2.09 g, 42%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϲ-1.60 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϲϰ-1.79 (4H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϰϯ ;ϯH, s, AƌCH3Ϳ; ɷϮ.ϵϳ ;ϯH, s, SO2CH3Ϳ; ɷϯ.ϭϭ-3.29 (2H, m, N(CH2)2(CH2)2CH2); 
ɷϯ.ϳϰ-3.93 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϳ.ϯϯ ;ϮH, d, J=ϳ.ϵHz, AƌHͿ; ɷϳ.ϴϭ ;ϮH, d, J=ϳ.ϴHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.ϵϯ (ArCH3), 23.85 (N(CH2)2(CH2)2CH2), 25.28 (N(CH2)2(CH2)2CH2), 26.06 
(N(CH2)2(CH2)2CH2), 42.63 (SO2CH3), 45.83 (N(CH2)2(CH2)2CH2), 48.83 (N(CH2)2(CH2)2CH2), 128.98 (Ar), 
130.00 (Ar), 132.04 (Ar), 146.29 (Ar), 161.45 (N=C-N), 192.54 (C=O). 
micrOTOF-Q MS m/z C15H20N2O3S+Na, calculated 331.1087, observed 331.1083. 
IR (cm-1): 804, 860, 968, 1114, 1132, 1227, 1294, 1449, 1546, 1673. 
 
 
 
 
(105) (116) 
C15H20N2O3S 
MW = 308.40g/mol 
Experimental   2 
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2.2.5  Experimental Procedures for the Synthesis of 3-Dialkylamino-4-hydroxy-4-
  aryl-isothiazoline-1,1-dioxides 
2.2.5.1  Synthesis of 3-(diethylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
 
 
 
To N,N-diethyl-N'-methylsulfonyl-2-oxo-2-phenyl-acetamidine (106) (3.50 g, 12.40 mmol) in dry 
tetrahydrofuran (28 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (6.96 ml, 12.40 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure to yield the product as an off-
white solid (2.85 g, 81%).  
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϳϰ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϰ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.Ϯϳ 
(2H, m, NCH2CH3Ϳ; ɷϯ.ϯϵ-3.58 (2H, m, NCH2CH3Ϳ; ɷϯ.ϲϳ (1H, d, J=14.1Hz, SO2CH2Ϳ; ɷϯ.ϵϭ ;ϭH, d, 
J=14.2Hz, SO2CH2Ϳ; ɷϱ.ϰϰ ;ϭH, ďƌoad, OHͿ; ɷϳ.ϯϰ ;ϭH, tt, J=ϳ.ϮHz, Ϯ.ϭHz, PhHͿ; ɷϳ.ϰϭ ;ϮH, t, J=ϳ.ϮHz, 
PhHͿ; ɷϳ.ϱϯ ;ϮH, appt. d, J=7.9Hz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϰ ;NCH2CH3), 12.60 (NCH2CH3), 43.43 (NCH2CH3), 44.90 (NCH2CH3), 
64.59 (SO2CH2), 83.65 (COH), 123.94 (PhC), 128.46 (PhC), 129.11 (PhC), 141.00 (PhC), 168.49 (N=C-
N). 
micrOTOF-Q MS m/z C13H18N2O3S+Na, calculated 305.0930, observed 305.0923. 
IR (cm-1): 762, 846, 917, 965, 1070, 1121, 1232, 1292, 1578, 3424. 
M.p.: 164-166 oC. 
(117) 
C13H18N2O3S 
MW = 282.36g/mol 
(106) 
Experimental   2 
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2.2.5.2  Synthesis of 3-(dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
   
 
 
 
To N'-methylsulfonyl-2-oxo-2-phenyl-N,N-dipropyl-acetamidine (107) (1.00 g, 3.22 mmol) in dry 
tetrahydrofuran (8 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (1.81 ml) was added rapidly at room temperature and the mixture set to 
stir for 24 hours. After this time, the reaction mixture was neutralised with 1M hydrochloric acid. 
The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the organic layers 
combined and washed with water. The organics were dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure yielding the product as an off-white solid (960 mg, 
96%).  
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϱϲ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϳϳ-0.87 (1H, m, NCH2CH2CH3); 
ɷϬ.ϵϬ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϭ.ϯϴ-1.52 (1H, m, NCH2CH2CH3); ɷϭ.ϱϲ-1.69 (1H, m, 
NCH2CH2CH3Ϳ; ɷϭ.ϳϬ-1.83 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϭϲ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϯ.ϯϲ ;ϮH, ŵ 
NCH2CH2CH3Ϳ; ɷϯ.ϲϲ ;ϭH, d, J=ϭϰ.ϬHz, SO2CH2Ϳ; ɷϯ.ϵϱ ;ϭH, d, J=ϭϰ.ϮHz, SO2CH2Ϳ; ɷϱ.ϲϵ ;ϭH, s, OH); 
ɷϳ.ϯϯ ;ϭH, ŵ, PhHͿ; ɷϳ.ϰϬ ;ϮH, t, J=ϳ.ϵHz, PhHͿ; ɷϳ.ϱϱ (2H, d, J=8.0Hz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϭ ;NCH2CH2CH3), 11.30 (NCH2CH2CH3), 19.27 (NCH2CH2CH3), 20.89 
(NCH2CH2CH3), 50.65 (NCH2CH2CH3), 52.13 (NCH2CH2CH3), 64.47 (SO2CH2), 83.72 (COH), 123.97 (PhC) 
128.41 (PhC), 129.02 (PhC), 141.24 (PhC), 169.00 (N=C-N). 
micrOTOF-Q MS m/z C15H22N2O3S+Na, calculated 333.1243, observed 333.1240. 
IR (cm-1): 767, 853, 905, 1070, 1122, 1146, 1223, 1282, 1580. 
M.p.: 136-138 oC. 
(118) 
C15H22N2O3S 
MW = 310.41g/mol 
(107) 
Experimental   2 
122 
 
2.2.5.3  Synthesis of 3-(dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
    
 
 
 
To N-[2-oxo-2-phenyl-1-(1-piperidyl)ethylidene]  methanesulfonamide (108) (896 mg, 3.04 mmol) in 
dry tetrahydrofuran (7 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (1.71 ml, 3.04 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure yielding the product as an 
orange solid (780 mg, 87%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϰ-0.97 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.Ϯϵ-1.42 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϰϱ-1.72 (5H, m, N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2); ɷϯ.ϯϰ ;ϮH, ŵ, 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϲϲ ;ϭH, d, J=ϭϰ.Ϯ, SO2CH2Ϳ; ɷϯ.ϲϳ-3.72 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϵϬ ;ϭH, d, 
J=14.2, SO2CH2Ϳ; ɷϲ.ϯϲ ;ϭH, ďƌoad, OHͿ; ɷϳ.Ϯϵ-7.35 (1H, m, PhHͿ; ɷϳ.ϰϬ ;ϮH, t, J=ϳ.ϯHz, PhHͿ; ɷϳ.ϱϯ 
(2H, appt. d, J=7.5Hz, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϲϵ ;N;CH2)2(CH2)2CH2Ϳ, ɷϮϱ.Ϯϰ ;N;CH2)2(CH2)2CH2Ϳ, ɷϮϱ.ϯϲ 
(N(CH2)2(CH2)2CH2Ϳ, ɷϮϱ.ϲϭ ;N;CH2)2(CH2)2CH2Ϳ, ɷϰϴ.ϯϳ ;N;CH2)2(CH2)2CH2Ϳ, ɷϲϱ.ϬϬ ;COHͿ, ɷϴϯ.ϰϵ 
(SO2CH2Ϳ, ɷϭϮϯ.ϳϵ ;PhCͿ, ɷϭϮϴ.ϱϮ ;PhCͿ, ɷϭϮϵ.ϭϳ ;PhCͿ, ɷϭϰϬ.ϳϰ ;PhCͿ, ɷϭϲϳ.ϲϰ ;N=C-N). 
IR (cm-1): 766, 859, 943, 1073, 1124, 1141, 1227, 1287, 1586. 
M.p.: 172-174 oC. 
(119) 
C14H18N2O3S 
MW = 294.37g/mol 
(108) 
Experimental   2 
123 
 
2.2.5.4  Synthesis of 3-(dipropylamino)-4-(4-methoxyphenyl)-1,1-dioxo-5H- 
  isothiazol-4-ol   
 
 
 
 
To 2-(4-methoxyphenyl)-N'-methylsulfonyl-2-oxo-N,N-dipropyl-acetamidine (109) (3.40 g, 9.98 
mmol) in dry tetrahydrofuran (12 ml) under an atmosphere of nitrogen, a 20% w/v solution of 
potassium t-butoxide in tetrahydrofuran (6.00 ml, 9.98 mmol) was added rapidly at room 
temperature and the reaction mixture set to stir for 24 hours. After this time, the reaction mixture 
was neutralised with 1M hydrochloric acid. The aqueous mixture was extracted with 
dichloromethane (3 x 25ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to 
yield the product as a yellow oil (3.35 g, 99%).  
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϬ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϴϳ-0.96 (4H, m, NCH2CH2CH3, 
NCH2CH2CH3Ϳ; ɷϭ.ϰϬ-1.51 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϱϳ-1.80 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.ϭϱ ;ϮH, ŵ, 
NCH2CH2CH3Ϳ; ɷϯ.ϯϱ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϯ.ϲϮ ;ϭH, d, J=ϭϰ.ϭHz, SO2CH2Ϳ; ɷϯ.ϴϮ ;ϯH, s, AƌOCH3); 
ɷϯ.ϴϵ ;ϭH, d, J=ϭϰ.ϬHz, SO2CH2Ϳ; ɷϱ.ϱϮ-5.89 (1H, broad, OHͿ; ɷϲ.ϵϭ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϳ.ϰϱ ;ϮH, 
d, J=8.9Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϴ ;NCH2CH2CH3), 11.29 (NCH2CH2CH3), 19.29 (NCH2CH2CH3), 21.01 
(NCH2CH2CH3), 50.62 (NCH2CH2CH3), 52.15 (NCH2CH2CH3), 55.36 (ArOCH3), 64.62 (SO2CH2), 83.54 
(COH), 114.31 (Ar), 125.28 (Ar), 133.03 (Ar), 159.52 (Ar), 169.02 (N=C-N). 
micrOTOF-Q MS m/z C16H24N2O4S+Na, calculated 363.1349, observed 363.1340. 
IR (cm-1): 834, 857, 913, 1033, 1127, 1147, 1229, 1264, 1513, 1581. 
(120) 
C16H24N2O4S 
MW = 340.44g/mol 
 
(109) 
Experimental   2 
124 
 
2.2.5.5  Synthesis of 3-(dipropylamino)-4-(4-methoxyphenyl)-1,1-dioxo-5H- 
  isothiazol-4-ol  
 
 
 
 
 
To N-[2-(4-methoxyphenyl)-2-oxo-1-(1-piperidyl)ethylidene] methanesulfonamide (110) (1.10 g, 3.39 
mmol) in dry tetrahydrofuran (9 ml) under an atmosphere of nitrogen, a 20% w/v solution of 
potassium t-butoxide in tetrahydrofuran (1.90 ml, 3.39 mmol) was added rapidly at room 
temperature and the mixture set to stir for 24 hours. After this time, the reaction mixture was 
neutralised with 1M hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 
x 25ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to yield the 
product as an off-white solid (660 mg, 60%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵϯ-1.05 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϲ-1.73 (6H, m, 
N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.Ϯϭ-3.30 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϰϰ-
3.52 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϲϰ ;ϭH, d, J=ϭϰ.ϭHz, SO2CH2Ϳ; ɷϯ.ϲϴ-3.73 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϴϭ ;ϯH, s, AƌOCH3Ϳ; ɷϯ.ϵϰ ;ϭH, d, J=ϭϰ.ϭHz, SO2CH2Ϳ; ɷϱ.ϯϵ-6.14 (1H, broad, 
OHͿ; ɷϲ.ϵϭ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϳ.ϰϰ ;ϮH, d, J=8.8Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϳϱ ;N;CH2)2(CH2)2CH2), 25.33 (N(CH2)2(CH2)2CH2), 25.39 
(N(CH2)2(CH2)2CH2), 48.28 (N(CH2)2(CH2)2CH2), 49.26 (N(CH2)2(CH2)2CH2), 55.30 (ArOCH3), 64.71 
(SO2CH2), 83.38 (COH), 114.28 (Ar), 125.26 (Ar), 133.17 (Ar), 159.41 (Ar), 168.20 (N=C-N). 
 
 
(121) 
C15H20N2O4S 
MW = 324.39g/mol 
(110) 
Experimental   2 
125 
 
2.2.5.6  Synthesis of 4-(4-chlorophenyl)-3-(diethylamino)-1,1-dioxo-5H-isothiazol-4-
  ol  
 
 
 
 
 
 
To 2-(4-chlorophenyl)-N,N-diethyl-N'-methylsulfonyl-2-oxo-acetamidine (112) (1.92 g, 6.06 mmol) in 
dry tetrahydrofuran (10 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (4.08 ml, 7.27 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure to yield the product as an off-
white solid (1.60 g, 83%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϭ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.ϮϮ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.Ϯϱ 
(2H, m, NCH2CH3Ϳ; ɷϯ.ϰϴ ;ϮH, ŵ, NCH2CH3Ϳ; ɷϯ.ϲϮ ;ϭH, d, J=14.2Hz, SO2CH2Ϳ; ɷϯ.ϵϭ ;ϭH, d, J=ϭϰ.ϮHz, 
SO2CH2Ϳ; ɷϱ.ϳϬ-5.94 (1H, broad, OHͿ; ɷϳ.ϯϵ ;ϮH, d, J=ϴ.ϳHz, AƌHͿ; ɷϳ.ϰϴ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϮ ;NCH2CH3), 12.80 (NCH2CH3), 43.43 (NCH2CH3), 44.99 (NCH2CH3), 
64.24 (SO2CH2), 83.30 (COH), 125.53 (Ar), 129.30 (Ar), 134.49 (Ar), 139.61 (Ar), 168.27 (N=C-N). 
micrOTOF-Q MS m/z C13H17ClN2O3S+Na, calculated 339.0541, observed 339.0533. 
IR (cm-1): 838, 916, 967, 1078, 1141, 1124, 1207, 1220, 1286, 1585. 
 
(123) 
C13H17ClN2O3S 
MW = 316.80g/mol 
(112) 
Experimental   2 
126 
 
2.2.5.7  Synthesis of 4-(4-chlorophenyl)-3-(dipropylamino)-1,1-dioxo-5H-isothiazol-
  4-ol  
 
 
 
 
To 2-(4-chlorophenyl)-N'-methylsulfonyl-2-oxo-N,N-dipropyl-acetamidine (113) (3.21 g, 9.31 mmol) 
in dry tetrahydrofuran (15 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (6.27 ml, 11.17 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure to yield the product as a red 
oil (2.45 g, 76%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϮ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϭ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϬ.ϵϰ-1.03 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϰϴ-1.53 (1H, m, NCH2CH2CH3); ɷϭ.ϱϰ-1.67 (1H, m, NCH2CH2CH3); 
ɷϭ.ϲϴ-1.78 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.Ϭϯ-3.20 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.Ϯϯ-3.33 (1H, m, NCH2CH2CH3); 
ɷϯ.ϯϵ-3.48 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϲϬ ;ϭH, d, J=ϭϰ.ϭHz, SO2CH2Ϳ; ɷϯ.ϵϬ ;ϭH, d, J=ϭϰ.ϮHz, SO2CH2); 
ɷϱ.ϱϭ-5.81 (1H, broad, OH); ɷϳ.ϯϵ ;ϮH, d, J=ϴ.ϳHz, AƌHͿ; ɷϳ.ϰϵ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϰ ;NCH2CH2CH3), 11.27 (NCH2CH2CH3), 19.27 (NCH2CH2CH3), 21.07 
(NCH2CH2CH3), 50.66 (NCH2CH2CH3), 52.18 (NCH2CH2CH3), 64.24 (SO2CH2), 83.37 (COH), 125.54 (Ar), 
129.25 (Ar), 134.46 (Ar), 139.69 (Ar), 168.56 (N=C-N). 
micrOTOF-Q MS m/z C15H21ClN2O3S+Na, calculated 367.0854, observed 367.0852. 
IR (cm-1): 815, 856, 912, 1081, 1129, 1143, 1226, 1276, 1578. 
(124) 
C15H21ClN2O3S 
MW = 344.86g/mol 
(113) 
Experimental   2 
127 
 
2.2.5.8  Synthesis of 3-(diethylamino)-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-4-ol 
   
 
 
 
 
To N,N-diethyl-N'-methylsulfonyl-2-oxo-2-(p-tolyl)acetamidine (115) (1.07 g, 3.41 mmol) in dry 
tetrahydrofuran (7 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (2.29 ml, 4.09 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure to yield the product as a 
yellow solid (780 mg, 77%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϳϴ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϯ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϮ.ϯϱ 
(3H, s, ArCH3); ɷϯ.Ϯϴ ;ϮH, Ŷ, J=ϴ.ϮHz, NCH2CH3Ϳ; ɷϯ.ϰϳ ;ϮH, ŵ, NCH2CH3Ϳ; ɷϯ.ϲϯ ;ϭH, d, J=14.0Hz, 
SO2CH2Ϳ; ɷϯ.ϵϯ ;ϭH, d, J=ϭϰ.ϬHz, SO2CH2Ϳ; ɷϱ.ϱϳ ;ϭH, s, OHͿ; ɷϳ.ϮϬ ;ϮH, d, J=ϴ.ϬHz, AƌHͿ; ɷϳ.ϰϭ ;ϮH, d, 
J=7.9Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϯ ;NCH2CH3), 12.71 (NCH2CH3), 21.09 (ArCH3), 43.45 (NCH2CH3), 
44.87 (NCH2CH3), 64.44 (SO2CH2), 83.64 (COH), 123.85 (Ar), 129.66 (Ar), 138.13 (Ar), 138.20 (Ar), 
168.85 (N=C-N). 
micrOTOF-Q MS m/z C14H20N2O3S+Na, calculated 319.1087, observed 319.1086. 
IR (cm-1): 820, 854, 916, 964, 1076, 1128, 1144, 1228, 1297, 1585, 3395. 
M.p.: 179-180 oC. 
(126) 
C14H20N2O3S 
MW = 296.38g/mol 
(115) 
Experimental   2 
128 
 
2.2.5.9  Synthesis of 3-(dipropylamino)-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-4-ol 
   
 
 
 
To N-[2-oxo-1-(1-piperidyl)-2-(p-tolyl)ethylidene] methanesulfonamide (116) (2.09 g, 6.78 mmol) in 
dry tetrahydrofuran (10 ml) under an atmosphere of nitrogen, a 20% w/v solution of potassium t-
butoxide in tetrahydrofuran (4.57 ml, 8.14 mmol) was added rapidly at room temperature and the 
mixture set to stir for 24 hours. After this time, the reaction mixture was neutralised with 1M 
hydrochloric acid. The aqueous mixture was extracted with dichloromethane (3 x 25ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was 
purified by gravity column chromatography with a 2:1 petroleum ether:ethyl acetate solvent system 
to yield the pure product as a dark brown solid (830 mg, 42%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵϱ-1.05 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϴ-1.53 (2H, m, 
N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϰ-1.63 (2H, m, N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϲϰ-
1.75 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϯϱ ;ϯH, s, AƌCH3Ϳ; ɷϯ.ϭϳ-3.26 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϰϱ-
3.54 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϲϯ-3.70 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϲϱ ;ϭH, d, J=ϭϰ.ϭHz, 
SO2CH2Ϳ; ɷϯ.ϳϮ-3.81 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϵϲ ;ϭH, d, J=ϭϰ.ϭHz, SO2CH2Ϳ; ɷϱ.ϱϲ ;ϭH, s, OH); 
ɷϳ.ϮϬ ;ϮH, d, J=ϳ.ϴHz, AƌHͿ; ɷϳ.ϰϬ ;ϮH, d, J=ϳ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.ϭϬ (ArCH3), 23.76 (N(CH2)2(CH2)2CH2), 25.25 (N(CH2)2(CH2)2CH2), 25.39 
(N(CH2)2(CH2)2CH2), 48.34 (N(CH2)2(CH2)2CH2), 49.27 (N(CH2)2(CH2)2CH2), 64.68 (SO2CH2), 83.54 (COH), 
123.80 (Ar), 129.66 (Ar), 138.09 (Ar), 138.18 (Ar), 168.21 (N=C-N). 
micrOTOF-Q MS m/z C15H20N2O3S+Na, calculated 331.1087, observed 331.1085. 
IR (cm-1): 803, 859, 942, 1073, 1138, 1217, 1289, 1442, 1594, 3348. 
(127) 
C15H20N2O3S 
MW = 308.40g/mol 
(116) 
Experimental   2 
129 
 
2.2.6  Experimental Procedures for the Synthesis of 3-Dialkylamino-4-chloro-4-
  aryl-isothiazoline-1,1-dioxides 
2.2.6.1  Synthesis of 4-chloro-N,N-diethyl-1,1-dioxo-4-phenyl-5H-isothiazol-3-amine 
  and N,N-diethyl-1,1-dioxo-4-phenyl-isothiazol-3-amine  
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (21.96ml, 302.70mmol) was added to 3-
(diethylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol (117) (2.85g, 10.09mmol) and the mixture set 
to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed under reduced 
pressure. The residues were then dissolved in dichloromethane and neutralised with 10% w/v 
aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude products were purified by gravity column chromatography with a 3:1 petroleum 
ether:ethyl acetate solvent system to yield a mixture of the chlorinated (1.69g, 56%) and 
dehydrochlorinated (828mg, 31%) products. 
 
2.2.6.1.1 Data for 4-chloro-N,N-diethyl-1,1-dioxo-4-phenyl-5H-isothiazol-3-amine 
(128) 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϮ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϵ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.Ϭϵ 
(2H, m, NCH2CH3Ϳ; ɷϯ.ϱϴ ;ϭH, ŵ, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϯ.ϲϭ-3.69 (1H, m, NCH2CH3Ϳ; ɷϯ.ϴϯ ;ϭH, d, 
J=14.6Hz, SO2CH2); ɷϰ.ϭϴ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϳ.ϯϴ-7.53 (5H, m, PhH). 
(117) 
(128) 
C13H17ClN2O2S 
MW = 300.80g/mol 
(137) 
C13H16N2O2S 
MW = 264.34g/mol 
Experimental   2 
130 
 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.Ϭϴ ;NCH2CH3), 12.17 (NCH2CH3), 44.06 (NCH2CH3), 45.03 (NCH2CH3), 
67.86 (SO2CH2), 71.20 (CCl), 124.65 (PhC), 129.41 (PhC), 129.64 (PhC), 138.57 (PhC), 164.43 (N=C-N). 
micrOTOF-Q MS m/z C13H17ClN2O2S+Na, calculated 323.0591, observed 323.0607. 
IR (cm-1): 697, 754, 771, 904, 1119, 1143, 1233, 1312, 1585. 
 
2.2.6.1.2 Data for N,N-diethyl-1,1-dioxo-4-phenyl-isothiazol-3-amine (137) 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵϬ ;ϯH, t, J=6.8Hz, NCH2CH3Ϳ; ɷϭ.ϯϭ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϯ.Ϭϴ 
(2H, q, J=7.0Hz, NCH2CH3Ϳ; ɷϯ.ϲϰ ;ϮH, Ƌ, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϳ.Ϯϭ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϬ-7.34 (2H, m, 
PhHͿ; ɷϳ.ϰϱ-7.49 (3H, m, PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϵϰ ;NCH2CH3), 14.03 (NCH2CH3), 43.84 (NCH2CH3), 46.69 (NCH2CH3), 
127.32 (PhC), 129.15 (PhC), 129.76 (PhC), 132.00 (SO2C=C), 139.62 (SO2C=C), 143.28 (PhC), 160.71 
(N=C-N). 
micrOTOF-Q MS m/z C13H16N2O2S+Na, calculated 287.0825, observed 287.0844. 
IR (cm-1): 703, 740, 765, 825, 911, 1076, 1121, 1194, 1288, 1555, 3133. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental   2 
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2.2.6.2  Synthesis of 4-chloro-1,1-dioxo-4-phenyl-N,N-dipropyl-5H-isothiazol-3-
amine  
 
 
 
 
 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (6.72 ml, 92.70 mmol) was added to 3-
(dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol (118) (960 mg, 3.09 mmol) and the mixture 
set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 10% 
w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude product was purified by gravity column chromatography with a 3:1 petroleum ether:ethyl 
acetate solvent system to yield the pure product as a white solid (1.34 g, 55%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϱϬ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϬ.ϴϱ-1.00 (1H, m, NCH2CH2CH3); 
ɷϬ.ϵϱ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϭ.ϰϭ-1.57 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϲϰ-1.85 (2H, m, 
NCH2CH2CH3Ϳ; ɷϮ.ϴϵ-3.05 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.ϯϴ-3.53 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.ϴϯ ;ϮH, d, 
J=14.6Hz, SO2CH2Ϳ; ɷϰ.ϭϴ ;ϮH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϳ.ϰϬ-7.50 (3H, m, PhHͿ; ɷϳ.ϱϭ-7.55 (2H, m, 
PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϳϰ ;NCH2CH2CH3), 11.20 (NCH2CH2CH3), 19.07 (NCH2CH2CH3), 20.53 
(NCH2CH2CH3), 51.22 (NCH2CH2CH3), 52.16 (NCH2CH2CH3), 68.00 (SO2CH2), 71.36 (CCl), 124.65 (PhC), 
129.42 (PhC), 129.61 (PhC), 138.51 (PhC), 164.69 (N=C-N). 
micrOTOF-Q MS m/z C15H21ClN2O2S+Na, calculated 351.0904, observed 351.0903. 
IR (cm-1): 751, 843, 896, 915, 1142, 1202, 1237, 1316, 1436, 1580. 
M.p.: 146-149 oC. 
(129) 
C15H21ClN2O2S 
MW = 328.86g/mol 
(118) 
Experimental   2 
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2.2.6.3  Synthesis of 4-chloro-4-phenyl-3-(1-piperidyl)-5H-isothiazole-1,1-dioxide 
   
 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (5.77 ml, 79.50mmol) was added to 3-
(dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol (119) (780 mg, 2.65 mmol) and the mixture 
set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 10% 
w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude product was purified by gravity column chromatography with a 1:1 petroleum ether:ethyl 
acetate solvent system to yield the pure product as a yellow oil (405 mg, 49%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϭ-1.42 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϵ-1.68 (2H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϳϬ-1.83 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.Ϭϱ-3.13 (2H, m, N(CH2)2(CH2)2CH2); 
ɷϯ.ϳϱ-3.87 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϳ.Ϯϱ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϬ-7.34 (2H, m, PhHͿ; ɷϳ.ϰϲ-7.49 (3H, 
m, PhH). 
micrOTOF-Q MS m/z C14H17N2O2SCl+Na, calculated 299.0825, observed 299.0837. 
IR (cm-1): 762, 801, 852, 1120, 1169, 1189, 1289, 1444, 1552, 1594. 
 
(130) 
C14H17ClN2O2S 
MW = 312.81g/mol 
(119) 
Experimental   2 
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2.2.6.4  Synthesis of 4-chloro-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-5H- 
  isothiazol-3-amine  
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (6.38 ml, 87.90 mmol) was added to 3-
(dipropylamino)-4-(4-methoxyphenyl)-1,1-dioxo-5H-isothiazol-4-ol (120) (1.00 g, 2.93 mmol) and the 
mixture set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
10% w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to 
yield the product as a yellow solid (1.06 g, 97%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϱϳ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϱ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϬϬ-1.14 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϰϱ-4.60 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϲϭ-1.87 (2H, m, CH2CH2CH3); 
ɷϮ.ϴϵ-3.08 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.ϯϱ-3.44 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϰϳ-3.56 (1H, m, NCH2CH2CH3); 
ɷϯ.ϴϭ ;ϭH, d, J=14.6Hz, SO2CH2Ϳ; ɷϯ.ϴϰ ;ϯH, s, AƌOCH3Ϳ; ɷϰ.ϭϲ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϲ.ϵϱ ;ϮH, 
appt. d, J=9.0Hz, ArHͿ; ɷϳ.ϰϮ ;ϮH, appt. d, J=8.9Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϰ ;NCH2CH2CH3), 11.24 (NCH2CH2CH3), 19.12 (NCH2CH2CH3), 20.68 
(NCH2CH2CH3), 51.21 (NCH2CH2CH3), 52.22 (NCH2CH2CH3), 55.51 (ArOCH3), 67.98 (SO2CH2), 71.22 
(COH), 114.75 (Ar), 126.15 (Ar), 130.48 (Ar), 160.15 (Ar), 164.87 (N=C-N). 
micrOTOF-Q MS m/z C16H23ClN2O3S+Na, calculated 381.1010, observed 381.1011. 
IR (cm-1): 832, 911, 1027, 1139, 1237, 1255, 1313, 1509, 1577, 2964. 
(131) 
C16H23ClN2O3S 
MW = 358.88g/mol 
(120) 
Experimental   2 
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2.2.6.5  Synthesis of 4-chloro-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-5H- 
  isothiazol-3-amine  
 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (4.42 ml, 60.90 mmol) was added to 3-
(dipropylamino)-4-(4-methoxyphenyl)-1,1-dioxo-5H-isothiazol-4-ol (121) (660 mg, 2.03 mmol) and 
the mixture set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
10% w/v aqueous sodium bicarbonate solution. The aqueous layers was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to 
yield the product as an off-white solid (618 mg, 89%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϭϬ-1.21 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϴ-1.49 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϭ-1.78 (5H, m, N(CH2)2(CH2)2CH2, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϬϮ-3.11 (1H, m, 
N(CH2)2(CH2)2CH2); ɷϯ.Ϯϰ-3.34 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϲ-3.87 (2H, m, N(CH2)2(CH2)2CH2); 
ɷϯ.ϳϵ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϯ.ϴϰ ;ϯH, s, AƌOCH3Ϳ; ɷϰ.ϭϳ ;ϭH, d, J=ϭϰ.ϱHz, SO2CH2Ϳ; ɷϲ.ϵϲ ;ϮH, d, 
J=8.8Hz, ArHͿ; ɷϳ.ϰϮ ;ϮH, d, J=ϴ.ϴHz, AƌH). 
 
 
 
 
 
 
(132) 
C15H19ClN2O3S 
MW = 342.84g/mol 
(121) 
Experimental   2 
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2.2.6.6  Synthesis of 4-chloro-4-(4-chlorophenyl)-N,N-diethyl-1,1-dioxo-5H- 
  isothiazol-3-amine  
 
 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (10.99 ml, 151.50 mmol) was added to 4-(4-
chlorophenyl)-3-(diethylamino)-1,1-dioxo-5H-isothiazol-4-ol (123) (1.60 g, 5.05 mmol) and the 
mixture set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
10% w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to 
yield the product as an off-white solid (1.39 g, 82%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵϭ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϵ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϵϳ-
3.22 (2H, m, NCH2CH3Ϳ; ɷϯ.ϰϱ-3.56 (1H, m, NCH2CH3Ϳ; ɷϯ.ϲϭ-3.72 (1H, m, NCH2CH3Ϳ; ɷϯ.ϳϵ ;ϭH, d, 
J=14.6Hz, SO2CH2Ϳ; ɷϰ.ϭϳ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϳ.ϰϮ-7.48 (4H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.Ϭϴ ;NCH2CH3), 12.37 (NCH2CH3), 44.07 (NCH2CH3), 45.11 (NCH2CH3), 
67.59 (SO2CH2), 70.64 (CCl), 126.21 (Ar), 129.84 (Ar), 135.68 (Ar), 137.17 (Ar), 163.93 (N=C-N). 
 
 
 
 
(123) (133) 
C13H16Cl2N2O2S 
MW = 335.25g/mol 
Experimental   2 
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2.2.6.7  Synthesis of 4-chloro-4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-5H- 
  isothiazol-3-amine 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (15.45 ml, 213.00 mmol) was added to 4-(4-
chlorophenyl)-3-(dipropylamino)-1,1-dioxo-5H-isothiazol-4-ol (124) (2.45 g, 7.10 mmol) and the 
mixture set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
10% w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to 
yield the product as a dark red oil (2.18 g, 85%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϱϴ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϱ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϬϮ-1.16 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϰϴ-1.84 (3H, m, NCH2CH2CH3Ϳ; ɷϮ.ϴϰ-3.04 (2H, m, NCH2CH2CH3); 
ɷϯ.ϯϱ-3.45 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϰϵ-3.56 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϳϵ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2); 
ɷϰ.ϭϳ ;ϭH, d, J=14.6Hz, SO2CH2Ϳ; ɷϳ.ϰϮ ;ϳ.ϱϬ, ϰH, ŵ, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϬ ;NCH2CH2CH3), 11.21 (NCH2CH2CH3), 19.10 (NCH2CH2CH3), 20.72 
(NCH2CH2CH3), 51.26 (NCH2CH2CH3), 52.26 (NCH2CH2CH3), 67.72 (SO2CH2), 70.78 (CCl), 126.24 (Ar), 
129.79 (Ar), 135.66 (Ar), 137.18 (Ar), 164.16 (N=C-N). 
 
 
(134) 
C15H20Cl2N2O2S 
MW = 363.30g/mol 
(124) 
Experimental   2 
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2.2.6.8  Synthesis of 4-chloro-N,N-diethyl-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-3- 
  amine 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (5.75 ml, 78.90 mmol) was added to 3-
(diethylamino)-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-4-ol (126) (780 mg, 2.63 mmol) and the mixture 
set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 10% 
w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude product was purified by gravity column chromatography with a 2:1 petroleum ether:ethyl 
acetate solvent system to yield the pure product as a yellow oil (545 mg, 66%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϳ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϵ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϯϴ 
(3H, s, ArCH3); ɷϯ.ϬϮ-3.24 (2H, m, NCH2CH3Ϳ; ɷϯ.ϰϱ-3.57 (1H, m, NCH2CH3Ϳ; ɷϯ.ϲϬ-3.71 (1H, m, 
NCH2CH3Ϳ; ɷϯ.ϳϵ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϰ.ϭϰ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϳ.Ϯϳ ;ϮH, d, J=ϴ.ϮHz, 
ArHͿ; ɷϳ.ϯϴ ;ϮH, d, J=ϴ.ϯHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.Ϭϱ ;NCH2CH3), 12.20 (NCH2CH3), 20.99 (ArCH3), 44.11 (NCH2CH3), 
44.97 (NCH2CH3), 67.86 (SO2CH2), 71.18 (CCl), 124.52 (Ar), 130.19 (Ar), 135.53 (Ar), 139.48 (Ar), 
164.54 (N=C-N). 
micrOTOF-Q MS m/z C14H19N2ClO2S+Na, calculated 337.0745, observed 337.0747. 
IR (cm-1): 781, 822, 905, 971, 1141, 1189, 1201, 1235, 1312, 1587. 
(135) 
C14H19ClN2O2S 
MW = 314.83g/mol 
(126) 
Experimental   2 
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2.2.6.9  Synthesis of 4-chloro-1,1-dioxo-N,N-dipropyl-4-(p-tolyl)-5H-isothiazol-3- 
  amine 
 
 
 
 
 
 
 
 
 
 
 
Under an atmosphere of nitrogen, thionyl chloride (5.85 ml, 80.70 mmol) was added to 3-
(dipropylamino)-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-4-ol (127) (830 mg, 2.69 mmol) and the mixture 
set to stir at reflux for 24 hours. After this time the excess thionyl chloride was removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 10% 
w/v aqueous sodium bicarbonate solution. The aqueous layer was removed and extracted with 
dichloromethane (3 x 25 ml) and the organic layers combined and washed with water. The organics 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude product was purified by gravity column chromatography with a 2:1 petroleum ether:ethyl 
acetate solvent system to yield the pure product as a brown oil (627 mg, 71%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϭ-1.20 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϲ-1.48 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϬ-1.79 (4H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϯϴ ;ϯH, s, AƌCH3Ϳ; ɷϮ.ϵϵ-3.07 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϮϮ-3.30 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϰ-3.82 (1H, m, N(CH2)2(CH2)2CH2); 
ɷϯ.ϳϵ ;ϭH, d, J=ϭϰ.ϲHz, SO2CH2Ϳ; ɷϯ.ϴϯ-3.91 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϰ.ϭϲ ;ϭH, d, J=ϭϰ.ϲHz, 
SO2CH2Ϳ; ɷϳ.Ϯϲ ;ϮH, d, J=ϴ.ϮHz, AƌHͿ; ɷϳ.ϯϵ ;ϮH, d, J=ϴ.ϯHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.Ϭϱ ;AƌCH3), 23.45 (N(CH2)2(CH2)2CH2), 24.99 (N(CH2)2(CH2)2CH2), 25.27 
(N(CH2)2(CH2)2CH2), 49.08 (N(CH2)2(CH2)2CH2), 49.62 (N(CH2)2(CH2)2CH2), 67.90 (SO2CH2), 71.07 (CCl), 
124.44 (Ar), 130.24 (Ar), 135.64 (Ar), 139.51 (Ar), 164.24 (N=C-N). 
micrOTOF-Q MS m/z C15H19N2ClO2S+Na, calculated 349.0748, observed 349.0748. 
IR (cm-1): 797, 805, 857, 930, 1120, 1143, 1201, 1234, 1310, 1593. 
(136) 
C15H19ClN2O2S 
MW = 326.84g/mol 
(127) 
Experimental   2 
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2.2.7  Experimental Procedures Synthesis of 3-Dialkylamino-4-aryl-isothiazole-1,1-
  dioxides 
2.2.7.1  Synthesis of 1,1-dioxo-4-phenyl-N,N-dipropyl-isothiazol-3-amine 
 
 
 
 
 
 
 
 
 
To 4-chloro-1,1-dioxo-4-phenyl-N,N-dipropyl-5H-isothiazol-3-amine (129) (1.34 g, 4.07 mmol) in dry 
acetone (10 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate (619 mg, 4.48 
mmol) was added and the reaction mixture set to stir at reflux for 24 hours. After this time the 
mixture was filtered to remove excess potassium carbonate and the solvents removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 1M 
aqueous hydrochloric acid. The aqueous layer was removed and extracted with dichloromethane (3 
x 25 ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure yielding the 
product as an orange solid (742 mg, 62%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϯϲ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϲ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϯϮ-1.44 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϭ-1.85 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϭ-2.98 (2H, m, NCH2CH2CH3); 
ɷϯ.ϱϬ-3.56 (2H, m, NCH2CH2CH3Ϳ; ɷϳ.ϮϬ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϭ-7.36 (2H, m, PhHͿ; ɷϳ.ϰϲ-7.51 (3H, m, 
PhH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.Ϯϴ ;NCH2CH2CH3), 11.32 (NCH2CH2CH3), 19.92 (NCH2CH2CH3), 22.56 
(NCH2CH2CH3), 51.44 (NCH2CH2CH3), 54.29 (NCH2CH2CH3), 127.31 (PhC), 129.16 (PhC), 129.64 (PhC), 
131.95 (PhC), 139.76 (SO2CH), 143.22 (C=C-Ph), 160.86 (N=C-N). 
micrOTOF-Q MS m/z C15H20N2O2S+Na, calculated 315.1138, observed 315.1130. 
IR (cm-1): 704, 765, 814, 845, 1096, 1119, 1184, 1285, 1299, 1562, 3094. 
M.p.: 114-116 oC. 
(129) (138) 
C15H20N2O2S 
MW = 292.40g/mol 
Experimental   2 
140 
 
2.2.7.2  Synthesis of 4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3- 
  amine 
 
 
 
 
To 4-chloro-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-5H-isothiazol-3-amine (131) (3.72 g, 10.34 
mmol) in dry acetone (50 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate 
(1.57 g, 11.37 mmol) was added and the reaction mixture set to stir at reflux for 24 hours. After this 
time the mixture was filtered to remove excess potassium carbonate and the solvents removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
1M aqueous hydrochloric acid. The aqueous layer was removed and extracted with dichloromethane 
(3 x 25 ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to yield the 
product as a brown solid (3.30 g, 76%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϰϯ ;ϯH, t, J=ϳ.ϮHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϱ ;ϯH, t, J=ϳ.ϮHz, NCH2CH2CH3); 
ɷϭ.ϯϮ-1.44 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϬ-1.83 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϴ ;ϮH, t, J=7.8Hz, 
NCH2CH2CH3Ϳ; ɷϯ.ϱϮ ;ϮH, t, J=ϳ.ϲHz, NCH2CH2CH3Ϳ; ɷϯ.ϴϱ ;ϯH, s, AƌOCH3Ϳ; ɷϲ.ϵϳ ;ϮH, d, J=ϴ.ϴHz, AƌH); 
ɷϳ.ϭϳ ;ϭH, s, SO2CHͿ; ɷϳ.Ϯϯ ;ϮH, d, J=ϴ.ϴHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϱϭ ;NCH2CH2CH3), 11.36 (NCH2CH2CH3), 19.98 (NCH2CH2CH3), 22.62 
(NCH2CH2CH3), 51.45 (NCH2CH2CH3), 54.29 (NCH2CH2CH3), 55.49 (ArOCH3), 114.59 (Ar), 123.86 (Ar), 
128.70 (Ar), 139.69 (Ar), 143.05 (SO2CH), 160.57 (C=C-Ar), 161.31 (N=C-N). 
micrOTOF-Q MS m/z C16H22N2O3S+Na, calculated 345.1243, observed 345.1244. 
IR (cm-1): 733, 835, 1027, 1123, 1189, 1249, 1290, 1506, 1556, 1603, 3102. 
(140) 
C16H22N2O3S 
MW = 322.42g/mol 
(131) 
Experimental   2 
141 
 
2.2.7.3  Synthesis of 4-(4-chlorophenyl)-N,N-diethyl-1,1-dioxo-isothiazol-3-amine  
 
 
 
 
 
To 4-chloro-4-(4-chlorophenyl)-N,N-diethyl-1,1-dioxo-5H-isothiazol-3-amine (133) (650 mg, 1.93 
mmol) in dry acetone (50 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate 
(290mg, 2.28mmol) was added and the reaction mixture set to stir at reflux for 24 hours. After this 
time the mixture was filtered to remove excess potassium carbonate and the solvents removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
1M aqueous hydrochloric acid. The aqueous layer was removed and extracted with dichloromethane 
(3 x 25 ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to yield the 
product as a brown, highly viscous semi-solid (500 mg, 79%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵ4 (3H, t, J=6.5Hz, NCH2CH3Ϳ; ɷϭ.ϯϭ ;ϯH, t, J=ϲ.ϱHz, ;NCH2CH3Ϳ; ɷϯ.Ϭϲ-
3.17 (2H, m, NCH2CH3Ϳ; ɷϯ.ϱϵ-3.71 (2H, m, NCH2CH3Ϳ; ɷϳ.Ϯϰ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϬ ;ϮH, appt. d, 
J=8.4Hz, ArHͿ; ɷϳ.ϰϲ ;ϮH, appt. d, J=8.5Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϴϱ ;NCH2CH3), 14.05 (NCH2CH3), 43.95 (NCH2CH3), 46.77 (NCH2CH3), 
128.78 (Ar), 129.47 (Ar), 130.39 (Ar), 136.05 (Ar), 138.58 (Ar), 143.87 (Ar), 160.39 (N=C-N). 
micrOTOF-Q MS m/z C13H15ClN2O2S+Na, calculated 321.0435, observed 321.0437. 
IR (cm-1): 741, 824, 913, 942, 1087, 1122, 1188, 1293, 1557, 1590, 2950. 
 
(141) 
C13H15ClN2O2S 
MW = 298.79g/mol 
(133) 
Experimental   2 
142 
 
2.2.7.4  Synthesis of 4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine
   
 
 
 
 
To 4-chloro-4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-5H-isothiazol-3-amine (134) (2.18 g, 6.00 
mmol) in dry acetone (40 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate 
(995 mg, 7.20 mmol) was added and the reaction mixture set to stir at reflux for 24 hours. After this 
time the mixture was filtered to remove excess potassium carbonate and the solvents removed 
under reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 
1M aqueous hydrochloric acid. The aqueous layer was removed and extracted with dichloromethane 
(3 x 25 ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to yield the 
product as a brown oil (2.07 g, 97%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϰϯ ;ϯH, t, J= ϳ.ϮHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϲ ;ϯH, t, J=ϳ.ϮHz, NCH2CH2CH3); 
ɷϭ.ϯϮ-1.45 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϳϬ-1.83 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϴϵ-2.98 (2H, m, NCH2CH2CH3); 
ɷϯ.ϰϵ-3.56 (2H, m, NCH2CH2CH3); ɷϳ.Ϯϯ ;ϭH, s, SO2CHͿ; ɷϳ.Ϯϱ-7.30 (2H, appt. d, ArHͿ; ɷϳ.ϰϲ ;ϮH, d, 
J=8.0Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϰϮ ;NCH2CH2CH3), 11.35 (NCH2CH2CH3), 19.96 (NCH2CH2CH3), 22.63 
(NCH2CH2CH3), 51.47 (NCH2CH2CH3), 54.39 (NCH2CH2CH3), 128.75 (Ar), 129.49 (Ar), 130.48 (Ar), 
136.03 (Ar), 138.50 (Ar), 144.05 (Ar), 160.58 (N=C-N). 
micrOTOF-Q MS m/z C15H19N2ClO2S+Na, calculated 349.0748, observed 349.0745. 
IR (cm-1): 747, 834, 908, 1088, 1186, 1123, 1295, 1556, 1590, 2964. 
(142) 
C15H19ClN2O2S 
MW = 326.84g/mol 
(134) 
Experimental   2 
143 
 
2.2.7.5  Synthesis of N,N-diethyl-1,1-dioxo-4-(p-tolyl)isothiazol-3-amine  
 
 
 
 
 
To 4-chloro-N,N-diethyl-1,1-dioxo-4-(p-tolyl)-5H-isothiazol-3-amine (135) (545 mg, 1.73 mmol) in dry 
acetone (40 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate (287 mg, 2.08 
mmol) was added and the reaction mixture set to stir at reflux for 24 hours. After this time the 
mixture was filtered to remove excess potassium carbonate and the solvents removed under 
reduced pressure. The residues were then dissolved in dichloromethane and neutralised with 1M 
aqueous hydrochloric acid. The aqueous layer was removed and extracted with dichloromethane (3 
x 25 ml) and the organic layers combined and washed with water. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to yield the 
product as a pale yellow solid (146 mg, 30%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϵϮ ;ϯH, t, J=ϳ.0Hz, NCH2CH3Ϳ; ɷϭ.ϯϭ ;ϯH, t, J=ϲ.ϴHz, NCH2CH3Ϳ; ɷϮ.ϰϭ 
(3H, s, ArCH3); ɷϯ.Ϭϳ-3.17 (2H, m, NCH2CH3Ϳ; ɷϯ.ϱϴ-3.70 (2H, m, NCH2CH3Ϳ; ɷϳ.ϭϳ ;ϭH, s, SO2CH); 
ɷϳ.ϭϴ-7.22 (2H, m, ArHͿ; ɷϳ.Ϯϰ-7.29 (2H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϴϵ ;NCH2CH3), 14.08 (NCH2CH3), 21.35 (ArCH3), 43.86 (NCH2CH3), 
46.66 (NCH2CH3), 127.19 (Ar), 128.91 (Ar), 129.78 (Ar), 139.88 (Ar), 139.97 (Ar), 142.96 (Ar), 160.90 
(N=C-N). 
micrOTOF-Q MS m/z C14H18N2O2S+Na, calculated 301.0981, observed 301.0981. 
IR (cm-1): 739, 775, 791, 826, 913, 940, 1122, 1187, 1284, 1572, 3008. 
M.p.: 122-124 oC. 
 
(143) 
C14H18N2O2S 
MW = 278.37g/mol 
(135) 
Experimental   2 
144 
 
2.2.7.6  Synthesis of 3-(1-piperidyl)-4-(p-tolyl)isothiazole-1,1-dioxide  
 
 
 
To 4-chloro-1,1-dioxo-N,N-dipropyl-4-(p-tolyl)-5H-isothiazol-3-amine (136) (627 mg, 1.91 mmol) in 
dry acetone (40 ml) under an atmosphere of nitrogen, anhydrous potassium carbonate (317 mg) was 
added and the reaction mixture set to stir at reflux for 24 hours. After this time the mixture was 
filtered to remove excess potassium carbonate and the solvents removed under reduced pressure. 
The residues were then dissolved in dichloromethane and neutralised with 1M aqueous hydrochloric 
acid. The aqueous layer was removed and extracted with dichloromethane (3 x 25 ml) and the 
organic layers combined and washed with water. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was 
purified by gravity column chromatography with a 2:1 petroleum ether:ethyl acetate solvent system 
to yield the pure product as a brown solid (112 mg, 20%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϯϯ-1.45 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϵ-1.67 (2H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϳϭ-1.84 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϰϭ ;ϯH, s, AƌCH3Ϳ; ɷϯ.Ϭϲ-3.21 (2H, m 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϰ-3.88 (2H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϳ.ϭϴ-7.23 (3H, m, ArH, SO2CHͿ; ɷϳ.Ϯϱ-7.29 
(2H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.ϯϳ (ArCH3), 23.75 (N(CH2)2(CH2)2CH2), 25.20 (N(CH2)2(CH2)2CH2), 26.09 
(N(CH2)2(CH2)2CH2), 49.54 (N(CH2)2(CH2)2CH2), 50.38 (N(CH2)2(CH2)2CH2), 127.00 (Ar), 128.82 (Ar), 
130.01 (Ar), 139.98 (Ar), 140.21 (Ar), 142.49 (Ar), 161.71 (N=C-N). 
micrOTOF-Q MS m/z C15H18N2O2S+Na, calculated 313.0981, observed 313.0982. 
IR (cm-1): 744, 800, 855, 941, 1114, 1127, 1179, 1191, 1296, 1548, 2986. 
M.p.: 178-180 0C. 
(144) 
C15H18N2O2S 
MW = 290.38g/mol 
(136) 
Experimental   2 
145 
 
2.2.8  Experimental Procedures for the Synthesis of 3,6-diaryl-7-dialkylamino- 
  isothiazolo-isoxazole-1,1-dioxides 
2.2.8.1  Synthesis of 3,6a-bis(4-methoxyphenyl)-4,4-dioxo-N,N-dipropyl-3aH- 
  isothiazolo[5,4-d]isoxazol-6-amine 
 
 
 
 
To a mixture of 4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (140) (100 mg, 0.31 
mmol) and 4-methoxy-N-hydroxybenzimidoyl chloride (58 mg, 0.31 mmol) (145) in dry chloroform 
;ϭϬ ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϱϬ μl, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ 
ml) was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. 
After this time the solvents were removed under reduced pressure. The crude product was purified 
by gravity column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield 
the pure product as a white crystalline solid (43mg, 29%). 
  
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϲ ;ϯH, t, J=8.0Hz, NCH2CH2CH3Ϳ; ɷϬ.ϵϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϬ.ϵϴ-1.11 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϰϵ-1.86 (3H, m, NCH2CH2CH3Ϳ; ɷϯ.ϬϬ-3.20 (2H, m, NCH2CH2CH3); 
ɷϯ.Ϯϭ-3.31 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϱϲ-3.65 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϴϮϳ ;ϯH, s, AƌOCH3Ϳ; ɷϯ.ϴϯϭ 
(3H, s, ArOCH3Ϳ; ɷϱ.Ϭϳ ;ϭH, s, SO2CHͿ; ɷϲ.ϵϮ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϲ.ϵϳ ;ϮH, d, J=ϵ.ϬHz, AƌHͿ; ɷϳ.ϯϳ 
(2H, d, J=8.8Hz, 1.9Hz, ArHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϵHz, Ϯ.ϵHz, AƌH). 
 
(147) 
C24H29N3O5S 
MW = 471.57g/mol 
(145) 
(140) 
Experimental   2 
146 
 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϳ (NCH2CH2CH3), 11.24 (NCH2CH2CH3), 19.40 (NCH2CH2CH3), 21.10 
(NCH2CH2CH3), 51.40 (NCH2CH2CH3), 52.15 (NCH2CH2CH3), 55.40 (ArOCH3), 55.47 (ArOCH3), 79.71 
(SO2CH), 98.98 (Cq), 114.37 (Ar), 115.00 (Ar), 119.28 (Ar), 125.12 (Ar), 129.23 (Ar), 129.25 (Ar), 
152.00 (Ar), 160.38 (Ar), 161.79 (C=N), 164.05 (C=N). 
micrOTOF-Q MS m/z C24H29N3O5S+Na, calculated 494.1720, observed 494.1717. 
IR (cm-1): 833, 888, 915, 1026, 1135, 1175, 1251, 1319, 1513, 1589. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental   2 
147 
 
2.2.8.2  Synthesis of 3-(4-chlorophenyl)-6a-(4-methoxyphenyl)-4,4-dioxo-N,N- 
  dipropyl-3aH-isothiazolo[5,4-d]isoxazol-6-amine  
 
 
 
To a mixture of 4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (140) (100 mg, 0.31 
mmol) and 4-chloro-N-hydroxybenzimidoyl chloride (59 mg, 0.31 mmol) (146) in dry chloroform (10 
ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϱϬ μl, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ ŵlͿ 
was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After 
this time the solvents were removed under reduced pressure. The crude product was purified by 
gravity column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the 
pure product as a white crystalline solid (44 mg, 30%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϳ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϬ.ϵϵ-1.12 (1H, m, NCH2CH2CH3); 1.49-1.86 (3H, m, NCH2CH2CH3Ϳ; ɷϯ.ϬϬ-3.30 (3H, m, NCH2CH2CH3); 
ɷϯ.ϱϲ-3.66 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϴϯ ;ϯH, s, AƌOCH3Ϳ; ɷϱ.Ϭϲ ;ϭH, s, SO2CHͿ; ɷϲ.ϵϴ ;ϮH, d, J=ϴ.ϵHz, 
ArHͿ; ɷϳ.ϯϲ ;ϮH, d, J=ϴ.ϴHz, AƌHͿ; ɷϳ.ϰϬ ;ϮH, d, J=ϴ.ϲHz, AƌHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϲHz, Ϯ.ϰHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϲ ;NCH2CH2CH3), 11.22 (NCH2CH2CH3), 19.40 (NCH2CH2CH3), 21.11 
(NCH2CH2CH3), 51.41 (NCH2CH2CH3), 52.23 (NCH2CH2CH3), 55.49 (ArOCH3), 79.08 (SO2CH), 99.54 (Cq), 
115.09 (Ar), 125.08 (Ar), 125.42 (Ar), 128.79 (Ar), 128.81 (Ar), 129.22 (Ar), 137.23 (Ar), 151.76 (Ar), 
160.50 (C=N), 163.86 (C=N). 
micrOTOF-Q MS m/z C23H26ClN3O4S+Na, calculated 498.1225, observed 498.1222. 
IR (cm-1): 729, 832, 923, 1091, 1134, 1174, 1250, 1320, 1511, 1589. 
(148) 
C23H26ClN3O4S 
MW = 475.99g/mol 
(146) 
(140) 
Experimental   2 
148 
 
2.2.8.3  Synthesis of 3,6a-bis(4-chlorophenyl)-N,N-diethyl-4,4-dioxo-3aH-  
  isothiazolo[5,4-d]isoxazol-6-amine 
 
 
 
To a mixture of 4-(4-chlorophenyl)-N,N-diethyl-1,1-dioxo-isothiazol-3-amine (141) (100 mg, 0.31 
mmol) and 4-chloro-N-hydroxybenzimidoyl chloride (58 mg, 0.31 mmol) (146) in dry chloroform (10 
ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϰϳ μl, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ ŵlͿ 
was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After 
this time the solvents were removed under reduced pressure. The crude product was purified by 
gravity column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the 
pure product as a white crystalline solid (23 mg, 17%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϵ ;ϯH, t, J=7.1Hz, NCH2CH3Ϳ; ɷϭ.Ϯϳ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.ϭϱ-
3.32 (2H, m, NCH2CH3Ϳ; ɷϯ.ϰϮ ;ϭH, appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϯ.ϲϵ ;ϭH, appt. sxt, J=7.1Hz, 
NCH2CH3Ϳ; ɷϱ.Ϭϴ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϴ-7.44 (4H, m, ArHͿ; ɷϳ.ϰϳ ;ϮH, d, J=ϴ.ϴHz, AƌHͿ; ɷϳ.ϳϭ ;ϮH, d, 
J=8.6Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϲ ;NCH2CH3), 12.82 (NCH2CH3), 44.29 (NCH2CH3), 45.23 (NCH2CH3), 
79.04 (SO2CH), 98.95 (Cq), 125.10 (Ar), 125.25 (Ar), 128.88 (Ar), 129.31 (Ar), 130.16 (Ar), 135.37 (Ar), 
136.01 (Ar), 137.49 (Ar), 151.91 (C=N), 162.94 (C=N). 
micrOTOF-Q MS m/z C20H19Cl2N3O3S+Na, calculated 474.0416, observed 474.0414. 
IR (cm-1): 728, 828, 890, 906, 1013, 1091, 1135, 1175, 1321, 1593. 
(149) 
C20H19Cl2N3O3S 
MW = 452.35g/mol 
(146) 
(141) 
Experimental   2 
149 
 
2.2.8.4  Synthesis of 6a-(4-chlorophenyl)-N,N-diethyl-3-(4-methoxyphenyl)-4,4- 
  dioxo-3aH-isothiazolo[5,4-d]isoxazol-6-amine 
 
 
 
To a mixture of 4-(4-chlorophenyl)-N,N-diethyl-1,1-dioxo-isothiazol-3-amine (141) (100 mg, 0.31 
mmol) and 4-methoxy-N-hydroxybenzimidoyl chloride (57 mg, 0.31 mmol) (145) in dry chloroform 
;ϭϬ ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϰϳ μl, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ 
ml) was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. 
After this time the solvents were removed under reduced pressure. The crude product was purified 
by gravity column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield 
the pure product as a white crystalline solid (57 mg, 42%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϳ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϳ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϯ.ϮϮ 
(2H, non, J=7.3Hz, NCH2CH3Ϳ; ɷϯ.ϰϮ ;ϭH, appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϯ.ϲϴ ;ϭH, appt. sxt, J=7.1Hz, 
NCH2CH3Ϳ; ɷ3.83 (3H, s, ArOCH3Ϳ; ɷϱ.Ϭϵ ;ϭH, s, SO2CHͿ; ɷϲ.ϵϯ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϳ.ϰϭ ;ϮH, d, 
J=8.7Hz, ArHͿ; ɷϳ.ϰϲ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϳ.ϳϭ ;ϮH, d, J=ϴ.ϵHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϴ ;NCH2CH3), 12.81 (NCH2CH3), 44.27 (NCH2CH3), 45.11 (NCH2CH3), 
55.44 (ArOCH3), 79.66 (SO2CH), 98.41 (Cq), 114.45 (Ar), 118.94 (Ar), 125.31 (Ar), 129.34 (Ar), 130.06 
(Ar), 135.77 (Ar), 135.79 (Ar), 152.15 (Ar), 161.96 (C=N), 163.13 (C=N). 
micrOTOF-Q MS m/z C21H22ClN3O4S+Na, calculated 470.0912, observed 470.0909. 
IR (cm-1): 828, 915, 966, 1092, 1135, 1174, 1254, 1320, 1350, 1591. 
(150) 
C21H22ClN3O4S 
MW = 447.94g/mol 
(145) 
(141) 
Experimental   2 
150 
 
2.2.8.5  Synthesis of 6a-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,4-dioxo-N,N- 
  dipropyl-3aH-isothiazolo[5,4-d]isoxazol-6-amine  
 
 
 
To a mixture of 4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (142) (100 mg, 0.31 
mmol) and 4-methoxy-N-hydroxybenzimidoyl chloride (58 mg, 0.31 mmol) (145) in dry chloroform 
;ϭϬ ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϱϬ μlͿ, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ 
ml) was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. 
After this time the solvents were removed under reduced pressure. The crude product was purified 
by gravity column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield 
the pure product as a white crystalline solid (37 mg, 25%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϴ ;ϯH, t, J=7.4Hz, NCH2CH2CH3Ϳ; ɷϬ.ϵϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϬ.ϵϵ-1.12 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϱϬ-1.83 (3H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϳ-3.16 (2H, m, NCH2CH2CH3); 
ɷϯ.ϮϮ-3.31 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϱϳ-3.66 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϴϰ ;ϯH, s, AƌOCH3Ϳ; ɷϱ.Ϭϵ ;ϭH, 
s, SO2CHͿ; ɷϲ.ϵϯ ;ϮH, d, J=ϴ.ϵHz, AƌHͿ; ɷϳ.ϰϬ-7.48 (4H, m, ArHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϵHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϯ ;NCH2CH2CH3), 11.21 (NCH2CH2CH3), 19.39 (NCH2CH2CH3), 21.15 
(NCH2CH2CH3), 51.43 (NCH2CH2CH3), 52.16 (NCH2CH2CH3), 55.41 (ArOCH3), 79.73 (SO2CH), 98.46 (Cq), 
114.43 (Ar), 118.93 (Ar), 125.26 (Ar), 129.32 (Ar), 130.00 (Ar), 135.76 (Ar), 135.93 (Ar), 152.13 (Ar), 
161.94 (C=N), 163.45 (C=N). 
micrOTOF-Q MS m/z C23H26ClN3O4S+Na, calculated 498.1225, observed 498.1241. 
IR (cm-1): 729, 832, 887, 917, 1092, 1135, 1175, 1255, 1321, 1589. 
(151) 
C23H26ClN3O4S 
MW = 475.99g/mol 
(145) 
(142) 
Experimental   2 
151 
 
2.2.8.6  Synthesis of 3,6a-bis(4-chlorophenyl)-4,4-dioxo-N,N-dipropyl-3aH- 
  isothiazolo[5,4-d]isoxazol-6-amine 
 
 
 
To a mixture of 4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (142) (100 mg, 0.31 
mmol) and 4-chloro-N-hydroxybenzimidoyl chloride (59 mg, 0.31 mmol) (146) in dry chloroform (10 
ŵlͿ uŶdeƌ aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϱϬ μl, Ϭ.ϯϰ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ ŵlͿ 
was added dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After 
this time the solvents were removed under reduced pressure. The crude product was purified by 
gravity column chromatography using a 7:1 petroleum ether:ethyl acetate solvent system to yield 
the pure product as a white crystalline solid (43 mg, 29%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϲϵ ;ϯH, t, J=7.3Hz, NCH2CH2CH3Ϳ; ɷϬ.ϵϯ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϬ.ϵϵ-1.13 (1H, m, NCH2CH2CH3Ϳ; ɷϭ.ϱϬ-1.83 (3H, m, NCH2CH2CH3Ϳ; ɷϮ.ϵϲ-3.18 (2H, m, NCH2CH2CH3); 
ɷϯ.ϮϮ-3.31 (1H, m, NCH2CH2CH3Ϳ; ɷϯ.ϱϵ-3.66 (1H, m, NCH2CH2CH3Ϳ; ɷϱ.Ϭϴ ;ϭH, s, SO2CHͿ; ɷϳ.ϯϴ-7.43 
(4H, m, ArHͿ; ɷϳ.ϰϳ ;ϮH, d, J=ϴ.ϴHz, AƌHͿ; ɷϳ.ϳϭ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϴϮ ;NCH2CH2CH3), 11.20 (NCH2CH2CH3), 19.38 (NCH2CH2CH3), 21.16 
(NCH2CH2CH3), 51.45 (NCH2CH2CH3), 52.45 (NCH2CH2CH3), 79.09 (SO2CH), 99.00 (Cq), 125.09 (Ar), 
125.21 (Ar), 128.86 (Ar), 129.28 (Ar), 130.09 (Ar), 130.35 (Ar), 135.49 (Ar), 135.97 (Ar), 137.46 (Ar), 
151.89 (C=N), 163.25 (C=N). 
micrOTOF-Q MS m/z C22H23N3Cl2O3S+Na, calculated 502.0729, observed 502.0729. 
IR (cm-1): 730, 830, 889, 922, 1013, 1090, 1135, 1174, 1321, 1590. 
(152) 
C22H23Cl2N3O3S 
MW = 480.41g/mol 
(146) 
(142) 
Experimental   2 
152 
 
2.2.8.7  Synthesis of N,N-diethyl-3-(4-methoxyphenyl)-4,4-dioxo-6a-(p-tolyl)-3aH-
  isothiazolo[5,4-d]isoxazol-6-amine  
 
 
 
To a mixture of N,N-diethyl-1,1-dioxo-4-(p-tolyl)isothiazol-3-amine (143) (75 mg, 0.27 mmol) and 4-
methoxy-N-hydroxybenzimidoyl chloride (50 mg, 0.27 mmol) (145) in dry chloroform (10 ml) under 
aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϰϮ μl, Ϭ.ϯϬ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ (100 ml) was added 
dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After this time 
the solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a white crystalline solid (45 mg, 39%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϰ ;ϯH, t, J=ϳ.ϬHz, NCH2CH3Ϳ; ɷϭ.Ϯϳ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϯϴ 
(3H, s, ArCH3); ɷϯ.Ϯϰ ;ϮH, ŶoŶ, J=ϳ.ϯHz, NCH2CH3Ϳ; ɷϯ.ϰϭ ;ϭH, appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϯ.ϲϵ 
(1H, appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϯ.ϴϯ ;ϯH, s, ArOCH3); ɷϱ.Ϭϴ ;ϭH, s, SO2CHͿ; ɷϲ.ϵϯ ;ϮH, d, J=ϴ.ϴHz, 
ArHͿ; ɷϳ.Ϯϲ ;ϮH, d, J=ϴ.ϯHz, AƌHͿ; ɷϳ.ϯϯ ;ϮH, d, J=ϴ.ϮHz, AƌHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϴHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϵ ;NCH2CH3), 12.71 (NCH2CH3), 21.20 (ArCH3), 44.26 (NCH2CH3), 
45.00 (NCH2CH3), 55.42 (ArOCH3), 79.77 (SO2CH), 99.03 (Cq), 115.40 (Ar), 119.29 (Ar), 123.63 (Ar), 
129.27 (Ar), 130.38 (Ar), 134.35 (Ar), 139.69 (Ar), 152.00 (Ar), 161.82 (C=N), 163.66 (C=N). 
micrOTOF-Q MS m/z C22H25N3O4S+Na, calculated 450.1458, observed 450.1455. 
IR (cm-1): 728, 822, 889, 916, 967, 1135, 1175, 1255, 1320, 1591. 
(153) 
C22H25N3O4S 
MW = 427.52g/mol 
(145) 
(143) 
Experimental   2 
153 
 
2.2.8.8  Synthesis of 3-(4-chlorophenyl)-N,N-diethyl-4,4-dioxo-6a-(p-tolyl)-3aH- 
  isothiazolo[5,4-d]isoxazol-6-amine  
 
 
 
To a mixture of N,N-diethyl-1,1-dioxo-4-(p-tolyl)isothiazol-3-amine (143) (75 mg, 0.27 mmol) and 4-
chloro-N-hydroxybenzimidoyl chloride (51 mg, 0.27 mmol) (146) in dry chloroform (10 ml) under an 
atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;ϰϮ μl, Ϭ.ϯϬ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ ŵlͿ ǁas added 
dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After this time 
the solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a white crystalline solid (16 mg, 14%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϴϱ ;ϯH, t, J=7.0Hz, NCH2CH3Ϳ; ɷϭ.Ϯϳ ;ϯH, t, J=ϳ.ϭHz, NCH2CH3Ϳ; ɷϮ.ϯϴ 
(3H, s, ArCH3); ɷϯ.ϭϱ-3.33 (2H, m, NCH2CH3Ϳ; ɷϯ.ϰϮ ;ϭH, appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϯ.ϲϵ ;ϭH, 
appt. sxt, J=7.1Hz, NCH2CH3Ϳ; ɷϱ.Ϭϳ ;ϭH, s, SO2CHͿ; ɷϳ.Ϯϲ-7.34 (4H, m, ArHͿ; ɷϳ.ϰϬ ;ϮH, d, J=8.6Hz, 
ArHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϲHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϭ.ϯϳ ;NCH2CH3), 12.72 (NCH2CH3), 21.21 (ArCH3), 44.30 (NCH2CH3), 
45.12 (NCH2CH3), 79.15 (SO2CH), 99.58 (Cq), 123.58 (Ar), 125.42 (Ar), 128.83 (Ar), 129.25 (Ar), 130.47 
(Ar), 133.94 (Ar), 137.26 (Ar), 139.91 (Ar), 151.74 (C=N), 163.46 (C=N). 
micrOTOF-Q MS m/z C21H22N3ClO3S+Na, calculated 454.0963, observed 454.0976. 
IR (cm-1): 729, 822, 906, 967, 1091, 1135, 1175, 1322, 1593, 2922. 
(154) 
C21H22ClN3O3S 
MW = 431.94g/mol 
(146) 
(143) 
Experimental   2 
154 
 
2.2.8.9  Synthesis of 3-(4-methoxyphenyl)-6-(1-piperidyl)-6a-(p-tolyl)-3aH- 
  isothiazolo[5,4-d]isoxazole 4,4-dioxide  
 
 
To a mixture of 3-(1-piperidyl)-4-(p-tolyl)isothiazole-1,1-dioxide (144) (50 mg, 0.17 mmol) and 4-
methoxy-N-hydroxybenzimidoyl chloride (32 mg, 0.17 mmol) (145) in dry chloroform (10 ml) under 
aŶ atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;Ϯϳ μl, Ϭ.ϭϵ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬϬ ŵlͿ ǁas added 
dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After this time 
the solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a white crystalline solid (40 mg, 54%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϱ-1.16 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϵ-1.49 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϬ-1.79 (4H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϯϳ ;ϯH, s, AƌCH3Ϳ; ɷϯ.ϭϰ-3.23 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϯϭ-3.40 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϴ ;ϮH, t, J=ϱ.ϮHz, N;CH2)2(CH2)2CH2); 
ɷϯ.ϴϯ ;ϯH, s, AƌOCH3Ϳ; ɷϱ.Ϭϴ ;ϭH, s, SO2CHͿ; ɷϲ.ϵϯ ;ϮH, d, ϴ.ϵHz, AƌHͿ; ɷϳ.Ϯϲ ;ϮH, d, J=ϴ.ϭHz, AƌH); 
ɷϳ.ϯϮ ;ϮH, d, J=ϴ.ϮHz, AƌHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϵHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.Ϯϭ (ArCH3), 23.55 (N(CH2)2(CH2)2CH2), 25.23 (N(CH2)2(CH2)2CH2), 25.36 
(N(CH2)2(CH2)2CH2), 48.99 (N(CH2)2(CH2)2CH2), 49.41 (N(CH2)2(CH2)2CH2), 55.43 (ArOCH3), 79.87 
(SO2CH), 98.92 (Cq), 114.41 (Ar), 119.35 (Ar), 123.59 (Ar), 129.27 (Ar), 130.36 (Ar), 134.30 (Ar), 
139.67 (Ar), 151.94 (Ar), 161.83 (C=N), 163.09 (C=N). 
micrOTOF-Q MS m/z C23H25N3O4S+Na, calculated 462.1458, observed 462.1458. 
IR (cm-1): 880, 910, 936, 1020, 1134, 1175, 1255, 1319, 1514, 1593. 
(155) 
C23H25N3O4S 
MW = 439.53g/mol 
(145) 
(144) 
Experimental   2 
155 
 
2.2.8.10 Synthesis of 3-(4-chlorophenyl)-6-(1-piperidyl)-6a-(p-tolyl)-3aH-  
  isothiazolo[5,4-d]isoxazole 4,4-dioxide  
 
 
To a mixture of 3-(1-piperidyl)-4-(p-tolyl)isothiazole-1,1-dioxide (144) (50 mg, 0.17 mmol) and 4-
chloro-N-hydroxybenzimidoyl chloride (32 mg, 0.17 mmol) (146) in dry chloroform (10 ml) under an 
atŵospheƌe of ŶitƌogeŶ, tƌiethǇlaŵiŶe ;Ϯϳ μl, Ϭ.ϭϵ ŵŵolͿ iŶ dƌǇ Đhloƌofoƌŵ ;ϭϬ ŵlͿ ǁas added 
dropwise over a period of 6 hours and the mixture allowed to stir for a further hour. After this time 
the solvents were removed under reduced pressure. The crude product was purified by gravity 
column chromatography with a 7:1 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a white crystalline solid (21 mg, 28%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.Ϭϳ-1.17 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϯϵ-1.49 (1H, m, 
N(CH2)2(CH2)2CH2Ϳ; ɷϭ.ϱϭ-1.80 (4H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϮ.ϯϴ ;ϯH, s, AƌCH3Ϳ; ɷϯ.ϭϱ-3.24 (1H, m 
(N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϯϮ-3.41 (1H, m, N(CH2)2(CH2)2CH2Ϳ; ɷϯ.ϳϴ ;ϮH, t, J=ϱ.ϮHz, N;CH2)2(CH2)2CH2); 
ɷϱ.Ϭϳ ;ϭH, s, SO2CHͿ; ɷϳ.Ϯϱ-7.33 (4H, m, ArHͿ; ɷϳ.ϯϵ ;ϮH, d, J=ϴ.ϲHz, AƌHͿ; ɷϳ.ϳϮ ;ϮH, d, J=ϴ.ϲHz, 
ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϭ.Ϯϭ (ArCH3), 23.53 (N(CH2)2(CH2)2CH2), 25.23 (N(CH2)2(CH2)2CH2), 25.37 
(N(CH2)2(CH2)2CH2), 49.02 (N(CH2)2(CH2)2CH2), 49.52 (N(CH2)2(CH2)2CH2), 79.25 (SO2CH), 99.48 (Cq), 
123.54 (Ar), 125.44 (Ar), 128.83 (Ar), 129.26 (Ar), 130.45 (Ar), 133.90 (Ar), 137.27 (Ar), 139.88 (Ar), 
151.68 (C=N), 162.89 (C=N). 
micrOTOF-Q MS m/z C22H22N3ClO3S+Na, calculated 466.0963, observed 466.0960. 
IR (cm-1): 814, 889, 936, 1012, 1092, 1135, 1176, 1258, 1321, 1595. 
(156) 
C22H22ClN3O3S 
MW = 443.95g/mol 
(146) 
(144) 
Experimental   2 
156 
 
2.2.9  Experimental Procedures The Synthesis of 3-Dialkylamino-4-aryl-5-bromo-
  isothiazole-1,1-dioxides 
2.2.9.1  Synthesis of 5-bromo-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl- 
  isothiazol-3-amine  
 
 
 
Under an atmosphere of nitrogen, a 1M solution of bromine in chloroform (6.20 ml, 6.20 mmol) was 
added dropwise to a solution of 4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine 
(140) (2.00 g, 6.20 mmol) in chloroform and stirred at room temperature for 48 hours. Following 
consumption of the starting material by TLC, triethylamine (0.86 ml, 6.20 mmol) was added 
dropwise and the reaction mixture stirred for a further 24 hours. The mixture was washed with 10% 
aqueous sodium metabisulfite (10 ml) and the aqueous layer removed and extracted with 
dichloromethane (3 x 25 ml). The organics were combined, dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure to yield the product as a thick dark brown semi-
solid (2.20 g, 88%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϯϯ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϴϳ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3); 
ɷϭ.Ϯϰ-1.33 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϲϮ-1.73 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϴϱ-2.92 (2H, m, NCH2CH2CH3); 
ɷϯ.ϰϭ-3.48 (2H, m, NCH2CH2CH3Ϳ; ɷϯ.ϳϵ ;ϯH, s, AƌOCH3Ϳ; ɷϲ.ϵϲ ;ϮH, d, J=ϴ.ϳHz, AƌHͿ; ɷϳ.ϭϭ ;ϮH, d, 
J=8.7Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϯϴ ;NCH2CH2CH3), 11.35 (NCH2CH2CH3), 20.04 (NCH2CH2CH3), 22.66 
(NCH2CH2CH3), 51.44 (NCH2CH2CH3), 54.16 (NCH2CH2CH3), 55.49 (ArOCH3), 115.00 (Ar), 123.22 (Ar), 
129.09 (Ar), 135.97 (Ar), 138.77 (SO2CH), 160.64 (C=C-Ar), 161.52 (N=C-N). 
 
(157) 
C16H21BrN2O3S 
MW = 401.32g/mol 
(140) 
Experimental   2 
157 
 
2.2.9.2  Synthesis of 5-bromo-4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-
  3-amine   
 
 
 
 
Under an atmosphere of nitrogen, a 1M solution of bromine in chloroform (4.90 ml, 4.90 mmol) was 
added dropwise to a solution of 4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (142) 
(1.60 g, 4.90 mmol) in chloroform and stirred at room temperature for 48 hours. Following 
consumption of the starting material by TLC, triethylamine (0.68 ml, 4.90 mmol) was added 
dropwise and the reaction mixture stirred for a further 24 hours. The mixture was washed with 10% 
aqueous sodium metabisulfite (10 ml) and the aqueous layer removed and extracted with 
dichloromethane (3 x 25 ml). The organics were combined, dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure to yield the product as a brown oil (1.60 g, 80%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϯϮ ;ϯH, t, J=ϳ.ϯHz, NCH2CH2CH3Ϳ; ɷϬ.ϴϲ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.Ϯϭ-1.33 (2H, m, NCH2CH2CH3Ϳ; ɷϭ.ϲϬ-1.71 (2H, m, NCH2CH2CH3Ϳ; ɷϮ.ϳϵ-2.86 (2H, m, NCH2CH2CH3); 
ɷϯ.ϯϵ-3.46 (2H, m, NCH2CH2CH3Ϳ; ɷϳ.ϭϯ ;ϮH, d, J=ϴ.ϰHz, AƌHͿ; ɷϳ.ϰϯ ;ϮH, d, J=ϴ.ϰHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϯϴ (NCH2CH2CH3), 11.33 (NCH2CH2CH3), 20.03 (NCH2CH2CH3), 22.66 
(NCH2CH2CH3), 51.44 (NCH2CH2CH3), 54.23 (NCH2CH2CH3), 129.18 (Ar), 129.96 (Ar), 130.00 (Ar), 
134.89 (Ar), 136.39 (Ar), 139.70 (Ar), 160.87 (N=C-N). 
micrOTOF-Q MS m/z C15H18N2
79BrClO2S+Na, calculated 426.9853, observed 426.9850. 
IR (cm-1): 871, 1011, 1088, 1152, 1307, 1396, 1487, 1560, 1589, 1616. 
 
(142) 
(158) 
C15H18BrClN2O2S 
MW = 405.74g/mol 
Experimental   2 
158 
 
2.2.10  Experimental Procedures for the Synthesis of 3-Dialkylamino-4-aryl-5- 
  thiomethoxy-isothiazole-1,1-dioxides 
2.2.10.1 Synthesis of 4-(4-chlorophenyl)-5-methylsulfanyl-1,1-dioxo-N,N-dipropyl-
  isothiazol-3-amine  
 
 
 
To 5-bromo-4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl-isothiazol-3-amine (158) (1.60 g, 3.94 mmol) 
in dichloromethane (40 ml) under an atmosphere of nitrogen, sodium thiomethoxide and 
triethylamine were added and the mixture stirred at room temperature for 24 hours. After this time, 
the mixture was washed with water (40 ml) and the aqueous layer removed and extracted with 
dichloromethane (3 x 25 ml). The organics were combined, dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude product was purified by gravity column 
chromatography with a 3:1 petroleum ether:ethyl acetate solvent system to yield the pure product 
as a yellow solid (596 mg, 41%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϯϴ ;ϯH, t, J=ϳ.ϮHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϮ ;ϯH, t, J=ϳ.ϭHz, NCH2CH2CH3); 
ɷϭ.ϯϯ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϭ.ϳϮ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϮ.ϳϴ ;ϯH, s, SCH3Ϳ; ɷϮ.ϴϴ ;ϮH, ŵ, 
NCH2CH2CH3Ϳ; ɷϯ.ϰϳ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϳ.ϭϵ ;ϮH, appt. d, J=8.6Hz, 2.3Hz, ArHͿ; ɷϳ.ϰϳ ;ϮH, appt. 
d, J=9.8Hz, 2.0Hz, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϯϯ (NCH2CH2CH3), 11.33 (NCH2CH2CH3), 12.96 (SCH3), 20.22 
(NCH2CH2CH3), 22.55 (NCH2CH2CH3), 50.96 (NCH2CH2CH3), 54.11 (NCH2CH2CH3), 124.42 (Ar), 129.75 
(Ar), 129.91 (Ar), 130.91 (Ar), 135.58 (Ar), 157.98 (Ar), 160.59 (N=C-N). 
(159) 
C16H21ClN2O2S2 
MW = 372.93g/mol 
(158) 
Experimental   2 
159 
 
2.2.11  The Synthesis of 3-Dialkylamino-4-aryl-5-methanesulfonyl-isothiazole-1,1-
  dioxides 
2.2.11.1 Synthesis of 4-(4-chlorophenyl)-5-methylsulfinyl-1,1-dioxo-N,N-dipropyl-
  isothiazol-3-amine  
 
 
 
 
 
To 4-(4-chlorophenyl)-5-methylsulfanyl-1,1-dioxo-N,N-dipropyl- isothiazol-3-amine (101) (590 mg, 
1.58 mmol) in dichloromethane (20 ml) under an atmosphere of nitrogen, mCPBA (545 mg, 3.16 
mmol) was added and the mixture allowed to stir at room temperature for 24 hours. After this time, 
the mixture was washed with 20% w/v aqueous sodium bicarbonate solution (25 ml) and the 
aqueous layer removed and extracted with dichloromethane (3 x 25 ml). The organics were 
combined, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced 
pressure. The crude product was purified by gravity column chromatography with a 2:1 petroleum 
ether:ethyl acetate solvent system to yield the pure product as a yellow crystalline solid (310 mg, 
48%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϬ.ϰϬ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3Ϳ; ɷϬ.ϵϰ ;ϯH, t, J=ϳ.ϰHz, NCH2CH2CH3); 
ɷϭ.ϯϲ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϭ.ϳϱ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϮ.ϵϲ ;ϮH, ŵ, NCH2CH2CH3Ϳ; ɷϯ.ϱϮ ;ϮH, ŵ, 
NCH2CH2CH3Ϳ; ɷϯ.ϴϳ ;ϯH, s, SO2CH3Ϳ; ɷϳ.Ϭϯ ;ϮH, d, J=ϴ.ϳHz, AƌHͿ; ɷϳ.ϭϴ ;ϮH, d, J=ϴ.ϰHz, AƌH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϭϬ.ϰϴ (NCH2CH2CH3), 11.35 (NCH2CH2CH3), 20.05 (NCH2CH2CH3), 22.67 
(NCH2CH2CH3), 51.43 (NCH2CH2CH3), 54.16 (NCH2CH2CH3), 55.48 (SCH3), 115.00 (Ar), 123.23 (Ar), 
129.09 (Ar), 135.95 (Ar), 138.79 (Ar), 160.64 (Ar), 161.52 (N=C-N). 
(102) 
C16H21ClN2O3S2 
MW = 388.93g/mol 
(101) 
Experimental   2 
160 
 
2.3 Experimental Procedures for Investigations into the 1,2,4-
Oxadiazole Unit as a Structural Feature of Novel, Potential 
Asymmetric Catalysts 
2.3.1 Experimental Procedures for the Synthesis of 2-Iodobenzoic Acids 
2.3.1.1 Synthesis of 2-Iodo-3-methylbenzoic acid  
 
 
 
At room temperature, 2-amino-3-methylbenzoic acid (160) (500 mg, 3.31 mmol) was stirred in 
sufuric acid/water (5:33 v/v, 8 ml) for 1 hour. Sodium nitrite (228 mg, 3.31 mmol) in water (2 ml) was 
then added dropwise over 1 hour. An aqueous solution of potassium iodide (714 mg, 4.30 mmol) 
was then added and the reaction mixture was allowed to stir at room temperature overnight. After 
this time, the reaction mixture was washed with saturated aqueous sodium chloride solution (10 
ml), saturated aqueous sodium thiosulfate solution (10 ml) and the aqueous mixture was removed 
and extracted with dichloromethane (3 x 10 ml). The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated by rotary evaporation to give the product as a white 
solid with no further purification required (750 mg, 86%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϱϴ ;ϯH, s, CH3Ϳ; ɷϳ.ϯϰ ;ϭH, t, J=ϳ.ϲHz, AƌHͿ; ɷϳ.ϰϯ ;ϭH, dd, J=ϳ.ϱHz, 
1.1Hz, ArHͿ; ɷϳ.ϲϲ ;ϭH, dd, J=ϴ.ϬHz, ϭ.ϱHz, AƌHͿ; ɷϴ.ϯϰ-11.39 (1H, broad, OH). 
13C NMR (100MHz, CDCl3): ɷϯϬ.ϭϭ ;CH3), 100.70 (Ar), 127.83 (Ar), 128.45 (Ar), 132.89 (Ar), 136.06 
(Ar), 143.99 (Ar), 173.05 (C=O). 
This data is consistent with that reported in the literature171. 
(165) 
C8H7IO2 
MW = 262.04g/mol 
(160) 
Experimental   2 
161 
 
2.3.1.2  Synthesis of 2-Iodo-3-(trifluoromethyl)benzoic acid  
 
 
 
At room temperature, 2-amino-3-trifluoromethylbenzoic acid (161) (500 mg, 2.44 mmol) was stirred 
in sulfuric acid/water (5:33 v/v, 8 ml) for 1 hour. Sodium nitrite (168 mg, 2.44 mmol) in water (2 ml) 
was then added dropwise over 1 hour. An aqueous solution of potassium iodide (526 mg, 3.17 
mmol) was then added and the reaction mixture was allowed to stir at room temperature overnight. 
After this time, the reaction mixture was washed with saturated aqueous sodium chloride solution 
(10ml), saturated aqueous sodium thiosulfate solution (10 ml) and the aqueous mixture was 
removed and extracted with dichloromethane (3 x 10 ml). The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated by rotary evaporation to give the product as a white 
solid with no further purification required (711 mg, 92%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϱϲ ;ϭH, t, J=ϳ.ϵHz, AƌHͿ; ɷϳ.ϴϯ ;ϭH, dd, J=ϴ.ϮHz, ϭ.ϰHz, AƌHͿ; ɷϳ.ϴϳ ;ϭH, 
dd, J=7.7Hz, 1.4Hz, ArHͿ; ɷϵ.ϱϱ-11.79 (1H, broad, OH). 
This data is consistent with that reported in the literature171. 
 
 
 
 
 
 
 
(166) 
C8H4F3IO2 
MW = 316.06g/mol 
(161) 
Experimental   2 
162 
 
2.3.1.3  Synthesis of 3,5-Dimethyl-2-iodobenzoic acid  
 
 
 
At room temperature 2-amino-3,5-dimethylbenzoic acid (162) (500 mg, 3.03 mmol) was stirred in 
sulfuric acid/water (5:33 v/v, 8 ml) for 1 hour. Sodium nitrite (209 mg, 3.03 mmol) in water (2 ml) 
was then added dropwise over 1 hour. An aqueous solution of potassium iodide (654 mg, 3.94 
mmol) was then added and the reaction mixture was allowed to stir at room temperature overnight. 
After this time, the reaction mixture was washed with saturated aqueous sodium chloride solution 
(10 ml), saturated aqueous sodium thiosulfate solution (10 ml) and the aqueous mixture was 
removed and extracted with dichloromethane (3 x 10 ml). The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated by rotary evaporation to give the product as a white 
solid with no further purification required (702 mg, 84%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϯϰ ;ϯH, s, CH3Ϳ; ɷϮ.ϱϯ ;ϯH, s, CH3Ϳ; ɷϳ.Ϯϰ-7.26 (1H, m, ArHͿ; ɷϳ.ϰϳ-7.49 
(1H, m, ArHͿ; ɷϳ.ϳϲ-7.78 (1H, m, ArHͿ; ɷϵ.ϳϵ-12.34 (1H, broad, OH). 
This data is consistent with that reported in the literature171. 
 
 
 
 
 
 
(162) (167) 
C9H9IO2 
MW = 276.07g/mol 
Experimental   2 
163 
 
2.3.1.4  Synthesis of 5-Chloro-2-iodo-3-methylbenzoic acid  
 
 
 
At room temperature 2-amino-3-methyl-5-chlorobenzoic acid (163) (500 mg, 2.69 mmol) was stirred 
in sulfuric acid/water (5:33 v/v, 8 ml) for 1 hour. Sodium nitrite (186 mg, 2.39 mmol) in water (2 ml) 
was then added dropwise over 1 hour. An aqueous solution of potassium iodide (581 mg, 3.50 
mmol) was then added and the reaction mixture was allowed to stir at room temperature overnight. 
After this time, the reaction mixture was washed with saturated aqueous sodium chloride solution 
(10 ml), saturated aqueous sodium thiosulfate solution (10 ml) and the aqueous mixture was 
removed and extracted with dichloromethane (3 x 10 ml). The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated by rotary evaporation to give the product as a white 
solid with no further purification required (728 mg, 91%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϱϲ ;ϯH, s, CH3Ϳ; ɷϳ.ϰϯ ;ϭH, d, J=Ϯ.ϴHz, AƌHͿ; ɷϳ.ϲϰ ;ϭH, d, J=Ϯ.ϮHz, AƌH). 
This data is consistent with that reported in the literature171. 
 
 
 
 
 
 
(168) 
C8H6ClIO2 
MW = 296.49g/mol 
(163) 
Experimental   2 
164 
 
2.3.1.5  Synthesis of 3-Chloro-2-iodobenzoic acid  
 
 
 
At room temperature 2-amino-3-chlorobenzoic acid (164) (500 mg, 2.91 mmol) was stirred in sulfuric 
acid/water (5:33 v/v, 8 ml) for 1 hour. Sodium nitrite (201 mg, 2.91 mmol) in water (2 ml) was then 
added dropwise over 1 hour. An aqueous solution of potassium iodide (628 mg, 3.78 mmol) was 
then added and the reaction mixture was allowed to stir at room temperature overnight. After this 
time, the reaction mixture was washed with saturated aqueous sodium chloride solution (10 ml), 
saturated aqueous sodium thiosulfate solution (10 ml) and the aqueous mixture was removed and 
extracted with dichloromethane (3 x 10 ml). The organics were dried over anhydrous magnesium 
sulfate, filtered and concentrated by rotary evaporation to give the product as a white solid with no 
further purification required (709 mg, 86%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϳ.ϰϬ ;ϭH, t, J= ϳ.ϴHz, AƌHͿ, ɷϳ.ϲϳ ;ϭH, dd, J=ϴ.ϬHz, ϭ.ϱHz, AƌHͿ; ɷϳ.ϳϯ ;ϭH, 
d, J=8.1Hz, ArH). 
This data is consistent with that reported in the literature171. 
 
 
 
 
 
 
 
(169) 
C7H4ClIO2 
MW = 282.46g/mol 
(164) 
Experimental   2 
165 
 
2.3.2  Experimental Procedures for the Synthesis of Chiral, Iodine Containing  
  Pre-catalytic Systems  
2.3.2.1  Synthesis of N-[(1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]-2-iodo-N- 
  methyl-benzamide  
 
 
 
To 2-iodo-3-methylbenzoic acid (170) (500 mg, 1.91 mmol) in dichloromethane (5 ml) was added 
dropwise oxalyl chloride (0.32 ml, 3.82 mmol) under an atmosphere of nitrogen with a catalytic 
amount of dimethylformamide (0.1 ml). The reaction mixture was allowed to stir at room 
temperature overnight. The solvents were removed by rotary evaporation to afford the crude acid 
chloride (171) which was immediately dissolved in dry THF (5 ml) under an atmosphere of nitrogen. 
This was added via cannula to a solution of (1S,2S)-pseudoephedrine hydrochloride (300 mg, 1.82 
mmol) and triethylamine (0.29 ml, 2.09 mmol) in dry THF (5 ml) at 0 oC and allowed to stir and reach 
room temperature overnight. The reaction mixture was then washed with saturated aqueous 
sodium chloride solution and the aqueous layer removed and extracted with ethyl acetate (3 x 25 
ml). The organics were dried over anhydrous magnesium sulfate, filtered and concentrated by rotary 
evaporation. The crude product was purified by flash column chromatography with a 3:1 petroleum 
ether:ethyl acetate solvent system to yield the pure product as a thick dark oil (393 mg, 52%), as a 
mixture of rotamers. 
1H NMR (400MHz, CDCl3): (Major rotamer only) ɷϭ.Ϯϳ ;ϯH, s, CHCH3Ϳ; ɷϭ.ϯϲ ;ϯH, s, NCH3Ϳ; ɷϮ.ϳϭ ;ϭH, 
broad, OHͿ; ɷϯ.Ϭϴ ;ϭH, s, CHCH3Ϳ; ɷϰ.ϯϵ ;ϭH, d, J=8.8Hz, CHOHͿ; ɷϲ.ϵϲ-7.02 (1H, m, ArHͿ; ɷϳ.ϭϴ-7.28 
(5H, m, ArHͿ; ɷϳ.ϯϬ-7.41 (2H, m, ArH). 
micrOTOF-Q MS m/z C17H18O2NI+Na, calculated 418.0274, observed 418.0289. 
IR (cm-1): 528, 568, 608, 701, 757, 1018, 1256, 1401, 1595, 3350. 
 
(170) (171) (176) 
C17H18INO2 
MW = 395.23g/mol 
Experimental   2 
166 
 
2.3.2.2  Synthesis of N-[(1S,2S)-2-Hydroxy-1-methyl-2-phenyl-ethyl]-2-iodo-N- 
  methyl-3-dimethylbenzamide  
 
 
 
To 2-iodo-3-methylbenzoic acid (165) (500 mg, 1.91 mmol) in dichloromethane (5 ml) was added 
dropwise oxalyl chloride (0.32 ml, 3.82 mmol) under an atmosphere of nitrogen with a catalytic 
amount of dimethylformamide (0.1 ml). The reaction mixture was allowed to stir at room 
temperature overnight. The solvents were removed by rotary evaporation to afford the crude acid 
chloride (172) which was immediately was dissolved in dry THF (5 ml) under an atmosphere of 
nitrogen. This was added via cannula to a solution of (1S,2S)-pseudoephedrine hydrochloride (313 
mg, 1.55mmol) and triethylamine (0.50 ml, 3.57 mmol) in dry THF (5 ml) at 0 oC and allowed to stir 
and reach room temperature overnight. The reaction mixture was then washed with saturated 
aqueous sodium chloride solution and the aqueous layer removed and extracted with ethyl acetate 
(3 x 25 ml). The organics were dried over anhydrous magnesium sulfate, filtered and concentrated 
by rotary evaporation. The crude product was purified by flash column chromatography with a 3:1 
petroleum ether:ethyl acetate solvent system to yield the pure product as a thick dark oil (461 mg, 
59%), as a mixture of rotamers. 
1H NMR (400MHz, CDCl3): (Major three rotamers only) ɷϬ.ϵϱ ;ϯH, d, J=ϲ.ϲHz, CHCH3Ϳ; ɷϭ.ϭϮ ;ϯH, d, 
J=7.2Hz, CHCH3Ϳ; ɷϭ.ϭϱ ;ϯH, d, J=ϳ.ϬHz, CHCH3Ϳ; ɷ1.44 (3H, d, J=7.2Hz, CHCH3Ϳ; ɷϮ.ϰϴ ;ϲH, s, AƌCH3); 
ɷϮ.ϰϵ ;ϯH, s, AƌCH3Ϳ; ɷϮ.ϲϬ ;ϯH, s, AƌCH3Ϳ; ɷϮ.ϴϬ ;ϯH, s, NCH3Ϳ; ɷϮ.ϴϲ ;ϯH, s, NCH3Ϳ; ɷϯ.ϭϲ ;ϯH, s, 
(NCH3Ϳ; ɷϯ.ϭϳ ;ϯH, s, NCH3Ϳ; ɷϯ.ϲϳ-3.77 (1H, m, CHCH3Ϳ; ɷϰ.Ϯϰ-4.34 (1H, m, CHCH3Ϳ; ɷϰ.ϱϰ ;ϭH, d, 
J=8.4Hz, CHOHͿ; ɷϰ.ϲϭ ;ϭH, d, J=ϵ.ϲHz, CHOHͿ; ɷϰ.ϳϭ ;ϭH, d, J=ϴ.ϴHz, CHOHͿ; ɷϰ.ϴϴ ;ϭH, d, J=ϲ.ϵHz, 
CHOHͿ; ɷϰ.ϵϲ-5.05 (1H, m, CHCH3Ϳ; ɷϱ.Ϭϳ-5.21 (1H, m, CHCH3Ϳ; ɷϲ.ϲϳ ;ϭH, dd, J=ϲ.ϴHz, ϭ.ϱHz, AƌH); 
ɷϲ.ϵϲ-7.05 (2H, m, ArHͿ; ɷϳ.Ϭϳ-7.13 (2H, m, ArHͿ; ɷϳ.Ϯϭ-7.51 (19H, m, ArH). 
 
(165) (172) 
(177) 
C18H20INO2 
MW = 409.26g/mol 
Experimental   2 
167 
 
13C NMR (400MHz, CDCl3): (Major three rotamers only) ɷϭϯ.ϳϵ, ϭϯ.ϴϰ, ϭϰ.ϮϮ, ϭϱ.ϱϱ, Ϯϲ.ϵϭ, Ϯϴ.ϳϭ, 
28.77, 28.97, 59.57, 60.44, 60.65, 75.77, 76.07, 76.17, 98.50, 98.83, 99.48, 124.03, 124.13, 124.40, 
126.14, 126.88, 126.99, 127.13, 127.61, 128.05, 128.06, 128.32, 128.34, 128.45, 128.59, 128.65, 
129.21, 129.37, 129.51, 129.57, 129.65, 129.87, 131.70, 141.39, 141.82, 142.20, 142.37, 142.60, 
142.71, 143.67, 143.87, 172.65, 172.93, 173.10. 
micrOTOF-Q MS m/z C18H20INO2+Na, calculated 432.0431, observed 432.0427. 
 
IR (cm-1): 618, 699, 748, 761, 786, 1010, 1402, 1441, 1613, 3350. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental   2 
168 
 
2.3.2.3  Synthesis of N-[(1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]-2-iodo-N- 
  methyl-3-(trifluoromethyl)benzamide  
 
 
 
To 2-iodo-3-(trifluoromethyl)benzoic acid (166) (500 mg, 1.58 mmol) in dichloromethane (5 ml) was 
added dropwise oxalyl chloride (0.27 ml, 3.16 mmol) under an atmosphere of nitrogen with a 
catalytic amount of dimethylformamide (0.1 ml). The reaction mixture was allowed to stir at room 
temperature overnight. The solvents were removed by rotary evaporation to afford the crude acid 
chloride (173) which was immediately dissolved in dry THF (5 ml) under an atmosphere of nitrogen. 
This was added via cannula to a solution of (1S,2S)-pseudoephedrine hydrochloride (262 mg, 1.30 
mmol) and triethylamine (0.42 ml, 2.99 mmol) in dry THF (5 ml) at 0 oC and allowed to stir and reach 
room temperature overnight. The reaction mixture was then washed with saturated aqueous 
sodium chloride solution and the aqueous layer removed and extracted with ethyl acetate (3 x 25 
ml). The organics were dried over anhydrous magnesium sulfate, filtered and concentrated by rotary 
evaporation. The crude product was purified by flash column chromatography with a 3:1 petroleum 
ether:ethyl acetate solvent system to yield the pure product as a thick dark oil (557 mg, 65%), as a 
mixture of rotamers. 
1H NMR (400MHz, CDCl3): (Major three rotamers only) ɷϬ.ϵϲ ;ϯH, d, J=ϳ.ϵHz, CHCH3Ϳ; ɷϭ.ϭϲ ;ϯH, d, 
J=3.9Hz, CHCH3Ϳ; ɷϭ.ϭϴ ;ϯH, d, J=ϰ.ϭHz, CHCH3); ɷϭ.ϰϳ ;ϯH, d, J=ϳ.ϬHz, CHCH3Ϳ; ɷϮ.ϲϮ ;ϯH, s, NCH3); 
ɷϮ.ϴϬ ;ϯH, s, NCH3Ϳ; ɷϯ.ϭϵ ;ϯH, s, NCH3Ϳ; ɷϯ.Ϯϭ ;ϯH, s, NCH3Ϳ; ɷϯ.ϱϱ-3.65 (1H, m, CHCH3Ϳ; ɷϰ.Ϯϯ-4.36 
(1H, m, CHCH3Ϳ; ɷϰ.ϱϴ ;ϭH, d, J=ϵ.ϮHz, CHOHͿ; ɷϰ.ϳϯ ;ϭH, d, J=ϴ.ϰHz, CHOHͿ; ɷϰ.ϴϴ-4.94 (1H, m, 
CHCH3); ɷϱ.ϬϮ-5.12 (1H, m (CHOHͿ; ɷϲ.ϵϲ ;ϭH, appt. d, J=7.8, ArHͿ; ɷϳ.Ϭϲ-7.11 (2H, m, ArHͿ; ɷϳ.Ϯϵ-
7.39 (6H, m, ArHͿ; ɷϳ.ϰϬ-7.46 (5H, t, J=7.8Hz, ArHͿ; ɷϳ.ϰϲ-7.55 (7H, m, ArHͿ; ɷϳ.ϲϰ ;ϯH, t, J=ϳ.ϴHz, 
ArH). 
 
(166) (173) (178) 
C18H17F3INO2 
MW = 463.23g/mol 
Experimental   2 
169 
 
13C NMR (400MHz, CDCl3): (Major three rotamers only) ɷϭϯ.ϳ7, 14.21, 15.63, 27.13, 31.85, 34.84, 
55.13, 59.67, 60.69, 75.73, 75.87, 75.97, 89.06, 89.30, 89.96, 126.05, 126.81, 126.83, 127.22, 127.28, 
127.40, 127.46, 127.51, 127.74, 128.02, 128.08, 128.22, 128.44, 128.50, 128.68, 128.79, 128.88, 
129.17, 129.65, 130.02, 131.60, 132.02, 134.16, 134.53, 141.24, 141.58, 142.05, 146.34, 146.53, 
146.59, 171.49, 171.75. 
micrOTOF-Q MS m/z C18H17F3INO2+Na, calculated 486.0148, observed 486.0148. 
IR (cm-1): 602, 678, 748, 816, 1117, 1148, 1178, 1312, 1606, 3310. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental   2 
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2.3.2.4  Synthesis of 5-chloro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]-2-iodo-
  N-methyl-3-dimethylbenzamide  
 
 
 
To 5-chloro-2-iodo-3-methylbenzoic acid (168) (500 mg, 1.69 mmol) in dichloromethane (5 ml) was 
added dropwise oxalyl chloride (0.29 ml, 3.38 mmol) under an atmosphere of nitrogen with a 
catalytic amount of dimethylformamide (0.1 ml). The reaction mixture was allowed to stir at room 
temperature overnight. The solvents were removed by rotary evaporation to afford the crude acid 
chloride (174) which was immediately dissolved in dry THF (5 ml) under an atmosphere of nitrogen. 
This was added via cannula to a solution of (1S,2S)-pseudoephedrine hydrochloride (278 mg, 1.38 
mmol) and triethylamine (0.44 ml, 3.17 mmol) in dry THF (5 ml) at 0 oC and allowed to stir and reach 
room temperature overnight. The reaction mixture was then washed with saturated aqueous 
sodium chloride solution and the aqueous layer removed and extracted with ethyl acetate (3 x 25 
ml). The organics were dried over anhydrous magnesium sulfate, filtered and concentrated by rotary 
evaporation. The crude product was purified by flash column chromatography with a 3:1 petroleum 
ether:ethyl acetate solvent system to yield the pure product as a thick dark oil (510 mg, 68%), as a 
mixture of rotamers. 
1H NMR (400MHz, CDCl3): (Major three rotamers only) ɷϬ.ϵϱ ;ϯH, d, J=ϲ.ϳHz, CHCH3Ϳ; ɷϭ.ϭϮ ;ϯH, d, 
J=7.2Hz, CHCH3Ϳ; ɷϭ.ϭϰ ;ϯH, d, J=ϲ.ϵHz, CHCH3); ɷϭ.ϯϴ ;ϯH, d, J=ϳ.ϬHz, CHCH3Ϳ; ɷϮ.ϰϭ ;ϯH, s, AƌCH3); 
ɷϮ.ϰϯ ;ϲH, s, AƌCH3Ϳ; ɷϮ.ϲϭ ;ϯH, s, AƌCH3Ϳ; ɷϮ.ϳϳ ;ϯH, s, NCH3Ϳ; ɷϯ.ϭϰ ;ϯH, s, NCH3Ϳ; ɷϯ.ϱϱ-3.63 (1H, 
m, CHCH3Ϳ; ɷϰ.Ϯϰ-4.38 (1H, m, CHCH3Ϳ; ɷϰ.ϰϵ ;ϭH, d, J=ϴ.ϰHz, CHOHͿ; ɷϰ.ϲϲ ;ϭH, d, J=ϴ.ϰHz, CHOH); 
ɷϰ.84 (1H, d, J=7.2Hz, CHOHͿ; ɷϰ.ϵϱ-5.04 (1H, m, CHCH3Ϳ; ɷϲ.ϲϱ ;ϭH, d, J=Ϯ.ϯHz, AƌHͿ; ɷϲ.ϴϭ ;ϭH, d, 
J=2.6Hz, ArHͿ; ɷϲ.ϴϳ ;ϭH, d, J=Ϯ.ϰ, AƌHͿ; ɷϳ.Ϭϳ-7.11 (2H, m, ArHͿ; ɷϳ.ϭϳ-7.20 (3H, m, ArHͿ; ɷϳ.ϯϬ-7.45 
(13H, m, ArH). 
 
(168) (174) 
(179) 
C18H19ClINO2 
MW = 443.71g/mol 
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13C NMR (400MHz, CDCl3): (Major three rotamers only) ɷϭϯ.ϳϱ, ϭϯ.ϳϳ, ϭϱ.ϳϯ, Ϯϳ.ϰϳ, Ϯϴ.ϱϴ, Ϯϴ.ϴϬ, 
54.79, 59.60, 60.49, 75.65, 75.70, 75.74, 95.93, 96.26, 96.89, 124.09, 124.31, 126.15, 126.44, 126.67, 
126.80, 127.10, 127.74, 127.97, 128.15, 128.41, 128.49, 128.65, 129.13, 129.30, 129.50, 129.68, 
130.60, 133.80, 134.18, 134.75, 141.80, 141.81, 141.95, 143.99, 144.39, 144.62, 144.86, 145.04, 
145.15, 171.09, 171.19, 171.42. 
micrOTOF-Q MS m/z C18H19ClINO2+Na, calculated 466.0041, observed 466.0041. 
IR (cm-1): 700, 1011, 1115, 1250, 1350, 1404, 1444, 1614, 3350. 
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2.3.2.5  Synthesis of 3-chloro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl]-2-iodo-
  N-methyl-benzamide  
 
 
 
To 3-chloro-2-iodobenzoic acid (169) (500 mg, 1.77 mmol) in dichloromethane (5 ml) was added 
dropwise oxalyl chloride (0.30 ml, 3.54 mmol) under an atmosphere of nitrogen with a catalytic 
amount of dimethylformamide (0.1 ml). The reaction was allowed to stir at room temperature 
overnight. The solvents were removed by rotary evaporation to afford the crude acid chloride (175) 
which was immediately dissolved in dry THF (5 ml) under an atmosphere of nitrogen. This was added 
via cannula to a solution of (1S,2S)-pseudoephedrine hydrochloride (290 mg, 1.44 mmol) and 
triethylamine (0.46 ml, 3.31 mmol) in dry THF (5 ml) at 0 oC and allowed to stir and reach room 
temperature overnight. The reaction mixture was then washed with saturated aqueous sodium 
chloride solution and the aqueous layer removed and extracted with ethyl acetate (3 x 25 ml). The 
organics were dried over anhydrous magnesium sulfate, filtered and concentrated by rotary 
evaporation. The crude product was purified by flash column chromatography with a 3:1 petroleum 
ether:ethyl acetate solvent system to yield the pure product as a thick dark oil (532 mg, 70%), as a 
mixture of rotamers. 
1H NMR (400MHz, CDCl3): (Major three rotamers only) ɷϬ.ϵϳ ;ϯH, d, J=ϲ.ϳHz, CHCH3Ϳ; ɷϭ.ϭϯ ;ϯH, d, 
J=6.7, CHCH3Ϳ; ɷϭ.ϭϱ ;ϯH, d, J=ϳ.ϬHz, CHCH3Ϳ; ɷϭ.ϰϱ ;ϯH, d, J=7.0Hz, CHCH3Ϳ; ɷϮ.ϲϯ ;ϯH, s, NCH3); 
ɷϮ.ϴϯ ;ϯH, s, NCH3Ϳ; ɷϯ.ϭϳ ;ϯH, s, NCH3Ϳ; ɷϯ.ϮϬ ;ϯH, s, NCH3Ϳ; ɷϯ.ϲϯ-3.71 (1H, m, CHCH3Ϳ; ɷϰ.Ϯϱ-4.35 
(1H, m, CHCH3Ϳ; ɷϰ.ϱϳ ;ϭH, d, J=ϴ.ϱHz, CHOHͿ; ɷϰ.ϳϯ ;ϭH, d, J=ϵ.ϮHz, CHOHͿ; ɷϰ.ϵϰ ;ϭH, d, J=ϳ.ϮHz, 
CHOHͿ; ɷϱ.Ϭϭ-5.11 (1H, m, CHCH3Ϳ; ɷϱ.ϰϴ-6.41 (1H, broad, OHͿ; ɷϲ.ϳϱ ;ϭH, dd, J=ϳ.ϰHz, ϭ.ϯHz, AƌH); 
ɷϳ.Ϭϱ-7.10 (3H, m, ArHͿ; ɷϳ.ϭϰ ;ϭH, dd, J=ϳ.ϳHz, ϭ.ϱHz, AƌHͿ; ɷϳ.Ϯϵ-7.44 (17H, m, ArHͿ; ɷϳ.ϰϱ-7.50 
(7H, m, ArHͿ; ɷϳ.ϲϭ ;ϭH, d, J=ϭ.ϱHz, AƌHͿ; ɷϳ.ϲϰ ;ϭH, dd, J=ϯ.ϴHz, ϭ.ϲHz, AƌHͿ; ɷϳ.ϲϲ ;ϭH, dd, J=7.7Hz 
& 1.5Hz, ArHͿ; ɷϳ.ϲϵ ;ϭH, dd, J=ϴ.ϮHz, ϭ.ϰHz, AƌHͿ; ɷϳ.ϵϰ ;ϭH, dd, J=ϴ.ϰHz, ϭ.ϯHz, AƌH). 
(169) (175) 
(180) 
C17H17ClINO2 
MW = 429.68g/mol 
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13C NMR (400MHz, CDCl3): (Major three rotamers only) ɷϭϯ.ϳϭ, ϭϯ.ϴϬ, ϭϱ.ϱϴ, ϱϱ.ϰϮ, ϱϵ.ϴϭ, ϲϬ.ϰϵ, 
75.71, 75.88, 76.03, 96.59, 97.21, 98.64, 124.57, 124.95, 126.07, 126.08, 126.86, 126.88, 127.68, 
127.75, 128.26, 128.36, 128.44, 128.53, 128.70, 128.76, 128.78, 129.03, 129.24, 129.30, 129.38, 
129.86, 129.96, 130.04, 131.81, 139.46, 139.78, 139.88, 141.00, 141.43, 141.91, 145.61, 169.58, 
171.82, 171.83. 
micrOTOF-Q MS m/z C17H17ClINO2+Na, calculated 451.9885, observed 451.9885. 
 
IR (cm-1): 699, 748, 803, 1036, 1190, 1246, 1353, 1396, 1608, 3328. 
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2.3.3  Experimental procedures for Catalyst Screening Reactions 
2.3.3.1  Synthesis of 5-Benzoyltetrahydrofuran-2-one  
 
 
 
To an organoiodine catalyst (0.052 mmol) in the appropriate solvent (2 ml, see Table 3.24), was 
added 5-oxo-5-phenylpentanoic acid (50 mg, 0.26 mmol), m-chloroperoxybenzoic acid (135 mg, 0.78 
mmol) and p-toluenesulfonic acid monohydrate (148 mg, 0.78 mmol). The reaction mixture was set 
to stir at room temperature overnight. After this time, the reaction mixture was washed with 
saturated aqueous sodium thiosulfate solution (15 ml) and saturated aqueous sodium bicarbonate 
solution (15 ml) and the aqueous layer removed and extracted with dichloromethane (3 x 25 ml). 
The organics were dried over anhydrous magnesium sulfate, filtered and concentrated by rotary 
evaporation. The crude product was purified by flash column chromatography with a 5:1 petroleum 
ether:ethyl acetate solvent to yield the pure product as an pale yellow oil (34 mg, 70%). 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϰϭ-2.63 (4H, m, CHCH2CH2COͿ; ɷϱ.ϳϴ-5.84 (1H, m, CHCH2Ϳ; ɷϳ.ϱϮ ;ϮH, 
appt. t, J=7.0Hz, ArHͿ; ɷϳ.ϲϰ ;ϭH, tt, J= ϳ.ϰ, ϭ.ϯHz, AƌHͿ; ɷϳ.ϵϱ-8.01 (2H, m, ArH). 
13C NMR (400MHz, CDCl3Ϳ: ɷϮϱ.ϯϳ ;CHCH2CH2CO), 27.21 (CHCH2CH2CO), 78.66 (CHCH2CH2CO), 129.16 
(Ar), 129.42 (Ar), 133.93 (Ar), 134.70 (Ar), 176.69 (PhC=O), 194.72 (OC=O). 
micrOTOF-Q MS m/z C11H10O3+Na, calculated 213.0522, observed 213.0516. 
IR (cm-1): 630, 686, 926, 972, 1062, 1172, 1226, 1448, 1692, 1766. 
This data is consistent with that reported in the literature150. 
 
(181) 
C11H10O3 
MW = 190.20g/mol 
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2.3.4  Experimental Procedures for the Synthesis of L-Proline Based, Chiral  
  1,2,4-oxadiazole Systems 
2.3.4.1  Synthesis of (2S)-N-Cbz-pyrrolidine-2-carboxamide  
 
 
 
 
 
To N-Cbz-L-proline (182) (1.00 g, 4.01 mmol) in tetrahydrofuran (50 ml) under an atmosphere of 
nitrogen, N-hydroxysuccinimide (693 mg, 6.02 mmol) and N,N-dicyclohexylcarbodiimide (827 mg, 
4.01 mmol) were added. The mixture was set to stir at room temperature overnight. After this time, 
concentrated aqueous ammonia (3 ml) was added and the reaction mixture was allowed to stir at 
room temperature overnight. After this time, the reaction mixture was washed with saturated 
ammonium chloride solution and extracted with ethyl acetate. The organics were dried over 
anhydrous magnesium sulfate, filtered and concentrated by rotary evaporation. The crude product 
was purified by gravity column chromatography with a 1:15 petroleum ether:ethyl acetate solvent 
system to yield the pure product as a pale yellow oil (494 mg, 49%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϭ.ϴϯ-2.34 (4H, m, NCHCH2CH2Ϳ; ɷϯ.ϯϳ-3.57 (2H, m, NCH2Ϳ; ɷϰ.Ϯϱ-4.37 (1H, 
m, NCHCH2Ϳ; ɷϱ.Ϭϴ-5.19 (2H, m, OCH2PhͿ; ɷϱ.ϴϴ-6.77 (2H, m, NH2Ϳ; ɷϳ.Ϯϳ-7.38 (5H, m, PhH). 
This data is consistent with that reported in the literature172. 
 
 
 
 
 
 
 
(183) 
C13H16N2O3 
MW = 248.28g/mol 
(182) 
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2.3.4.2  Synthesis of (2S)-N-Cbz-2-cyanopyrrolidine  
 
 
 
 
 
 
 
 
 
To (2S)-N-Cbz-pyrrolidine-2-carboxamide (183) (494 mg, 1.98 mmol) under an atmosphere of 
nitrogen in dichloromethane (20 ml), was added pyridine (0.80 ml, 9.90 mmol) followed by p-
toluenesulfonyl chloride (755 mg, 3.96 mmol). The reaction mixture was allowed to stir at room 
temperature for 72 hours. After this time, the reaction mixture was washed with saturated 
ammonium chloride solution and extracted with ethyl acetate. The organics were dried over 
anhydrous magnesium sulphate, filtered and concentrated by rotary evaporation. The crude product 
was purified by gravity column chromatography with a 2:1 petroleum ether:ethyl acetate solvent 
system to yield the pure product as a pale yellow oil (217 mg, 48%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.Ϭϳ-2.36 (4H, m, NCHCH2CH2Ϳ; ɷϯ.ϯϳ-3.51 (1H, m, NCH2Ϳ; ɷϯ.ϱϲ-3.67 (1H, 
m, NCH2Ϳ; ɷϰ.ϲϭ ;ϭH, ddd, J=Ϯϱ.ϳHz, ϳ.ϱHz, Ϯ.ϲHz, NCHCH2Ϳ; ɷϱ.ϭϱ-5.26 (2H, m, OCH2PhͿ; ɷϳ.ϯϮ-7.46 
(5H, m, PhH). 
This data is consistent with that reported in the literature172. 
 
 
 
 
 
 
 
 
 
 
(184) 
C13H14N2O2 
MW = 230.26g/mol 
(183) 
Experimental   2 
177 
 
2.3.4.3  Synthesis of 5-[(2S)-N-Cbz-pyrrolidin-2-yl]-3-(2-pyridyl)-1,2,4-oxadiazole 
   
 
 
 
To N-Cbz-L-proline (182) (500 mg, 2.01 mmol) in dichloromethane (20 ml) was added dropwise 
oxalyl chloride (0.19 ml, 2.21 mmol) under an atmosphere of nitrogen with a catalytic amount of 
dimethylformamide (0.1 ml). The reaction mixture was allowed to stir at room temperature 
overnight. The solvents were removed by rotary evaporation to afford the crude acid chloride (186) 
which was immediately dissolved in xylene under an atmosphere of nitrogen. Immediately to this 
were added N'-hydroxypyridine-2-carboxamidine (248 mg, 1.81 mmol) and pyridine (0.16 ml, 1.99 
mmol) and the reaction mixture was set to stir at reflux overnight. After this time the solvents were 
removed under reduced pressure. The crude product was purified by gravity column 
chromatography with a 2:1 petroleum ether:ethyl acetate solvent system to yield the pure product 
as an orange oil (350 mg, 50%), as a mixture of rotamers. 
 
1H NMR (400MHz, CDCl3): (Major rotamer only) ɷϭ.ϵϵ-2.51 (4H, m, NCHCH2CH2Ϳ; ɷϯ.ϱϱ-3.71 (1H, m, 
NCH2Ϳ; ɷϯ.ϳϲ-3.86 (1H, m, NCH2Ϳ; ɷϱ.ϭϮ ;ϮH, t, J=17.2Hz, OCH2PhͿ; ɷϱ.Ϯϵ ;ϭH, dd, J=8.4Hz, 3.4Hz, 
NCHCH2Ϳ; ɷϳ.ϭϯ-7.22 (3H, m, PhHͿ; ɷϳ.ϯϮ-7.40 (2H, m, PhHͿ; ɷϳ.ϰϮ-7.49 (1H, m, ArHͿ; ɷϳ.ϴϮ-7.90 (1H, 
m, ArHͿ; ɷϴ.ϭϭ ;ϭH, dd, J=Ϯϲ.ϰHz, ϳ.ϴHz, AƌHͿ; ɷϴ.ϴϬ-8.85 (1H, m, ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϯ.ϲϮ (Major and minor rotamers) (NCH2CH2), 24.44 (NCH2CH2), 31.56 
(NCHCH2), 32.49 (NCHCH2), 46.58 (NCH2), 47.00 (NCH2), 53.77 (NCHCH2), 54.29 (NCHCH2), 67.28 
(OCH2Ph), 67.33 (OCH2Ph), 123.27 (Ar), 123.35 (Ar), 125.47 (Ar), 125.57 (Ar), 127.85 (Ar), 127.90 (Ar), 
128.03 (Ar), 128.11 (Ar), 128.34 (Ar), 128.52 (Ar), 136.08 (Ar), 136.40 (Ar), 136.98 (Ar), 137.01 (Ar), 
146.21 (Ar)146.37 (Ar), 150.41 (Ar), 150.44 (Ar), 154.08 (Ar), 154.82 (Ar), 168.18 (Ar), 168.30 (Ar), 
180.64 (C=O), 180.73 (C=O). 
micrOTOF-Q MS m/z C19H18N4O3+Na, calculated 373.1266, observed 373.1271. 
IR (cm-1): 724, 908, 1090, 1114, 1176, 1353, 1408, 1447, 1581, 1700. 
(187) 
C19H18N4O3 
MW = 350.37g/mol 
(186) (182) 
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2.3.4.4  Synthesis of 5-[(2S)-N-boc-pyrrolidin-2-yl]-3-(2-pyridyl)-1,2,4-oxadiazole 
   
 
 
To N-boc-L-proline (189) (1.00 g, 4.65 mmol) in dichloromethane (50 ml) under an atmosphere of 
nitrogen, N-hydroxysuccinimide (1.22 g, 6.98 mmol) and N,N-dicyclohexylcarbodiimide (959 mg, 4.65 
mmol) were added. The mixture was set to stir at room temperature overnight. After this time, N'-
hydroxypyridine-2-carboxamidine (44) (638 mg, 4.65 mmol) was added and the reaction mixture was 
allowed to stir at room temperature overnight. After this time, the reaction mixture was filtered and 
the filtrate was concentrated under reduced pressure. The residues were redissolved in toluene and 
the reaction mixture was set to stir at reflux overnight. The crude product was purified by gravity 
column chromatography with a 1:2 petroleum ether:ethyl acetate solvent system to yield the pure 
product as a mixture of rotamers as a pale yellow oil (1.21 g, 82% two steps). 
 
1H NMR (400MHz, CDCl3): (Major rotamer only) ɷϭ.Ϯϳ-1.51 (9H, m, OC(CH3)3Ϳ; ɷϭ.ϵϳ-2.49 (4H, m, 
NCHCH2CH2Ϳ; ɷϯ.ϰϬ-3.77 (2H, m, NCH2Ϳ; ɷϱ.Ϭϵ-5.27 (1H, m, NCHCH2Ϳ; ɷϳ.ϯϵ-7.47 (1H, m, ArHͿ; ɷϳ.ϴϭ-
7.89 (1H, m, ArHͿ; ɷϴ.ϭϮ ;ϭH, d, J=7.7Hz, ArHͿ; ɷϴ.ϳϳ-8.83 (1H, m, ArH). 
13C NMR (100MHz, CDCl3): (Major rotamer only) ɷϮϴ.ϭϱ ;OC;CH3)3), 28.39 (OC(CH3)3), 31.60 
(OC(CH3)3), 33.54 (OC(CH3)3), 33.23 (NCH2CH2), 33.61 (NCH2CH2), 46.39 (NCHCH2), 46.71 (NCHCH2), 
53.86 (NCH2), 53.94 (NCH2), 80.38 (NCHCH2), 80.56 (NCHCH2), 123.17 (Ar), 123.31 (Ar), 125.42 (Ar), 
125.60 (Ar), 136.97 (Ar), 137.12 (Ar), 146.24 (Ar), 150.33 (Ar), 150.50 (Ar), 153.31 (Ar), 168.22 (Ar), 
181.09 (C=O), 181.47 (C=O). 
micrOTOF-Q MS m/z C16H20N4O3+Na, calculated 339.1428, observed 339.1429. 
IR (cm-1): 745, 771, 1117, 1157, 1247, 1364, 1387, 1693, 2931, 2975. 
(191) 
C15H20N4O3 
MW = 316.36g/mol 
(189) (44) 
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2.3.4.5  Synthesis of 3-(2-pyridyl)-5-[(2S)-pyrrolidin-2-yl]-1,2,4-oxadiazole  
 
 
 
 
To [(2S)-N-boc-pyrrolidin-2-yl]-3-(2-pyridyl)-1,2,4-oxadiazole (191) (1.00 g, 3.16 mmol) under an 
atmosphere of nitrogen was added a 1:20 solution of trifluoroacetic acid in dichloromethane ( 10ml). 
The reaction mixture was allowed to stir at room temperature overnight. After this time, the 
solvents were removed under reduced pressure and the residues redissolved in water (20 ml) and 
extracted with diethyl ether (3 x 20 ml). The organics were dried over anhydrous magnesium sulfate, 
filtered and concentrated by rotary evaporation to yield the product as a pink semi-solid (567 mg, 
83%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϮ.ϭϱ-2.34 (2H, m, NCH2CH2Ϳ; ɷϮ.ϰϮ-2.69 (2H, m, NCHCH2Ϳ; ɷϯ.ϱϰ-3.69 (2H, 
m, NCH2Ϳ; ɷϱ.Ϯϴ ;ϭH, t, J=ϴ.ϬHz, NCHCH2Ϳ; ɷϳ.ϰϭ ;ϭH, dd, J=ϳ.ϳHz, ϱ.ϭHz, AƌH); ɷϳ.ϴϮ ;ϭH, t, J=ϳ.ϯHz, 
ArHͿ; ɷϴ.Ϭϯ ;ϭH, d, J=ϴ.ϬHz, AƌHͿ; ɷϴ.ϲϵ ;ϭH, d, J=ϰ.ϰHz, AƌHͿ; ɷϴ.ϴϬ-10.20 (1H, broad, NH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϮϱ.ϰϬ ;NCH2CH2), 31.19 (NCHCH2), 46.94 (NCH2), 54.44 (NCHCH2), 123.25 
(Ar), 125.53 (Ar), 137.06 (Ar), 146.29 (Ar), 150.45 (Ar), 168.02 (Ar), 182.79 (Ar). 
micrOTOF-Q MS m/z C11H12N4O+Na, calculated 239.0903, observed 239.0906. 
 
 
 
 
 
 
 
(191) 
(188) 
C11H12N4O 
MW = 216.24g/mol 
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2.3.4.6 Synthesis of N'-hydroxy-2-iodo-benzamidine  
 
 
 
 
To hydroxylamine hydrochloride (500 mg, 7.20 mmol) in water (50 ml) was added in small portions, 
sodium carbonate (670 mg, 7.20 mmol). To this, 2-iodobenzonitrile (194) (1.50 g, 6.55 mmol) in 
ethanol (50 ml) was added and the reaction mixture set to stir at reflux for 24 hours. After this time, 
the reaction mixture was extracted with dichloromethane. The organics were dried over anhydrous 
magnesium sulfate, filtered and concentrated by rotary evaporation to yield the product as a white 
solid (240 mg, 61%). 
 
1H NMR (400MHz, CDCl3Ϳ: ɷϱ.ϴϱ-6.21 (2H, broad doublet, NH2Ϳ; ɷϳ.ϭϰ ;ϭH, appt. td, J=7.7Hz, 1.6Hz, 
ArHͿ; ɷϳ.ϰϭ ;ϭH, appt. t, J=7.3Hz, ArHͿ; ɷϳ.ϰϵ ;ϭH, dd, J=ϳ.ϱHz, ϭ.ϱHz, AƌHͿ; ɷϳ.ϵϭ ;ϭH, d, J=ϳ.ϴHz, 
ArH). 
13C NMR (100MHz, CDCl3Ϳ: ɷϵϭ.ϵϳ, ϭϮϴ.ϭϰ, ϭϮϴ.ϭϵ, 131.40, 140.09, 141.21. 
IR (cm-1): 1021, 1448, 2830, 2942, 3315. 
M.p.: 139-140 oC. 
 
(195) 
C7H7IN2O 
MW = 262.05g/mol 
(194) 
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3  Results and Discussion 
This chapter is divided into three sub-chapters, each discussing in detail a particular area of research 
in which the 1,2,4-oxadiazole unit has been explored.  
The first of these subchapters concerns the potential suitability of the chemistry of the 1,2,4-
oxadiazole unit as a useful component in ligands in supramolecular chemistry.  
The second of these sub-chapters looks at the potential incorporation of 1,2,4-
oxadiazloles/oxadiazolines and subsequent biological effects of the products in extensions of our 
gƌoup͛s ǁoƌk oŶ β-sultaŵs, ɶ-sultams and similar, related systems. In this chapter a competing 
reaction resulted in the formation of isoxazoles/isoxazolines rather than 1,2,4-
oxadiazoles/oxadiazolines. 
The third sub-chapter considers the 1,2,4-oxadiazole unit as a feature of asymmetric organocatalysis. 
This subchapter involves the incorporation of the 1,2,4-oxadiazole into novel L-proline bases and 
moves on to look at their potential in hypervalent iodine based systems. 
 
3.1  The 1,2,4-Oxadiazole as a Key Feature in Ligand Systems 
As introduced earlier, the 1,2,4-oxadiazole nucleus carries major potential as a coordination unit in 
ligand strands, though remains relatively unexplored in any depth. There are several reasons for this 
potential. The first is that each nitrogen atom of the 1,2,4-oxadiazole is fully available for co-
ordination to metal ions. This is beĐause the oǆǇgeŶ atoŵ doŶates oŶe of its loŶe paiƌs to the π-
electron system of the ring, thus enabling one or both of the oxadiazole nitrogen atoms to utilise 
their lone pairs and form dative, co-ordinate bonds to metal ions without loss of aromaticity. The 
imine-nitrogen (N4) and oxime-nitrogen sites (N2) provide two realistic co-ordination options and 
thus give the 1,2,4-oxadiazole versatility as a potential component in ligand systems.  
A second highly suitable feature of the 1,2,4-oxadiazole unit in ligand systems, is the attractive bite 
angle created when the unit is 3,5-disubstituted with other potential binding domains, such as 2-
pyridyl units, for example. The lone pairs of the pyridine nitrogen and oxadiazole nitrogens are 
angled very nicely towards a central focus, at approximately 500. The oxadiazole nitrogens and those 
of adjacent 2-N-heterocycles provide a perfect potential bidentate binding domain for metal ions.  
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Another interesting feature of the 1,2,4-oxadiazole in ligand synthesis is the fact that they are so 
under-researched in this area. There are a handful of 1,2,4-oxadiazole containing ligands in the 
literature and these are detailed in the introduction. 
The work in this section was inspired through collaboration with Prof. Craig Rice of the University of 
Huddersfield. Rice and co-workers have focussed largely on thiazole containing ligand systems. The 
parallels between the thiazole and 1,2,4-oxadiazole units were highlighted in the introduction.  
 
3.1.1  The Synthesis of 1,2,4-Oxadiazole-Containing Ligand Precursor Materials 
The precursor materials required for the synthesis of the 1,2,4-oxadiazole ligand were not all 
commercially available and thus were synthesised in-house where necessary.  
Initially, the 1,3-dipolar cycloaddition route to the 1,2,4-oxadiazole nucleus served as our primary 
mode of synthesis. However, following a series of practical difficulties with some of the ligand 
precursor materials, it was decided to switch focus to the amidoxime/reactive-carboxylic mode.  
The general scheme for ligand construction is shown below: 
 
Scheme 3.1 
 
Occasionally, some of the cyano- compounds also had to be synthesised. These syntheses and those 
of the corresponding ligand-metal complexes are detailed below. 
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3.1.1.1  Synthesis of N'-Hydroxypyridine-2-carboxamidine 
 
 
 
 
 
Scheme 3.2 
 
The synthesis of the simple pyridine-2-amidoxime (44) was achieved in 77% yield through reaction 
with hydroxylamine in a water-ethanol solvent under reflux. 
This simple precursor was used to synthesise several ligands in this chapter and was an important 
and regularly utilised precursor.  
The synthesis of the product was confirmed by 1H NMR spectroscopy. The broad NH2 signal is seen 
ĐleaƌlǇ at ɷϱ.ϲϳ. The OH is ǀisiďle as a ďƌoad siŶglet also, at ɷϴ.ϱϴ. The fouƌ pyridine protons 
resonate as doublets of varying multiplicity at ɷϳ.Ϯϰ, ɷϳ.ϲϰ, ɷϳ.ϴϲ aŶd ɷϴ.ϱϬ. 
 
 
 
 
 
Figure 3.1 
 
 
 
 
(44) (43) 
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3.1.1.2  Synthesis of 1-Oxido-2-(2-pyridyl)pyridin-1-ium 
 
 
 
 
Scheme 3.3 
 
Mono-oǆidatioŶ of Ϯ,Ϯ͛-bipyridine (45) to yield (46) was achieved through treatment with mCPBA in 
dichloromethane. This was achieved in 50% yield. The product was purified by column 
chromatography to remove remaining mCPBA starting material and the mCBA by-product. 
The use less than 1eq of mCPBA minimised oxidation of both pyridine nitrogen atoms. 
The structure of the product was confirmed by 1H NMR spectroscopy. The apparent triplet of 
doublets at ɷϳ.Ϭϱ aŶd ɷϳ.ϲϬ aŶd the ŵultiplet at ɷϳ.ϭϬ-7.16 are likely to resonate from protons b,c, f 
and g. The fouƌ ƌeŵaiŶiŶg split douďlets at ɷϳ.ϵϱ, ɷϴ.ϭϭ, ɷϴ.ϱϭ aŶd ɷϴ.ϲϵ aƌe likelǇ to ƌesoŶate fƌoŵ 
protons a, d, e and h. The sigŶal at ɷϴ.ϲϵ is likelǇ to ďe pƌotoŶ a, due to the deshielding influence of 
the nearby pyridinium oxide.  
 
 
 
 
Figure 3.2 
 
The identity of the product was further confirmed by 13C NMR spectroscopy which showed the 
correct number of aromatic signals, and by HRMS which measured an accurate mass of the [M+Na]+ 
ion as 195.0536 for 195.0529 calculated.  
 
(46) (45) 
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3.1.1.3  Synthesis of 1-Oxido-2-(1-oxidopyridin-1-ium-2-yl)pyridin-1-ium 
 
 
Scheme 3.4 
 
The bipyridine bis-N-oxide (47) was synthesised by oxidation with hydrogen peroxide in glacial acetic 
acid and was achieved in 93% yield. 
The structure of this symmetrical product was strongly suggested by 1H NMR spectroscopy, and 
confirmed by HRMS which delivered an accurate mass for the [M+Na]+ ion of 211.0482 for the 
theoretical figure of 211.0478 for this ion. 
 
3.1.1.4  Synthesis of 6-(2-Pyridyl)pyridine-2-carbonitrile  
Scheme 3.5 
 
The nucleophilic substitution by cyanide to the 2-position of the bipyridine mono-N-oxide (46) was 
achieved in 55% yield through treatment of the N-oxide with a total of two equivalents of benzoyl 
chloride and two equivalents of trimethylsilyl cyanide in refluxing dichloromethane. The mono-2-
(47) 
(48) (46) 
(45) 
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cyanated product (48) was purified by column chromatography to remove benzoic acid and 
trimethylsilyl side products. 
The structure of the product was confirmed by 1H NMR spectroscopy. Assignment of signals suggests 
that the clean, apparent triplet at ɷϳ.ϴϲ is pƌotoŶ b. The doublet of doublets of doublets and 
apparent triplet of doublets at ɷϳ.Ϯϵ and ɷϳ.ϳϲ respetively are likely to account for protons e and f. 
The ƌeŵaiŶiŶg douďlets at ɷϳ.ϲϮ, ɷϴ.ϯϱ, ɷϴ.ϱϳ aŶd ɷϴ.ϱϵ ĐoƌƌespoŶd to pƌotoŶs iŶ positioŶs a, c, d, 
and g. 
 
 
 
 
 
 
Figure 3.3 
 
The structure of the product was confirmed by HRMS with the accurate mass of the [M+Na]+ ion 
measured as 204.0537 for the calculated figure of 204.0532. 
 
3.1.1.5  Synthesis of 6-(6-Cyano-2-yridyl)pyridine-2-carbonitrile  
-
-
 
 
Scheme 3.6 
 
(47) 
(49) 
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The bipyridine bis-cyano compound (49) was synthesised in 74% yield by reaction of (47) with a total 
of 2.5 equivalents of both benzoyl chloride and trimethylsilyl cyanide in refluxing dichloromethane. 
The structure of the product was suggested by 1H NMR spectroscopy, and confirmed by HRMS which 
delivered an accurate mass for the [M+Na]+ ion of 229.0488 for the calculated figure of 229.0485 for 
this ion. 
 
3.1.1.6  Synthesis of N'-Hydroxy-6-(2-pyridyl)pyridine-2-carboxamidine  
 
Scheme 3.7 
 
The Ϯ,Ϯ͛-bipyridyl-2-amidoxime (50) was synthesised in 90% yield by applying the same conditions as 
per the synthesis of (44). The primary amine of the amidoxime was clearly present as a broad singlet 
at ɷϱ.ϲϵ iŶ the 1H NMR spectrum. Two split douďlets ǁeƌe oďseƌǀed, at ɷϳ.ϴϵ aŶd ɷϴ.ϲϰ, together 
ǁith a ŵultiplet ƌesoŶatiŶg at ɷϴ.ϯϱ-8.40. Considering the splitting patterns, the doublet of doublets 
douďlets at ɷϳ.Ϯϴ aŶd the overlapping apparent triplet of doublets and doublet of doublets at ɷϳ.ϳϴ 
aŶd ɷϳ.ϳϵ ĐoƌƌespoŶd to pƌotoŶs b, e and f respectively.  
 
 
 
 
 
Figure 3.4 
(48) (50) 
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The 13C NMR supports this structure, giving the appropriate number of signals. 
The IR spectrum shows good support for this structure, the absorption band at 1651.8cm-1 is most 
likely resultant from the amidoxime imine bond. The broader stretch at approx. 2750-3100cm-1 and 
3100cm-1 are likely to be caused by the amidoxime OH and NH bonds respectively.  
 
3.1.1.7  Synthesis of N'-hydroxy-6-[6-[(Z)-N'-hydroxycarbamimidoyl]-2-pyridyl] 
pyridine-2-carboxamidine  
 
 
 
Scheme 3.8 
 
The Ϯ,Ϯ͛-bipyridine bis-amidoxime (51) was not successfully synthesised by the above means. This 
was largely due to an extremely impractical reaction mixture which, upon extraction attempts, 
formed an unworkable emulsion.  
 
 
 
 
 
(51) (49) 
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3.1.1.8  Synthesis of N'-Hydroxypyrimidine-2-carboxamidine  
 
 
 
 
 
Scheme 3.9 
 
The synthesis of the pyrimidine-2-amidoxime (53) from pyrimidine-2-carbonitrile (52) was achieved 
in 68% via the same synthetic protocol as (44). This particular amidoxime product was isolated as a 
brilliant yellow/golden crystalline solid. 
The 1H NMR spectrum is predictably simple with the primary amine protons resonating as a broad 
siŶglet at ɷϱ.ϴϱ aŶd the OH pƌotoŶ oďseƌǀaďle fuƌtheƌ upfield at ɷϭϬ.Ϯϭ. The aƌoŵatiĐ pƌotoŶs aƌe 
oďseƌǀed at ɷϳ.ϱϭ aŶd ɷϴ.ϴϰ. The douďlet at ɷϴ.ϴϰ aŶd tƌiplet at ɷϳ.ϱϭ aƌe likelǇ to ĐoƌƌespoŶd to 
protons a and b, respectively.  
 
 
 
 
 
Figure 3.5 
 
This structure was confirmed by 13C NMR, IR spectroscopy and HRMS which delivered an accurate 
mass of the [M+Na]+ ion of 161.0438 for the theoretical figure of 161.0434. 
 
(53) (52) 
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3.1.1.9  Synthesis of N'-Hydroxy-4,6-dimethyl-pyrimidine-2-carboxamidine  
 
 
 
 
 
Scheme 3.10 
 
The synthesis of the dimethyl pyrimidine amidoxime (55) from (54) was also achieved also via the 
same process as amidoxime (44). 
As with previous amidoximes, 1H NMR spectroscopy remains a strongly diagnostic tool with the 
pƌiŵaƌǇ aŵiŶe pƌotoŶs seeŶ as a ďƌoad siŶglet at ɷϱ.ϲϯ aŶd the OH pƌotoŶ a little higheƌ at ɷϲ.ϴϳ. 
The lone aromatic proton b ƌesoŶates as the eǆpeĐted siŶglet at ɷϳ.Ϭϲ ǁith the ŵethǇl pƌotoŶs a as 
a siŶglet at ɷϮ.ϱϱ.  
 
 
 
 
 
Figure 3.6 
 
The structure was further confirmed by 13C NMR and HRMS which measured an accurate mass of the 
[M+Na]+ ion of 189.0752 for the expected figure of 189.0747. 
 
 
(55) (54) 
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 3.1.1.10 Synthesis of 1,4-Dibromobutane-2,3-dione  
 
 
 
 
Scheme 3.11 
 
This precursor was synthesised in order to generate two thiazole ligands, (75) and (77) (see sections 
3.1.2.16 and 3.1.2.17). The synthesis was achieved via the dropwise addition of 2 equivalents of 
bromine in chloroform to 2,3-butanedione (56) in refluxing chloroform in 91% yield. The di-α-
brominated product (57) was purified by recrystallisation from chloroform92,167,168. 
The structure of the product was confirmed by 1H NMR spectroscopy, the methylene protons 
ƌesoŶatiŶg at ɷϰ.ϯϰ, ŶotiĐeaďlǇ higheƌ thaŶ the ŵethǇl pƌotoŶs of the staƌtiŶg ŵateƌial dioŶe.  
 
3.1.2  The Synthesis of Novel 1,2,4-Oxadiazole Ligand Systems 
The vast majority of ligands in this section are novel. A handful of the ligands in this section 
[compounds (58), (75) and (77)] have been synthesised previously. Crystallisation of ligands with 
divalent metal ions was achieved using acetonitrile and nitromethane solvents, with slow diffusion 
from various co-solvents including dichloromethane, chloroform, diethyl ether, ethyl acetate and 
diisopropyl ether. To aid dissolution, small amounts (2/3 drops) of methanol were occasionally 
added where necessary. The divalent metal ions selected were used consistently throughout all 
synthesised ligand systems and included in all cases; cadmium(II), mercury(II), zinc(II), copper(II), 
iron(II), nickel(II), cobalt(II) and lead(II) perchlorates. Occasionally, the more reactive zinc(II) and 
lead(II) triflates were used, pending availability.  
In most cases, the ligands reacted with the metal ions to form aggregated complexes visible with the 
naked eye, however only complexes of a crystalline nature were examinable by X-ray diffraction. X-
ray crystal structures of such crystalline materials are included where applicable. The synthetic 
schemes for each ligand are similar; however, it is important to show the subtle differences in these 
syntheses since they ultimately lead to drastically different crystalline materials.  
(57) (56) 
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3.1.2.1  Synthesis of 5-phenyl-3-(2-pyridyl)-1,2,4-oxadiazole  
 
Scheme 3.12 
 
The synthesis of ligand (58) was achieved in 32% yield by treating amidoxime (44) with benzoyl 
chloride and pyridine in refluxing xylene. The reaction was also attempted in toluene; however this 
choice of solvent limited the reaction to very low yields. This ligand was synthesised previously by 
Pace in 201161, and explored as a ligand with copper, nickel and zinc. 
The data was fully consistent with the proposed structure and with that published by Pace. 
This is the simplest ligand in our synthetic library. With just three nitrogen atoms in total, only two of 
which able to coordinate to any one metal ion, the ligand is only able to operate as a basic bidentate 
unit, as Pace and co-workers have shown61. With metals other than those used by Pace, no 
crystalline materials were observed. 
3.1.2.2  Synthesis of 5-phenyl-3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-oxadiazole  
 
 
 
Scheme 3.13 
(58) 
(44) 
(59) (50) 
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In an extension from the previous ligand (58), ligand (59) was developed through reaction of the 
pƌeǀiouslǇ sǇŶthesised Ϯ,Ϯ͛-bipyridine amidoxime (50) with benzoyl chloride in the presence of 
pyridine in refluxing xylene. The product was obtained in 98% yield. 
The ligand features a phenyl group substituted at the 5-positioŶ of the oǆadiazole aŶd the Ϯ,Ϯ͛-
bipyridine unit at the 3-position. The ligand poses potentially interesting metal ion coordination 
options, since the bipyridine ring, whilst an attractive bidentate possibility in itself, forms an 
attractive tridentate domain with one of either oxadiazole ring nitrogens.  
Analysis by 1H NMR spectroscopy reveals a complex aromatic region. Individual signals are not split 
cleanly. Multiplicity is not obvious and coupling constants are somewhat compromised. The 13C NMR 
spectrum showed the correct number of unique carbon atoms. HRMS confirms the structure with an 
accurate mass for the [M+H]+ ion measured to be 301.1085, comparing well with the theoretical 
figure of 301.1070. 
Reaction of (59) with an equimolar amount of Cd(ClO4)2·6H2O in MeCN resulted in a colourless 
solution. Following slow diffusion of ethyl acetate, colourless crystalline materials were observed. 
Analysis of these materials by single crystal X-ray diffraction revealed a mononuclear complex. The 
crystal structure in Figure 3.8 shows (59) coordinating as a tridentate ligand, with binding through 
the nitrogen atoms of the bipyridine unit and through the N4 nitrogen of the oxadiazole. Just as 
previous literature concerning 1,2,4-oxadiazole units in ligands has suggested, the N4 nitrogen of the 
oxadiazole is able to form an attractive bite angle with 2-pyridyl nitrogens substituted at the 
oxadiazole 3- or 5-positions. This coordination represents one of very few examples of the 1,2,4-
oxadiazole unit coordinating as part of a successful tridentate domain in ligand systems58.  
Please see Tables 3.1 and 3.2 for bond distances and angles. 
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Figure 3.7 – Crystal structure of mononuclear complex featuring ligand (59) and Cd2+. 
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Bond Bond Distance (Å) 
Cd(1) – O(2) 2.241(3) 
Cd(1) – O(3) 2.283(2) 
Cd(1) – N(6) 2.305(3) 
Cd(1) – N(2) 2.305(2) 
Cd(1) – N(1) 2.343(2) 
Cd(1) – N(3) 2.419(2) 
 
Table 3.1 – Bond distance data for (59) complex. 
 
 Bond Bond Angle (0) 
O(2) – Cd(1) – O(3) 157.01(11) 
O(2) – Cd(1) – N(6) 83.91(10) 
O(3) – Cd(1) – N(6) 80.73(10) 
O(2) – Cd(1) – N(2) 101.21(9) 
O(3) – Cd(1) – N(2) 97.68(9) 
N(6) – Cd(1) – N(2) 166.26(9) 
O(2) – Cd(1) – N(1) 97.62(11) 
O(3) – Cd(1) – N(1) 101.00(9) 
N(6) – Cd(1) – N(1) 96.45(10) 
N(2) – Cd(1) – N(1) 70.35(8) 
O(2) – Cd(1) – N(3) 87.87(10) 
O(3) – Cd(1) – N(3) 85.98(8) 
N(6) – Cd(1) – N(3) 122.22(9) 
N(2) – Cd(1) – N(3) 71.03(8) 
N(1) – Cd(1) – N(3) 141.33(8) 
 
Table 3.2 - Bond angle data for (59) complex. 
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3.1.2.3 Synthesis of 3-(2-pyridyl)-5-[3-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]phenyl]-
1,2,4-oxadiazole  
 
Scheme 3.14 
 
The crystallisation of the previous ligand (59) with Cd2+ ions resulting in a simple mononuclear 
complex provided our oxadiazole research with good credibility and merited further ligand 
development. Taking the promising oxadiazole-pyridine bidentate system (58) developed by Pace 
and co-workers61 as a model, our group developed the dimeric ligand (60) with the introduction of a 
phenylene spacer unit. This interesting prospect introduced symmetry to the ligand, and distance 
between the oxadiazoles. The result of this oxadiazole separation is two potential pyridine-
oxadiazole bidentate binding domains. At a glance, this provides a highly attractive prospect for 
metal ion coordination. 
Ligand (19) was synthesised via the usual method in 27% yield. Isophthaloyl chloride was reacted 
with two equivalents of pyridine amidoxime (44) to yield the desired 5-ringed system.  
The structure of the product was confirmed by the 1H NMR spectrum. Though assignment of each 
individual proton is tricky, the multiplicity and integration is as expected. The triplet integrating as 
oŶe pƌotoŶ at ɷϳ.ϴϬ ŵust oƌigiŶate fƌoŵ pƌotoŶ f. Likeǁise, the siŶglet at ɷϵ.Ϯϯ is likelǇ Đaused ďǇ 
the bridging phenylene proton g.  
 
 
 
 
Figure 3.8 
(44) (60) 
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Confirmation of the structure was provided by 13C NMR spectroscopy, which indicated the 11 
environmentally unique carbons atoms, and via HRMS which delivered an accurate mass for the 
[M+Na]+ ion of 391.0915. The theoretical mass for this compound was calculated to be 391.0901. 
Whilst some products of ligand (60) with various metal ions were observed, these products did not 
possess crystallinity that made them suitable for x-ray crystallographic analysis. 
 
3.1.2.4 Synthesis of 3-(2-pyridyl)-5-[6-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]-2-pyridyl]-
1,2,4-oxadiazole  
 
Scheme 3.15 
 
Ligand (61) was synthesised in 15% yield through reaction of pyridine-2,6-dicarbonyl dichloride with 
amidoxime (44). 
Whist the function of the spacer units is to partition potential binding domains, the installation of a 
further potential nitrogen binding domain in the spacer unit was attractive. At a glance, this nitrogen 
atom sits in the middle of a potential tridentate domain with the oxadiazole nitrogens with what 
appears to be a reasonably attractive (though perhaps slightly tight/convergent) bite angle. Amongst 
other denticities of this ligand are the oxadiazole-pyridine bidentate domains either side of the 
central pyridine unit and also the theoretical possibility of pentadenticity across the length of the 
ligand. Due to the high potential of this ligand and in spite of the lack of crystalline products 
observed with the analogous phenylene spaced ligand (60), it was considered very worthwhile 
attempting crystallisation with this interesting, pentadentate ligand.   
Analysis of ligand (61) by 1H NMR spectroscopy is not entirely diagnostic. The triplet integrating as 
one protoŶ at ɷϴ.Ϯϰ ŵust aĐĐouŶt foƌ pƌotoŶ f, in the 4-position of the central pyridine unit. 
(61) 
(44) 
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Douďlets at ɷϴ.ϯϯ, ɷϴ.ϲϴ, the multiplet-type doublet at ɷϴ.ϴϵ aŶd the ŵultiplet at ɷϳ.ϱϭ Đoŵplete 
the NMR spectrum which shows some complex long range coupling.  
Fortunately the 13C NMR spectrum provides good evidence for this structure with all carbon signals 
present and correct. HRMS measured an accurate mass of the [M+Na]+ ion of 392.0866 for the 
calculated figure of 392.0864. 
 
 
 
 
 
Figure 3.9 
 
Unfortunately, the inclusion of the nitrogen atom within the spacer unit proved to be an 
unsuccessful venture since no crystalline products were formed with divalent metal ions.  
Whilst no crystals were observed, it was felt that the inclusion of a central pyridine unit remained a 
reasonably attractive option. The bite angle between central pyridine nitrogen and oxadiazole 
nitrogen atoms appears too appealing to ignore. This central tridentate domain may be marginally 
more sterically congested than the outer bi- and tridentate domains. Similar ligands will be discussed 
later. 
3.1.2.5 Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[3-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
oxadiazol-5-yl]phenyl]-1,2,4-oxadiazole  
 
Scheme 3.16 
(50) 
(62) 
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The heptacyclic ligand (62), analogous with ligand (60), was synthesised in 35% yield by reaction of 
isophthaloǇl Đhloƌide ǁith the Ϯ,Ϯ͛-bipyridine amidoxime (50) in the presence of pyridine in refluxing 
xylene. 
This ligand features a central phenylene unit serving to partition the ligand and create two uniform, 
tridentate binding domains in the shape of the proven oxadiazole-pyridine-pyridine system. This 
system appears highly attractive at a glance. The metallocrystallisation observed with (59) provided 
much encouragement with this ligand, however the lack of metal ion crystallisation with ligands (60) 
and (61) was an unpredicted disappointment.  
The 1H NMR spectrum is consistent with the assigned structure of this product. The spectrum shows 
two doublets of doublets potentially accounting for protons b and c, and two triplets for protons f 
and i. Thƌee fuƌtheƌ douďlets ǁeƌe pƌeseŶt togetheƌ ǁith a seƌies of ŵultiplets at ɷϳ.ϳϭ-7.77 and 
ɷϴ.ϴϭ-8.88 integrating overall foƌ the ĐoƌƌeĐt Ŷuŵďeƌ of pƌotoŶs. The siŶglet ǀisiďle at ɷϵ.ϭϳ is 
diagnostic of phenylene proton j.  
 
 
 
 
 
 
Figure 3.10 
 
The 13C NMR spectrum is consistent with the suggested structure, indicating the presence of sixteen 
environmentally unique carbon atoms. The structure was confirmed unequivocally by HRMS which 
provided a value of 523.1648 for the [M+H]+ ion, correlating with the calculated figure of 523.1626. 
To our surprise and disappointment, this ligand did not produce any crystalline products. This was 
extremely disappointing since, as described before, the ligand seems perfectly set up for intricate 
metal ion complexation and thus the possibility of self-assembled, metallosupramolecular 
structures. Unfortunately, though semi-crystalline materials were harvested, none were suitable for 
analysis by X-ray crystallography. 
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3.1.2.6 Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[6-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
oxadiazol-5-yl]-2-pyridyl]-1,2,4-oxadiazole  
 
Scheme 3.17 
 
The seven-heterocycle-strong ligand (63) was synthesised via the conventional method with the 
pyridine 2,6-diacid chloride and (50) in refluxing xylene with pyridine as base, in 11% yield. 
Following the disappointment of the phenylene and pyridine spaced, pyridine and bipyridine, 
oxadiazole ligands, there seemed little chance of any crystalline structures forming from this 
particular ligand. However, this ligand completed a series and so the synthesis and crystallisation 
setup was carried out as per the usual methods. 
The ligand itself has a plethora of potential metal binding sites. Bidentate domains through the 
bipyridine units, tridentate domains through the bipyridine-oxadiazole systems, a potential 
tridentate domain across the central oxadiazole-pyridine-oxadiazole system and even a potential 
tetradentate domain across four heterocycles through the bipyridine-oxadiazole-pyridine system; 
the potential bite angles of which look highly attractive.  
The 1H NMR spectrum is strongly supportive of this structure. The triplet integrating as one proton at 
ɷϴ.ϱϮ is highlǇ likelǇ to ďe geŶeƌated ďǇ pƌotoŶ i of the central pyridine unit, suggesting that both 
acid chlorides of the 2,6-pyridine diacid chloride have reacted with the amidoxime to form the 
symmetrical ligand. Further exact assignment is difficult, since the aromatic region is predictably 
crowded. Despite the signals integrating well, the splitting patterns are not clearly observed, with 
only three doublets of doublets (or apparent triplets) being seen.  
 
 
(63) (50) 
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Figure 3.11 
 
On this occasion, 13C NMR was not available due to the extremely poor organic solubility of the 
ligand. Fortunately the mass spectrum provided an accurate mass of 546.1396 for the [M+Na]+ ion 
with the calculated figure determined to be 546.1397.  
Unfortunately, in keeping with the trend of previous ligands of this nature, no crystalline products 
were formed. Again this is highly surprising given the number of alluring coordination prospects 
throughout this molecule.  
Whilst Rice and co-workers observed remarkable results with many thiazole ligands featuring spacer 
units65-69, it appears that the spacer unit is a poor feature in 1,2,4-oxadiaozole systems. Whilst we 
have shown that the bipyridine-oxadiazole system is capable of behaving as a tridentate domain, it 
appears that the presence of spacer units partitioning two such domains does not afford crystalline, 
self-assembled, metallosupramolecular structures.  
 
3.1.2.7  Synthesis of 3-(2-pyridyl)-5-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]-1,2,4- 
  oxadiazole  
 
Scheme 3.18 (64) (44) 
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The potentially tetradentate ligand (64) was synthesised in 10% yield by switching to the simple two-
carbon diacid chloride, oxalyl chloride. The reaction was set up under the usual conditions.  
In a change of strategy, we decided to leave the spacer unit tactic and explore ligands with a central, 
bis-oxadiazole core. In this particular ligand the bis-oxadiazole core, linked at the 5-positions, is 
flanked by single 2-pyridyl units. In terms of potential metal ion coordination, this ligand is more 
compact with two potential bidentate pyridine-oxadiazole units. The theoretical prospect of the 
ligand behaving as a tetradentate ligand seems unlikely. It has been shown by Steel and co-workers 
that the parent bis-oxadiazole unit can coordinate with metal ions to form simple mononuclear 
assemblies53. This undesired coordination is a potential consequence. However, it was thought that 
the inclusion of pyridine units at the 3-positions of the bis-oxadiazole core would modify this 
coordination. 
The 1H NMR spectrum of the product is simple, showing doublets at ɷϴ.Ϯϵ aŶd ɷϴ.ϴϴ ĐoƌƌespoŶdiŶg 
to protons a and d, along with an apparent triplet of doublets at ɷϳ.ϵϱ aŶd a douďlet of douďlet of 
douďlets at ɷϳ.ϱϰ. These split sigŶals aƌe pƌotoŶs b and c. 13C NMR spectroscopy supports this 
structure very well. The structure was confirmed by HRMS which measures an accurate mass for the 
[M+Na]+ ion of 315.0601, correlating well with the calculated figure of 315.0612. 
 
 
 
 
 
Figure 3.12 
 
To our surprise, this ligand produced some quite unexpected and spectacular results when 
crystallised with metal ions. 
Thiazole ligand (75) containing the bis-thiazole core flanked by pyridine units, has been 
demonstrated to react with divalent metal ions capable of octahedral geometry to produce a 
dinuclear double helicate [M2(L
75)3]
4+,65,115,116. Since strong molecular comparisons between the 
thiazole unit and 1,2,4-oxadiazole unit can be drawn, it was hoped that if any self-assembled 
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architecture were to form, it may be of the same dinuclear double helicate format, although such 
predictions are often inaccurate. 
 
 
 
 
Figure 3.13 
 
Though analogous to the thiazole ligand (75), it seems that the 1,2,4-oxadiazole unit displays 
distinctly different coordination behaviour since no dinuclear double helicates were observed.  
Reaction of (64) with an equimolar amount of Hg(ClO4)2·6H2O in MeCN resulted in a colourless 
solution. Following slow diffusion of ethyl acetate, colourless crystals were observed. Analysis of 
these materials by single crystal X-ray diffraction revealed a tetranuclear cyclic helicate complex. 
This elaborate metallosupramolecular system features the ligand (64) partitioned into two bidentate 
pyridine-oxadiazole domains (clearly the spacer units were unnecessary to promote this effect). The 
Hg2+ ions adopt octahedral geometry, coordinating as they do with the bidentate pyridine-oxadiazole 
domains of two ligands (64). The remaining equatorial positions of the Hg2+ ion are filled by 
coordination to perchlorate counter anions. Coordination of the oxadiazole unit occurs via the 
imine-N-4 atom rather than the oxime N-2 atom. The second bidentate domain of each ligand 
coordinates a second Hg2+ ion in the same manner with an approximate 1800 twist of the central 
oxadiazole-oxadiazole bond. This twist is often a common, diagnostic theme of helicate assemblies. 
In grid-type assemblies the twist is absent, creating a more linear architecture. The twisting helicate 
creates a quite beautiful, overlap-underlap effect about the metals ions. This coordination is 
extended through four Hg2+ metal ions resulting in a self-assembled, tetranuclear cyclic helicate 
(Figure 3.14). Bond angle and bond distance data is currently in refinement.  
 
 
 
 
(75) 
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Figure 3.14 – Crystal structure of tetranuclear complex featuring ligand (64) and Hg2+. 
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Further exploration of this ligand with alternative metal ions led to another completely unexpected 
and rather remarkable result. The reaction of ligand (64) with Pb(ClO4)2·6H20 in MeCN produced a 
pale yellow solution. Following slow diffusion of diisopropyl ether, pale yellow, perfectly cubic 
crystals were observed. Examination of these materials by single crystal X-ray diffraction revealed a 
two-dimensional helicate polymer. This 2D-polymer exists as chains of ligand (64) and Pb2+ ions, 
which are linked by a further molecule of (64). Close examination of the structure shows a Pb2+ ion 
coordinated to the pyridine-oxadiazole bidentate domain of a total of three ligands. The Pb2+ ion 
however, does not sit in octahedral geometry as above, but in an 8-coordinate state due to the 
coordination of two perchlorate counter anions. Each Pb2+ ion coordinates a bidentate pyridine-
oxadiazole domain of two ligands; the remaining bidentate units are coordinated by other Pb2+ ions 
forming a helicating chain. In this helicating chain, coordination of the oxadiazole unit is achieved 
solely through the imine N4 atoms. The helicating chain is linked to another helicating chain by a 
third ligand, the bidentate pyridine-oxadiazole domains each coordinating a Pb2+ ion of separate 
chains. This chain-linking coordination is achieved through the very rarely observed oxime N2 atom 
of the oxadiazole. Overall, this results in a very beautiful, two-dimensional helicate polymer, 
structural images of which are shown in Figures 3.15 and 3.16, with crystal structures shown in 
Figures 3.17 and 3.18. Bond distance and angle data is shown in Tables 3.3 and 3.4. 
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Figure 3.15 – Image of helicate polymer complex featuring (64) and Pb2+. 
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Figure 3.16 – Alternative image of helicate polymer complex featuring (64) and Pb2+. 
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Figure 3.17 - Crystal structure of approximate unit cell of helicate polymer complex featuring (64) and Pb2+, 
with bridging ligand on left. 
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Figure 3.18 - Crystal structure of approximate unit cell of helicate polymer complex featuring (64) and Pb2+,  
(alternative view) with bridging ligand in background. 
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Bond Bond Distance (Å) 
Pb(1) – N(7) 2.618(2) 
Pb(1) – N(4) 2.697(2) 
Pb(1) – N(5) 2.7358(18) 
Pb(1) – N(1) 2.737(2) 
Pb(1) – N(2) 2.800(2) 
Pb(1) – N(8) 2.800(2) 
 
Table 3.3 – Bond distance data for helicate polymer complex featuring (64) and Pb2+. 
 
Bond Bond Angle (0) 
N(7) – Pb(1) – N(4) 85.01(6) 
N(7) – Pb(1) – N(5) 74.36(6) 
N(4) – Pb(1) – N(5) 60.72(6) 
N(7) – Pb(1) – N(1) 86.13(7) 
N(4) – Pb(1) – N(1) 140.72(6) 
N(5) – Pb(1) – N(1) 80.04(6) 
N(7) – Pb(1) – N(2) 130.67(6) 
N(4) – Pb(1) – N(2) 97.76(6) 
N(5) – Pb(1) – N(2) 64.99(6) 
N(1) – Pb(1) – N(2) 61.04(6) 
N(7) – Pb(1) – N(8) 62.86(6) 
N(4) – Pb(1) – N(8) 75.66(6) 
N(5) – Pb(1) – N(8) 120.51(6) 
N(1) – Pb(1) – N(8) 131.89(6) 
N(2) – Pb(1) – N(8) 165.09(6) 
 
Table 3.4 – Bond angle for helicate polymer complex featuring (64) and Pb2+. 
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3.1.2.8 Synthesis of 3-[6-(2-pyridyl)-2-pyridyl]-5-[3-[6-(2-pyridyl)-2-pyridyl]-1,2,4-
oxadiazol-5-yl]-1,2,4-oxadiazole 
 
 
Scheme 3.19 
 
In light of the excellent results obtained with the previous ligand, it was decided to extend the ligand 
by one pyridine unit at either end by utilising the bipyridine amidoxime (50). This extended ligand 
length, would possibly eliminate the formation of the polymeric system observed with (64). The 
ligand itself contains the bis-oxadiazole core as previous. Coordination solely through this central 
bidentate system is possible as shown by Steel and coworkers53, however since this coordination was 
not observed with (64) this was not considered a likelihood. Instead, the main potential of the ligand 
in coordination terms was thought to be through the two tridentate pyridine-pyridine-oxadiazole 
domains.  
The potentially hexadentate ligand (65) was synthesised via the usual amidoxime-acid chloride 
ŵethod. The Ϯ,Ϯ͛-bipyridyl-amidoxime was reacted with oxalyl chloride in refluxing xylene with 
pyridine as the scavenger for the HCl. The yield for this product was very low at just 8%. 
Protons a, d, e, and g were expected to resonate as doublets, however only three of these doublets 
aƌe oďseƌǀed. Thƌee tƌiplets aƌe oďseƌǀed as oŶe ǁould eǆpeĐt hoǁeǀeƌ, a tƌiplet oďseƌǀed at ɷϴ.ϲϬ 
is peculiar since it integrates as four protons. Therefore it was assumed that the missing doublet 
resides beneath this signal. However, there is no sign of any overlap whatsoever as the triplet is very 
clean. The 13C NMR showed twelve environmentally unique carbon atoms offering support for the 
assigned structure. HRMS delivered an accurate mass of 447.1320 for the [M+H]+ ion, consistent with 
the calculated figure of 447.1312, which all but confirmed the structure and permitted attempts at 
crystallisation.  
 
(65) (50) 
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Figure 3.19 
 
When reacted with Cu(ClO4)·6H2O in acetonitrile via slow diffusion of ethyl acetate, this ligand 
produced an elaborate tetranuclear cyclic helicate in much the same style as the previous ligand 
(64). The differences between the two metallosupramolecular structures are subtle. The differences 
are caused by the extra coordination potential from the terminal pyridine units around the Cu2+ ion 
(see Figure 3.20). The ligand is, as before, partitioned into two polydentate domains; the tridentate 
nature of these domains enables the ligand to wrap further around the metal ion, thus producing a 
larger assembly. The metal ions remain in octahedral geometry, with the oxadiazole N4 atom and 
terminal pyridine N-donor atom coordinating in opposite equatorial positions, the internal pyridine 
N-donor atom coordinates in the axial position with no coordination to solvent molecules. 
Interestingly, the same self-assembling structure was also obtained in reaction with Ni2+ ions, 
presumably since copper and nickel atoms are of similar size. Bond angle and bond distance data for 
these helicates are currently in refinement.  
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Figure 3.20 – Crystal structure of tetranuclear helicate complex featuring (65) and Cu2+. 
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3.1.2.9  Synthesis of 5-(2-pyridyl)-3-[5-(2-pyridyl)-1,2,4-oxadiazol-3-yl]-1,2,4- 
  oxadiazole  
 
 
 
Scheme 3.20 
 
In a marginal change from the usual reaction of a 2-pyridyl amidoxime with an acid chloride, this 
synthesis involves the simplest diamidoxime (diaminoglyoxime) (67) in reaction with picolinoyl 
chloride (66) in the usual basic, refluxing xylene conditions. This furnished the ligand (68) in 8% yield. 
This simple change reverses the N-O bond of the oxadiazole. The oxadiazole core is now bound at 
the 3-position rather than the 5-position. It was anticipated that this change might have an 
interesting impact on the synthesis of the cyclic helicates observed with ligand (64) since 
coordination in all cases is through the oxadiazole N4. However, the reversal of the N-O bond may 
alter the formation of the previously observed Pb2+ polymer since the coordinating N4 atom is now 
in a different position.  
The structure of this ligand is supported by the 1H NMR spectrum. Comparison with the 1H NMR 
spectrum produced by (64) shows a strong correlation. The doublet of doublet of doublets observed 
at ɷϳ.ϲϮ aŶd the apparent triplet of douďlets at ɷϴ.Ϭϭ ĐoƌƌespoŶd to pƌotoŶs b and c respectively. 
The split douďlets at ɷϴ.ϰϴ aŶd ɷϴ.ϵϮ likelǇ ƌepƌeseŶt pƌotoŶs a and d. A minor impurity is present at 
ɷϳ.ϭϱ-7.30. 13C NMR spectroscopy was unavailable due to poor sample solubility. 
 
 
 
 
Figure 3.21 
(66) (68) 
(67) 
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The presence of the desired product was confirmed by HRMS which delivered an accurate mass of 
the [M+Na]+ ion of 315.0605 for the calculated figure of 315.0601.  
Reaction of this ligand with Pb(ClO4)2·6H2O in MeCN gave a colourless solution which, upon slow 
diffusion of diisopropyl ether, produced colourless crystalline materials. Examination of these 
crystals by X-ray diffraction afforded the crystal structure shown in Figure 3.23. This 
metallosupramolecular system is similar to the helicate polymer formed from reaction of (64) with 
Pb2+. The system produced by (68) is similar to the helicating chain observed with the two-
dimensional helicate polymer from (64), but lacks the third bridging ligand between chains. As such, 
this new system exists as a one-dimensional helicate polymer. Coordination through the oxadiazole 
is in all cases through the N4 nitrogen. 
Each Pb2+ ion exists in seven-coordinate geometry. Each Pb2+ ion coordinates to the bidentate 
pyridine-oxadiazole domain of two separate ligands, two water molecules and one perchlorate 
molecule. Below is a picture of a segment of this helicating polymer chain. 
 
 
 
Figure 3.22 – Image of 1D helicating polymer featuring (68) and Pb2+. 
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Figure 3.23 - Crystal structure of approximate unit cell of 1D helicate polymer complex featuring (68) and 
Pb2+. 
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Figure 3.24 - Crystal structure of approximate unit cell of 1D helicate polymer complex featuring (68) and Pb2+ 
(alternative view). 
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Bond Bond Distance (Å) 
Pb(1) – O(3) 2.4632(19) 
Pb(1) – N(5) 2.689(2) 
Pb(1) – N(4) 2.690(2) 
Pb(1) – N(1) 2.717(2) 
Pb(1) – N(2) 2.728(2) 
 
 
Table 3.5 – Bond distance data for 1D helicate polymer complex featuring (68) and Pb2+. 
 
 
Bond Bond Angle (0) 
O(3) – Pb(1) – N(5) 77.19(6) 
O(3) – Pb(1) – N(4) 107.87(7) 
N(5) – Pb(1) – N(4) 62.34(6) 
O(3) – Pb(1) – N(1) 79.13(7) 
N(5) – Pb(1) – N(1) 102.44(6) 
N(4) – Pb(1) – N(1) 159.95(7) 
O(3) – Pb(1) – N(2) 126.04(7) 
N(5) – Pb(1) – N(2) 76.17(6) 
N(4) – Pb(1) – N(2) 99.77(6) 
N(1) – Pb(1) – N(2) 62.30(6) 
 
 
Table 3.6 – Bond angle data for 1D heliacte polymer complex featuring (68) and Pb2+. 
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3.1.2.10 On the Formation of Cyclic Helicates from Ligands Featuring a Bis-
oxadiazole Core   
The interesting array of structures obtained with ligands (64), (65) and (68) reflect the enormous 
impact that minor heterocyclic changes in ligand systems can have on the ultimate supramolecular 
assembly. The metallosupramolecular structures observed with the thiazole ligands produced by 
Rice and co-workers are very different from those obtained with the analogous 1,2,4-oxadiazole 
ligands developed in this project. 
 
 
 
 
 
Figure 3.25 – Structural comparison of thiazole (left) and 1,2,4-oxadiazole (right). 
 
The additional nitrogen atom of the oxadiazole gives this heterocycle extra versatility; as exemplified 
with coordination through both the N2 and N4 nitrogens in the helicate polymer formed from ligand 
(64). Comparison of the two heterocycles above reveals some interesting features. Coordinations at 
the 3-position of the thiazole and 4-position of the oxadiazole, (i.e opposite the chalcogen) are 
analogous. At the thiazole 2-position, the sp2 hybridised imine carbon is comparable to the oxime N2 
nitrogen of the oxadiazole. These atoms are of very similar size and thus (unless N2 coordination is 
observed) one would not expect these atomic changes to have dramatic effects on the resultant self-
assembled structure. The same can be said of nitrogen/sp2 carbon comparisons in the 3 position of 
the thiazole and 3 position of the oxadiazole. Since the 5-positions are identical, the major difference 
in supramolecular behaviour must be attributed to the influence of the chalcogen atoms at the 1-
position.  
Molecular modelliŶg studies of these tǁo tetƌadeŶtate ligaŶds ;see ϯ.ϭ.Ϯ.ϭϬ.ϭ foƌ detailsͿ, ‘iĐe͛s 
thiazole (75) aŶd ouƌ gƌoup͛s Ŷeǁ oǆadiazole (64), reveal some subtle but very interesting and 
significant contrasts. These contrasts serve to strongly impact upon the bite angles of the thiazole/2-
pyridyl nitrogens in (75) and the oxadiazole-N4/2-pyridyl nitrogens in (64). 
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Extrapolation along the thiazole-thiazole bond and thiazole-pyridine bond in (75) (see Figure 3.26) 
reveals a bond angle of 134.60. Very interestingly, extrapolation of similar bonds in the oxadiazole 
ligand (64) reveals a bond angle of 149.60- substantially larger than that of the thiazole. This larger 
angle translates as a wider bite angle between N-donor atoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 – Bond angle and bond length diagram, contrasting thiazole and oxadiazole ligands. 
 
In the thiazole ligand (75), the carbon-sulfur bond length is on average 1.75Å. In the oxadiazole 
containing ligand (64), the nitrogen-oxygen bond length is on average 1.40Å, considerably shorter 
than that observed with the thiazole ligand. This is attributed to the larger covalent radius of the 
sulfur atom. The shorter N-O ďoŶd at the ͚ďaĐk͛ of the of the oǆadiazole seƌǀes to effeĐtiǀelǇ pull the 
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pyridine ring round towards this N-O bond thus increasing the linearity of the molecule and creating 
a more divergent bite angle of 149.60. By contrast, the larger sulfur atom and consequentially longer 
C-S bond length forces the thiazole-pyridine bidentate domain to act as a tighter, more convergent 
system. This explains the nuclearity and the overall nature of the self-assembled, supramolecular 
structures formed with the thiazole and oxadiazole ligands. The more divergent nature of the 
bidentate domains of the oxadiazole ligand enables the overall ligand strand to adopt a greater 
͚ƌeaĐh͛. The lesseƌ ƌeaĐh of the thiazole ƌestƌiĐts it fƌoŵ foƌŵiŶg loŶgeƌ aŶd laƌgeƌ heliĐate 
structures. The more convergent nature of the thiazole ligand only enables shorter, sharper, 
dinuclear double and triple helicate systems65,67, compared with the more elaborate, larger, 
tetranuclear systems observed with the 1,2,4-oxadiazole ligands. 
 
3.1.2.10.1 Molecular Modelling Data for Ligands (64) and (75) 
The relaxed structures of (75) and (64) in the gas phase were determined using the computational 
package GAMESS-UK125-127 using the hybrid B3LYP methodology with 20% contribution from Hartree-
Fock and 80% from Density Functional theory, employing the 6-31G* basis set128-129. The 
convergence threshold in the optimization run was 0.001 eV (~1 kJ mol-1). 
The angle between bonds described by the vectors r1 and r2 was calculated for each molecule using 
the formula: 
Cos θ = rϭ●r2 / |r1||r2| 
where rϭ●r2 is the dot product of the two vectors and |r1| |r2| are the magnitudes of the two vectors 
(essentially the bond length in this context). 
 
3.1.2.11 On the Formation of Helicate Polymers from Ligands Featuring a Bis-
oxadiazole Core   
The bis-oxadiazole centred ligands (64) and (68) (Figure 3.27) each formed very interesting helicate 
polymers in reaction with Pb2+ ions. The critical structural difference in these ligands is the positions 
of oxygen and N2 nitrogen atoms. With (64), the bis-oxadiazole core is linked at the 5-positions of 
each oxadiazole whereas with (68) the oxadiazoles are linked at the 3-position. This effectively 
swaps the positions of the oxygen and N2 nitrogen in the ligands strands.  
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Figure 3.27 – Structural comparison of bis-oxadiazole centred ligands. 
 
With the 2-dimensional helicate polymer observed with ligand (64), very interestingly, the pyridine-
oxadiazole binding domains of the ligands linking the helicating chains are coordinated to the Pb2+ 
ion through the N2 nitrogens. This is particularly interesting since, as discussed previously, the oxime 
nitrogen (N2) is less nucleophilic than the N4 nitrogen, therefore coordination through this atom is 
far less observed than with the N4 nitrogen. This peculiar, alternative, oxime nitrogen coordination 
showcases the versatility of the 1,2,4-oxadiazole unit in ligand systems. As far as our group are 
aware, this is only the second occasion (see section 1.2.5.2) where N2 coordination has been 
observed in 1,2,4-oxadiazole ligand systems. However, examination of the helicate polymer 
observed when ligand (68) is reacted with Pb2+ ions shows the helicating chain very similar to that 
obtained with (64), ďut ǁithout aŶǇ ͚ďƌidgiŶg͛ ligaŶd. Due to the aďseŶĐe of these bridging ligands, it 
ĐaŶ ďe deteƌŵiŶed that the shift of NϮ ŶitƌogeŶ fƌoŵ ͚outside͛ the oǆadiazole ;i.e Ŷeaƌ the Ϯ-pyridyl 
uŶitͿ to ͚iŶside͛ the oǆadiazole ;i.e. Đloseƌ to the ďis-oxadiazole centre), denies a third ligand the 
opportunity to coordinate favourably with the Pb2+ ioŶs of tǁo sepaƌate ĐhaiŶs. The ͚outeƌ͛ positioŶ 
of the N2 nitrogen it appears is critical for this rare, highly interesting N2 coordination and the 
subsequent development of the two-dimensional helicate polymer.  
(64) 
(68) 
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3.1.2.12 Synthesis of 3-pyrimidin-2-yl-5-(3-pyrimidin-2-yl-1,2,4-oxadiazol-5- 
  yl)-1,2,4-oxadiazole 
 
Scheme 3.21 
 
In a bid to extend the ligand series an attempt was made at incorporating 2,6-pyrimidine units into 
the system, instead of regular 2-pyridyls units. It was hoped that this would offer some possible 
alternative assemblies due to the extra coordination options made possible by the inclusion of 
pyrimidine functionality. 
Unfortunately, the desired compound (69) was not synthesised through the amidoxime route. No 
evidence of product (69) was observed upon analysis. However, a new product was observed. The 1H 
NM‘ speĐtƌuŵ shoǁs tǁo tƌiplets at ɷϳ.ϳϴ aŶd ɷϳ.ϴϱ, ďoth iŶtegƌatiŶg as oŶe pƌotoŶ aŶd tǁo 
douďlets higheƌ up at ɷϵ.ϭϬ aŶd ɷϵ.ϭϲ, ďoth integrating as two protons. This is consistent with two 
different pyrimidine rings rather than the two identical pyrimidine rings that would be seen in (69). 
The product was eventually identified as the dipyrimidine oxadiazole (70) (see Figure 3.28). 
Unfortunately due to poor solubility in NMR solvents, we were not able to examine the compound 
by 13C NMR spectroscopy or by HRMS. The decision was made to proceed on the mediocre strength 
of the 1H NMR spectrum and set up the ligand with metal ions for possible crystallisation. 
Fortunately, some crystalline products were observed.  
 
 
 
 
Figure 3.28 
(69) (53) 
(70) 
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Reaction of this ligand with an equimolar amount of Cd(ClO4)2·6H2O in MeCN gave a colourless 
solution. Following slow diffusion of diethyl ether a colourless crystalline material was observed. 
Subsequent examination of these materials by single crystal X-ray diffraction revealed a 
mononuclear double helicate complex formed from ligand (70). The ligands coordinate to the Cd2+ 
ion via the bidentate pyrimidine-oxadiazole domain. The oxadiazole N4 nitrogen and a pyrimidinyl 
nitrogen at the oxadiazole 3-position coordinate to the Cd2+ centre. The metal ion retains octahedral 
geometry through coordination with two molecules of MeCN in equatorial positions, with the 
bidentate ligands opposed in an approximate 900 dihedral angle (Figures 3.29 and 3.30).  
The successful complexation behaviouƌ of this ligaŶd dƌaǁs iŶteƌestiŶg paƌallels ǁith PaĐe͛s ligaŶd, 
re-synthesised in this project as (58) (see Scheme 3.18). Using this ligand, no crystalline materials 
were observed with Cd2+ ions. The crystal structure for (70) with Cd2+ ions appears to be in strong 
correlation with that obtained by Pace in 2011 with their 3-(2-pyridyl)-5-phenyl-1,2,4-oxadiazole 
ligand (Figure 1.20). However, most interestingly, despite ligand (70) being more similar in nature 
aŶd deŶtiĐitǇ to PaĐe͛s ϯ,ϱ-bi(2-pyridyl)-1,2,4-oxadiazole ligand (Figure 1.18), no similar structures 
were observed with ligand (70). 
Research into this result is continuing with much focus around the mechanism of the reaction that 
formed ligand (70). It should be noted at this stage that the yield of this product was just 3%. One 
possible mechanism is shown below; variations are clearly possible: 
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Scheme 3.22 
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Figure 3.29 – Crystal structure mononuclear complex featuring (70) and Cd2+. 
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Figure 3.30 - Crystal structure mononuclear complex featuring (70) and Cd2+ (alternative view). 
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Bond Bond Distance (Å) 
Cd(1) – N(13) 2.287(3) 
Cd(1) – N(4) 2.289(3) 
Cd(1) – N(14) 2.290(4) 
Cd(1) – N(1) 2.344(3) 
Cd(1) – N(8) 2.473(3) 
Cd(1) – N(2) 2.539(3) 
 
 
Table 3.7 – Bond distance data for complex featuring (70) and Cd2+. 
 
 
Bond Bond Angle (0) 
N(13) – Cd(1) – N(4) 95.65(10) 
N(13) – Cd(1) – N(14) 96.81(11) 
N(4) – Cd(1) – N(14) 146.75(10) 
N(13) – Cd(1) – N(1) 154.05(10) 
N(4) – Cd(1) – N(1) 94.12(9) 
N(14) – Cd(1) – N(1) 87.90(10) 
N(13) – Cd(1) – N(8) 84.30(10) 
N(4) – Cd(1) – N(8) 121.40(10) 
N(14) – Cd(1) – N(8) 90.48(11) 
N(1) – Cd(1) – N(8) 70.12(9) 
N(13) – Cd(1) – N(2) 92.81(10) 
N(4) – Cd(1) – N(2) 68.67(10) 
N(14) – Cd(1) – N(2) 80.02(11) 
N(1) – Cd(1) – N(2) 113.14(9) 
N(8) – Cd(1) – N(2) 169.70(10) 
 
Table 3.8 - Bond angle data for complex featuring (70) and Cd2+. 
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3.1.2.13 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[3-(4,6-dimethylpyrimidin-2-
yl)-1,2,4-oxadiazol-5-yl]-1,2,4-oxadiazole  
 
 
 
Scheme 3.23 
 
In light of the curious case of the absent oxadiazole observed in the synthesis of (70), the decision 
was made to attempt the synthesis of an analogous pyrimidine system in a bid to see if similar 
unexpected products were formed. 
The dimethyl-pyrimidine ligand (71) was synthesised in the conventional manner, though again in 
very low yield at 3%. In this case, the expected di-(1,2,4-oxadiazole) was formed. 
Ligand (71) itself boasts a wealth of coordination potential. The pyrimidine-oxadiazole systems offer 
bidentate domains on both the imine-N4 and oxime-N2 sides and a further bidentate domain across 
the central bis-oxadiazole N4-N4 system, therefore housing a total of five potential bidentate 
domains. The ligand itself includes a possible tetradentate domain across its length. The ligand is of 
highly condensed denticity with the four likely pyrimidine-oxadiazole bidentate units spanning just 
four heterocyclic units, thus rendering this ligand one of the most interesting of the series.   
The structure of the product was largely confirmed through 1H and 13C NMR spectroscopy. The 1H 
NMR spectrum is very simple as one would expect due to the high degree of symmetry. The 
pyrimidine-4,6-dimethyl protons a ĐaŶ ďe oďseƌǀed at ɷϮ.ϲϳ aŶd the uŶsuďstituted pǇƌiŵidiŶe ϱ-
position protons (bͿ ĐaŶ ďe oďseƌǀed at ɷϳ.Ϯϰ iŶ the 1H NMR spectrum.  
 
 
(71) (55) 
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Figure 3.31 
 
The 13C NMR spectrum was extremely simple; the methyl carbons resonated predictably low in the 
speĐtƌuŵ at ɷϮϰ.ϭϰ. The ƌeŵaiŶiŶg fiǀe ĐaƌďoŶ atoŵs aƌe ǀisiďle iŶ the tǇpiĐal aƌoŵatiĐ ƌegioŶ.  
Analysis by HRMS delivered an accurate mass of the [M+Na]+ ion of 373.1133 for the calculated 
figure of 373.1132. 
Several crystalline products featuring this ligand are awaiting analysis by XRD, and are part of the 
future work section of this project. 
 
3.1.2.14 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[3-[3-(4,6-dimethylpyrimidin-
2-yl)-1,2,4-oxadiazol-5-yl]phenyl]-1,2,4-oxadiazole  
 
 
Scheme 3.24 
 
(72) (55) 
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The phenylene spaced pyrimidine ligand (72) was synthesised in 7% yield. A switch to toluene as 
solvent was made in order to afford a cleaner, more isolable product. 
The ligand itself is split into two bis-bidentate oxadiazole-dimethylpyrimidine domains. With 
coordination possible on both sides of the oxadiazole through both the imine-N4 and oxime-N2 
donor atoms and both sides of the pyrimidine units, this ligand carries immense potential. 
The assignment of the structure of the ligand is supported by 1H NMR spectroscopy. The spectrum 
shows the very iŶteŶse siŶglet at ɷϮ.ϲϵ, iŶtegƌatiŶg as ϭϮ pƌotoŶs, ĐoƌƌespoŶdiŶg to pǇƌiŵidiŶe 
methyl protons a.   
 
 
  
 
Figure 3.32 
 
The siŶglet at ɷϳ.Ϯϯ ĐoƌƌespoŶds to pƌotoŶs b since this signal integrates for two protons. The very 
slightlǇ split siŶglet at ɷϵ.Ϯϳ, iŶtegrating as one, is likely to correspond to proton c. A remaining 
douďlet at ɷϴ.ϲϬ aŶd a tƌiplet at ɷϳ.ϴϬ aĐĐouŶt foƌ pƌotoŶs d and e. The 13C NMR spectrum provides 
further confirmation by accounting for all ten unique carbon atoms, the methyl signal significant at 
ɷϮϰ.Ϯϱ aŶd the ŶiŶe aƌoŵatiĐ ĐaƌďoŶs ďetǁeeŶ ɷϭϮϭ.ϱϱ aŶd ɷϭϳϱ.ϳϱ. 
Analysis by HRMS delivered an accurate mass of the [M+Na]+ ion of 449.1452 comparing well with 
the calculated value of 449.1445. 
Several crystalline products featuring this ligand are awaiting analysis by XRD and again form part of 
the future work section of this project. 
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3.1.2.15 Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-5-[6-[3-(4,6-dimethylpyrimidin-
2-yl)-1,2,4-oxadiazol-5-yl]-2-pyridyl]-1,2,4-oxadiazole  
 
 
Scheme 3.25 
 
The pyridine spaced dimethylpyrimidine ligand (73) was synthesised in 4% yield, again using toluene 
as solvent, which gave a cleaner reaction mixture than xylene, an easier work-up and consequently a 
cleaner product.  
As an extension of the previous ligand (72), this ligand features a central pyridine unit in place of the 
phenylene unit. With the additional prospect of a central tridentate, oxadiazole-pyridine-oxadiazole 
domain, this ligand is an interesting prospect. The wealth of coordination options throughout the 
ligand makes it a good candidate for potentially self-assembling structures.  
Analysis by 1H NMR spectroscopy supported the assigned structure. The methyl protons a, are 
oďseƌǀed as a siŶglet at ɷϮ.ϳϬ. The loŶe pƌotoŶ of the pǇƌiŵidiŶe ƌiŶgs, b, is observed as a singlet at 
ɷϳ.Ϯϱ. The ƌeŵaiŶiŶg pƌotoŶs c and d ƌesoŶate as the douďlet aŶd tƌiplet seeŶ at ɷϴ.ϮϮ aŶd ɷϴ.ϳϮ, 
integrating as two and one protons, respectively. 
 
 
 
 
Figure 3.33 
 
(73) (55) 
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The 13C spectrum lends support to this structure, with all nine signals present and correct. The 
accurate mass of the compound was determined by HRMS. The measured figure for the [M+Na]+ ion 
was 450.1407 with the theoretical figure determined to be 450.1397.  
Several crystalline products featuring this ligand are also awaiting future analysis by XRD. 
 
3.1.2.16  Synthesis of 2-(2-pyridyl)-4-[2-(2-pyridyl)thiazol-4-yl]thiazole 
 
 
Scheme 3.26 
 
The supramolecular chemistry of thiazole ligand (75) has been thoroughly explored by Rice, Ward 
and co-workers as explained in the introduction. The synthesis involves combination of pyridine-2-
thioamide and dibromodiacetyl in refluxing methanol. 
It was necessary to synthesise this ligand in a bid to draw full comparison with ligand (64). This was 
due to the fact that this particular ligand, though thoroughly explored by Rice, had not seen any 
attempt at crystallisation with Pb2+ ions, whereas (64) formed interesting complexes with this metal. 
This known compound gave identical spectroscopic data to that reported previously92. 
Unfortunately, no crystalline products were observed with Pb2+. 
 
 
 
 
(75) (74) 
(57) 
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3.1.2.17 Synthesis of 2-[6-(2-pyridyl)-2-pyridyl]-4-[2-[6-(2-pyridyl)-2-pyridyl]thiazol-
  4-yl]thiazole  
 
 
Scheme 3.27 
 
As with ligand (75), this particular thiazole ligand has been synthesised and thoroughly explored by 
Rice and co-workers65-69. Again however, the ligand had not seen attempts at crystallisation with Pb2+ 
ions whereas the oxadiazole analogue (65) had. Thus the ligand was synthesised via the same 
refluxing methanol protocol as (75) and gave spectroscopic data consistent with the literature. 
No further self-assembled products were observed through reaction of ligand (77) with Pb2+ ions.  
 
 
 
 
 
 
 
 
 
 
(77) (76) 
(57) 
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3.1.3 Conclusions 
It has been demonstrated in this section of the thesis that the 1,2,4-oxadiazole unit, despite a 
distinct lack of recent research, is a highly effective coordination unit in ligand strands in 
metallosupramolecular chemistry,  
The 1,2,4-oxadiazole unit was shown to be a very versatile unit, with coordination through both the 
N4 nitrogen and, for only the second time in the history of its coordination chemistry, through the 
N2 nitrogen. 
It has also been demonstrated that the use of spacer units is unnecessary, since ligands with a bis-
oxadiazole centre partition effectively into both bidentate and tridentate domains with suitable 2-
pyridǇl aŶd Ϯ,Ϯ͛-bipyridyl substitution. 
For the first time in metallosupramolecular chemistry, the 1,2,4-oxadiazole has been shown to be a 
feature of ligand systems promoting the self-assembly of one and two-dimensional helicate 
polymers.   
Additionally, we have further underlined that very subtle differences in the electronics and 
heteroatomic content of 5-membered heterocycles drastically affects the nature of the 
metallosupramolecular structures formed. 
Several new ligands have been synthesised, from which crystals have been prepared and crystal 
structures obtained. Further crystals have been obtained for analysis in future crystallographic 
programmes.  
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3.2 The 1,2,4-Oxadiazole in Extensions of Biologically Active 
Isothiazole and Thiazete Dioxides 
This part of the thesis looks at 1,2,4-oxadiazoles and derivatives as potential biologically active 
compounds based on some systems of existing interest in our research group.  
Ouƌ gƌoup haǀe loŶg ďeeŶ iŶteƌested iŶ the oƌgaŶiĐ aŶd ŵediĐiŶal ĐheŵistƌǇ of β-sultaŵs, ɶ-sultams 
and larger ring systems. This chapter of the thesis discusses some of the advances our group have 
made towards novel thiazete- and isothiazole-1,1-dioǆides ;i.e. β- aŶd ɶ-sultams) and cycloaddition 
products thereof, and the investigation into their biological properties. The inspiration for this 
exploration into sultam chemistry was taken from previous successes of the group. As described in 
the introduction, the group have successfully synthesised a 3-amino-4-aryl-isothiazole-1,1-dioxide 
(see Figure 3.34). The chemical reactivity of this isothiazole-1,1-dioxide and the corresponding 
thiazete-1,1-dioxide has been a major focal point within our research group, and the objective in this 
thesis is to make further examples. This isothiazole was synthesised in accordance with the 
pioneering synthetic work of Francesca Clerici and co-workers. A previous worker in our group 
explored its chemistry and the biological activity of the compound and its cycloadducts. The 
chemistry to be explored is summarised in Scheme 3.28.  
 
 
 
 
Figure 3.34 – The 3-amino-4-arylisothiazole-1,1-dioxide. 
 
Variation in the Ar and NR2 groups gives some scope for exploration, but it is the reactivity of this 
system that offers the most scope. As shown below in Scheme 3.28, this system can be converted 
iŶto a β-sultam with two potential dipolarophilic sites and offers two dipolarophilic sites of its own 
(along with those offered by the intermediates). 
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Scheme 3.28 
 
 
 
 
 
'
'
'
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3.2.1   The Synthesis 3-Phenyl-α,β-unsaturated Arylketones 
 
 
Scheme 3.29 
 
The campaign towards the isothiazole-1,1-dioxides shown in Scheme 3.28 and the subsequent 
cycloaddition products begins with a simple base catalysed aldol reaction between benzaldehyde 
aŶd aŶ aĐetopheŶoŶe to giǀe a ƌaŶge of siŵple α,β-unsaturated ketones, as shown in Table 3.9.  
 
Entry Aryl Acetophenone Product Yield (%) 
1 Ph (80) 61 
2 4-NO2Ph (82) 16 
3 4-MeOPh (84) 71 
4 4-ClPh (86) 91 
5 4-MePh (88) 52 
 
Table 3.9 
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3.2.2 The Synthesis of 3-phenyl-α,β-dibrominated Arylketones 
 
Scheme 3.30 
 
The second step of the synthesis was a simple alkene dibromination. This was achieved by reacting 
the 1-aryl-3-phenyl-α,β-unsaturated ketones with bromine in chloroform at room temperature. All 
the reactions proceeded smoothly and gave useable quantities of the desired products, shown in 
Table 3.10. 
 
Entry Acyl Arene Product Yield (%) 
1 Ph (89) 34 
2 4-NO2Ph (90) 67 
3 4-MeOPh (91) 30 
4 4-ClPh (92) 21 
5 4-MePh (93) 47 
 
Table 3.10 
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3.2.3 The SǇŶthesis of α,β-unsaturated-3-phenyl-2-dialkylamino Arylketones 
 
Scheme 3.31 
 
The synthesis of the enamines proved to be the most inconvenient step of the synthesis. It is at this 
point that the amine functionality is introduced, in the form of a nucleophilic secondary amine. The 
synthesis is achieved by room temperature reaction of the α,β-dibrominated ketone with a 
secondary amine in ethanol80,81. After 24 hours, the reaction mixture is treated with sodium ethoxide 
to generate the enamine product81. 
In all cases, the product did not form cleanly. This made for an extremely challenging separation, 
meaning that the products were never isolated in a pure enough quality to permit characterisation. 
In addition to this problem, the semi-clean product often took the form of a very adhesive, viscous, 
unworkable semi-solid. Thus, in light of the practical difficulties associated with purity and physical 
state, the enamine was taken forward to the next stage as a crude material. Fortunately in most 
cases, this had little effect on the next stage of the synthesis, at which point the product could be 
purified and characterised.   
A mechanism for this reaction is shown in Scheme 3.32 below80,118: 
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Scheme 3.32 
 
The highly reversible nature of the steps in this mechanism, as well as alternative avenues, may well 
account for the highly impure nature of the reaction mixture. It is very possible that several of the 
intermediate materials in this mechanism may be present by TLC.  
No attempts were made to isolate the intermediate components of this reaction.  
The range of amines and dibromo compounds used is shown in Table 3.11. It is notable that only 
entry 4 failed in the next step. 
 
 
 
 
 
 
.
-
.
-
.
-
.
.
.
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Entry Arene Amine Product Evidence of Formation* 
1 Ph Et2 (94) Y 
2 Ph Pr2 (95) Y 
3 Ph Piperidinyl (96) Y 
4 4-NO2Ph Et2 (97) N 
5 4-MeOPh Pr2 (98) Y 
6 4-MeOPh Piperidinyl (99) Y 
7 4-MeOPh Morpholinyl (100) Y 
8 4-ClPh Et2 (101) Y 
9 4-ClPh Pr2 (102) Y 
10 4-ClPh Piperidinyl (103) Y 
11 4-MePh Et2 (104) Y 
12 4-MePh Piperidinyl (105) Y 
 
Table 3.11 
 
(*) Evidence of formation refers to the success of the following amidine synthesis, as discussed 
below.  
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3.2.4 The Synthesis of 2-Dialkylamino-N-methanesulfonyl Arylketoamidines 
Scheme 3.33 
 
Fortunately, to counter the unreliable and unworkable enamine step discussed previously, the N-
methanesulfonyl amidine synthesis was often very simple and highly practical. The enamine starting 
material could be taken as a crude mixture and successfully reacted with methanesulfonyl azide to 
form the amidine in good yields after a simple purification. Due to this high reliability, it was 
assumed that all reactions that failed at this stage were probably unsuccessful at the previous 
enamine stage. So convenient was this reaction that occasionally the products could be purified by 
simple recrystallisation from ethanol.  
Methanesulfonyl azide was prepared in solution by reaction of sodium azide with methanesulfonyl 
chloride119. Reaction with the enamine proceeds as shown below in Scheme 3.34 to yield the desired 
N-methanesulfonyl ketoamidines. 
 
Scheme 3.34 – Reaction mechanism for synthesis of amidines from corresponding enamines. 
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The reaction mechanism initiates with the 1,3-dipolar cycloaddition of the azide across the 
dipolarophilic C=N bond of the enamine. This yields an unstable 1,2,3-triazoline which, following a 
spontaneous cycloreversion, yields the desired amidine product with phenyldiazomethane and 
ethoxide120,121. The range of amidines and yields are summarised in Table 3.12. The individual 
reactions are discussed below. 
 
Entry Arene Amine Product Yield (%) 
1 Ph Et2 (106) 57 
2 Ph Pr2 (107) 48 
3 Ph Piperidinyl (108) 17 
4 4-MeOPh Pr2 (109) 55 
5 4-MeOPh Piperidinyl (110) 24 
6 4-MeOPh Morpholinyl (111) 3 
7 4-ClPh Et2 (112) 42 
8 4-ClPh Pr2 (113) 67 
9 4-ClPh Piperidinyl (114) 44 
10 4-MePh Et2 (115) 20 
11 4-MePh Piperidinyl (116) 42 
 
Table 3.12 
 
NMR spectroscopy and mass spectrometry proved significant analytical techniques for structural 
determination of the amidine series. Though carried out, analysis by FT-IR spectroscopy was not 
commented upon due to the significance of other analytical data. 
Lack of observation of any amidine product suggested that the nitro derivative dibromo compound 
(97) (entry 7 in Table 3.11) was not successfully converted to the enamine. This derivative was not 
pursued further.  
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3.2.4.1  Synthesis of N,N-diethyl-N'-methylsulfonyl-2-oxo-2-phenyl-acetamidine 
   
 
Scheme 3.35 
 
Analysis of the product by 1H NMR spectroscopy revealed some interesting features. Firstly the 
success of the reaction was inferred by the presence of the singlet integrating as three protons at 
ɷϮ.ϵϳ ǁhiĐh ŵust aĐĐouŶt foƌ pƌotoŶs a.  
 
 
 
 
 
Figure 3.35 
 
The phenyl protons d, e, and f are present as the expected doublet, doublet of doublets and triplet 
at ɷϳ.ϵϬ, ɷϳ.ϲϱ aŶd ɷϳ.ϱϯ ƌespeĐtiǀelǇ. Hoǁeǀeƌ, the ŵost iŶteƌestiŶg featuƌe of the NM‘ speĐtƌuŵ 
is the nature of the N-ethyl groups. Protons c resonate as tǁo ǁell estaďlished tƌiplets ;ɷϭ.Ϭϵ aŶd 
ɷϭ.ϯϰͿ, ƌatheƌ thaŶ oŶe. This suggests the teƌŵiŶal ŵethǇl gƌoup of pƌotoŶs aƌe distiŶĐt aŶd ŶoŶ-
equivalent.  
A similar situation is observed with the methylene protons b which resonate as distinct signals also. 
Interestingly, these protons resonate as 3 signals. These signals consist of an apparent quintet at 
(106) (94) 
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ɷϯ.ϭϱ ǁhiĐh iŶtegƌates as tǁo pƌotoŶs aŶd as tǁo ŵultiplets at ɷϯ.ϰϲ-ϯ.ϱϵ aŶd ɷϯ.ϲϳ-3.83 which 
each integrate as one proton. 
Analysis of the molecule by 13C NMR spectroscopy seems to confirm the above structure. The amine 
ŵethǇl ĐaƌďoŶs aƌe ǀisiďle at ɷϭϭ.ϵϮ aŶd ɷϭϯ.ϲϵ aŶd the ŵethǇleŶe ĐaƌďoŶs at ɷϰϮ.ϲϳ aŶd ɷϰϰ.Ϯϰ. 
The ŵethaŶesulfoŶǇl ĐaƌďoŶ is oďseƌǀed at ɷϰϮ.ϱϴ. Otheƌ ĐƌuĐial sigŶals pƌeseŶt iŶ the speĐtƌuŵ are 
the aŵidiŶe ĐaƌďoŶ aŶd ketoŶe ĐaƌďoŶ at ɷϭϲϭ.ϵϰ aŶd ɷϭϵϮ.ϱϳ, ƌespeĐtiǀelǇ.  
The molecular structure of this compound was confirmed by HRMS which delivered an accurate 
mass of 305.0930 for the [M+Na]+ ion comparing well with the expected 305.0928.  
 
3.2.4.2  Synthesis of N'-methylsulfonyl-2-oxo-2-phenyl-N,N-dipropyl-acetamidine 
   
 
Scheme 3.36 
 
The dipropyl derivative amidine (107) was synthesised in the same manner as the above, by 
refluxing the crude enamine in ethanol with methanesulfonyl azide, in 48% yield. 
The dipropylamino section of this molecule led to much anticipation in terms of what we would 
potentially observe by 1H NMR spectroscopy, given the peculiarities of the diethylamino analogue 
(106). The 1H NMR spectrum is exactly as expected for the remainder of the molecule. In the 1H NMR 
speĐtƌuŵ, the diagŶostiĐ ŵethaŶesulfoŶǇl pƌotoŶs aƌe oďseƌǀed as a siŶglet at ɷϮ.ϵϳ aŶd the triplet-
doublet of doublets-douďlet sǇsteŵ foƌ the pheŶǇl pƌotoŶs at ɷϳ.ϱϯ, ɷϳ.ϳϱ aŶd ɷϳ.ϵϬ. The ŵost 
interesting feature is the dipropylamine group. The two terminal methyl groups (protons d) are once 
agaiŶ uŶiƋue aŶd aƌe oďseƌǀed as tƌiplets at ɷϬ.ϳϮ aŶd ɷϭ.ϬϮ. The pƌotoŶs of the ŵethǇleŶe gƌoups 
(protons cͿ ƌesoŶate as tǁo ŵultiplets at ɷϭ.ϰϬ-ϭ.ϲϱ aŶd ɷϭ.ϳϮ-1.88. One set of methylene protons b 
(107) (95) 
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resonates as an apparent quartet-type signal, somewhat masked by the strong methanesulfonyl 
singlet. The methylene protons of the remaining methylene each resonate as individual signals at 
ɷϯ.ϯϯ-ϯ.ϰϰ aŶd ɷϯ.ϲϮ-3.76, which again shows inequivalency.  
 
 
 
 
 
 
Figure 3.36 
 
The 13C NMR spectrum supports the structure well and as before, illustrates the non-equivalent 
Ŷatuƌe of the aŵiŶe stƌaŶds. The teƌŵiŶal ŵethǇl ĐaƌďoŶs aƌe oďseƌǀed at ɷϭϬ.ϴϳ aŶd ɷϭϭ.ϰϱ, the β-
ŵethǇleŶe ĐaƌďoŶs at ɷϭϵ.ϴϳ aŶd ɷϮϭ.ϲϳ aŶd fiŶallǇ the α-ŵethǇleŶe ĐaƌďoŶs at ɷϰϵ.ϲϰ aŶd ɷϱϭ.ϯϴ. 
The diagnostic methanesulfonyl carbon signal is observed at ɷϰϮ.ϱϳ. 
The HRMS spectrum confirms this molecular structure. The theoretical mass for the [M+Na]+ ion was 
determined to be 333.1243, which compared well with the measured accurate mass of 333.1241. 
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3.2.4.3  Synthesis of N-[2-oxo-2-phenyl-1-(piperidyl)ethylidene] 
methanesulfonamide    
 
 
Scheme 3.37 
 
The phenyl amidine derivative featuring the piperidinyl substituent was synthesised in 17% yield, 
which suggests that the previous enamine step may not have worked well; the bulky and more rigid 
nature of the piperidine unit may possibly offer some explanation. 
The 1H NM‘ speĐtƌuŵ shoǁs a ďƌoad ŵultiplet at ɷϭ.ϯϱ-ϭ.ϱϲ iŶtegƌatiŶg as tǁo pƌotoŶs foƌ the ɶ-
methylene protons d. Protons c of the β-ŵethǇleŶe uŶits ƌesoŶate at ɷϭ.ϲϱ-1.80. The protons of 
methylenes b appeaƌ at ǀeƌǇ diffeƌeŶt shifts, as ŵultiplets at ɷϯ.ϭϭ-ϯ.Ϯϵ aŶd ɷϯ.ϳϴ-3.92. This 
suggests that the α-methylene groups either side of the piperidine heterocycle are different. 
 
 
 
 
 
 
Figure 3.37 
 
(108) (96) 
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AdditioŶallǇ, a siŶglet at ɷϮ.ϵϴ iŶdiĐates the pƌeseŶĐe of the ŵethaŶesulfoŶǇl gƌoup. The pheŶǇl 
protons are observed in the typical region in the expected pattern.  
The 13C NM‘ speĐtƌuŵ shoǁs the pƌeseŶĐe of the ɶ-ŵethǇleŶe ĐaƌďoŶ at ɷϮϯ.ϴϳ, the tǁo β-
ŵethǇleŶe ĐaƌďoŶs at ɷϮϱ.Ϯϳ aŶd ɷϮϲ.Ϭϯ aŶd fiŶallǇ the tǁo α-ŵethǇleŶe ĐaƌďoŶs at ɷϰϱ.ϵϬ aŶd 
ɷϰϴ.ϴϰ. The ŵethaŶesulfoŶǇl ĐaƌďoŶ is pƌeseŶt at ɷϰϮ.ϲϭ. 
The molecular structure was fully confirmed by HRMS which, for the calculated [M+Na]+ ion of 
317.0930, delivered an accurate mass for of 317.0922.  
 
3.2.4.4 Synthesis of 2-(4-methoxyphenyl)-N'-methylsulfonyl-2-oxo-N,N-dipropyl-
acetamidine  
 
Scheme 3.38 
 
The first of the 4-methoxyphenyl derivative enamines (98), was successfully converted to the 
amidine product (109) in a moderate 55% yield.   
The 1H NMR spectrum is consistent with the previous dipropyl amidine.  
The 13C NMR spectrum is fully consistent with what one would expect and the structure was 
confirmed by HRMS with an accurate mass for the [M+Na]+ ion of 363.1348, correlating well with the 
theoretical mass of 363.1349.  
 
(98) (109) 
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3.2.4.5 Synthesis of N-[2-(4-methoxyphenyl)-2-oxo-1-(1-piperidyl)ethylidene] 
methanesulfonamide  
 
Scheme 3.39 
 
The 4-methoxyphenyl/piperidine amidine (110) was successfully synthesised, though in low yield of 
24%. Lower yields were consistently observed with piperidinyl derivatives throughout this project.  
The 1H NMR spectrum was consistent with the expected structure. The 13C NMR spectrum and HRMS 
confirmed the structural assignment. 
 
3.2.4.6  Synthesis of 2-(4-chlorophenyl)-methylsulfonyl-2-oxo-acetamidines  
 
 
 
Scheme 3.40 
 
The 4-chlorophenyl amidines (112-114) were synthesised effectively in 42-67% yield, giving fully 
consistent spectroscopic data.  
 
 
(110) (99) 
(101-103) 
(112) R = Et, 42% 
(113) R = Pr, 67% 
(114) R = -(CH2)5-, 44% 
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3.2.4.7  Synthesis of methylsulfonyl-2-oxo-2-(p-tolyl)acetamidines 
 
 
 
Scheme 3.41 
 
The tolyl/diethylamine amidine system (115) and corresponding piperidinyl system (116) were 
successfully synthesised yields of 20% and 42% respectively. Both gave fully consistent spectroscopic 
data. 
 
3.2.5  The Synthesis of 3-Dialkylamino-4-hydroxy-4-aryl-isothiazoline-1,1-dioxides 
 
 
 
 
 
Scheme 3.42 
 
The cyclisation of the methanesulfonyl amidine to the 3-amino-4-hydroxy-4-aryl isothiazoline-1,1-
dioxide was achieved by treatment with one equivalent of potassium tert-butoxide in dry THF at 
room temperature79 in mostly good to excellent yields throughout.  
The key diagnostic feature of this cyclisation is the conversion of the carbonyl group to a tertiary 
alcohol due to nucleophilic attack by the methanesulfonyl carbon which becomes the isothiazoline 
5-position methylene, as shown in Scheme 3.43.  
(115) R = Et, 20% 
(116) R = -(CH2)5-, 42% 
(104-105) 
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Scheme 3.43 – Reaction mechanism for base mediated cyclisation of amidine to isothiazoline. 
 
The reaction mechanism proceeds with the deprotonation of the methanesulfonyl group by BuO- 
yielding the corresponding methanesulfonyl carbanion which triggers the nucleophilic attack of the 
carbonyl followed by protonation of the isothiazoline oxide to yield the 4-hydroxyisothiazoline 
compound79. The compounds shown in Table 3.13 were synthesised via this reaction and some of 
the details of their characterisation are given below. 
 
Entry Arene Amine Product Yield (%) 
1 Ph Et2 (117) 81 
2 Ph Pr2 (118) 96 
3 Ph Piperidinyl (119) 87 
4 4-MeOPh Pr2 (120) 99 
5 4-MeOPh Piperidinyl (121) 60 
6 4-MeOPh Morpholinyl (122) - 
7 4-ClPh Et2 (123) 87 
8 4-ClPh Pr2 (124) 76 
9 4-ClPh Piperidinyl (125) - 
10 4-MePh Et2 (126) 77 
11 4-MePh Piperidinyl (127) 42 
 
Table 3.13 
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3.2.5.1  Synthesis of 3-(Diethylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
   
 
 
Scheme 3.44 
 
The 3-diethylamino-5-hydroxy-5-phenyl isothiazoline derivative (117) was successfully synthesised 
via reaction with tBuOK in THF in 81% yield. 
Confirmation of the structure of the above compound was achieved by NMR spectroscopy. The 
diagnostic features of the spectrum are the disappearance of the methanesulfonyl singlet of (106) 
and the appearance of a broad singlet representing the OH proton at ɷϱ.ϰϰ. The new methylene 
pƌotoŶs aƌe ƌepƌeseŶted ďǇ tǁo douďlets at ɷϯ.ϲϳ aŶd ɷϯ.ϵϭ, Đoupled ǁith a fƌeƋueŶĐǇ of J=ϭϰ.ϮHz. 
This splitting shows the protons of this α-sulfonylmethylene group are non-equivalent due to the 
adjacent chiral centre. The terminal ŵethǇl gƌoups ƌesoŶate as tǁo tƌiplets at ɷϬ.ϳϰ aŶd ɷϭ.Ϯϰ. The 
diethylamine methylene groups remain non-equivalent and now resonate as two sets of two 
oǀeƌlappiŶg douďlets of Ƌuaƌtets at ɷϯ.Ϯϳ aŶd ɷϯ.ϰϴ. 
The 13C NMR spectrum is perfectly as expected, with the loss of the carbonyl carbon and 
methanesulfonyl carbon signals. The structure was confirmed by HRMS which presented an accurate 
mass for the [M+Na]+ ion of 305.0923. The theoretical mass figure of this ion was determined to be 
305.0930. 
 
 
 
 
 
 
(117) (106) 
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3.2.5.2  Synthesis of 3-(Dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
   
 
 
Scheme 3.45 
 
 
Amidine (107) reacted well with potassium tert-butoxide to form the cyclised product (118) in 96% 
yield. 
The structure of the product was confirmed by 1H NM‘ speĐtƌosĐopǇ. EaĐh pƌotoŶ of the α-
sulfonylmethylene group resonated as a doublet, one at ɷϯ.ϲϲ aŶd the otheƌ at ɷϯ.ϵϱ. The hydroxyl 
proton is observed as a singlet at ɷϱ.ϲϵ. The terminal methyl protons follow the usual pattern; all 
fouƌ β-methylene protons now each resonate each as separate multiplets at ɷϬ.ϳϳ-Ϭ.ϴϳ, ɷϭ.ϯϴ-1.52, 
ɷϭ.ϱϲ-ϭ.ϲϵ aŶd ɷϭ.ϳϬ-ϭ.ϴϯ. The α-methylene protons show complex splitting patterns resulting in 
tǁo sigŶals at ɷϯ.ϭϲ aŶd ɷϯ.ϯϲ. 
The structure was fully consistent with the observed 13C NMR spectrum and HRMS, with the 
accurate mass for the [M+Na]+ ion determined to be 333.1240. The theoretical mass figure of this 
ion was determined to be 333.1243. 
 
 
 
 
 
 
(118) (107) 
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3.2.5.3  Synthesis of 3-(Dipropylamino)-1,1-dioxo-4-phenyl-5H-isothiazol-4-ol 
    
Scheme 3.46 
 
Piperidine-isothiazoline (119) was synthesised in a yield of 87%. 
The structure of compound (119) was assigned by 1H NM‘ speĐtƌosĐopǇ ǁhiĐh shoǁed the α-
sulfonylmethylene protons as two expected doublets at ɷϯ.ϲϲ aŶd ɷϯ.ϵϬ. The hǇdƌoǆǇl pƌotoŶ is 
ǀisiďle as the ďƌoad stƌetĐh at appƌoǆiŵatelǇ ɷϲ.ϯϲ. The pipeƌidiŶe pƌotoŶs aƌe oďseƌǀed as seǀeƌal 
multiplets resonating at ɷϬ.ϴϰ-Ϭ.ϵϳ aŶd ɷϭ.Ϯϵ-ϭ.ϰϮ foƌ the ɶ-ŵethǇleŶe pƌotoŶs aŶd ɷϭ.ϰϱ-1.72 for 
fouƌ β-ŵethǇleŶe pƌotoŶs aŶd oŶe α-ŵethǇleŶe pƌotoŶ. Tǁo of the ƌeŵaiŶiŶg thƌee α-methylene 
pƌotoŶs ĐaŶ ďe oďseƌǀed as a paiƌ of ŵultiplets at ɷϯ.ϯϰ, ǁith the last of these pƌotoŶs ŵasked by 
the α-sulfonylmethylene doublet at approximately ɷϯ.ϲϲ.  
The 13C NMR spectrum is in accordance with this structure, showing five CH2 signals for the 
piperidine ring. 
 
3.2.5.4  Synthesis of Remaining Isothiazol-4-ols 
 
Most of the remaining isothiazoles (120-122, 123,124, 126,127) in Table 3.14 were synthesised in 
the same manner and all gave fully consistent spectroscopic data and were obtained in the yields 
shown. Morpholinyl and piperidinyl derivative Isothiazoles (122) and (125) were not observed. Given 
the variety of the series, these derivatives were not pursued further.  
 
 
(119) (108) 
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3.2.6  The Synthesis of 3-Dialkylamino-4-chloro-4-aryl-isothiazoline-1,1-dioxides 
 
 
 
 
 
Scheme 3.47 
 
The 4-hydroxylisothiazolines were converted to the 4-chloroisothiazolines in order provide a more 
reliable opportunity to generate the fully unsaturated isothiazoles. The installation of chlorine at the 
4-position provides a sensible, mild route to the fully unsaturated heterocycle due to easy 
elimination of HCl. The chlorination was achieved by treatment with excess thionyl chloride under 
reflux conditions. The compounds synthesised by this method are shown in Table 3.14, below. It is 
notable that the first few reactions attempted gave some of the (desired) elimination products, the 
synthesis of which is done deliberately in the next step. 
 
 Entry Arene Amine Chlorinated 
Product 
Yield Dehydrochlorinated 
Product 
Yield 
1 Ph Et2 (128) 56 (137) 31 
2 Ph Pr2 (129) 55 (138) 5 
3 Ph Piperidinyl (130) 33 (139) 4 
4 4-MeOPh Pr2 (131) 97 - - 
5 4-MeOPh Piperidinyl (132) 89 - - 
6 4-ClPh Et2 (133) 82 - - 
7 4-ClPh Pr2 (134) 85 - - 
8 4-MePh Et2 (135) 66 - - 
9 4-MePh Piperidinyl (136) 71 - - 
 
Table 3.14 
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All of the chlorinated products (128-136), gave the expected spectroscopic analysis. The major 
dehydrochlorinated product (137) also gave the expected spectroscopic characteristics, with the loss 
of the chiral centre resulting in the diethyl unit becoming much simpler. Dehydrochlorinated 
products (138-139) were also observed, but as insignificant minority products. The chlorinated 
products showed splitting patterns in the 1H NMR that were broadly similar to those observed in the 
alcohols and this will not be detailed further here. 
 
 
3.2.7  The Synthesis of 3-Dialkylamino-4-aryl-isothiazole-1,1-dioxides 
 
 
 
 
 
 
Scheme 3.48 
 
 
Entry Arene Amine Product Yield (%) 
1 Ph Pr2 (138) 62 
2 4-MeOPh Pr2 (140) 76 
3 4-MeOPh Piperidinyl - - 
4 4-ClPh Et2 (141) 79 
5 4-ClPh Pr2 (142) 97 
6 4-MePh Et2 (143) 30 
7 4-MePh Piperidinyl (144) 20 
 
Table 3.15 
 
This straightforward reaction gave six further examples of the 3-dialkylamino-4-aryl-isothiazole-1,1-
dioxides to add to compound (137) (see Table 3.14). The loss of chirality in each of the products 
(140-144) and the formation of the planar fully unsaturated heterocycle simplified the 1H NMR 
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spectra considerably, since the dialkyl chain showed equivalent alkyl groups. The new singlet in the 
unsaturated isothiazole-1,1-dioǆide ƌiŶg tǇpiĐallǇ appeaƌed aƌouŶd ɷϳ.2 in the 1H NMR spectrum and 
at ɷϭϯϮ iŶ the 13C NMR spectrum. The phenyl derivatives generated by spontaneous 
dehydrochlorinarion in the previous step were taken on by another group member. Unfortunately, 
the dehydrochlorination of piperidinyl derivative (132) was unsuccessful. This derivative was not 
pursued further.  
 
 
3.2.8  The Synthesis of 3,6-diaryl-7-dialkylamino-isothiazolo-isoxazole-1,1- 
  dioxides 
 
Scheme 3.49 
 
The major motive for synthesising the isothiazole-1,1-dioxides was to explore the possibility of 1,3-
dipolar cycloaddition at the imine bond of the heterocycle, thereby enabling access to isothiazolo-
oxadiazoles. We have found that in all cases, cycloaddition occurs only across the alkene bond, with 
zero evidence of any cycloaddition across the imine bond, in either the starting material or the newly 
formed product.  
To the best of our knowledge, only a small number of isothiazolo-isoxazole systems have been 
synthesised with very few investigations conducted into their anti-cancer activity78. Thus, a small 
series of these molecules were screened for anti-cancer activity. This will be described later.  
The isothiazolo-isoxazoles were obtained by careful treatment of previously prepared imidoyl 
halides with triethylamine to generate the in-situ 1,3-dipolar nitrile oxide species which reacted 
successfully with the dipolarophilic isothiazole-1,1-dioxides across the C=C bond:  
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Scheme 3.50 
 
Significantly, this reaction produces two new chiral centres, located at the isothiazolo-isoxazole 
bridging carbon atoms. In all cases, a single diastereomer was observed. 
 
Table 3.16 shows the range of isothiazolo-isoxazoles that were produced in this study. In this thesis, 
the compounds synthesised via this route focused upon substituted benzene rings meaning that 
isothiazoles (137) and (138) were taken on by another group member. Some of the typical 
spectroscopic data of these compounds is discussed below. 
 
Entry Isothiazole 
Arene 
Isothiazole 
Amine 
1,3-Dipole 
Arene 
Product Yield (%) 
1 4-MeOPh Pr2 4-MeOPh (147) 29 
2 4-MeOPh Pr2 4-ClPh (148) 44 
3 4-ClPh Et2 4-ClPh (149) 17 
4 4-ClPh Et2 4-MeOPh (150) 42 
5 4-ClPh Pr2 4-MeOPh (151) 25 
6 4-ClPh Pr2 4-ClPh (152) 29 
7 4-MePh Et2 4-MeOPh (153) 39 
8 4-MePh Et2 4-ClPh (154) 14 
9 4-MePh Piperidinyl 4-MeOPh (155) 54 
10 4-MePh Piperidinyl 4-ClPh (156) 28 
 
Table 3.16 
-
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3.2.8.1   Synthesis of 3,6a-bis(4-methoxyphenyl)-4,4-dioxo-N,N-dipropyl-3aH-
isothiazolo[5,4-d]isoxazol-6-amine  
 
 
Scheme 3.51 
 
The 1,3-dipolar cycloaddition of insitu generated 4-methoxyphenyl nitrile oxide from (145) with 
(140) occurred solely across the isothiazole alkene bond in 29% yield. 
The isothiazolo-isoxazole structure was confirmed by 1H NMR spectroscopy which showed the 
dipropylamine chains to be intact and appearing again as characteristically complex signals. The two 
sets of aryl methoxy protons appear very close together at ɷϯ.ϴϮϳ aŶd ɷϯ.ϴϯϭ. The siŶglet at ɷϱ.Ϭϳ is 
the stereocentre bridgehead proton. All aryl protons are accountable by the presence of doublets at 
ɷϲ.ϵϮ, ɷϲ.ϵϳ, ɷϳ.ϯϳ aŶd ɷϳ.ϳϮ. The aďseŶĐe of the isothiazole ɷ-proton singlet is also notable and 
provides clear evidence that the compound is not the isothiazolo-oxadiazole, but is indeed the 
isothiazolo-isoxazole. 
AŶalǇsis of the HSQC speĐtƌuŵ shoǁs the sulfoŶe α-ĐaƌďoŶ steƌeoĐeŶtƌe at ɷϳϵ.ϳϭ. 
The stereochemistry of the ring junction was established as cis- due to the pƌotoŶ oŶ the sulfoŶe α-
carbon and the protons at the ortho position of the bridgehead p-methoxyphenyl showing a signal in 
the NOESY spectrum. A previous worker in the group established this unequivocally by x-ray 
crystallography on similar adducts. 
The structure was further confirmed by HRMS which indicated an accurate mass of 494.1717 for the 
[M+Na]+ ion with the theoretical mass of this ion calculated to be 494.1720. 
(140) (145) 
(147) 
Results and Discussion   3 
261 
 
3.2.8.2 Synthesis of 3-(4-chlorophenyl)-6a-(4-methoxyphenyl)-4,4-dioxo-N,N-
dipropyl-3aH-Isothiazolo[5,4-d]isoxazol-6-amine  
 
 
 
Scheme 3.52 
 
Synthesis of the bicyclic product (148) was achieved in 30% yield.  
Confirmation was provided by 1H NMR spectroscopy which showed the new bridgehead proton at 
ɷϱ.Ϭϲ, ǁith the ŵethiŶe ĐaƌďoŶ appeaƌiŶg at ɷϳϵ.Ϭϴ iŶ the 13C NMR spectrum. The spectrum was 
completely in accordance with that of adduct (147), with the only major difference being the 
presence of one methoxy singlet rather than two.  
Analysis by HRMS delivered an accurate mass of 498.1222 for the [M+Na]+ ion compared with the 
expected figure of 498.1225. 
 
The NOESY spectrum agaiŶ shoǁed a stƌoŶg ĐoƌƌelatioŶ ďetǁeeŶ the pƌotoŶ oŶ the sulfoŶe α-
carbon and the ortho protons on the p-methoxyphenyl, again inferring cis- stereochemistry across 
the ring junction. 
 
 
 
 
 
 
(140) (146) 
(148) 
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3.2.8.3   Synthesis of Remaining Isothiazolo-isoxazoles 
 
 
 
 
 
 
 
 
 
 
Scheme 3.53 
 
 
All isothiazolo-isoxazole structures were determined by 1H NMR spectroscopy, the diagnostic singlet 
observed at approximately ɷϱ.Ϭϴ deŶotiŶg the presence of the bridgehead proton, which confirmed 
addition across the C=C bond. All other signals and data were consistent with the assigned 
structures. All gave 1H NMR, 13C NMR, IR and HRMS data that were fully consistent with the assigned 
structures (see experimental section 2.2.8). 
The structural details and yields of compounds (150-156) are detailed in Table 3.16. 
The biological data from the synthesised isothiazolo-isoxazoles is discussed in section 3.2.11. 
Tǁo isothiazoles ǁeƌe ĐhoseŶ as suďstƌates to atteŵpt ƌiŶg ĐoŶtƌaĐtioŶ to a β-sultam and this is 
discussed next.  
 
 
 
(149) Ar - 4-ClPh, Ar2 - 4-ClPh, R - Et2 (153) Ar - 4-MeOPh, Ar2 - 4-MeOPh-, R - Et2 
(150) Ar - 4-ClPh, Ar2 - 4-MeOPh, R - Et2 (154) Ar - 4-MeOPh, Ar2 - 4-ClPh, R - Et2 
(151) Ar - 4-ClPh, Ar2 - 4-MeOPh, R - Pr2 (155) Ar - 4-MeOPh, Ar2 - 4-MeOPh-, R - Piperidinyl 
(152) Ar - 4-ClPh, Ar2 - 4-ClPh, R - Pr2 (156) Ar - 4-MeOPh, Ar2 - 4-ClPh, R - Piperidinyl 
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3.2.9  The Synthesis of 3-Dialkylamino-4-aryl-5-bromo-isothiazole-1,1-dioxides 
 
 
 
 
 
 
Scheme 3.54 
 
As studied above, tǁo isothiazoles ǁeƌe eǆploƌed as suďstƌates foƌ β-sultam formation. The first step 
iŶ this seƋueŶĐe ǁas ďƌoŵiŶatioŶ. The α-bromination of the isothiazole was achieved by treatment 
with one equivalent of a solution of bromine in chloroform (1M), which affords the dibrominated 
pƌoduĐt. DepƌotoŶatioŶ of the α-ĐaƌďoŶ ďǇ ďase theŶ tƌiggeƌs β-elimination of bromide and the 
suďseƋueŶt loss of HBƌ ƌesultiŶg iŶ the α-brominated isothiazole-1,1-dioxide77, as shown below. 
 
 
 
 
 
 
 
 
Scheme 3.55 – Reaction mechanism foƌ the α-bromination of isothiazole-1,1-dioxides. 
 
The two isothiazoles selected for this study are discussed below. 
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3.2.9.1  Synthesis of 5-bromo-4-(4-methoxyphenyl)-1,1-dioxo-N,N-dipropyl- 
  isothiazol-3-amine  
 
 
Scheme 3.56 
 
 
The α-bromination of the 3-dipropylamino-4-(4-methoxyphenyl) derivative isothiazole-1,1-dioxide 
(140) was successfully achieved in 88% yield.  
The 1H NMR spectrum was consistent with previous spectra with the propyl chains resonating as two 
triplets and two sets of multiplets. Critically, the 1H NM‘ sigŶal ƌepƌeseŶtiŶg the α-proton of (140) is 
no longer present.  
The 13C NMR spectrum supports the assignment and, most importantly, showed loss of the 
isothiazole ring CH and appearance of a new quaternary carbon. The consistent NMR data and 
concerns about stability meant that this compound was deemed sufficiently characterised for 
continuation.  
 
 
 
 
 
 
 
 
 
(140) (157) 
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3.2.9.2  Synthesis of 5-bromo-4-(4-chlorophenyl)-1,1-dioxo-N,N-dipropyl- 
  isothiazolo-3-amine   
 
 
Scheme 3.57 
 
The α-bromination of the 3-dipropylamino-4-(4-chlorophenyl) derivative (142) was successfully 
achieved in 80% yield.  
Analysis by 1H NMR spectroscopy is strongly supportive of the formation of compound (158); the 
aďseŶĐe of the isothiazole α-proton giving the most clear indication; an assignment supported by the 
13C NMR spectrum. The remainder of the spectroscopic data accounts for the rest of the structure of 
the product with little change from the spectra of (142).  
The product was confirmed beyond reasonable doubt by HRMS which provided an accurate mass for 
the [M+Na]+ ion of 426.9850 for the expected figure of 426.9853. 
 
 
 
 
 
 
 
 
(142) (158) 
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3.2.10  The Synthesis of 3-Dialkylamino-4-aryl-5-thiomethoxy-isothiazole-1,1- 
  dioxides 
 
 
 
 
 
Scheme 3.58 
 
The 3-amino-4-aryl-5-methylsulfide derivatives were synthesised by simple nucleophilic 
displacement of bromide by thiomethoxide in the presence of triethylamine in dichloromethane. 
The presence of triethylamine was necessary to minimise the protonation risk of the thiomethoxide 
ion, thereby preserving its nucleophilicity77.  
 
3.2.10.1 Synthesis of 4-(4-chlorophenyl)-5-methylsulfanyl-1,1-dioxo-N,N-dipropyl-
  isothiazol-3-amine  
 
Scheme 3.59 
 
 
The synthesis of compound (159) was achieved successfully in 41% yield. 
(158) (159) 
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Analysis by 1H NM‘ speĐtƌosĐopǇ alloǁed the oďseƌǀatioŶ of a Ŷeǁ siŶglet at ɷϮ.ϳϴ, ǁhiĐh iŶtegƌates 
perfectly as three protons and so confirms the methylsulfidation.  
The structure of the product is confirmed further by 13C NMR spectroscopy which shows the new 
methylsulfide sigŶal at ɷ12.96.  
The compound was noted to be very unstable and, unfortunately, we were unable to synthesise any 
β-sultams. These remain a priority for future work and are described in this later section. 
 
3.2.11  The Anti-cancer Activity of Synthesised Isothiazolo-Isoxazoles 
Eight of the ten synthesised isothiazolo-isoxazoles were submitted for cell proliferation studies, 
however only four of these (147), (149), (151) and (152) showed good ethanol solubility. The cell 
proliferation studies were carried out by the research group of Dr Farideh Javid at the University of 
Huddersfield.  
MCF-7 cells, human breast (American Type Culture Collection) were grown and maintained in RPMI 
1640 medium and were supplemented with 10% fetal bovine serum at 37 oC under 5% CO2. The cells 
were plated in 96-well culture plates at a density of 1 x 104 cells per well and were allowed to 
adhere at 37 oC for 24 hours. The following day, various doses of compounds (147), (149), (151) and 
(152) were added to the cells and incubated for a further 24 h, 48 h, 72 h or 96 h. Following removal 
of the supernatant, MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was added 
over 4 hours. The ability of cells to form formazan crystals by active mitochondrial respiration was 
determined by using a Microplate reader after dissolving the crystals in DMSO. Cytotoxicity was 
expressed as the relative percentage of the absorbance measured at 540nm in the control and 
extract-treated cells.  
The data points in the following graphs were presented as the mean +s.e. mean of n=2, with each 
point representing the mean of four separate experiments of eight readings for each concentration 
of compound used. 
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Graph 1 - The effect of (147) on human breast carcinoma over 24, 48, 72 and 96 hour periods (IC50 for 96 h 
eǆposuƌe tiŵe ϯ.ϳϱ μM + ϭ.Ϯϱ; ϳϮ h eǆposuƌe tiŵe ϲ.Ϯϱ μM + ϭ.Ϯϱ; ϰϴ h eǆposuƌe tiŵe ϴ.ϱ μMͿ. 
 
 
 
 
 
Graph 2 - The effect of (149) on human breast carcinoma over 24, 48, 72 and 96 hour periods (IC50 for 96 h 
eǆposuƌe tiŵe ϭ.ϱ μM + Ϭ.ϱ; ϳϮ h eǆposuƌe tiŵe ϯ.ϳϱ μM + ϭ.Ϯϱ; ϰϴ h eǆposuƌe tiŵe ϯ.ϭ μM +2.4). 
 
Results and Discussion   3 
269 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3 - The effect of (151) on human breast carcinoma over 24, 48, 72 and 96 hour periods (IC50 for 96 h 
eǆposuƌe tiŵe ϱ.ϱ μM + Ϭ.ϱͿ. 
 
 
Graph 4 - The effect of (152) on human breast carcinoma over 24, 48, 72 and 96 hour periods (IC50 for 96 h 
eǆposuƌe tiŵe ϲ.ϱ μM + Ϭ.ϱ; ϳϮ h eǆposuƌe tiŵe ϱ.ϱ μM + Ϭ.ϱ; ϰϴ h eǆposuƌe tiŵe ϴ.Ϯϱ μM + Ϭ.ϳϱͿ. 
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All compounds submitted for cancer cell screening showed greatest promise when exposed to cells 
over a 96 hour period. Compound (149) was the most effective, showing an IC50 of 1.5µm and total 
cell death at 1 x 10-4 M concentrations following 96 hours of cell exposure. The concentration of 1 x 
10-5 M seems significant, with all compounds showing a sharp rise in activity at this dosage.  
 
3.2.12  Conclusions 
In conclusion, a range of hitherto unreported isothiazolo-isoxazoles have been successfully 
developed through a challenging, seven-step synthesis via a series of also previously unreported 
isothiazole-1,1-dioxides. Several of the synthesised isothiazolo-isoxazoles were tested on MCF-7 cells 
and shown to have promising anti-proliferation activity.   
Attempts at sǇŶthesisiŶg the ĐoƌƌespoŶdiŶg β-sultams were not successful and this remains a 
current target of our research group. 
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3.3  The 1,2,4-Oxadiazole Unit as Structural Feature For  
  Asymmetric Catalysts 
 
In this chapter progress towards the development of 1,2,4-oxadiazole based chiral catalysts for 
investigations into asymmetric catalysis will be described. These systems were developed around an 
aspect of this research which focussed on the discovery of hypervalent iodine catalysts. This chapter 
starts by describing the development of a pseudoephedrine based hypervalent iodine system and 
describes its use for the synthesis of lactones. On the basis of this, the chapter moves on to describe 
the synthesis of a potential 1,2,4-oxadiazole based chiral catalyst before describing progress towards 
an iodine containing analogue.  
 
3.3.1  The Synthesis and Catalytic Activity of Pseudoephedrine based Hypervalent
  Iodine System 
As described in the introduction, in hypervalent iodine chemistry, the iodine atom is usually in the 2-
position on the arene. This, during catalysis, enables closer proximity of the chiral components of the 
catalyst with the substrate and in theory, offers the catalyst a better opportunity to impart its 
chirality by promoting a specific facial attack.  
The initial chiral amine selected for this project was (1S,2S)-pseudoephedrine. This amine was 
selected for a number of reasons. The first was that since pseudoephedrine is a secondary amine, 
the product of subsequent Schotten-Baumann amide synthesis will be a fully substituted tertiary 
amide, reducing the likelihood of unwanted reactivity. Secondly, pseudoephedrine is relatively 
simple, and aside from the hydroxyl group, does not possess any reactive centres of concern. 
Additionally, pseudoephedrine has a strong pedigree in asymmetric synthesis, demonstrating 
significance as a chiral auxiliary by Myers and co-workers in 1994122 and later in 1997, where systems 
including pseudoephedrine were developed further to demonstrate superiority as a chiral auxiliary 
in asymmetric transformations123. 
Whilst only a few substituted 2-iodobenzoic acids are commercially available, a good range of 2-
aminobenzoic acid derivatives are available. Whilst the iodination of such aminoarenes involved 
adding another step to the synthesis, a far greater range of potential catalysts is enabled by sourcing 
these materials. Having selected appropriate starting materials, the synthesis of chiral iodine(I) and 
subsequent hypervalent iodine(III) catalysts were planned thusly:  
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Scheme 3.60 – Target synthesis for pseudoephedrine based iodo-catalysts. 
 
Sandmeyer reaction of the 2-aminobenzoic acid derivatives enables access to the iodinated product. 
Subsequent synthesis of the acid chloride from the 2-iodobenzoic acid derivative enables Schotten-
Baumann coupling with (S,S)-pseudoephedrine, yielding the desired iodine(I) precatalyst.  
Once synthesised, it was planned that the hypervalent iodine(III) species would be generated in-situ 
in accordance with current research methods (detailed in the introduction). The oxidant selected 
was mCPBA, which is a proven reagent in organoiodine oxidations. The selected activating agent 
chosen to generate the reactive hypervalent iodine(III) species was p-toluenesulfonic acid.  
Once the pseudoephedrine systems had been made, the idea was to produce the corresponding 
1,2,4-oxadiazole systems as potential isosteres as shown in Scheme 3.61: 
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Scheme 3.61 – Potential array of isosteres from aryliodide-pseudoephedrine scaffold. 
 
The choice of reaction for investigating these catalysts was the lactonisation reaction discussed 
previously: 
 
Scheme 3.62 
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3.3.1.1  The Synthesis of Iodine(I) Precursor Materials 
The iodination of the 2-aminobenzoic acid derivatives was achieved via Sandmeyer reaction. 
Scheme 3.63 
 
In strongly acidic solution, the 2-aminobenzoic acid derivatives were treated with sodium nitrite, 
which is protonated and dehydrated insitu yielding the nitrosonium ion which then reacts with the 
aryl primary amine yielding the diazo compound following a further dehydration. The diazo group is 
displaced by nucleophilic iodide and leaves as nitrogen, thereby yielding the desired 2-iodobenzoic 
acid derivatives as shown in Table 3.17.    
 
 
Entry R1 R2 Product Yield (%) 
1 Me H (165) 86 
2 CF3 H (166) 92 
3 Me Me (167) 84 
4 Me Cl (168) 91 
5 Cl H (169) 86 
 
Table 3.17 
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3.3.1.2  The Synthesis of Chiral Iodine(I) Pre-catalysts 
The 2-iodobenzoic acid derivatives were converted to the corresponding acid chlorides (171-175) 
and immediately coupled with (1S,2S)-pseudoephedrine in a standard Schotten-Baumann amide 
synthesis.  
 
 
 
 
 
 
 
Scheme 3.64 
 
 
Entry R1 R2 Product Yield (%) 
1 H H (176) 52 
2 Me H (177) 59 
3 CF3 H (178) 65 
4 Me Cl (179) 68 
5 Cl H (180) 70 
 
Table 3.18 
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The first iodine(I) precatalyst to be synthesised was the 2-iodophenyl derivative (176). This was 
synthesised by chlorination of 2-iodobenzoic acid (170) by oxalyl chloride under catalytic DMF 
conditions to give the acid chloride (171) which was subsequent coupled by Schotten-Baumann 
reaction with (1S,2S)-pseudoephedrine. The product was synthesised in 52% yield. 
Analysis by HRMS delivered an accurate mass for the [M+Na]+ ion of 418.0289 which corresponds 
with the expected value of 418.0274. 
Analysis by 1H NMR spectroscopy suggests that this compound exists as a mixture of rotamers. This 
can be postulated since in the majority of cases, each 1H NMR signal is partnered with a 
corresponding minor signal.   
The synthesis of the 3-methyl-2-iodophenyl derivative (177) was achieved via acyl chlorination of 
(165) and subsequent coupling with (1S,2S)-pseudoephedrine in 59% yield. 
The structure of this product was confirmed by HRMS which delivered an accurate mass of 432.0427 
for the [M+Na]+ ion, with the expected mass determined to be 432.0431. 
The 1H NM‘ speĐtƌuŵ shoǁs douďlets at ɷϬ.ϵϱ, ɷϭ.ϭϮ, ɷϭ.ϭϱ aŶd ɷϭ.ϰϰ, eaĐh of ǁhiĐh is likelǇ to 
correspond to the stereocentre methyl protons of one rotamer. Three of these signals are major and 
one minor (ɷϬ.ϵϱͿ suggestiŶg thƌee ƌotaŵeƌiĐ foƌŵs are present. The integration ratios of these 
signals suggests a 3:3:3:1 relationship of rotamers. Singlets at ɷϮ.ϰϴ, ɷϮ.ϰϵ aŶd ɷϮ.ϲϬ oƌigiŶate fƌoŵ 
the aƌǇl ŵethǇl pƌotoŶs. The sigŶal at ɷϮ.ϰϴ is sigŶifiĐaŶtlǇ stƌoŶgeƌ thaŶ those at ɷϮ.ϰϵ aŶd ɷϮ.ϲϬ, 
which are of the same intensity. This may suggest that this stronger signal is masking that of the 
ŵiŶoƌ ƌotaŵeƌ. SiŶglets at ɷϮ.ϴϬ, ɷϮ.ϴϲ, ɷϯ.ϭϲ aŶd ɷϯ.ϭϳ ĐoƌƌespoŶd to the N-methyl protons. The 
ƌegioŶ ďetǁeeŶ ɷϯ.ϱ to ɷϱ.ϱ is ďusǇ ǁith sigŶals. These aƌe likely to originate from each of the two 
steƌeoĐeŶtƌe CH pƌotoŶs. SigŶals at ɷϰ.ϱϰ, ɷϰ.ϲϭ, ɷϰ.ϳϭ aŶd ɷϰ.ϴϴ ƌesoŶate as douďlets aŶd thus 
ĐoƌƌespoŶd to the ďeŶzǇliĐ pƌotoŶs. Multiplets at ɷϯ.ϲϳ-ϯ.ϳϳ, ɷϰ.Ϯϰ-ϰ.ϯϰ, ɷϰ.ϵϲ-ϱ.Ϭϱ aŶd ɷϱ.Ϭϳ-5.21 
originate from the remaining CH proton. The rotameric effect is once again observed and in 
approximately the same ratio as that suggested by other signals. 
The 3-trifluoromethyl derivative precatalyst (178) was successfully synthesised from (166) via the 
usual protocol in 65% yield.  
The structure of this product is supported by 1H NMR spectroscopy, which again appears to show the 
existence of four rotamers. Three rotamers of this compound are major, with one minor rotamer 
and these exist in an appƌoǆiŵate ϲ:ϲ:ϲ:ϭ ƌatio. Fouƌ douďlets at ɷϬ.ϵϲ, ɷϭ.ϭϲ, ɷϭ.ϭϴ aŶd ɷϭ.ϰϳ 
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ĐoƌƌespoŶdiŶg to the steƌeoĐeŶtƌe ŵethǇl pƌotoŶs deŵoŶstƌate this ƌatio. SiŶglets at ɷϮ.ϲϮ, ɷϮ.ϴϬ, 
ɷϯ.ϭϵ aŶd ɷϯ.Ϯϭ ĐoƌƌespoŶd to the N-methyl protons, which demonstrate a similar ratio of rotamers.   
The structure was confirmed by HRMS which delivered an accurate mass for the [M+Na]+ ion of 
486.0148 corresponding exactly with the calculated figure. 
The 3-chloroaryl derivative precatalyst (180) was successfully synthesised in 70% yield.  
The structure was confirmed by HRMS. For the expected value of 451.9885, determination of the 
accurate mass of the [M+Na]+ ion delivered an exact match. 
The 1H NMR spectrum once again reveals the presence of rotamers strongly suggested by doublets 
at ɷϬ.ϵϳ, ɷϭ.ϭϯ, ɷϭ.ϭϱ aŶd ɷϭ.ϰϱ ǁhiĐh oƌigiŶate fƌoŵ the steƌeoĐeŶtƌe ŵethǇl pƌotoŶs. The sigŶal at 
ɷϬ.ϵϳ is ƌepƌeseŶtatiǀe of the ŵiŶoƌ ƌotaŵeƌ ǁhiĐh appeaƌs to eǆist iŶ a ϲ:ϲ:ϲ:ϭ ƌatio ǁith the thƌee 
ŵajoƌ ƌotaŵeƌs. The siŶglets at ɷϮ.ϲϯ, ɷϮ.ϴϯ, ɷϯ.ϭϳ aŶd ɷϯ.ϮϬ oƌigiŶate fƌoŵ the N-methyl protons, 
the iŶtegƌatioŶs of ǁhiĐh suggest a siŵilaƌ ƌatio of ƌotaŵeƌiĐ foƌŵs. Douďlets at ɷϰ.ϱϳ, ɷϰ.ϳϯ aŶd 
ɷϰ.ϵϰ ĐoƌƌespoŶd to the benzylic stereocentre. 
The 5-chloro-3-methyl pre-catalyst derivative (179) was successfully synthesised from (168) in 68% 
yield. 
Confirmation of the product was achieved by HRMS which delivered an accurate mass of the 
[M+Na]+ ion of 466.0041 which correlated exactly with the theoretical figure for this ion. 
The 1H NMR spectrum showed doublets at ɷϬ.ϵϱ, ɷϭ.ϭϮ, ɷϭ.ϭϰ aŶd ɷϭ.ϯϴ ĐoƌƌespoŶdiŶg to the 
methyl protons on the stereocentre and again suggests the presence of three major rotamers and 
one minor in a 6:6:6:1 ratio. The protons of the arene methyl group appear at ɷϮ.ϰϭ, ɷϮ.ϲϭ aŶd 
ɷϮ.ϰϯ, the latter of which features two overlapping signals. Doublets which are likely originate from 
the ďeŶzǇliĐ CH pƌotoŶ aƌe ǀisiďle at ɷϰ.ϰϵ, ɷϰ.ϲϲ aŶd ɷϰ.ϴϰ. The otheƌ steƌeoĐeŶtƌe pƌotoŶ 
ƌesoŶates as a seƌies as of Đoŵpleǆ sigŶals at ɷϯ.ϱϱ-ϯ.ϲϯ, ɷϰ.Ϯϰ-ϰ.ϯϴ aŶd ɷ4.95-5.04.  
The 3,5-dimethyl-2-iodobenzoic acid derivative (167) was not effectively coupled to 
pseudoephedrine following analysis by 1H NMR spectroscopy. No further attempts were made to 
synthesise this particular derivative. 
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3.3.1.3  The Rotameric Nature of Pseudoephedrine Based 2-Iodoaryl Precatalysts 
As seen from analysis by 1H NMR spectroscopy, the pseudoephedrine based catalysts synthesised in 
this project exist as up to four rotamers, some in greater prevalence than others. Reviewing the 
literature, it has been seen previously with tertiary aromatic amides, even with a small degree of 
steric constraint from substitution about the arene, that two rotational conformers about the arene-
carbonyl bond are possible124. Taking (177) as an example catalyst (Scheme 3.65), the two potential 
aryl-carbonyl rotamers are shown below: 
 
Scheme 3.65 – Ar-CO bond rotation with dihedral angle of 90o. 
 
It has also been observed that for less hindered tertiary aryl amides, that rotation about the 
carbonyl-nitrogen bond is possible124, as shown in Scheme 3.66. 
 
Scheme 3.66 – N-CO bond rotation with dihedral angle of 90o. 
 
Given the rotation about the Ar-CO bond and the rotation about the N-CO bond, the 
pseudoephedrine compounds synthesised can exist in up to four rotational conformers. This is 
concurrent with much of the 1H NMR analysis, which has suggested the presence of four rotamers, 
often with one as a minor component and the remaining three in approximately the same ratio as 
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major conformers. The observation of rotamers was less significant with catalyst (176). The lack of 
aryl substitution with this catalyst reduces the number of potential rotamers to two as was observed 
by 1H NMR analysis.  
 
3.3.1.4  The Catalytic Activity of Pseudoephedrine Based 2-Iodoaryl Precatalysts 
As described in the introduction, reactive hypervalent iodine(III) reagents are usually synthesised by 
firstly oxidising the iodide to the iodosyl iodine(III) compound, followed by the addition of an organic 
acid such as AcOH or TFA to create the active iodine(III) species. Both of these steps are often 
conducted in-situ. In order to make this species catalytic, the presence of a co-oxidant is required to 
re-oxidise the reacted organoiodine back to iodine(III). 
The oxidant selected for the generation of the hypervalent iodine(III) catalysts was mCPBA and the 
acid additive selected was p-toluenesulfonic acid. 
 
Scheme 3.67 
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3.3.1.5  Synthesis of 5-Benzoyltetrahydrofuran-2-one 
As described in the introduction, there are a wealth of potential asymmetric reactions in which 
hypervalent iodine catalysts can be screened. Given the poor results obtained by Wirth and co-
workers with the lactonisation reaction first examined by Moriarty in 1990101 and also the distinct 
lack of asymmetric induction reported from other HVI research groups, this reaction provides the 
perfect screening reaction. 
 
Scheme 3.68 
 
The lactonisation of 5-oxo-5-phenylpentanoic acid to the tetrahydrofuranone (181) was successfully 
achieved with all described PSE catalysts, in 58-72% yield. The catalysts were screened in 20%mol 
concentrations. A high excess of mCPBA and p-TsOH was used to ensure reproduction of the reactive 
iodine(III) species. In all cases the catalyst was retrievable, post-reaction.  
The structure of the product is strongly suggested by 1H NMR spectroscopy which shows the two 
sets of tetrahydrofuranone CH2 pƌotoŶs as a Đoŵpleǆ ŵultiplet at ɷϮ.ϰϭ-2.63. The stereocentre 
pƌotoŶ is oďseƌǀaďle as a Đoŵpleǆ sigŶal at ɷϱ.ϳϴ-5.84. The protons of the mono-substituted 
ďeŶzeŶe ƌiŶg aƌe oďseƌǀaďle iŶ the eǆpeĐted patteƌŶ at ɷϳ.ϱϮ, ɷϳ.ϲϰ aŶd ɷϳ.ϵϱ-8.01. 
The structure was further confirmed by 13C NMR spectroscopy which clearly showed the 
tetrahydrofuranone CH2 ĐaƌďoŶs at ɷϮϱ.ϯϳ aŶd ɷϮϳ.Ϯϭ. The steƌeoĐeŶtƌe carbon resonates as a 
sigŶal at ɷϳϴ.ϲϲ ǁith the fouƌ aƌoŵatiĐ ĐaƌďoŶs at ɷϭϮϵ.ϭϲ, ɷϭϮϵ.ϰϮ, ɷϭϯϯ.ϵϯ aŶd ɷϭϯϰ.ϳϬ. The 
ĐoŵpouŶd ĐoŶtaiŶs tǁo ĐaƌďoŶǇl ĐaƌďoŶs at ɷϭϵϰ.ϳϮ aŶd ɷϭϳϲ.ϲϵ. 
The structure of the cyclised product is fully confirmed by HRMS which delivered an accurate mass 
of the [M+Na]+ ion of 213.0516 with the theoretical figure determined to be 213.0522.    
This data is consistent with literature reports101. 
(181) 
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3.3.1.6  Asymmetric Induction by (1S,2S)-Pseudoephedrine Based Hypervalent  
  Iodine(III) Catalysts 
The purified lactone enantiomers were separated by HPLC analysis using a Hewlett-Packard Series 
1050 chromatogram with a Chiralpak I-B column. Conditions for separation were 85% hexane:15% 
IPA solvent system, with a flow rate of 1ml/min. 
The results of asymmetric induction by the (1S,2S)-pseudoephedrine based hypervalent iodine(III) 
catalysts are tabulated below: 
 
 
 
 
 
Entry Catalyst Yield (%) e.e (%) 
1 (176) 66 14 
2 (177) 70 53 
3 (178) 58 7 
4 (179) 72 48 
5 (180) 67 29 
 
 Table 3.19 
Pleasingly all catalysts induced asymmetry in the lactonisation reaction. Catalysts (177) and (179) 
peƌfoƌŵed ŵost ŶotaďlǇ, deliǀeƌiŶg good e.e͛s of ϱϯ% aŶd ϰϴ%, ƌespeĐtiǀelǇ, gƌeateƌ thaŶ aŶǇ 
reported in the literature for this reaction.  
The most apparent observation when considering the critical structural features of the catalysts 
(177) and (179) is the apparent necessity of the methyl group at the 3-position of the iodoarene. 
Without this group the catalyst performs less well, delivering an e.e of just 14%.  
Upon the introduction of a chlorine atom at the 5-position (179), retaining the methyl group at the 
3-position, the activity of the catalyst is slightly reduced giving an e.e. of 48%.  
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Following the promising results obtained with catalyst (177), a solvent screen was conducted. 
 
Entry Solvent Yield (%) e.e (%) 
1 DCM 70 53 
2 CHCl3 42 36 
3 1,2,-DCE 48 49 
4 TFE 50 32 
5 MeCN 83 27 
6 EtOAc - - 
7 Et2O 20 36 
8 IPA - - 
9 MeOH - - 
10 PhMe 27 44 
11 C6H14 12 6 
 
Table 3.20 – Results of solvent screen with catalyst (177). 
 
Whilst the results of the solvent screen were interesting, unfortunately no improvement in 
enantiomeric excess was observed, with the original DCM solvent proving to be the most suitable, 
although DCE and toluene also proved promising.  
Following the determination that DCM was the most effective solvent for inducing selectivity in this 
reaction using compound (177) as catalyst, a brief temperature screening was conducted. No 
improvement in enantiomeric excess was observed. 
 
Entry Temperature (oC) Yield (%) e.e (%) 
1 0 16 49 
2 25 70 53 
3 40 56 40 
 
Table 3.21 – Results of temperature screen for (177) in DCM. 
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A catalyst loading screen was not conducted due to time constraints.  
A plausible mechanism by which the synthesised hypervalent iodine(III) compound catalyses the 
lactonisation is shown: 
 
 
Scheme 3.69 
 
Substitution of tosylate from the nucleophilic attack of the carboxylic oxygen of the substrate at the 
hypervalent iodine(III) centre results in the generation of the acylated iodane and the net loss of 
toluenesulfonic acid. Cyclisation by further nucleophilic attack of the acylated iodane centre from 
the enol functionality of the substrate prompts the elimination of a molecule of water and the 
generation of a 6-membered iodoxanone intermediate. Reductive elimination of the catalyst and 
subsequent ring contraction generates the tetrahydrofuranone, lactonised product (181).  
 
It is imaginable that during the enantiodetermining, cyclisation step, the pseudoephedrine scaffold 
may successfully hinder attack of the iodane from the enol at one face more so than the other. Bond 
rotation about the iodine-arene bond enables the pseudoephedrine scaffold to partially block one 
face over the other. However, it is very difficult to suggest reasons how the 3-methyl group 
contributes so significantly to preferential attack of one face of the iodane over the other, possibly 
implying its influence may be electronic and not steric. 
R = Aryl-PSE scaffold 
(181) 
Results and Discussion   3 
284 
 
 
Figure 3.38 – Diagram illustrating the steric results of iodine-arene bond rotation. 
 
In summary, it has been demonstrated that a range of iodoarenes featuring the chiral scaffold of 
(1S,2S)-pseudoephedrine induce promising asymmetry in the lactonisation of 5-oxo-5-
phenylpentanoic acids.  
 
3.3.2 The Synthesis and Catalytic Activity of L-Proline Based Chiral 1,2,4-
Oxadiazole Systems 
The target of this part of the project was to synthesise a potential catalytic system featuring the 
1,2,4-oxadiazole as a structural feature. L-Proline was selected as the unit with which to provide the 
system with chirality. L-Proline was also selected since it has been the subject of much research as a 
catalyst by virtue of its versatility to act as an acid, base and nucleophile89.  
The initial target of this project was an L-proline-1,2,4-oxadiazole–pyridine type system, as shown 
below; chosen by virtue of our interesting results with ligands based on this motif. Ultimately, our 
aim was to replace the pyridine ring with an ortho-iodo substituted aryl ring.  
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Figure 3.39 – Early potential 1,2,4-oxadiazole catalyst targets. 
 
Four routes to the compounds shown in Figure 3.39 were explored and these are discussed below.  
 
3.3.2.1 Route One; Via Reaction of Cbz-Protected-L-Proline Amidoximes with 
Pyridine Acid Chlorides 
In order to prevent unwanted reactivity towards the acid chloride, it was necessary to select an N-
protected L-proline. The first of these to be explored was Cbz-L-proline.  
All previous syntheses of 1,2,4-oxadiazoles to this point had been achieved via the acid 
chloride/amidoxime reaction route. Thus, this route was deemed a sensible initial focus and is 
detailed below:  
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Scheme 3.70 
 
The conversion of carboxylic acid (182) to primary amide (183) ǁas aĐhieǀed iŶ ϰϵ% Ǉield ďǇ N,N͛-
dicyclohexylcarbodiimide coupling of ammonia. Activation of the DCC was achieved using an excess 
of N-hydroxysuccinimide, as reported by Ley117. 
The conversion of the primary amide (183) to nitrile (184) was achieved via reaction with p-
toluenesulfonyl chloride in the presence of pyridine in 48% yield. 
Analysis by NMR spectroscopy showed a product that was consistent with that reported by Ley117. 
Efforts to synthesise the amidoxime (185) using the classic hydroxylamine method, were not 
successful and subsequently this route towards the desired system was abandoned. 
 
 
 
 
Scheme 3.71 
(104) (104a) 
(185) (184) 
(182) 
(185) 
(184) (183) 
Results and Discussion   3 
287 
 
3.3.2.2 Route Two; Via Reaction of the Cbz-Protected-L-Proline Acid Chloride with 
Pyridine Amidoxime 
The second route towards the synthesis of an L-proline-1,2,4-oxadiazole system involved reversing 
the acid chloride/amidoxime conditions, as shown below:  
 
Scheme 3.72 
 
The Cbz-protected protected system (187) was successfully synthesised in 55% yield. This was 
achieved through conversion of Cbz-L-proline (182) to the corresponding pyrrolidine-2-carbonyl 
chloride (186) by chlorination with (COCl)2 in the presence of catalytic DMF and subsequent coupling 
with pyridine-2-amidoxime (44) in the presence of pyridine in refluxing xylene. 
The structure of the product was confirmed by NMR spectroscopy, the 1H NMR spectrum of which 
shows the six pyrrolidine CH2 pƌotoŶs as the ŵultiplet at ɷϭ.ϵϵ-2.51 integrating as four protons, and 
the tǁo ŵultiplets at ɷϯ.ϱϱ-ϯ.ϳϭ aŶd ɷϯ.ϳϲ-3.86, each integrating as one proton for those adjacent 
to the pǇƌƌolidiŶe ŶitƌogeŶ. A sigŶal at ɷϱ.ϭϮ aĐĐouŶts foƌ the Cďz gƌoup CH2 protons and adjacent to 
this sigŶal at ɷϱ.Ϯϵ is aŶ appaƌeŶt douďlet of douďlets of douďlets ƌepƌeseŶtiŶg the steƌeoĐeŶtƌe 
proton. All of the aromatic protons were present in the expected regions, with the complexity of the 
peaks suggesting that the compound exists as a mixture of rotamers.  
The 13C NMR spectrum is particularly interesting since each signal appears to be doubled, or 
shadowed, by an almost identical signal. Assuming each of these pairs of signals corresponds to one 
(44) 
(187) 
(188) 
(182) (186) 
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carbon atom, the spectrum is fully consistent with that which one would expect for this structure, 
but that it is present in two major rotameric forms.  
This structure was confirmed by HRMS which delivered an accurate mass of 373.1271 for the 
[M+Na]+ ion, correlating well with the calculated value of 373.1266. 
The N-Cbz deprotection to (188) was attempted under standard catalytic hydrogenation conditions. 
This reaction was not successful despite several attempts under a variety of conditions (including an 
attempted HBr reaction). In all cases, the hydrogenation led to the destruction of the 1,2,4-
oxadiazole ring with analysis by TLC showing many spots. Attempts to purify the crude products by 
column chromatography were hindered with many of the spots too close and too dilute to permit 
effective separation. However, persistent purification did enable separation of one particular spot 
which on all occasions appeared to be the more major of the many products.  
The 1H NMR data suggests that both the pyridine and pyrrolidine units are intact, with loss of the Cbz 
gƌoup also appaƌeŶt, ǁith the ďƌoad sigŶal at ɷϲ.ϳϲ likelǇ deŶotiŶg the pƌeseŶĐe of the pǇƌƌolidiŶe 
NH proton. A C-H at ɷϱ.Ϯϯ iŶtegƌates as oŶe pƌotoŶ aŶd ŵaǇ iŶdiĐate the CH oŶ the Đhiƌal ĐeŶtƌe. 
The 13C NMR spectrum was not consistent with the expected structure. This, together with the very 
low yield and literature evidence that the 1,2,4-oxadiazole ring may have been reduced under these 
conditions, meant that this route was not explored further. 
 
3.3.2.3 Route Three; Via Reaction of Boc-Protected-L-Proline Acid Chloride with 
Pyridine Amidoxime 
The third attempt at synthesising the desired compounds involved a switch in starting material from 
Cbz-L-proline to Boc-L-proline since it was envisaged that Boc removal would be less problematic 
than removing Cbz from such systems, since hydrogenation could be avoided. 
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Scheme 3.73 
 
The acid chloride (190) was synthesised with predictable simplicity. However, reaction in refluxing 
xylene with pyridine-2-amidoxime (44) resulted in an unworkable mixture upon cooling to room 
temperature. Having attempted to work-up the mixture with various washes and extraction, no 
sensible or identifiable amount of product was isolated. 
These practical problems led to attempts with alternative solvents such as toluene. However, the 
same, intractable mixture was observed, and rendered this an unfeasible synthesis to pursue 
further.     
 
 
 
 
(191) 
(189) (190) 
(188) 
(44) 
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3.3.2.4 Route Four; Via DCC Mediated Coupling Reaction of Boc-Protected-L-Proline 
with Pyridine Amidoximes 
Following the difficulties with acid chloride-amidoxime couplings involving these compounds, it 
seemed sensible to pursue alternative coupling conditions. The most attractive initially was via the 
DCC/NHS conditions, which had proven successful in coupling N-Cbz-L-proline to ammonia, 
discussed earlier, and shown below in Scheme 3.74: 
 
 
Scheme 3.74 
 
DCC mediated coupling of N-boc-L-proline (189) to pyridine-2-amidoxime (44) was achieved in DCM 
at room temperature using NHS as activating agent.  
Analysis by 1H NMR spectroscopy showed evidence for the O-acylated compound (193). The 
presence of the Boc protons was confirmed by stƌoŶg sigŶals at ɷϭ.ϯϴ aŶd ɷϭ.ϰϰ, ƌatheƌ thaŶ just 
one signal. The NH2 pƌotoŶs ǁeƌe oďseƌǀed as a ďƌoad siŶglet at ɷϲ.ϰϱ. The ƌeŵaiŶdeƌ of the 
spectrum observed was in accordance with previous similar structures in this sub-chapter. The 
strong evidence for this structure by 1H NMR spectroscopy was deemed sufficient to proceed to ring 
closure.  
 
 Δ 
(188) 
(191) 
(44) 
(193) 
(189) 
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3.3.2.4.1 Synthesis of 5-[(2S)-N-boc-pyrrolidin-2-yl]-3-(2-pyridyl)-1,2,4-oxadiazole 
   
 
 
Scheme 3.75 
 
Cyclodehydration of the O-acylated intermediate (193) was successfully achieved by using toluene at 
reflux in 82% yield over the two steps. 
Confirmation of the ring-closed structure (191) was determined largely by NMR spectroscopy, the 1H 
spectrum of ǁhiĐh shoǁs loss of the ďƌoad siŶglet at ɷϲ.ϰϱ, pƌeǀiouslǇ ĐoƌƌespoŶdiŶg to the NH2 
protons. The pyridyl and pyrrolidinyl protons remain intact with a moderate shift downfield. The Boc 
protecting group remains intact also. The highly complex nature of many of the signals suggests that 
this compound, like the pseudoephedrine and Cbz-protected analogues, exists as a mixture of 
rotamers.  
The 13C NM‘ speĐtƌuŵ shoǁed the pƌeseŶĐe of the BoĐ ĐaƌďoŶǇl at ɷϭϴϭ.ϰϳ. The speĐtƌuŵ also 
showed the presence of seven aromatic carbons. Interestingly, duplication of signals is observed 
with the majority of those present in this spectrum, confirming the presence of two rotamers. 
The structure of the cyclodehydrated product (191) was confirmed by HRMS which delivered a 
measured value of 339.1429 with the theoretical mass of this ion calculated to be 339.1428.  
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3.3.2.4.2 Synthesis of 3-(2-pyridyl)-5-[(2S)-pyrrolidin-2-yl]-1,2,4-oxadiazole  
 
 
Scheme 3.76 
 
The removal of the Boc-protecting group from the pyrrolidine unit of (191) was successfully achieved 
by treatment with trifluoroacetic acid in dichloromethane. The free pyrrolidine-oxadiazole-pyridine 
system (188) was synthesised in 83% yield.  
As per the usual trend with all of the proline-oxadiazole-pyridine systems discussed previously, the 
reaction did not proceed with immediate success. The removal of Boc protecting groups via 
treatment with TFA is well documented in the literature with the use of low concentration dilutions 
in DCM popular, with 1:1 mixtures the general upper limit. Treatment of the above Boc-protected 
system with 1:1 DCM:TFA resulted in destruction of the 1,2,4-oxadiazole. Following efforts to 
remove the Boc protecting group in many other concentrations of TFA:DCM systems, deprotection 
in good yield (83%) was finally achieved with a 20:1 DCM:TFA system.  
Analysis by 1H NMR spectroscopy reveals the disappearance of all signals corresponding to the Boc 
group protons and the appearance of a ďƌoad sigŶal at ɷϴ.ϴϬ-10.20 corresponding to the pyrrolidine 
freebase NH proton. Following removal of the Boc protecting group, all signals of the spectrum 
simplify, from highly complex multiplets to more defined signals. This confirms that previous 
structures with pyrrolidine N-protection in place existed as two rotameric forms, causing complexity 
of the 1H NMR spectrum.   
The 13C NMR spectrum also provides strong support for the desired structure, although a high 
aƌoŵatiĐ ĐaƌďoŶ sigŶal at ɷϭϴϮ.ϳϵ pƌoǀided a little cause for concern. 
Fortunately the structure was later fully confirmed by HRMS which determined the accurate mass of 
the [M+Na]+ ion to be 239.0906 for the expected figure of 239.0903. 
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3.3.2.5  The Catalytic Activity of L-Proline Enriched, Chiral 1,2,4-Oxadiazole Systems 
Due to the unexpected difficulties encountered during the synthesis of L-proline based 1,2,4-
oxadiazole-pyridine compound (188), there was insufficient time to explore the use of compound 
(188) as a ligand in asymmetric synthesis and this aspect of the work was taken up by another group 
member. The remaining time in this PhD project was dedicated to an initial exploration into 
producing the ortho-iodoaryl analogue of compound (188).  
 
3.3.3 The Attempted Synthesis of a Chiral, L-Proline, Iodo-containing 1,2,4-
Oxadiazole Derivative 
Having synthesised a catalyst featuring the proline-oxadiazole unit, it was decided to modify the 
compound to include some iodide character (Scheme 3.77). This could enable the development of an 
in-situ hypervalent iodine system, which could be modified to behave in an asymmetric catalytic 
manner due to the inherent chirality from the proline unit. It was intended that this system could 
then be screened in the furanone synthesis discussed previously in this chapter and described above 
in the chapter aims.  
 
Scheme 3.77 
 
 Δ 
(194) (195) 
(196) 
(197) 
Results and Discussion   3 
294 
 
3.3.3.1  Synthesis of N'-Hydroxy-2-iodo-benzamidine 
 
Scheme 3.78 
 
Conversion of the nitrile to the amidoxime was achieved as described previously. All attempts to 
couple it to N-Boc-L-proline were unsuccessful. This compound remains the target of future work 
that will be undertaken by another group member. A second target will be to incorporate the 
pseudoephedrine unit into the system, as such a system (as described previously), showed some 
success. These systems are shown below: 
 
 
Figure 3.40 – Target iodoaryl pseudoephedrine based 1,2,4-oxadiazole systems. 
 
It was hoped that these systems may offer the advantage of a simplified system that would not have 
the complications presented by rotamers observed with pseudoephedrine systems derived from aryl 
amides, described above. Further ideas for future work in this area are described in the relevant 
section.  
(195) (194) 
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3.3.4  Conclusions 
In conclusion for this section, a range of iodoaryl-pseudoephedrine pre-catalytic systems were 
successfully synthesised. The oxidation of the iodine to the iodine(III) system and the catalytic 
regeneration of these systems was observed. The asymmetric catalytic activity of the oxidised 
hypervalent iodine(III) derivative was assessed through screening via a lactonisation reaction, the 
lactone product of which bears one stereocentre. Although modest enantioselectivities were 
observed, an e.e. of 53% suggests such 2-iodoaryl-pseudoephedrine species possess good potential 
in the asymmetric catalysis of oxidative ring formation reactions. Unfortunately, the opportunity to 
develop a 1,2,4-oxadiazole analogue was not possible due to time constraints. This, however, is now 
the focus of other students within our research group.   
The synthesis of an L-proline-based, 1,2,4-oxadiazole system has also been achieved. Though 
opportunity to screen this compound and synthesise derivatives was not possible, the wealth of 
opportunity for such compounds is such that this is also now the focus of a colleague within our 
research group.  
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IV  Future Work 
This section aims to briefly consider any potential future work or interesting ideas that may have 
arisen from the work described in this thesis. 
The examination of the supramolecular potential of the 1,2,4-oxadiazole in ligand systems proved to 
be a highly successful venture. In an extension from this success, many interesting ideas can be 
proposed.  
One of the most interesting pieces of potential future work is the synthesis of 1,2,4-oxadiazole 
containing ligand systems by 1,3-dipolar cycloaddition. Whilst synthesis via the amidoxime method 
was reliable, products were only formed in low yields. Therefore it would be very interesting to 
examine the corresponding 1,3-dipolar cycloaddition synthesis in a bid to boost these low yields. 
Additionally, the 1,3-dipolar cycloaddition of nitrile oxides to nitriles opens up the possibility of some 
previously inaccessible ligands, for example, a pyridine-oxadiazole-bipyridine-oxadiazole-pyridine 
ligand (200), aŶalogous ǁith ‘iĐe͛s thiazole ligaŶd (26). This is shown in Scheme 4.1. The synthesis of 
this ligand was not possible by the amidoxime method due to the lack of success observed with the 
synthesis of the bipyridine-Ϯ,Ϯ͛-diamidoxime (51). Synthesis via the 1,3-dipolar cycloaddition method 
could enable the synthesis of this ligand, since the bipyridine-dinitrile would suffice as a precursor.  
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Scheme 4.1 
 
Stepping away from the 1,2,4-oxadiazole and on to similar heterocycles, it has been discovered that 
to the best of our knowledge, no supramolecular advances have been made using 1,2,4-thiadiazole 
containing ligands. Given the only structural difference between the 1,2,4-oxadiazole and the 1,2,4-
thiadiazole is the chalcogen switch, it would be very interesting to attempt the synthesis and 
crystallisation of some metal-organic ligand complexes featuring this heterocycle. In a further 
chalcogen switch, it has been noted that no published supramolecular work exists featuring 
selenium heterocyclic ligands. This could also be a very interesting piece of future work.  
Moving onto the medicinal chemistry of the isothiazolo-isoxazoles, it was unfortunate that 
oppoƌtuŶities to sǇŶthesise the ĐoƌƌespoŶdiŶg β-sultams were not forthcoming. This was due to time 
constraints caused by the successes observed with the isothiazolo-isoxazole analogues which 
-
(200) 
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deŵaŶded ŵost of the ƌeseaƌĐh atteŶtioŶ. The sǇŶthesis of these β-sultams and investigation into 
theiƌ ďiologiĐal aĐtiǀitǇ ƌeŵaiŶs at the foƌefƌoŶt of the gƌoup͛s ƌeseaƌĐh iŶ this aƌea.  
An additional and interesting potential piece of future work concerns the reactivity of the 
isothiazolo-isoǆazoles. The ďƌidgehead pƌotoŶ is likelǇ to ďe aĐidiĐ due to its α-sulfonyl position. 
Extension of these biologically active bicyclic compounds may be possible by investigating the 
chemistry at this position.   
There is much scope for further development of the catalytic systems described in this thesis. First 
and foremost, our group plan to screen the proline-oxadiazole catalyst (187) and, providing results 
show some promise, synthesise a range of derivatives and optimise the reactivity. Additionally, the 
synthesis of an iodide derivative of this proline-oxadiazole as a pre-hypervalent iodine catalyst 
remains a priority, followed by screening of this catalyst on the lactonisation reaction described 
earlier. Finally, it should be possible to synthesise 1,2,4-oxadiazole analogues of the 
pseudoephedrine hypervalent iodine catalysts in a bid to examine the impact of this heterocycle on 
the catalytic potential.  
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